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Abstract 
 
 
Repression of the pro-apoptotic bik gene by the Epstein-Barr virus. 
Eva Campion 
 
The Epstein-Barr virus, or EBV, is a B-lymphotrophic herpesvirus, which is prevalent 
in over 95% of the population. EBV, the first human cancer virus to be discovered, is 
currently associated with numerous lymphoid and solid tissue malignancies in both 
immuno-competent and immuno-compromised individuals. Inhibition of B-cell 
apoptosis is central to the EBV strategy and may play an important role in the 
development of EBV-related diseases. The Bcl-2 family of proteins constitutes a 
critical checkpoint in the apoptotic cascade and it is now generally accepted that pro-
apoptotic members of the Bcl-2 family are essential for the initiation of those 
pathways to apoptosis that are regulated by their anti-apoptotic relatives. The so-
called BH3-only proteins, which share only the short BH3 domain with the other Bcl-
2 family members, bind via the alpha-helical BH3 to pro-survival Bcl-2 proteins and 
this interaction is required for their ability to kill cells. Bik, the founding member of 
the BH3-alone group is a potent inducer of apoptosis, and the loss of Bik expression 
has been implicated in the development of cancers and the sensitisation of tumour 
cells to various therapeutic agents. 
 
Here it is shown for the first time that that loss of Bik protein appears to be a general 
feature of cells expressing the EBV growth programme, in which the full spectrum of 
viral latent proteins are expressed, but not the more restricted EBV latency 
programme. Introduction of ectopic Bik led to apoptosis by a mechanism that is 
dependent on its BH3 domain.  The data presented here demonstrates for the first time 
that the bik gene is activated through a transcriptional mechanism driven by EBNA2, 
and that c-Myc can also drive bik repression independently of EBNA2 during the 
EBV growth programme. It is also shown for the first time that inactivation of the 
EBV growth programme leads to the de-repression of bik.  The findings indicate that 
EBNA2 may down-regulate bik by decreasing transcription from the bik promoter and 
that neither the Notch pathway associated protein CBF1 nor the EBNA2-CBF1 
interaction are required for repression. The EBV latent membrane protein LMP1, 
 VI 
itself a major effector of phenotypic change in B-cells, did not affect bik expression. 
Together, these results indicate for the first time that down-regulation of the pro-
apoptotic bik gene promotes B-cell survival during the EBV growth programme. It is 
concluded that this host-virus interaction contributes to the survival of EBV-infected 
B-cells proliferating on the viral growth programme, thus implicating a contributory 
role for Bik in setting the elevated threshold of resistance of these EBV-infected cells. 
Mechanistic studies of the contribution of Bik to cell survival will provide important 
information about both normal B-cell development and potential routes to B-cell and 
non-B-cell malignancy. 
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Introduction  
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1.1  The discovery of the Epstein Barr Virus 
   
The Epstein Barr Virus (EBV) was first identified in 1964 in cell cultures derived 
from a Burkitt’s lymphoma (BL) biopsy (Epstein et al, 1964b). Denis Burkitt, first 
described this common aggressive B-cell lymphoma primarily
 
affecting children in 
specific regions of Africa in the late 1950s and early 1960s (Burkitt and O'Conor, 
1961; Burkitt, 1962a). Burkitt suspected
 
a virus might be responsible for the cancer, 
given the climatic
 
and geographic distribution of the lymphoma as well as its 
increased incidence in African children, but was unsuccessful in identifying a 
candidate agent (Burkitt, 1962b; Burkitt and Wright, 1966). EBV was not successfully 
identified
 
until 1964 when Anthony Epstein along with colleagues Yvonne Barr and 
Bert Achong succeeded in culturing lymphoma cells from BL patients and discerned 
herpesvirus particles in these cells by electron microscopy (Epstein and Barr, 1964a; 
Epstein et al, 1964b) (As reviewed in Kutok and Wang, 2006). Further studies 
revealed that sera from patients with the lymphoma that
 
Burkitt had described had 
much higher antibody titres to EBV
 
than did the controls. Subsequently EBV DNA 
was detected in BL and the experimental
 
production of lymphomas in cotton-top 
marmosets and owl monkeys
 
linked this infection with Burkitt's lymphomas and 
identified EBV as the first virus directly associated with a human cancer (Thompson 
and Kurzrock, 2004). Later, epidemiological studies made it clear that BL is a rare 
neoplasm relative to the large pool of EBV-infected individuals. EBV is present in all 
populations, infecting more than 95% of human beings within the first decades of life 
(Thompson and Kurzrock, 2004).  
 
1.2  Classification  
 
Humans are the exclusive natural host for EBV/ HHV4 (Middeldorp et al, 2003; 
Thompson and Kurzrock, 2004), which is classed as a herpes virus based on its 
structural properties (IARC Monographs, 1997).    EBV is one of the most extensively 
characterised members of the gamma subfamily of herpesviruses. This subfamily 
includes two genera, the gamma-1 herpesviruses, or lymphocryptoviridae (LCV), and 
the gamma-2 herpesviruses, or rhadinoviridae (RV). EBV belongs to the former. LCV 
are found only in primates, with EBV representing the only LCV to infect humans 
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(Kutok and Wang, 2006). The gamma-herpes viruses are classified on the basis of 
their biological properties rather than their genomic organisation (Kieff, 1996). 
Common features of these viruses are their tropism for lymphoid cells and their 
capacity to induce cell proliferation in vivo and cell immortalisation in vitro 
(Middeldorp et al, 2003).   
 
1.3  Structure of the virion. 
 
EBV is a 172 kilo-base pair (kbp) linear double-stranded DNA
 
genome encoding 
more than 85 genes. The viral genome consists
 
of a series of 0.5kb terminal direct 
repeats at either end,
 
and internal repeat sequences that serve to divide the genome
 
into short and long unique sequence domains that harbour most of
 
the coding capacity 
(as reviewed in Young and Murray, 2003; Thompson and Kurzrock, 2004). Similar to 
other herpesviruses,
 
EBV has a toroid-shaped protein core wrapped with double-
stranded
 
DNA (Figure 1.3.1). This DNA wrapped protein core is contained within a 
nucleocapsid with 162 capsomeres approximately 100 nanometres (nm) in diameter. 
A protein tegument
 
surrounds the nucleocapsid and this is enclosed by the outer 
envelope, which has external glycoprotein spikes, the most abundant of which is 
Gp350/220 (Middeldorp et al, 2003; Thompson and Kurzrock, 2004).  
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Figure 1.3.1: A Schematic representation of the herpes virus structure.   
 
EBV consists of a toroid protein core (illustrated in black) that is wrapped with 
double-stranded DNA (DS DNA, green). The DNA wrapped protein core is contained 
within a nuclecapsid (red).  A protein tegument surrounds the nucleocapsid and is 
enclosed by an outer envelope with external glycoprotein spikes. 
 
1.4  EBV Strains 
 
EBV strains are categorised into two distinct types; EBV type I and EBV type II (or 
EBV-A and EBV-B respectively). EBV-1 and EBV-2 differ in the organisation of 
their EBV nuclear antigen (EBNA)2 genes, and in their EBNA3A, EBNA3B,
 
and 
EBNA3C genes (Dambaugh et al, 1984b; Sample et al, 1990). Minor ‘sub-strain’ 
variations in the EBNA1, latent membrane protein 1 (LMP1), and BZLF1 have also 
been reported (Middeldorp et al, 2003). EBV-2 is known to transform B-cells less 
efficiently
 
than EBV-1 in vitro and the viability of EBV-2 lymphoblastoid
 
cell lines 
(LCLs) is also less than that of EBV-1 cell lines (Buisson et al, 1994; Middeldorp et 
al, 2003). The difference
 
in transforming efficiency of the EBV subtypes is thought to 
relate to a
 
variation in the EBNA2 sequences (Rickinson et al, 1987; Cohen et al, 
1989 and also reviewed in Thompson and Kurzrock, 2004). 
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1.5  Epidemiology of EBV  
 
EBV-1 and EBV-2 show considerable geographical variation (Thompson and 
Kurzrock, 2004). However, there is no apparent correlation between genotype and the 
specific type of neoplasma found, nor is there a relationship between genotype and 
healthy individuals or neoplasma patients (Khanim et al, 1996). Type 1 is detected 
worldwide, generally in Central Africa,  Papua New Guinea, North America and Asia, 
whereas type 2 is less ubiquitous, detected mainly in southern countries such as 
Central Africa, Reunion Island and Papua New Guinea (reviewed in Thompson and 
Kurzrock, 2004; Serraino et al, 2005).  
 
1.6  EBV Associated Malignancies 
 
While EBV infection is generally benign without any detectable clinical symptoms in 
the majority of carriers, the link connecting EBV infection and human tumours is 
irrefutable. The presence of EBV in various stages of B-cell development, and its 
ability to infect certain epithelial cells, can have pathogenic consequences, and can 
contribute to the development of a diverse group of lymphomas and carcinomas in a 
small percentage of individuals (Thompson and Kurzrock, 2004; Kutok and Wang, 
2006). In this regard EBV has been detected in tissues from patients with 
Nasopharyngeal carcinoma (NPC), non-Hodgkin lymphoma (NHL), and T-cell and 
Hodgkin lymphomas (HL) (as reviewed in Kutok and Wang, 2006) and is currently 
associated with numerous lymphoid and solid tissue malignancies in both immuno-
competent and immuno-compromised individuals (Thompson and Kurzrock, 2004; 
Kutok and Wang, 2006). Known EBV-associated diseases are listed in Table 1.6-1.  
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Table 1.6-1: The spectrum of EBV-associated disease. 
 
 
Adapted from Kutok and Wang, 2006. 
 
 
 
 
 
Disease State  Host Status Specific Site  
Of Infection 
Associated Malignancy 
 
+on-malignant  
   
Oral hairy leukoplakia,  
Chronic active infection,  
Infectious mononucleosis (IM) 
 
 
 
 
 
 
 
 
B-cell  
 
 
AIDS-associated B-cell lymphomas,  
Post-transplantation lymphoproliferative 
disorder (PTLD),  
Lymphomatoid granulomatosis, 
Methotrexate-associated B-cell 
lymphoma 
Severe combined immuno-deficiency–
associated B-cell lymphomas,  
Wiskott-Aldrich syndrome–associated B-
cell lymphomas,    
X-linked lymphoproliferative disorder–
associated B-cell lymphomas 
 
 
 
 
 
 
 
 
Immuno-compromised  
 
Mesenchymal 
 
 
Leiomyosarcoma 
 
B-cell  
 
Burkitt lymphoma, 
Classical Hodgkin lymphoma 
 
T-cell 
 
Extranodal NK/T-cell lymphoma, (nasal 
type), 
Virus-associated hemophagocytic 
syndrome T-cell lymphomas 
 
Epithelial  
 
Nonglandular nasopharyngeal carcinoma, 
Lymphoepithelioma-like carcinoma 
(salivary, thymus, lungs, stomach), Breast 
carcinoma,  Hepatocellular carcinoma 
 
 
 
 
 
 
 
 
 
 
 
Malignant  
 
 
 
 
 
 
Immuno-competent 
 
Mesenchymal Follicular dendritic cell sarcoma 
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1.7  EBV infection and persistence in vivo. 
 
EBV is transmitted from host to host via salivary contact. Upon infection, the 
individual remains a lifelong
 
carrier of the virus. Primary infections occurring during 
the first few years of life are generally silent or asymptomatic (Thompson and 
Kurzrock, 2004). In developed countries, primary infection can be
 
delayed until late 
adolescence or early adulthood and may result in the self-limiting non-malignant 
lymphoproliferative syndrome infectious mononucleosis (IM), which is also referred 
to as glandular fever or ‘kissing disease’ (Gerber et al, 1972; IARC Monographs, 
1997; Kuppers, 2003). Infection that is delayed and associated with IM is 
characterised by a variety of symptoms, including fever, malaise, lymphadenopathy 
(obvious swelling of peripheral lymphoid tissues) and the presence of atypical 
dividing lymphocytes in the peripheral blood (Kutok and Wang, 2006). The 
development of an EBV-specific immune response controls primary infection, but it is 
unable to eliminate the infection completely from the body since the virus can hide 
within long-lived memory B-cells. Thus, EBV infection persists asymptomatically 
during the host's life, maintaining a perpetual equilibrium between the immune 
response and a stealthy virus infection. A low level of active viral replication 
continues asymptomatically in EBV carriers, leading to virus shedding via oral 
secretions and transmission of EBV from one individual to another (Kutok and Wang, 
2006). 
 
EBV has two distinct life cycles in the human host; a lytic form of infection that 
describes the full cycle of infection, leading to the production of new infectious 
virions, and eventual lysis of the infected cell, and a latent form of infection that 
allows the virus to persist in a dormant state for the lifetime of the host in circulating 
memory B-cells (Thorley-Lawson, 2001). Incoming virus establishes a primary focus 
of lytic replication at the oropharyngeal epithelium. Oropharyngeal infection is 
followed by a latent infection of B-cells as they pass in close proximity to the infected 
epithelial cells (Figure 1.7.1), resulting in B-cell proliferation and viral spread 
throughout the B-cell compartment (Young and Rickinson, 2004).     
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Figure 1.7.1: Putative in vivo interactions between Epstein-Barr virus and host 
cells 
 
(A) Primary EBV infection. Different views of these events are described in the text 
and are illustrated above. (B) Persistent EBV infection. (From Young and Rickinson, 
2004).   
 
EBV infection of B-cells is instigated with the attachment of the gp
 
350/220 viral 
membrane glycoprotein to the CD21 molecule on lymphocytes (Middeldorp et al, 
2003). After-attachment CD21 becomes cross-linked, which triggers an initial 
activating
 
signal that is thought to prepare the cell for EBV infection.
 
EBV binding to 
CD21 immediately activates tyrosine kinase lck
 
and mobilises calcium (Gordon et al, 
1986; Cheung and Dosch, 1991). This is followed by an increase
 
in mRNA synthesis, 
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blast transformation, homotypic cell adhesion,
 
surface CD23 expression (a 
characteristic surface marker for
 
activated B-cells), and interleukin (IL)-6 production 
(as reviewed in Thompson and Kurzrock, 2004). The viral genome is then uncoated 
and delivered to the
 
nucleus where it immediately becomes a circular episome. 
Circularisation and
 
W (EBNA) promoter expression launch an ordered sequence of 
events that
 
leads to the expression of all of the EBNA proteins and the
 
three latent 
membrane proteins (LMPs) (Young and Rickinson, 2004). EBV does not encode an 
RNA polymerase, and uses host cell RNA polymerase II for transcription of viral 
RNAs (Kieff, 1996).  The EBV nuclear
 
antigen leader protein (EBNA-LP) and 
EBNA2 proteins are the
 
first proteins to be detected upon EBV infection (Middeldorp 
et al, 2003). A promoter shift occurs 24 to 48 hours after infection where
 
the C 
promoter (Cp) is used in favour of the initial W promoter to drive EBNA expression 
(reviewed in Rowe, 1999). Many transcripts now pass the polyladenylation site 
downstream of EBNA2 and extend to the EBNAs 1, 3A, 3B and 3C (Kieff, 1996) 
open reading frames (ORFs) located downstream (Figure 1.7.2). The different EBNAs 
are encoded by individual mRNAs generated by differential splicing of the same long 
“rightward” primary transcript expressed from either Cp or Wp which are located in 
close proximity to each other in the BamHI C and W regions of the genome (Murray 
and Young, 2001; Middeldorp et al, 2003) (Figure 1.7.2).  The processing of the 
transcripts is then determined by their polyadenylation sites (Kieff, 1996).  All of the 
EBNA transcriptional
 
products are involved in transcriptional control and participate
 
in the activation of the expression of the viral LMP-encoding
 
genes (LMP1 and LMP-
2) and several cellular genes (as reviewed in Thompson and Kurzrock, 2004). The 
combined
 
action of these viral and cellular proteins serves to initiate
 
cellular S-phase 
24 to 48 hours after infection (Rowe, 1999).  
 
By 32 hours post-infection, all of the EBNAs and the LMPs are expressed.  The LMP 
transcripts are expressed from separate promoters in the BamHI N region of the EBV 
genome, with the “leftward” LMP1 and “rightward” LMP2B mRNAs apparently 
controlled by the same bi-directional promoter. EBV encoded RNA (EBER) 
expression follows at approximately 24 hours and does not reach substantial levels 
until approximately 70 hours after-infection (Murray and Young, 2001). A diagram 
showing the location and transcription of the EBV latent genes on the double-stranded 
viral DNA episome is shown in Figure 1.7.3. 
 10 
US IRTR TRUL
172 kb
0               20                     40                  60 80                100                120 140                   160kb
EBNA2
Cp/W
EBNA3A
EBNA3B
EBNA1
EBNA3C
 
Figure 1.7.2: A simplified outline of the splicing of the EBV nuclear antigen 
coding mR+As.  
 
All the EBNAs are transcribed from either the Cp or Wp promoter; the different 
EBNAs are encoded by individual mRNAs generated by differential splicing and 
alternate polyadenylation.  
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Figure 1.7.3:  EBV latent genes. 
 
(A) A schematic representation indicating the location and transcription of the EBV 
latent genes on the double-stranded viral DNA episome.  The origin of replication 
(OriP) is shown in orange.  The large green solid arrows represent exons encoding 
each of the latent proteins, and the arrows indicate the direction in which the genes are 
transcribed.  The terminal repeat (TR) region, formed during the circularisation of the 
linear DNA to produce the viral episome is shown in purple. The blue arrows at the 
top represent EBER1 and EBER2. The long outer green arrow represents EBV 
transcription during type III latency, in which all the EBNAs are transcribed from 
either the Cp or Wp promoter. The inner, shorter red arrow represents the EB"A1 
transcript, which originates from the Qp promoter during latency type I and latency 
type II. The locations of the BARF-0 and BARF-1 coding regions are also illustrated. 
(B) Locations of the open reading frame (ORF) for the EBV latent proteins on the 
Bam HI restriction endonuclease map of the prototype B95-8 genome (From Young 
and Rickinson, 2004).   
 
 
 
 
 
A 
B 
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In addition to its recognised B-cell tropism, EBV infection may also target epithelial 
cells, T-cells, and
 
cells of the macrocytic, granulocytic, and natural killer lineages 
(Thompson and Kurzrock, 2004).
 
It is thought
 
that these cells may be infected by 
mechanisms other than the
 
CD21-mediated pathway used in B-cells, given that 
epithelial cells generally do not express CD21 (Thompson and Kurzrock, 2004).  
Various human epithelial cells can be infected in vitro either by direct contact with 
high-titre virus supernatant or by co-cultivation with EBV-producing B-cells, such as 
AKATA (Imai et al, 1998).  This suggests an in vivo model of EBV infection 
whereby epithelial tissues might be infected by virtue of their close proximity to (i) 
infectious virus present in saliva or (ii) lytically infected B-cells resident near or 
within epithelial tissues, for example adjacent to the sub-epithelial sinus in tonsil or 
within nasopharyngeal mucosa  (Murray and Young, 2001). 
 
After initial infection, the EBV genome persists in a latent form (latency III), 
circulating in a division
 
of the resting memory B-cells in healthy individuals at a low 
frequency
 
of approximately 1 in 1 X 10
5
 to 1 X 10
6
 cells. Immuno-suppressive states 
allow spontaneous replication
 
of the episomal virus in circulating B-cells (as observed 
in
 
acute IM). Immuno-competent carriers control
 
latent EBV infection via their 
cytotoxtic T lymphocyte (CTL) response. Some of these proliferating cells avoid 
detection by down-regulating antigen expression and establishing a stable reservoir of 
resting EBV-positive memory B-cells, in which viral antigen expression is mostly 
suppressed (latency 0). EBNA3A, EBNA3B, and EBNA3C
 
all elicit specific CTL 
responses and the loss of the EBV-specific CTL
 
may play an important role in EBV-
associated malignancies (Young and Rickinson, 2004).  
EBV is persists in the peripheral blood within the IgD
-
 memory B-cell pool, with a 
limited EBV gene expression of latent membrane protein 2A (LMP2A) and EBNA1 
(Babcock et al, 1998). The exact route of entry to the memory B-cell pool is still a 
matter of much contention since in vitro studies indicate that both naïve and memory 
B lymphocytes seem equally susceptible to EBV infection (Young and Rickinson, 
2004). One view is that naïve B-cells are the main target of incoming EBV infections 
in vivo. In this model, viral transformation drives naïve cells into memory by 
mimicking the physiological process of antigen-driven memory-cell development, a 
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process involving somatic immuno-globulin-gene hypermutation during transit 
through a germinal centre (Figure 1.7.1). However, the finding that EBV-infected B-
cells in tonsils from patients with IM are known to localise to extrafollicular areas and 
not to the germinal centres, and in addition show no evidence of hypermutation within 
expanding clones, makes this hypothesis difficult to reconcile (Young and Rickinson, 
2004). This strategy gives the virus the opportunity to recruit infected cells into 
germinal centres, activating their latency programmes, resulting in progeny that either 
return to the circulating memory pool or differentiate to become plasma cells, which 
may migrate to mucosal sites in the oropharynx (Young and Rickinson, 2004). 
Alternatively it is thought that infection of pre-existing memory cells may provide 
direct entry into the memory compartment (Figure 1.7.1). This view is concurrent 
with the above observations in IM tonsils, but still leaves in question the apparent 
disappearance of the infected naïve cell pool (Young and Rickinson, 2004). 
The reservoir of EBV-infected memory B-cells is stably maintained and befalls to the 
same physiological regulation that governs memory B-cell migration and 
differentiation (Laichalk et al, 2002). Occasionally, these EBV-infected cells might be 
recruited into germinal-centre reactions, involving the activation of different latency 
programmes, after which they might either return to the reservoir as memory cells or 
differentiate to become plasma cells, which may migrate to mucosal sites in the 
oropharynx, in the process, activating the viral lytic cycle. Progeny produced at these 
sites might initiate foci of lytic replication in receptive epithelial cells, allowing low-
level shedding of infectious virus in the oropharynx, and might also initiate new 
latency III infections of naïve and/or memory B-cells. New infections may possibly 
replenish the B-cell reservoir, but are more likely to be efficiently removed by the 
CTL response (Young and Rickinson, 2004). The interactions between EBV and host 
cells are summarised Figure 1.7.1.   
 
EBV has evolved a life cycle that mimics the natural differentiation pathway of 
antigen-activated B-cells, giving the virus access to its site of latent infection, the 
resting memory B-cell. By guiding infected cells through the stages of lymphocyte 
differentiation, EBV takes advantage of a cell type suitable for long-term latent 
persistence and periodic reactivation (Pattle and Farrell, 2006). 
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1.8  The Genes of the Lytic and Latent Cycles of EBV 
 
 
The uncontrolled replication of a virus, which is harmful to the host is also 
detrimental to the virus (Shen and Shenk, 1995). Most viruses are unable to compete 
with the complex defence mechanisms of the host immune system and as a result 
become eliminated during the course of infection. Consequently, only the time 
between the initial infection and the elimination remains for these viruses to replicate 
and spread (Shen and Shenk, 1995). EBV however, has developed a strategy for 
persisting long-term, usually asymptomatically, concealed from the immune system 
while also producing infectious progeny periodically. This strategy depends on a 
separation of latency and lytic replication (Schwarzmann et al, 1998). 
 
1.9  EBV Lytic Genes 
 
 
Infection
 
of epithelial cells by EBV in vitro results in active replication,
 
leading to 
production of virus progeny and ultimately lysis of the infected cell (reviewed in 
Cohen, 2000). EBV encodes lytic cycle proteins that are important during viral 
replication for (1) regulating the expression of viral
 
genes, (2) replicating viral DNA, 
(3) forming structural components
 
of the virion, and (4) modulating the hosts immune 
response (Cohen, 2000).  
 
1.9.1  Immediate Early, Early and Late Lytic Cycle Genes 
 
Not unlike several other herpesviruses, EBV encodes lytic cycle genes that can 
prevent or delay death of the host cell, resulting from apoptosis triggered by the cell 
recognising the replication of the virus as DNA damage (Wensing and Farrell, 2000). 
The genes of the viral lytic cycle are expressed in a regimented cascade and are 
directly responsible for viral DNA replication (Lu and Chen, 2006). Some of these 
genes also encode structural proteins or proteins that modify the infected cells to 
facilitate viral envelopment (IARC Monographs, 1997; Cohen, 2000).   
 15 
Lytic cycle gene expression follows a temporal and sequential order (Amon and 
Farrell, 2005; Lu and Chen, 2006) (Figure 1.9.1). Some viral genes are expressed 
independently of new protein synthesis early after lytic cycle induction, and are 
classified as immediate early genes (Amon and Farrell, 2005). These include the 
BZLF1, BRLF1 and BI’LF4 encoded proteins which are potent trans-activators of 
early EBV lytic genes (Takada and Ono, 1989; Kieff, 1996 and Young and Murray, 
2003).  Viral immediate early genes are induced directly by signal transduction from 
the B-cell receptor (BCR), independent of the expression of other proteins (Amon and 
Farrell, 2005). These immediate early genes are also involved in the transition from 
latent to lytic infection, cellular differentiation and cell cycle progression (Sinclair et 
al, 1992; Zacny et al, 1998; Swenson et al, 1999; Young and Murray, 2003). BZLF1 
is expressed as early as 1.5 hours after EBV infection (Wen et al, 2007), and 
expression of this protein alone is sufficient to trigger the entire lytic cascade (Amon 
and Farrell, 2005). BZLF1 is a transcription factor which has sequence homology to 
c-Fos and harbours binding sites in several viral early gene promoters and promoters 
of cellular genes, as well as the lytic origins of replication. BZLF1 also further 
activates its own expression by binding to its promoter, an event that also activates the 
adjacent gene BRLF1, which is also a transcription factor. Together BZLF1 and 
BRLF1 activate most of the early genes in the next phase of the lytic cycle (Amon and 
Farrell, 2005). The early lytic viral genes are expressed slightly later and there are at 
least 30 EBV mRNAs classified as early gene products (Hummel and Kieff, 1982). 
Two of the most abundant early proteins are the BALF2 protein which is homologous 
to a HSV DNA binding protein and is important in DNA replication (Hummel and 
Kieff, 1982) and the BHRF1 protein, which shows partial (25%) sequence homology 
to the human bcl-2 proto-oncogene, both of which protect human B lymphocytes from 
apoptosis (Henderson et al, 1993; Young and Murray, 2003). The late proteins are 
formally categorised as late based on a marked reduction in expression after inhibition 
of viral DNA synthesis (Kieff, 1996) and are those that encode structural 
glycoproteins or proteins that modify the infected cells in order to permit viral 
envelopment or egress (IARC Monographs, 1997). Amoung the non-glycoproteins, 
BCLF1, BNRF1 and BXRF1 encode the major nucleocapsid protein, the major 
external non-glycoprotein of the virion and the basic core protein respectively. The 
genes encoding the EBV glycoproteins include BCRF1, which shows 84% sequence 
homology to the human IL-10 (Vieira et al, 1991).  EBV-derived IL-10 is thought to 
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play a role in the establishment of latent infection by suppression of the host immune 
system (Rousset et al, 1992; Kurilla et al, 1993; Helminen et al, 1999; Young and 
Murray, 2003). An overview of the EBV lytic cycle is illustrated in Figure 1.9.1. 
 
 
 
 
 
Figure 1.9.1: Overview of EBV lytic cycle.  
 
Immediate early, early and late genes are expressed in sequential order. These genes 
are responsible for viral DNA replication and some genes also encode structural 
proteins or proteins that modify the infected cells to facilitate viral envelopment 
Adapted from Amon and Farrell, 2005.   
 
1.9.2  Early, Membrane, and Viral Capsid Antigens. 
 
  
The EBV lytic cycle is the replicative stage of the virus life cycle and is crucial for the 
production of infectious virus, which can then be spread to EBV naïve hosts through 
oral secretions into the saliva. The replicative proteins of the EBV lytic cycle have 
been classified as early antigens (EA), membrane antigens (MA), and viral capsid 
antigens (VCA) (Figure 1.9.2).  The early antigens have been further subdivided into 
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diffuse early antigens (EA-D) and restricted early antigens (EA-R) (Kieff, 1996). 
Following induction of the lytic cycle, cells that have become permissive to viral 
replication, undergo cytopathic changes characteristic of herpesviruses, including 
margination of nuclear chromatin, synthesis of viral DNA, assembly of nucleocapsids, 
envelopment of the virus by budding through the inner nuclear membrane and 
inhibition of host macromolecular synthesis (Kieff, 1996). Viral
 
replication is 
spontaneously activated in only a small percentage
 
of latently infected B-cells, and in 
these cells the viral DNA is amplified several hundred fold by a lytic origin of 
replication oriLyt (Hiraki et al, 2001). A schematic diagram illustrating early and late 
EBV gene expression is seen in Figure 1.9.2. 
 
  
Figure 1.9.2:  A schematic representation of early and late EBV gene expression  
 
The VCA, the MA and the EA are illustrated and their ORF are written in bold. 
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1.10  EBV Latent Genes 
 
Infection of B-cells by EBV in vitro results in a latent infection,
 
with immortalisation 
of the cells (Cohen, 2000). The transformation of B-cells by EBV involves the 
synchronised action of several latent gene products (Young et al, 2000).  EBV uses its 
viral proteins, the actions of which mimic several growth factors, transcription factors 
and apoptotic factors, to usurp control of cellular pathways that regulate diverse 
homeostatic cellular functions, allowing both cellular transformation and the 
establishment of a latent infection in the memory B-cell compartment. 
   
1.10.1 The EBV-encoded nuclear antigens 
 
1.10.1.1  EB+A1 
 
EBV nuclear antigen 1 (EBNA1), a 641 amino acid protein, is the only viral protein 
consistently expressed in all EBV-associated malignancies and EBV-proliferating 
cells in healthy carriers (Knecht et al, 1997; Young and Murray, 2003; Young and 
Rickinson, 2004). EBNA1 is essential for lifelong viral persistence and is required for 
maintenance and replication of the EBV genome, through specific binding of EBNA1 
to the EBV-origin of replication (oriP) (reviewed in Young and Murray, 2003). 
EBNA1 can also activate expression of critical cellular genes affecting cellular 
growth control and is known to possess oncogenic properties (Wilson and Levine, 
1992 and Young and Murray, 2003). This ~80kDa protein consists of a short amino-
terminal region, a 20kDa-40kDa glycine-alanine (Gly-Ala) repetitive sequence 
flanked by arginine rich sequences and a highly charged acidic carboxy-terminal 
sequence (Hennessy and Kieff, 1983; Young and Murray, 2003; Young and 
Rickinson, 2004). The presence of the Gly-Ala repeat domain in EBNA1 prevents 
processing by the proteasome (Dantuma et al, 2002), and has also been found to 
inhibit EB"A1 mRNA translation. In this manner EBNA1 greatly reduces its own 
recognition by cytotoxic T-cells, enabling infected cells to evade the immune 
response (Yin et al, 2003).  
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1.10.1.2  EB+A2 
 
EBNA2 is an 83 kDa transcription factor that localises to large nuclear granules and is 
associated with nucleoplasmic chromatin and nuclear matrix fractions (Petti et al, 
1990). EBNA2 plays a critical role in the immortalisation of primary B lymphocytes.  
EBNA2, together with EBNA-LP, is the first protein expressed after infection of 
resting B-cells, underscoring its function as a transcriptional activator of cellular and 
viral gene expression (Middeldorp et al, 2003). The inability of the P3HR-1 EBV 
strain, (which carries a deletion of the gene that encodes EBNA2 and the last two 
exons of that for EBNA-LP) to transform B-cells in vitro was the first indication of 
the crucial role of this protein in the transformation process. Restoration of the 
EBNA2 gene in P3HR-1 has indisputably confirmed the importance of EBNA2 in B-
cell transformation (Dambaugh et al, 1984a; Hennessy and Kieff, 1985; Mueller-
Lantzsch et al, 1985 and as reviewed in Young and Rickinson, 2004). Since this time 
experiments have shown that EBNA2 is not only essential for initiation but also for 
maintenance of B-cell immortalisation (Kempkes et al, 1995a). Sequencing of the 
EBNA2 gene in different EBV strains has revealed two alleic isoforms of EBNA2, 
namely EBNA2A and EBNA2B, which are found in type 1 and type 2 EBV isolates 
respectively (Aitken et al, 1994). These proteins share only about 50% sequence 
homology with each other (Adldinger et al, 1985). While both genes are essential for 
immortalisation of EBV infected cell lines, EBNA2B displays a significantly reduced 
ability to transform B-lymphocytes relative to the EBNA2A gene (Dambaugh et al, 
1984c; Cohen et al, 1989; Hammerschmidt and Sugden, 1989) and accordingly these 
genes are thought to be responsible for the biological difference that enables the type 
1 strains to transform B lymphocytes more efficiently than type 2 (Rickinson et al, 
1987 and reviewed in Zimber-Strobl and Strobl, 2001). EBNA2A, identified from the 
B95.8 strain of EBV consists of 483 amino acids, whereas EBNA2B represented by 
the AG876 cell line consists of 455 amino acids.  
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1.10.1.2.1  Structure of EB+A2 
 
The EBNA2 protein consists of: (i) a negatively charged region at the amino-
terminus, which is reported to participate in homo-dimerisation (ii) a polyproline 
stretch, consisting of 10–40 successive prolines depending on the virus strain; (iii) a 
diversity region at the centre of the protein, where very low homology between 
EBNA2A and EBNA2B exists; (iv) a domain responsible for the interaction with the 
DNA-binding protein CBF1; (v) an arginine–glycine rich stretch of around 18 amino 
acids; (vi) a negatively charged region, which contains a trans-activation domain; and 
(vii) a nuclear localisation signal at the carboxy-terminus (Figure 1.10.1). (Zimber-
Strobl and Strobl, 2001). 
 
Regions of the protein fundamental to the transforming ability of EBNA2 have been 
charted by extensive mutational analysis (as discussed in Zimber-Strobl and Strobl, 
2001). Several stretches of the protein could be deleted without abrogating the 
immortalisation function of the protein. At the amino-terminus, the first 230 amino 
acids excluding the amino acids 94–110 which encompass seven prolines were found 
to be unnecessary for B-cell transformation. Two further regions were established as 
crucial for B-cell immortalisation; the area harbouring the amino acids 280–337 
which is necessary for mediating the indirect contact of EBNA2 with DNA through 
the Cp Binding Factor 1(CBF1) transcription factor (see below) and the region 
containing the amino acids 425–462; which contains an acidic trans-activation 
domain (Cohen and Kieff, 1991; Ling et al, 1993a; Zimber-Strobl and Strobl, 2001).  
 
 
 
Figure 1.10.1: Structure of the EB+A2A protein of the B95.8 strain of EBV. 
 
Characteristic parts of the EBNA2 protein: a negatively charged region at the amino-
terminus, (Dim), a polyproline stretch (Pro), a diversity region, a domain responsible 
for the interaction with RBP-Jκ (RBP-J), an arginine–glycine rich stretch (ArgGly), a 
trans-activation domain (TAD) and a nuclear localisation signal (NLS) at the 
carboxy-terminus. (From Zimber-Strobl and Strobl, 2001). 
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1.10.1.2.2  Function of EB+A2 
 
EBNA2 is a specific trans-activator of latent viral genes and is known to regulate the 
expression of all other viral proteins expressed in LCLs through the trans-activation 
of (i) the BamHI-C-promoter (Cp) from which transcription of all EBNA genes is 
regulated (Woisetschlaeger et al, 1990; Sung et al, 1991); and (ii) the promoters of the 
latent membrane proteins LMP1, LMP2A and LMP2B (Abbot et al, 1990; Fahraeus et 
al, 1990; Wang et al, 1990; Zimber-Strobl et al, 1991; Laux et al, 1994b). In addition 
to this, EBNA2 trans-activates various cellular genes (CD23, CD21, CCR7,
 
hes-1, c-
fgr, AML-2, BATF
 
, bcl-2 and bfl-1, c-myc, FcRH5 and EBI1/BLR2) (Wang et al, 
1987; Cordier et al, 1990; Knutson, 1990; Patel et al, 1990; Finke et al, 1992; 
Burgstahler et al, 1995; Sakai et al, 1998; Kaiser et al, 1999; Spender et al, 2001; 
Spender et al, 2002; Johansen et al, 2003; Maier et al, 2005; Mohan et al, 2006; 
Pegman et al, 2006) and to date is known to transcriptionally repress only one cellular 
gene, the immuno-globulin heavy chain locus (IgM) (Jochner et al, 1996). Many of 
these genes are in turn involved in the immortalisation process. Furthermore, it has 
been shown that EBNA2 and EBNA-LP co-operate to induce the transition of the 
infected cells from G0 to G1 (Sinclair et al, 1994). 
1.10.1.2.3  Mechanism of promoter targeting by EB+A2  
 
Although EBNA2 does not bind to DNA directly, it achieves promoter specificity of 
interaction through contact with other sequence specific DNA binding proteins 
(Zimber-Strobl and Strobl, 2001; Young and Murray, 2003). The recruitment of 
EBNA2 to DNA can occur via interactions with the recombinant signal-binding 
protein Jκ (RBP-Jκ)/Cp Binding Factor 1 (CBF1) (Figure 1.10.2), the Ets family 
protein Spi-1/PU.1, ATF/CRE, the CREB-binding protein CBP and the SWI/SNF 
chromatin remodeling complex (Zimber-Strobl et al, 1993; Henkel et al, 1994; Laux 
et al, 1994a; Ling et al, 1994; Waltzer et al, 1994; Johannsen et al, 1995; Wu et al, 
1996; Sjoblom et al, 1998; Wang et al, 2000; Wu et al, 2000; Pegman et al, 2006). 
EBNA2 can also interact through its acidic trans-activation domain with components 
of the basal transcription machinery (BTM) including TFIIH, TFIIE, TFIIB, TAF40, 
and RPA70 to regulate promoter activity (Tong et al, 1995a; Tong et al, 1995b; Tong 
et al, 1995c). In addition to this there is also an established association of EBNA2 and 
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the DEAD-box protein, DP103, (Grundhoff et al, 1999), which has an established role 
in transcriptional repression (Yan et al, 2003). Furthermore, trans-activation is 
augmented by binding to the EBV encoded EBNA-LP protein (Harada and Kieff, 
1997; Nitsche et al, 1997; Young and Murray, 2003; Young and Rickinson, 2004). Of 
particular interest, CBF1 is ubiquitously expressed and highly conserved during 
evolution (Zimber-Strobl and Strobl, 2001).  The cognate DNA sequence element to 
which CBF1 binds is 5’-GTGGGAA-3’ (Zimber-Strobl et al, 1993). The first 
indication of this cellular protein mediating binding of EBNA2 to its response element 
was described in a study on the LMP2A promoter (Zimber-Strobl et al, 1993). 
Following this, the promoters
 
of several EBV latent genes and also several cellular 
genes were also shown to contain
 
functional CBF1-binding motifs and to be targets of 
EBNA2-CBF1 signaling including EB"A Cp, LMP1, LMP-2B, CD21, CD23, CCR7, 
FcRH5 and bfl-1 (Ling et al, 1993a; Zimber-Strobl et al, 1993; Ling et al, 1994; 
Johannsen et al, 1995; Maier et al, 2005; Mohan et al, 2006).  
1.10.1.2.4  CBF1 as a link between EB+A2 and the cellular +otch pathway 
 
CBF1 is established as a transcriptional repressor, and can mediate this effect (i) 
through directly binding with elements of the BTM, disturbing the TFIIA-TFIID 
interaction, which is a requisite for the initiation of transcription and also (ii) as a 
result of histone deacetylation, which results in chromatin remodelling and the 
consequential loss of transcription factor access to the nucleosome-associated 
promoter sequences.  The CBF1 repressor complex (Figure 1.10.2) includes the 
proteins SMRT/NcoR, HDAC1, HDAC2, SIN3-associated protein 30 (SAP30), the 
CBFI-interacting co-repressor (CIR) and SKIP (Ski interacting protein).   
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Figure 1.10.2: Model for EB+A2 Activation of CBF1 Repressed Promoters.  
 
(A) The CBF1 (RBP-Jκ above) repressor complex includes the proteins SMRT/NcoR, 
HDAC1, HDAC2, SAP30, CIR and SKIP. (B) EBNA2 abolishes CBF1 mediated 
repression by competing for the SMRT–HDAC co-repressor complex through binding 
to both CBF1 and SKIP, followed by recruitment of the BTM to activate 
transcription. From Young and Rickinson, 2004. 
 
EBNA2 trans-activates promoters by (i) binding to the repression domain of CBF1 to 
alleviate repression and (ii) by presenting a strong transcriptional activation domain to 
the promoter (Hsieh and Hayward, 1995). During EBNA2 displacement of the CBF1 
co-repressor complex, neighbouring domains make contact with CBF1 and SKIP to 
dislodge SMRT (Figure 1.10.2).  Direct competition for binding to SKIP has been 
demonstrated for SMRT and EBNA2 (Zhou et al, 2000a).  Conserved region (CR) 5 
of EBNA2 binds SKIP and conserved region 6 (CR6) binds to CBF1.  The positions 
of CR5 and CR6 on the EBNA2 protein can be seen in Figure 1.10.3 below.  A 
mutation within CR6 that abolishes EBNA2 binding to CBF1 (ww323sr) also entirely 
eliminates EBNA2-associtated trans-activation (Ling et al, 1993a; Ling and Hayward, 
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1995). In addition, when incorporated into the virus, this mutation results in a non-
immortalising EBV (Yalamanchili et al, 1994). Mutations within CR5, such as the 
II307 mutant, which are impaired for SKIP interaction, are equally detrimental to the 
trans-activating function of EBNA2 (Zhou et al, 2000a). Furthermore, the 
introduction of deletions that span CR5 into the EBV genome led to a mutant virus 
that either failed to immortalise B-cells in vitro or resulted in B-cell colonies that 
grew more slowly than the wild type virus-immortalised controls (Harada et al, 1998). 
Overall, this data indicates that EBNA2 requires interaction with both SKIP and 
CBF1 for effective activation of CBF1 responsive promoters.   
 
 
 
 
Figure 1.10.3 : The locations of the SKIP and CBF1 interaction regions on the 
EB+A2 protein.    
 
A schematic representation of the EBNA2 protein illustrating the relative locations of 
characterised functional domains and the position of the ww323sr mutation. The 
amino acid numbers are indicated. CR5, CR6 and a nuclear localisation signal (NLS) 
are also indicated. From Zhou et al, 2000a. 
 
 
The CBF1 homologue in Drosophila (suppressor of hairless, (SuH) is involved in 
signal transduction from the Notch receptor. The Notch pathway is an essential cell-
cell interaction mechanism, which controls processes such as cell proliferation, cell 
fate decisions, differentiation and stem cell maintenance (Pinnix and Herlyn, 2007).   
 
In mammals four Notch receptor-coding genes have been described (Notch1, Notch2, 
Notch3 and Notch4). "otch1 encodes an evolutionarily conserved 300kDa trans-
membrane receptor, which is translated as a full-length protein but is subsequently 
cleaved in the trans-golgi network into two subunits by furin-like convertases 
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(Blaumueller et al, 1997; Logeat et al, 1998; Pinnix and Herlyn, 2007). Following 
transport to the membrane, the subunits form the hetero-dimeric Notch receptor 
through calcium-dependent, non-covalent interactions. The Notch signaling cascade is 
instigated upon binding of membrane-bound ligand (DSL family members Jagged 1,2 
and DSL 1,3,4) to one of four hetero-dimeric trans-membrane Notch receptors 
(Notch1–4) in mammalian cells. Upon ligand binding two sequential proteolytic 
events occur to liberate active Intracellular Notch (NotchIC). The first cleavage is 
mediated by a metalloprotease, TNF-α-converting enzyme (TACE) (Brou et al, 2000; 
Hartmann et al, 2002) and the second and final cleavage is performed by a γ-secretase 
complex (Edbauer et al, 2003; Edbauer et al, 2003).  
 
NotchIC is then targeted to the nucleus by its nuclear localisation signal (NLS), where 
it binds to the CSL family of transcription factors (CBF1/RBP-Jκ, Suppressor of 
Hairless Su(H) or Lag-1) where it forms a large transcriptional activation complex 
together with the human homolog of Drosophila Mastermind MAML1 protein (Pinnix 
and Herlyn, 2007). CBF1 is a constitutive repressor of Notch target genes (Kao et al, 
1998; Taniguchi et al, 1998; Hsieh et al, 1999; Zhou et al, 2000b; Oswald et al, 
2002). Upon entering the nucleus, NotchIC displaces co-repressors and their 
associated chromatin-modifying proteins from CBF1 and forms a transcription-
activating complex (Fortini and Artavanis-Tsakonas, 1994; Tamura et al, 1995; Kato 
et al, 1997; Tani et al, 2001). NotchIC interacts via its RAM (RBPJκ-associated 
molecule) domain and ankyrin repeats with CBF1 (Jarriault et al, 1995).   
 
Several target genes have been described, which are induced through the interaction 
of NotchIC with CBF1, for example the hairy enhancer of split complex  related 
genes Hes-1 and Hes-5, Hey-1, Hey-2 and Hey-L (Jarriault et al, 1995; Nishimura et 
al, 1998; Maier and Gessler, 2000), ERBB-2 (Chen et al, 1997), "F-κB2 (Oswald et 
al, 1998) and the hairy-related transcription factor (HRT) (Nakagawa et al, 2000). In 
addition, alpha-actin, calponin, myosin, and smoothelin expression are down-
regulated by Notch-mediated CBF-1-dependent interaction in vascular smooth muscle 
cells (Morrow et al, 2005). However, regulation by Notch is context dependent.  The 
activation of NotchIC as a result of ligand binding is summarised in Figure 1.10.4. 
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Figure 1.10.4: The +otch signaling pathway.   
 
(1) Ligand on a neighbouring cell binds to the Notch receptor.  (2) The ligand-
receptor interaction results in a series of cleavages of the Notch receptor, which 
releases NotchIC.  (3) NotchIC is translocated to the nucleus, where it interacts with 
CBF1.  (5) Binding of NotchIC to CBF1 displaces the co-repressor complex, allowing 
transcriptional activation of Notch responsive genes.  (6) Expression of Notch 
responsive genes determines the fate of the cell. From Smith, 2005. 
 
1.10.1.2.5  EB+A2 and +otchIC overlap in their functions and in their target 
genes 
 
Since EBNA2 associates with the CBF1 repression complex in order to relieve 
repression and subsequently trans-activate target genes, EBNA2 can be regarded as a 
functional homologue of the activated Notch receptor (Hsieh et al, 1996 and 
Hayward, 2004). Although there is no obvious sequence homology between these two 
proteins, it is clear that both EBNA2 and NotchIC trans-activate genes by interacting 
with CBF1, thereby relieving repression by replacing the HDAC co-repressor 
complex with their trans-activation domains.   
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The mechanism of NotchIC and EBNA2 displacement of the CBF1 co-repressor 
complex appears to be identical in that in each case adjacent domains make contact 
with CBF1 and SKIP to displace SMRT (Figure 1.10.5). The RAM domain of 
NotchIC is the major contact with CBF1 (Tamura et al, 1995; Hsieh et al, 1996; 
Hsieh et al, 1997) while the ankyrin repeats bind SKIP (Zhou et al, 2000b). CR5 of 
EBNA2 binds SKIP and CR6 binds CBF1. Thus it is clear that both EBNA2 and 
NotchIC each require contacts with SKIP as well as CBF1 for effective activation of 
promoters containing CBF1-binding sites. 
 
 
Figure 1.10.5: Mechanism of +otchIC and EB+A2 displacement of the CBF1 co-
repressor complex 
Both EBNA2 and NotchIC require contacts with SKIP as well as CBF1 for effective 
modulation of promoters containing CBF1-binding sites. The RAM domain of 
NotchIC is the major contact with CBF1 while the ankyrin repeats bind SKIP. CR5 of 
EBNA2 binds SKIP and CR6 binds CBF1. Transcriptional activation of target genes 
occurs through the combination of loss of repression and the positive effects of the 
activation domain (ACT). N, amino terminus; C, carboxy terminus. From Hayward, 
2004. 
There are additional similarities between EBNA2 and NotchIC in the manner in 
which transcriptional activation through CBF1 is effected. The activation domains of 
both EBNA2 and NotchIC bind co-activating molecules that modify chromatin 
structure through histone acetylase activity and make contact with the BTM.  In this 
regard EBNA2 is known to recruit p300, PCAF and CBP (Wang et al, 2000) a co-
activator, p100 that interacts with TFIIE (Tong et al, 1995c) and the NotchIC
 
activation domain binds GCN4, PCAF and p300.  Indeed, both proteins have a co-
activator molecules in common (PCAF and p300). Further to this, EBNA2 trans-
activation is potentiated by the EBNA-LP protein (Harada and Kieff, 1997; Nitsche et 
al, 1997) and also through interactions with the SWI/SNF complex (Wu et al, 2000) 
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and the DEAD-box protein DP103 (Yan et al, 2003), while full transcriptional 
activation by NotchIC involves MAML1 (Pinnix and Herlyn, 2007). 
Responses to Notch and EBNA2 are highly concentration-dependent and negative 
regulation of the activity of the CBF1 complex occurs through modulation of CBF1 
DNA binding. During EBV infection, EBNA3A, 3B and 3C can compete with 
EBNA2 for binding to CBF1 (reviewed in Hayward, 2004) whilst NotchIC activity is 
also regulated by loss of CBF1 binding due to interference from the cellular proteins 
KyoT2 and MINT/SHARP (Hayward, 2004).   
Since both EBNA2 and NotchIC proteins share a common mechanism of regulation 
through CBF1 and SKIP, it not surprising then that they also overlap in the range of 
functional activities and in the genes that they regulate. In this regard both molecules 
have been implicated in the regulation of Hes-1, LMP2A, BATF, CD21 and IgH 
expression in B-cells (Zimber-Strobl and Strobl, 2001). Additionally EBNA2 and 
Notch-IC have been shown to protect cells from apoptosis by binding to the cellular 
"ur77 (TR3/"GF1B) transcription factor (Jehn et al, 1999; Lee et al, 2002).  In 
contrast only EBNA2, but not NotchIC, can induce LMP1, CD23 and c-myc 
(reviewed in Zimber-Strobl and Strobl, 2001).   
 
Although the role of Notch in the B-cell compartment remains to be fully elucidated, 
it has been postulated that the EBNA2 mimicry of Notch function may facilitate a 
sustained life-long EBV infection in the host (Hayward, 2004). In support of this, 
there is evidence that Notch signaling increases the formation of hematopoietic stem 
cells. EBNA2-driven B-cell proliferation may thus be recapitulating a precursor stem 
cell response. This proliferation is thought to be important in expanding the infected 
cell population after primary EBV infection to permit establishment of a life-long 
latency in the B-cell compartment. Additionally, the fact that EBNA2 is selectively 
expressed in the same compartment of the germinal centre where Notch2 expression 
is essential for B-cell development further strengthens the concept that EBV is using 
EBNA2 as a virally controlled, constitutive Notch surrogate (Hayward, 2004). 
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1.10.1.3  The EB+A3 family (EB+A3A, EB+A3B and EB+A3C) 
 
The EBNA3 family consists of 3 nuclear proteins, EBNA3A, -3B and -3C (previously 
referred to as EBNA3, EBNA4, and EBNA6 respectively). The nuclear proteins are 
encoded by alternatively spliced transcripts initiated at the Cp promoter (Kieff, 1996) 
and are composed of 944, 937 and 992 amino-acid residues, respectively (Petti et al, 
1990). While EBNA3A and -3C are essential for the growth transformation of 
lymphocytes in vitro, EBNA3B is not required for B-cell immortalisation under these 
conditions (Young and Murray, 2003).  EBNA3C can induce the up-regulation of both 
cellular and viral gene expression, and is also known to repress the Cp promoter (as 
reviewed in West, 2006). EBNA3C interacts with the retinoblastoma protein, pRb, to 
promote cell transformation (Parker et al, 1996). In addition, EBNA3A and EBNA3C 
co-operate as the main determinants of drug resistance in BL cells and in the down-
regulation of the pro-apoptotic Bcl-2-family member Bim (Anderton et al, 2007). 
EBNA3B has been shown to induce expression of vimentin and CD40 (Silins and 
Sculley, 1995).  All three EBNA3 proteins can also bind CBF1, negatively regulating 
gene expression in the Notch pathway. This results in repression of EBNA2 trans-
activation, which in turn regulates the synthesis of the EBNA3 proteins themselves 
(Robertson et al, 1995; Waltzer et al, 1995; Robertson, 1997). Thus the EBNA3 
proteins counterbalance and fine-tune the action of EBNA2, precisely regulating 
CBF1 activity, thereby regulating the expression of cellular and viral promoters 
containing CBF1 binding sites (Cludts and Farrell, 1998; Young and Rickinson, 
2004).  
 
1.10.1.4  EB+A-LP 
 
The EBNA Leader Protein (EBNA-LP/EBNA5) is one of the first viral proteins 
produced during EBV infection of B-lymphocytes (Kieff, 1996). EBNA-LP is 
encoded by the first ORF (leader sequence) of the extensively spliced primary 
transcript, originating from either the Wp or Cp promoter, and is composed a multi-
repeat domain (W1W2) and a unique carboxyl-terminal domain (Y1Y2) (Figure 
1.10.6). EBNA-LP encodes a protein of variable size (20-130kDa) depending on the 
number of BamHI W repeats contained by a particular EBV isolate.  While EBNA-LP 
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is known to localise primarily to the nucleus, the distribution of EBNA-LP within the 
nucleus is variable. During early infection in B-cells and following expression of 
EBNA-LP in type I BL cell lines (Kieff, E. and Rickinson, A.B, 2001), EBNA-LP is 
distributed throughout the nucleus (Szekely et al, 1995). Whereas in LCLs, EBNA-LP 
localises to promyelocytic leukemia nuclear bodies (PML NBs) (Szekely et al, 1995; 
Szekely et al, 1996). Although not essential for transformation, EBNA-LP enhances 
the efficiency of the process (Hammerschmidt and Sugden, 1989).  
 
EBNA-LP is known principally as a transcriptional co-activator of EBNA2. It has 
previously been shown that EBNA-LP co-operates with EBNA2 in the up-regulation 
of LMP1/LMP2 and EBV BamHI C latency promoters in B-cells (Harada and Kieff, 
1997; Nitsche et al, 1997; Peng et al, 2005) and that EBNA-LP and EBNA2 co-
operative to stimulate expression of cyclin D2 in resting B-cells in addition to 
mediating G0 to G1 transition during immortalisation (Sinclair et al, 1994). 
Furthermore, studies in the laboratory indicate that co-transfection of EBNA-LP also 
considerably potentiates EBNA2 trans-activation of the bfl-1 promoter (Pegman, P.M. 
unpublished data). 
 
 
Figure 1.10.6: Detailed representation of how EB+A2 and EB+A-LP mR+As 
are generated from a unique R+A precursor by facultative 
splicing.  
 
Boxes represent exon sequences and broken lines represent intron sequences. The 
exons coding for EBNA2 or EBNA-LP respectively, are indicated by the grey boxes. 
The EBNA-LP protein AUG is created following the use of an alternative acceptor 
splice site, five bases into the W1 exon. This alternate splice provides the G of the 
EBNA-LP initiation codon. In latency III, only the Cp promoter is active (From 
Manet et al, 1998). 
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EBNA-LP co-activates EBNA2 through interacting with the promyelocytic leukemia 
nuclear body (PML NB)-associated protein Sp100 and displacing Sp100 and 
heterochromatin protein 1 α (HP1α) from PML NBs (Ling et al, 2005). Numerous 
other potential co-factors that mediate EBNA-LP activity have been identified 
including pRb, p53, hsp72/hsc73, hsp27, Hax-1, ERR1, p14ARF, DNA-Pkcs, α-
tubulin, β-tubulin, prolyl-4-hydroxylase, and HA95 (Ling et al, 2005 and the 
references therein). However, to date, no correlation has been made between the 
association with these factors and their ability to co-operate with EBNA2.  
 
1.10.2  The EBV-encoded latent membrane proteins 
 
1.10.2.1  LMP1 
 
Latent Membrane Protein 1 (LMP1) is a major transforming protein of EBV. Several 
studies have shown that this protein functions as a classic oncogene and is essential 
for EBV-induced B-cell transformation in vitro (reviewed in Li and Chang, 2003; 
Young and Rickinson, 2004). LMP1 has pleiotropic effects when it is expressed in 
BL-derived cells, resulting in many of the phenotypic changes observed during EBV-
infection, including induction of cell adhesion molecules and activation markers 
(Kieff, E. and Rickinson, A.B, 2001), and the up-regulation of anti-apoptotic proteins 
Bcl-2, Mcl-1, Bfl-1, A20 and c-IAPs (Henderson et al, 1991; Laherty et al, 1992; 
Fries et al, 1996; Wang et al, 1996; D'Souza et al, 2000; Hong et al, 2000). This 
63kDa integral membrane phosphoprotein functions as a constitutively activated 
receptor (Gires et al, 1997; Li and Chang, 2003) and is a member of the tumour 
necrosis factor receptor (TNFR) superfamily, activating several signaling pathways in 
a ligand-independent manner (as reviewed in Young and Rickinson, 2004). 
Functionally, LMP1 mimics the cellular growth signal that normally results from the 
binding of CD40 ligand (another member of the TNFR superfamily) (Thompson and 
Kurzrock, 2004) and can partially substitute for CD40 in vivo, providing both growth 
and differentiation signals to B-cells (Uchida et al, 1999).  
 
The LMP1 protein can be divided into three domains (Figure 1.10.7).  Firstly, an 
amino-terminal cytoplasmic tail (amino acids 1-23), which tethers LMP1 to the 
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plasma membrane and orientates the protein.  Secondly, a trans-membrane region, 
consisting of six hydrophobic trans-membrane loops, which are involved in self-
aggregation and oligomerisation (amino acids 24-186).  Third, a long carboxy-
terminal cytoplasmic region (amino acids 187-386), which possesses most of the 
signaling activity of the molecule (Young and Rickinson, 2004).  LMP1 signals 
mainly from the intracellular compartments (Lam and Sugden, 2003). Both 
oligomerisation and localisation within glycosphingolipid-rich membrane rafts are 
essential for the initiation of signaling (Clausse et al, 1997; Eliopoulos and Young, 
2001; Higuchi et al, 2001) which results in the activation of several signaling 
pathways that contribute to the many phenotypic consequences of LMP1 expression. 
At least four signaling pathways have been implicated in the function of LMP1, 
namely nuclear factor κB (NF-κB), c-Jun NH2 terminal kinase (JNK), p38/mitogen 
activated protein kinase (p38/MAPK) and janus kinase/signal transducers and 
activators of transcription (JAK/STAT) (Murray and Young, 2001).  It is the 
cytoplasmic C-terminus of LMP1 that is responsible for the transduction of signaling 
cascades that result in primary B-cell transformation and phenotypic changes.  Within 
the C-terminus of LMP1 there are at least two major activating domains (Figure 
1.10.7), C-terminal activating region 1 (CTAR1) and CTAR2 (Young and Rickinson, 
2004).  CTAR1 (also known as transformation effector site 1, TES1) is located 
proximal to the membrane (amino acids 186-231), binds TNFR-associated factors 
(TRAFs) (Huen et al, 1995; Devergne et al, 1996), and is essential for EBV-mediated 
B-cell immortalisation (Kaye et al, 1993; Izumi and Kieff, 1997).  CTAR2/TES2, 
which is located near the C-terminus (amino acids 351-386), supports the long-term 
growth of immortalised B-cells (Izumi and Kieff, 1997) and recruits the TNFR-
associated death domain (TRADD) protein and receptor-interacting protein (RIP) 
(Huen et al, 1995; Eliopoulos et al, 1999a).  The activities of CTAR1 and CTAR2 
affect diverse signaling cascades and provide the basis for the molecular explanation 
of the transforming properties of LMP1. A diagram illustrating the structure and 
function of LMP1 is shown in Figure 1.10.7. 
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Figure 1.10.7: Structure and Function of LMP1.  
 
The C-terminus of LMP1 contains two activating regions, the C-terminus activation 
regions 1 and 2 (CTAR1 and CTAR2).  CTAR1, is essential for EBV-mediated B-cell 
immortalisation, and binds TRAF1, TRAF2, TRAF3 and TRAF5 activating the NF-
κB and p38 signaling pathways. CTAR2 supports the long-term growth of 
immortalised B-cells and recruits TRADD to activated downstream signals, such as 
NF-κB, JNK, and p38.  Both of the C-terminal domains also mediate the activation of 
the JAK/STAT pathway (From Eliopoulos and Young, 2001). 
 
1.10.2.2  LMP2A and LMP2B 
 
Transcription of LMP2 is regulated by two separate promoters 3kb apart in the viral 
DNA (Sample et al, 1989). Two mRNAs that have unique
 
5' exons followed by eight 
common exons encode two distinct
 
proteins of 2.0 and 1.7kb in length, namely 
LMP2A and LMP2B, respectively (Laux et al, 1989; Sample et al, 1989). Thus the 
structures of LMP2A and LMP2B are similar; LMP2A contains an N-terminal
 
cytoplasmic domain of 119 amino acids with eight tyrosines that
 
are phosphorylated 
in LCLs, 12 trans-membrane domains, and a
 
C-terminal domain of 12 amino acids. 
LMP2B, however, lacks the entire N-terminal cytoplasmic
 
domain (Kieff, 1996 and 
Young and Rickinson, 2004).   
 
LMP2A is known to block BCR signal transduction through specific phosphotyrosine 
motifs
 
in its N-terminal domain, prohibit induction of lytic EBV infection and 
promote B-cell survival (Longnecker et al, 1991; Miller et al, 1994; Fruehling et al, 
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1996; Fruehling and Longnecker, 1997; Babcock and Thorley-Lawson, 2000a; 
Babcock et al, 2000b; Swart et al, 2000). Neither LMP2A nor LMP2B are essential 
for EBV-induced B-cell transformation in vitro (Longnecker, 2000). While most of 
the research to date has focused upon LMP2A, LMP2B has been shown to colocalise
 
with LMP2A in the membrane where the C terminus of both splice
 
variants can 
interact and regulate the activity of one another
 
(Lynch et al, 2002). LMP2B was 
shown to negatively regulate LMP2A
 
activity by interfering with its aggregation 
(Rovedo and Longnecker, 2007). Furthermore, LMP2B has recently been found to 
regulate susceptibility to induction of lytic EBV infection (Rechsteiner et al, 2008). 
Taken together, these data support a role for LMP2A in modifying the normal 
programme of B-cell development to favour the maintenance of EBV latency and to 
prevent inappropriate activation of the EBV lytic cycle. It is also evident that
 
LMP2B 
is involved in the regulation of switching from latent
 
to lytic EBV in B-cells 
harbouring functional EBV through impacting the activity of LMP2A (Rechsteiner et 
al, 2008). 
1.10.3  Other EBV latent transcripts 
 
1.10.3.1  EBER1 and EBER2 
 
EBV encodes two small non-polyadenylated RNAs termed Epstein-Barr virus-
encoded RNAs 1 and 2 (EBER 1 and EBER 2), the most abundant viral transcripts in 
latently EBV infected cells with the exception of oral hairy leukoplakia lesions from 
AIDS patients and some hepatocellular carcinomas (Sugawara et al, 1999). In 
addition to the latent proteins, EBER1 and EBER2 are expressed in all forms of 
latency. EBERs 1 and 2 are uncapped, non-coding RNAs of 167 and 172 nucleotides 
respectively (Thompson and Kurzrock, 2004). The EBERs are not essential for the 
EBV-induced transformation of primary B lymphocytes, since recombinant EBV 
harouring EBER gene deletions can transform lymphocytes (Swaminathan et al, 
1991). Expression of the EBERs in BL cell lines has been found to increase 
tumourigenicity, promote cell survival and induce IL-10 expression (Kitagawa et al, 
2000; Ruf et al, 2000; Nanbo and Takada, 2002) and it has been suggested that 
EBER-mediated inhibition of PKR (a latent, IFN-inducible Ser/Thr kinase) function 
might be important for viral persistence (Nanbo and Takada, 2002). Furthermore, 
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transfection of the EBER genes into the EBV-negative AKATA cell line restored the 
oncogenic potential that was originally present in the EBV-positive AKATA cells but 
was lost in the EBV-negative subclones (Komano et al, 1999).  
 
1.10.3.2  BARTs/ CSTs 
 
The EBV Bam HI A rightward transcripts (BARTs) or complementary-strand 
transcripts (CSTs) (Karran et al, 1992; Smith et al, 2000) are a group of abundantly 
expressed RNAs that are encoded by the Bam HI A region of the EBV genome and 
were originally identified in NPC tumour tissues (Hitt et al, 1989), but were 
subsequently found to be expressed in other EBV-associated malignancies, such as 
BL, HL and nasal T-cell lymphoma, as well as in the peripheral blood of healthy 
individuals (Young and Rickinson, 2004). The protein products of these highly 
spliced transcripts remain to be conclusively identified. Another transcript that is 
generated from the Bam HI A region is BARF1, which encodes a 31 kDa protein that 
was originally identified as an early antigen expressed on induction of the EBV lytic 
cycle (Young and Rickinson, 2004). The BARTs are often expressed in circumstances 
in which the EBNA2 and EBNA3 proteins are not synthesised, such as epithelial cell 
infection and in EBV-associated malignancies in immuno-competent individuals 
(Hayward, 2004).  
1.10.3.3 EBV microR+As (miR+As) 
 
EBV also encodes at least 22 miRNAs arranged within three clusters (Pfeffer et al, 
2004; Cai et al, 2006; Grundhoff et al, 2006). A total of 14 of these miRNAs are 
located within
 
the region deleted in the B95-8 strain of EBV and accordingly this 
transformation competent strain is known to encode
 
only eight miRNA genes [miR-
BHRF1-1-, -2, -3, miR-BART-1, -2,
 
-3, -4 and the partially deleted miR-BART5] 
(Barth et al, 2008). The coding potential of the majority of these transcripts is 
unknown and
 
indeed, their potential to serve as pri-miRNAs remains uncertain 
(Grundhoff et al, 2006). It has however been established that the mature EBV-
encoded miR-BHRF1-1 and
 
-2 are down-regulated upon TPA induction of the two 
EBV-infected
 
BL cell lines Daudi and Mutu I (Cai et al, 2006). In addition, miR-
BART2
 
associates with Ago2 directing the sequence-specific cleavage
 
of the BALF5 
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mRNA. Upon induction of the lytic cycle, miR-BART2
 
expression is down-regulated 
which results in reduced cleavage of
 
BALF5 mRNA (Barth et al, 2008). Recent 
reports have also identified EBV BHRF1-3 miRNA and findings indicated that 
changes
 
in BHRF1-3 miRNA levels in a pair of isogenic type I/III BL
 
cell lines were 
inversely correlated with CXCL-11/I-TAC levels.
 
Furthermore, antisense delivery of 
the BHRF1-3 miRNA could relieve
 
BHRF1-3 miRNA repression of CXCL-11/I-TAC 
(Xia et al, 2008). It has been broadly speculated
 
that the viral miRNAs function to 
establish and maintain latency (Barth et al, 2008). In keeping with this induction of 
lytic EBV replication was found to enhance the expression of many, although not all, 
of the EBV miRNAs. Indeed the BART miRNAs are highly expressed in latently 
infected epithelial cells and at lower levels in B-cells. In contrast to this, the BHRF1 
miRNAs are found at high levels in B-cells undergoing stage III latency but are 
undetectable in B-cells or epithelial cells in stage I or II latency (Cai et al, 2006).  
 
1.11 EBV Latency Programmes. 
 
Phenotypically distinct human B-cell lines and EBV tumour carrying biopsies display 
three transcriptionally distinct forms of EBV latency frequently described as latency I, 
II and III (Young et al, 2000). The different types of EBV latency are summarised in 
Table 1.11-1. These modes of viral latency were suggested on the basis of differential 
expression of viral latent genes and promoter usage in EBV associated tumours and 
immortalised B-cell lines (Kerr et al, 1992).  
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Table 1.11-1: Distinct latency programs of the EBV virus 
 
Type of Latency Viral Genes Expressed Associated Malignancies 
Type I  EBNA1, EBERs, 
BARTs 
Burkitts Lymphoma, 
Gastric Carcinoma 
Type II EBNA1, EBERs, 
BARTs, , BARF0 
LMP1,LMP2A, LMP2B 
 
Hodgkins Disease, 
Nasopharyngeal 
Carcinoma, Peripheral 
T/NK lymphoma 
Type III All EBV Latent Genes AIDS-associated 
lymphomas 
PTLD*,  
IM* 
Other EBNA1, 2, LMP1 T-cell Lymphomas 
Other EBERs, EBNA1,2 Smooth Muscle tumors 
Other EBNA1, 2, LP, LMP1 OHL* 
 
 
*PTLD-Post Transplant Lymphoproliferative Disorder, IM- Infectious 
mononucleosis, OHL- Oral Hairy Leukoplakia. Adapted from Young et al, 2000. 
 
 
Specifically in EBV-positive BL latency programme I, the EBNA1-only programme 
is expressed, permitting only the synthesis of EBNA1 transcripts clustered around one 
other open reading frame; BARF-0, as well as large copy numbers of EBER1 and 
EBER2 (Young et al, 2000). In most other EBV-containing malignant tumours (NPC, 
EBV-positive HL and gastric cancers), latency programme II is expressed. In these 
cells both LMP1 and LMP2A/B are expressed in addition to EBNA1 and the EBER 
RNAs (Young et al, 2000). Finally, latency programme III is observed in EBV-
induced lymphoblastoid proliferation and in EBV-positive B-cell lymphomas arising 
under conditions of immuno-suppression and in some B-cell blasts in patients with IM 
(Kerr et al, 1992; Young et al, 2000). Latency III (also known as the growth 
programme) is designed to drive the limited proliferation of B-cells prior to 
differentiation and the establishment of persistent infection in memory B-cells. EBV 
preferentially infects B lymphocytes and possesses the unique ability to transform 
resting B-cells into permanent, latently infected LCLs in vitro (Young and Rickinson, 
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2004). B-cell transformation by EBV, resulting in the establishment of LCLs, 
therefore remains the dominant in vitro model of infection (Young and Rickinson, 
2004). In EBV-transformed LCLs, every cell carries multiple extra-chromosomal 
copies of the viral episome and is driven to proliferate by the EBV growth programme 
(Lat III) In addition LCLs display transcripts from the Bam HI A region of the viral 
genome (BART transcripts) and abundant expression of EBER1 and EBER2. (Murray 
and Young, 2001).  
 
EBV-infected LCLs show high levels of expression of the B-cell activation markers 
CD23, CD30, CD39 and CD70, and of the cell adhesion molecules lymphocyte-
function-associated antigen 1 (LFA1; also known as CD11a/18), LFA3 (also known 
as CD58) and intercellular cell adhesion molecule 1 (ICAM1; also known as CD54) 
(Young and Rickinson, 2004).  These markers are usually absent or expressed at low 
levels on resting B-cells, but are transiently induced to high levels when these cells 
are activated into short term growth by antigenic or mitogenic stimulation, indicating 
that EBV-induced immortalisation can be elicited through the constitutive activation 
of the same cellular pathways that drive physiological B-cell proliferation (Young and 
Rickinson, 2004).  The ability of EBNA2, EBNA3C and LMP1 to induce LCL-like 
phenotypic changes when expressed individually in human B-cell lines indicates that 
these viral proteins are key effectors of the immortalisation process (Wang et al, 
1990).  The role of EBV latent genes in the in vitro transformation of B-cells has been 
confirmed by the generation of recombinant forms of EBV that lack individual latent 
genes.  Studies using such viruses have confirmed the absolute requirement for 
EBNA2 and LMP1 in the transformation process, and have also highlighted a crucial 
role for EBNA1, EBNA-LP, EBNA3A and EBNA3C (Kieff, E. and Rickinson, A.B, 
2001). 
 
Other less well-characterised patterns of EBV gene expression have been identified in 
further EBV associated diseases. For example it had been proposed that EBV may be 
associated with some breast and hepatic cancers where EBNA1 but not EBER 
expression has been observed; however other studies indicate that breast and hepatic 
cancers are not EBV associated diseases (reviewed by Herrmann and Niedobitek, 
2003).  
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1.12  EBV-mediated regulation of cell growth and survival 
 
Suppression of the cellular apoptotic program by EBV is central to both the 
establishment of latent infection and the development of EBV-associated 
malignancies. When EBV infects resting B lymphocytes it primarily encounters 
resting B-cells in the oropharyngeal mucosal lymphoid tissue (Young and Rickinson, 
2004). It drives the infected cells into cycle and maintains cell division, increasing the 
population of infected cells and allowing them to progress, via the B-cell maturation 
pathways, to the site of latent persistence of the virus, in resting memory B-cells 
(Young and Rickinson, 2004). The complex mechanisms by which EBV affects cell 
growth and can prevent cell death are a result of a combination of EBV-induced 
pathways that affect both cell growth and apoptosis, and the co-operative roles of the 
latent genes, especially EBNA2, EBNA3C and LMP1 in these processes has long 
been established (Wang et al, 1990). 
 
1.12.1 EBV affects Cell Cycle Progression 
 
 
Cells typically progress through the cell cycle in a orderly fashion through a growth 
phase (G0/G1) to a synthetic phase in which the DNA is copied (S), to a second 
growth phase (G2) prior to cell division or mitosis (M) and back to a quiescent cell 
arrest phase (G0/G1) following cell division (Flaitz and Hicks, 1998) (Figure 1.12.1). 
This cell cycle is designed to have several checkpoints to assess cells harbouring 
damaged or mutated DNA, which if not repaired or eliminated from the cell pool 
could potentially result in the development of a malignancy (Park and Lee, 2003). 
Progression through the cell cycle is regulated by many different proteins, such as 
tumour suppressor gene products, p53 and pRb (retinoblastoma gene product), which 
act within the cell cycle facilitating the repair of damaged or mutated DNA within 
single cells, or alternatively, induce these injured cells to undergo apoptosis (Flaitz 
and Hicks, 1998; Park and Lee, 2003). EBV exploits normal cellular pathways to 
regulate cell cycle progression. Indeed EBV genes can manipulate the proliferation 
machinery of the infected cell through the deregulation of the function of several 
oncogenes and tumour suppressor genes implicated in the cell cycle such as c-myc, 
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p53 and pRb, thus inhibiting the ability of these proteins to redirect cells with 
damaged or mutated DNA toward a DNA repair pathway or apoptosis. As a 
consequence, host cells with latent viral infection are allowed to proliferate without 
regulation. Although rare events, these virally-infected cells may then develop 
mutations induced by ‘DNA-damaging’ events, including tobacco, alcohol, 
carcinogens, toxins, ionizing radiation, prolonged ultraviolet light/sun exposure, 
chemical insult, or even other viral infections which may result in the development of 
a malignant tumour (Flaitz and Hicks, 1998).  
 
 
Figure 1.12.1: Phases of lymphocyte cell cycle  
 
The cell cycle is regulated in four distinct phases; G1, S-phase, G2 and M-phase.  The 
first biochemical event observed, in early G1 phase, is the induction of the D-type 
cyclins and their partners, cyclin dependent kinases (cdks), cdk4 and cdk6.  One of 
either cdk4 or cdk6 partners a D- type cyclin, in the absence of cyclin dependent 
kinase inhibitors (CDKIs), to become catalytically active.  The induction of D-type 
cyclins is paralleled by a loss in CDKIs.  The most important substrate of the cyclin 
D/cdk4/6 complex is the family of pocket proteins, including pRb, p130 and p107.  
These proteins repress the E2F family of transcription factors, and the E2F-pocket 
protein complexes act as gene suppressors.  Phosphorylation of pRb by the cyclin 
D/cdc4/6 complex results in the release of E2F transcription factors and transcription 
of E2F-responsive genes.  In many systems, the induction of E2F transcriptional 
activity results in entry into the cell cycle (From Brennan, 2001). 
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1.12.2  Interactions of EBV proteins with the cell cycle 
 
Cyclin D2 is probably the first cell cycle protein to be induced following EBV 
infection of B-cells (Spender et al, 1999) and it is accompanied by a loss of the CDKI 
p27kip1.  Phosphorylation of the pocket protein pRb is observed approximately 6 
hours later.  All these events correspond to those seen during normal B-cell 
proliferation, thus implying that EBV exploits normal cell pathways to regulate pRb 
phosphorylation during the cell cycle (Kempkes et al, 1995a; Cannell et al, 1996).   
 
1.12.2.1  pRb 
 
Retinoblastoma protein (pRb) is a central regulator of cellular proliferation, 
controlling entry into G1/S in the cell cycle, mainly through its interaction with the 
cellular transcription factor E2F, which activates genes important in DNA synthesis 
(Leiderman et al, 2007). EBV has been shown to regulate pRb-modulated
 
pathways 
and to drive cells through the G1/S restriction point (Cannell et al, 1996) (Figure 
1.12.1). Through the up-regulation of cyclins involved in the inactivation of pRb, such 
as cyclin D2 and cyclin A, or by directly inactivating pRb itself, EBV liberates the 
E2F transcription factors to drive potentially infected cells through the cell cycle. In 
this regard, it has been shown that EBNA2 and EBNA-LP are sufficient to activate 
the expression of cyclin D2 during immortalisation of resting human B lymphocytes 
(Sinclair et al, 1994) and LMP1 is also thought to regulate D2 (Arvanitakis et al, 
1995). Moreover, the c-myc oncogene, a direct target of EBNA2 (Kaiser et al, 1999; 
Spender et al, 2001) has also been shown to trans-activate the D2 promoter 
(Bouchard et al, 1999). EBV may also repress cyclin dependent kinase inhibitors in 
order to facilitate the inactivation of pRB. The induction of cyclin D2 is paralleled by 
the loss of the CDKI p27kip1 in response to EBV (Slingerland and Pagano, 2000; 
Spender et al, 2001) and EBNA3C has been shown to play a role in the regulation of 
p27kip1 (Parker et al, 2000).  Since cyclin D2 and p27kip1 together regulate the 
cyclin dependent kinases, cdk4 and cdk6 activity, the link between EBNA3C and 
p27kip1 suggests that EBNA3C along with EBNA2, EBNA-LP and LMP1 is 
implicated in the progression through the G1 phase of the cell cycle (Brennan, 2001).  
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Cyclin A, an activator of S phase progression, has been shown to interact with the 
carboxy
 
terminus of EBNA3C in vitro. EBNA3C stimulated cyclin A-dependent 
kinase
 
activity and rescued p27-mediated inhibition of cyclin A/Cdk2
 
kinase activity 
by decreasing the molecular association between
 
cyclin A and p27 in cells (Knight 
and Robertson, 2004). In addition, EBNA3C can target
 
the SCF
Skp2
 complex, thereby 
regulating the activity and stability
 
of cyclin A/cdk2 and pRb complexes (Knight and 
Robertson, 2004; Knight et al, 2004; Knight et al, 2005a; Knight et al, 2005b). 
 
1.12.2.2  p53  
 
The p53 pathway is targeted for inactivation in most human cancers either directly or 
indirectly, highlighting its critical function as a tumour suppressor gene. p53 is 
normally activated by cellular stress and mediates a growth-suppressive response that 
involves cell cycle arrest and apoptosis (Kuribayashi and El-Deiry, 2008). Elevated 
incidences of p53 mutation have been identified in BL tumour biopsies and BL cell 
lines (Farrell et al, 1991). In addition BL cells with p53 mutations have been shown to 
be relatively resistant to DNA-damaging drugs such as cisplatin compared to those 
cell lines harboring wild-type p53 (Allday et al, 1995). EBV LMP1 can protect 
against wild-type p53 mediated apoptosis (Okan et al, 1995; Fries et al, 1996). 
Moreover, LMP1 regulates p53 both at transcriptional and translational level (Li et al, 
2007; Li et al, 2008). In addition, BZLF1 has been shown to interact with p53 and 
inhibit its trans-activating function in lymphoid cells (Cayrol and Flemington, 1996) 
and EBNA-LP can also interact with p53 in vitro, although the functional significance 
of this interaction has not yet been determined (Szekely et al, 1993). 
 
1.12.2.3  c-Myc  
  
c-Myc, a helix-loop-helix leucine zipper transcription factor, is known to be involved 
in numerous cellular functions such as cell proliferation, apoptosis, metabolism, 
adhesion, and differentiation in a variety of different cell types. Myc promotes 
proliferation and growth through both the induction of genes involved in cell cycle 
control (including CDK4, CDC25A, cyclin D1, D2, A, and E), and through the 
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suppression of growth-arresting genes (such as GADD45,p15I"K4b, p21CIP1, 
p27KIP1, GAS1) (Rui and Goodnow, 2006). The C-terminal basic helix–loop–helix
 
zipper domain facilitates binding to DNA sequences with the
 
core consensus sequence 
5’-CACGTG’3’ known as an "E-box",
 
and requires the association
 
of its hetero-
dimeric partner, Max (Brady et al, 2007). Myc also possesses an N-terminal
 
trans-
activation domain through which it drives the expression
 
of a multitude of target 
genes (Brady et al, 2007). To date, there are approaching 1,700 genes which have 
been identified as Myc-responsive genes (www.myccancergene.org). However, only a 
minority of the Myc-responsive genes have been implicated as direct target genes 
(Zeller et al, 2006). c-Myc expression is required to drive cells through the G1 into the 
S phase of the cell cycle (Figure 1.12.1). A model explaining the role of c-Myc in the 
apparently diverse roles of apoptosis and proliferation, predicts that c-Myc expression 
preferentially results in proliferation under favorable growth conditions with this 
activity being dependent on its apoptosis-promoting activity being blocked (Evan et 
al, 1994; Jamerson et al, 2000).  
 
Myc over-expression has been observed in tumour cells from 91% of BL cases. 
Indeed, chromosomal translocations of c-myc into the Ig loci is observed in practically 
all BLs, and the most frequent translocation, the c-myc/IgH t(8; 14), accounts for 
approximately 80% of these. The remaining 20% of
 
cases are split between the 
translocations with the IgK and
 
IgL (t(2;8) and t(8;22) respectively). The c-myc gene 
becomes transcriptionally activated as a consequence of the chromosomal 
translocation and is sustained by up-stream c-myc regulators such as NF-κB or Bcl-6 
(Rui and Goodnow, 2006). Thus under certain circumstances, Myc deregulation is 
regarded as priming normal proliferating cells for apoptosis.  
 
  
It is clear that c-Myc expression is deregulated in EBV-immortalised (non-tumour-
derived) B-cells (Cherney et al, 1994). Studies using an LCL in which the function of 
EBNA2 is dependent on the presence of estrogen have revealed that EBNA2 is the 
EBV protein predominantly responsible for driving c-Myc in LCLs (Kempkes et al, 
1995a) and that c-Myc is a direct target gene of EBNA2 in this context (Kaiser et al, 
1999; Moore et al, 2001). Myc is also induced to moderate levels by LMP1 (Schlee et 
al, 2004). In addition EBNA3C has been shown to stabilise c-Myc expression, and 
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this recruitment of both c-Myc together with its cofactor Skp2 to c-Myc-dependent 
promoters can enhance c-Myc-dependent transcription (Bajaj et al, 2008). 
 
1.12.3  Cytokines activated during EBV-mediated immortalisation 
 
Following B lymphocyte activation, EBV also induces the synthesis of several 
cytokines including TNF, IL-1, IL-6 and IL-10. IL-6 and IL-10 both play a significant 
role in the growth of EBV-transformed cells (Beatty et al, 1997; Kitagawa et al, 2000; 
Haddad et al, 2001). LMP1 has been implicated in the regulation of both these 
cytokines via NF-κB and the p38 stress activated protein kinase (Nakagomi et al, 
1994; Eliopoulos et al, 1997; Eliopoulos et al, 1999b; Vockerodt et al, 2001).  Further 
studies indicate that IL-10 may also be regulated by the EBERs (Kitagawa et al, 
2000). The receptor molecules that IL-6 and IL-10 use to mediate their activities both 
activate the JAK family of tyrosine kinases, and downstream signaling cascades 
including STAT proteins and the PI3K pathway (Brennan, 2001). Significantly, IL-10 
has been shown to act as a co-factor for B-cell growth (Moore et al., 2001), and it has 
been demonstrated that PI3K is important for IL-10-mediated cell growth of both 
primary monocytes and a murine mast cell line (Crawley et al, 1996). Interestingly, 
EBV vIL-10 enhances the growth transformation of a B-cell infected with EBV 
(Stuart et al, 1995) and both human and EBV-encoded IL-10 can induce LMP1 in the 
absence of EBNA2 in the Daudi, P3HR1, and other BL cell lines. Furthermore, 
exposure of the KMH2-EBV cells to CD40-ligand and IL-4 induced LMP1 
expression, in the absence of EBNA2 and IL-10 could induce the expression of LMP1 
in tonsillar B-cells infected with the non-transforming, EBNA2-deficient EBV strain 
P3HR1 and enhance LMP1 expression in two EBV-positive NK lymphoma lines 
suggesting that IL-10 might contribute to the establishment of type II EBV latency 
(Kis et al, 2006). 
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1.12.4  Signaling Molecules involved in EBV-mediated immortalisation 
 
Constitutively active signaling pathways are a common feature of many malignant 
cells.  Thus, it is important to characterise the potential role of signaling molecules 
that are activated by EBV-induced cytokines and by the EBV genes themselves.  The 
pathways activated by IL-6 and IL-10 (JAK family of tyrosine kinases, PI3K and 
STATs) have previously been implicated in lymphocyte growth and transformation 
(Brennan et al, 1997; Bowman et al, 2000; Imada and Leonard, 2000; Ihle, 2001). 
The STAT family of transcription factors are one substrate of the JAK family of 
tyrosine kinases.  STATs have been shown to be active in EBV-immortalised cells 
(Weber-Nordt et al, 1996) and are thought to play a role in oncogenesis (Bowman et 
al, 2000).  It has also been reported that LMP1 can activate JAK3 and STAT1 (Gires 
et al, 1999) and a STAT reporter that is known to bind STAT1, STAT3 and STAT5 
(Brennan, 2001).   
 
PI3K, a lipid kinase that is involved in lymphocyte survival (Pogue et al, 2000; Carey 
and Scott, 2001) and proliferation (Brennan et al, 1997; Craddock et al, 1999), can be 
activated by oncogenic Ras (Vanhaesebroeck and Alessi, 2000). Reports indicate that 
pathways downstream of the small G protein Ras are active in EBV-immortalised 
cells (Roberts and Cooper, 1998) and significantly inhibition of PI3K using a 
chemical inhibitor, inhibits the proliferation of EBV-immortalised cells (Brennan, 
2001). Interestingly, LMP2 was found to activate a PI3K-mediated pathway, Akt 
(Scholle et al, 2000; Swart et al, 2000).  Furthermore, PI3K has also been shown to 
affect D-type cyclin expression in EBV-immortalised B-cells (Brennan, 2001), 
suggesting a mechanism for its role in EBV-induced lymphocyte growth.   
 
1.12.5 EBV and the Six Hallmarks of Cancer 
 
The basis for the development of cancerous cells has been explained by the 
philosophy that cancer cells harbour defects in regulatory pathways that control 
normal cellular proliferation and homeostasis. It has been suggested that the vast 
majority of cancer cell genotypes are due to the manifestation of six essential 
alterations in cell physiology that together dictate malignant growth. These are: (1) 
self-sufficiency in growth signals, (2) insensitivity to growth-inhibitory signals, (3) 
 46 
evasion of apoptosis, (4) limitless replicative potential, (5) sustained angiogenesis, 
and (6) tissue invasion and metastasis (as reviewed in Hanahan and Weinberg, 2000). 
These six capabilities are thought to be a common factor in all types of human 
tumours (Hanahan and Weinberg, 2000). Each of these physiologic changes is 
represented during tumour development attributed to EBV infection. EBV-infected 
cells generate many of their own growth signals, including among others, the virally 
encoded protein LMP1 (Section 1.10.2.1) which is required to drive cells into S phase 
and through the cell cycle, thereby reducing dependence on stimulation from their 
normal tissue microenvironment (1). In addition EBV encodes many viral proteins, 
which target crucial cell cycle regulatory proteins and has been shown to regulate 
pRb-modulated pathways (through which all anti-proliferative signals are funnelled) 
driving cells through the G1/S restriction point, (see Section 1.12.2.1) (2). EBV is 
known to evade apoptosis through the activation of NF-κB, Bcl-2 family members, 
A20 and Akt activity (Hayward, 2004) (3) and is known to immortalise B-cells in 
culture to generate continually proliferating B lymphoblastoid cell lines (Hayward, 
2004) (4). It has also been shown that lytically infected cells may contribute to the 
growth of EBV-associated malignancies by enhancing angiogenesis (Hong et al, 
2005) (5). Finally, the down-regulation of the adhesion protein E-cadherin in EBV-
infected NPC has recently been identified (Krishna et al, 2005). E-cadherin acts as an 
invasion/metastasis-suppressor gene and loss of E-cadherin function has been shown 
to potentiate tumour cell invasion (6).  
1.12.6  Apoptosis 
 
Apoptosis is a genetically controlled pre-programmed cellular suicide, in which 
individual cells are destroyed while the integrity of the surrounding tissue is 
preserved.  While this targeted cell destruction is essential in many physiological 
contexts including embryogenesis, immune cell maturation and response, tissue 
homeostastis and in the cellular response to injury, it also functions as an emergency 
response to aberrant growth induced by the activation of oncogenes and viral infection 
and its deregulation is implicated in many pathological states. The process involves 
dramatic morphological changes including cell shrinkage, nuclear re-organisation, 
plasma membrane blebbing and eventual fragmentation of the cell into membrane 
bound apoptotic bodies (Saraste and Pulkki, 2000; Olson and Kornbluth, 2001).  The 
 47 
induction of early cell death in response to viral infection would limit virus 
production and consequently diminish or eliminate spread of virus progeny in a 
population (Shen and Shenk, 1995). Thus, in order to maximise their replicative 
capacity many viruses deregulate the normal cell cycle and secure selective advantage 
and biological success by developing mechanisms which suppress either the triggers 
of apoptosis or indeed the programme itself. EBV is one such virus (Shen and Shenk, 
1995). By preventing infected lymphocytes from undergoing apoptosis, EBV ensures 
survival/persistence in the host system. 
Apoptosis is orchestrated by a family of cysteine proteases known as the caspases. 
These molecules are activated upon receipt of divergent pro-apoptotic
 
stimuli and play 
an essential role in the implementation of apoptosis co-ordinating the efficient 
dismantling and engulfment of targeted cells (Cryns and Yuan, 1998; Saraste and 
Pulkki, 2000). Caspases
 
are synthesised as relatively inactive precursors that
 
require 
proteolytic processing in order to achieve activation (Thornberry and Lazebnik, 1998; 
Saraste and Pulkki, 2000).  The family is generally divided into two distinct groups; 
initiator caspases at the apex of the cascade, which are activated first by the action of 
caspase adaptor molecules, such as Fas-associated
 
protein with death domain (FADD) 
or apoptotic protease-activating factor-1 (Apaf-1). These molecules instigate a 
caspase cascade, activating the effector caspases further downstream, whose function 
is principally to dismantle cellular structures. There are three main apoptotic cascades 
activated by specific initiator caspases: the death receptor pathway, the mitochondrial 
pathway, and the ER pathway. These are activated by caspase-8, caspase-9, and 
caspase-12, respectively (Gupta et al, 2005).  
Two separate pathways of apoptotic cell death can be distinguished by the 
involvement of the Bcl-2 family proteins and by which caspases are required for their 
execution (Figure 1.12.2) (Youle and Strasser, 2008). The intrinsic pathway, (also 
called the Bcl-2-regulated or mitochondrial pathway), is activated by various 
developmental triggers or cytotoxic insults, such as viral infection, DNA damage and 
growth-factor deprivation, and is regulated by the Bcl-2 family of proteins. This 
pathway predominantly leads to the activation of caspase-9 (Hakem et al, 1998) but in 
certain cell types is known to take place in the absence of caspase-9 or Apaf-1 
(Marsden et al, 2002; Youle and Strasser, 2008). The extrinsic (or death-receptor 
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pathway) is triggered by ligation of the death receptor molecules such as Fas or 
tumour necrosis factor (TNF) receptor-1 (TNFR1) (members of the TNF receptor 
family) which harbour an intracellular death domain with the ability to recruit and 
activate caspase-8 through FADD at the cell surface (Youle and Strasser, 2008). This 
recruitment causes subsequent activation of downstream effector caspases, such as 
caspase-3, -6 or -7, independently of any involvement of the Bcl-2 family (described 
in Figure 1.12.2). Interestingly, it has been suggested that the two pathways may also 
be interconnected and that the molecules in one pathway have the ability to influence 
those of the other. In this regard it has been established that the extrinsic pathway can 
intersect the intrinsic pathway through caspase-8 cleavage-mediated activation of the 
pro-apoptotic BH3-only protein Bid (Yin et al, 1999; Kaufmann et al, 2007) in which 
the C-terminal truncated form of Bid (tBid) translocates to mitochondria from where 
it promotes further caspase activation through the intrinsic pathway (Caspase 9) (Yin 
et al, 1999).  
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Figure 1.12.2: Schematic depicting intrinsic and extrinsic pathways of apoptosis 
The intrinsic apoptotic pathway (left) begins with BH3-only protein induction or post-
translational activation, resulting in the inactivation of Bcl-2 family members. This 
relieves inhibition of Bax and Bak activation, thus promoting apoptosis. Some BH3-
only proteins (Bim and Puma), activate Bax/Bak (dotted line). Activated, Bax and 
Bak promote cytochrome c release ultimately leading to the activation of the caspases 
which in turn orchestrate the destruction of the cell. The extrinsic pathway (right) can 
bypass the mitochondrial step and activate caspase-8 directly. The Bcl-2 family 
regulates the intrinsic pathway and can also modulate the extrinsic pathway when 
cleavage of Bid communicates between the two pathways. A detailed discussion of 
Bcl-2 family can be found in Section 1.13 (From Youle and Strasser, 2008). 
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The extrinsic and intrinsic pathways both converge upon the execution phase, which 
is considered the final chapter of apoptosis, beginning with the activation of the 
effector caspases. Caspase-3, caspase-6, and caspase-7 function as effector caspases 
activating cytoplasmic endonucleases and proteases, which degrade nuclear material 
and cytoskeletal proteins (Elmore, 2007). These effector caspases cleave various 
substrates including cytokeratins, PARP, the plasma membrane cytoskeletal protein 
alpha fodrin, the nuclear protein NuMA and others, ultimately causing the 
morphological and biochemical alterations seen in apoptotic cells (Slee et al, 2001). 
Caspase-3 is thought to be the most important of the effector caspases, and is 
activated in response to any of the initiator caspases. Caspase-3 specifically activates 
the endonuclease caspase-activated DNase (CAD). In healthy proliferating cells CAD 
is complexed with its inhibitor, ICAD (inhibitor
 
of caspase-activated DNase). In 
apoptotic cells, activated caspase-3 cleaves ICAD to release CAD (Sakahira et al, 
1998). CAD then degrades chromosomal DNA within the nuclei and causes 
chromatin condensation. Caspase-3 also induces cytoskeletal reorganisation and 
disintegration of the cell into apoptotic bodies and facilitates disruption of the 
cytoskeleton, intracellular transport, cell division, and signal transduction (Kothakota 
et al, 1997). 
 
Phagocytic absorption of apoptotic cells is the final phase of apoptosis. In vivo, 
apoptotic bodies are promptly cleared via phagocytosis, by either phagocytotic cells 
or by cells in the direct vicinity of the apoptotic bodies. Phospholipid asymmetry and 
externalisation of phosphatidylserine (PS) on the surface of apoptotic cells and their 
fragments is a key characteristic of this stage. A PS receptor is involved in 
phagocytosis of apoptotic cells. Usually, PS is maintained at the inner layer of the 
plasma membrane by the action of an ATP dependent PS flippase enzyme. This 
flippase is inactivated through the action of the caspases, and a scramblase is 
activated, which ultimately leads to the redistribution of PS to the outer leaflet of the 
plasma membrane. PS externalisation is widely used to analyse apoptosis in FACS 
analysis due to PS binding to annexin V (Lawen A, 2003). The mechanism of PS 
translocation to the outer leaflet of the cell during apoptosis is not completely 
understood, and research indicates that Fas, caspase-8, and caspase-3 are involved in 
the regulation of PS externalisation on oxidatively stressed erythrocytes. However, it 
should be noted that, caspase-independent PS exposure occurs during apoptosis of 
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primary T lymphocytes (Ferraro-Peyret et al, 2002; Mandal et al, 2005). The 
appearance of PS on the outer leaflet of apoptotic cells then assists non-inflammatory 
phagocytic recognition, facilitating their early uptake and subsequent disposal (Fadok 
et al, 2001). 
1.13 Bcl-2 Family proteins 
 
Key players in the determination of cell survival and death are the members of the 
Bcl-2 family of proteins. The Bcl-2 family, both pro- and anti-apoptotic, are 
responsible for controlling the intrinsic pathway of apoptosis in mammals (Youle and 
Strasser, 2008). The founder of this family the B-cell lymphoma-2 (bcl-2) gene was 
discovered at the t(14;18) chromosome translocation breakpoint in B-cell follicular 
lymphomas, where its transcription becomes excessively driven by the immuno-
globulin heavy chain gene promoter and enhancer on chromosome 14 (Bakhshi et al, 
1985; Tsujimoto et al, 1985; Cleary et al, 1986). One key early discovery that 
introduced a new paradigm for carcinogenesis was that over-expression of bcl-2 does 
not promote cell proliferation as most previously discovered oncogenes do; rather, 
over-expression of bcl-2 inhibits cell death (Vaux et al, 1988). The Bcl-2 family of 
regulators function upstream of the caspase cascade (Igaki and Miura, 2004) and 
display a range of bioactivities, from inhibition to promotion of apoptosis (Youle and 
Strasser, 2008).  
 
In mammals, there are at least 23 Bcl-2 family members, including Bcl-2 itself and 
proteins that have either three-dimensional (3D) structural similarity or a predicted 
secondary structure that is similar to Bcl-2 (Figure 1.13.1) (Youle and Strasser, 2008). 
Bcl-2 family members possess up to four conserved Bcl-2 homology (BH) domains 
designated BH1, BH2, BH3 and BH4 which correspond to α-helical segments 
(Adams and Cory, 1998; Gross et al, 1999). A characteristic of the Bcl-2 family 
proteins is their ability to form homo- and hetero-dimers, as well as their ability to 
become integral membrane proteins (Gross et al, 1999). 
 
The anti-apoptotic members of this family (Bcl-2, Bcl-XL, Bcl-w, Mcl-1, A1, Boo/Diva, 
Bcl-B, and C. elegans CED-9) are known to contain at least three of the four Bcl-2 
homology domains. The pro-apoptotic members can be further characterised into to 
 52 
sub-categories being either “Bax-like” in their structure (Bax, Bak, Bcl-XS, Bok/Mtd 
and Bcl-GL) i.e. containing two or three BH domains, or alternatively, the so-called 
“BH3-only” proteins which share homology with each other and the remainder of the 
Bcl-2 protein family only through the short BH3 motif (Bad, Bik, Blk, Bid, Hrk, 
Bim/Bod, Bmf, "oxa, Puma and C. elegans Egl-1) (Bouillet and Strasser, 2002). 
Overall the structures of the BH3-only proteins seem to be unrelated and appear to 
lack a close evolutionary relationship to the core members of the Bcl-2 family 
(Aouacheria et al, 2005). However, all BH3-only proteins interact with and regulate 
the core Bcl-2 family proteins to promote apoptosis. The BH3 domains of the Bcl-2 
family members are crucial to their function. Indeed, just the 51 amino acids that code 
the domain in bak are enough to have a pro-apoptotic effect, while mutations of the 
BH3 regions in bax, bak and bik were found to render the proteins ineffective 
(Elangovan and Chinnadurai, 1997; Tong et al, 2001).    
 
 
 
 
Figure 1.13.1: X-ray crystallography suggests that both pro-apoptotic and anti-
apoptotic Bcl-2 family members share a common structure.  
Bcl-2 family members possess up to four conserved Bcl-2 homology (BH) domains 
designated BH1, BH2, BH3 and BH4 which correspond to α-helical segments. Each 
of the BH domains is indicated above. α1-7 indicates helices in Bcl-XL, while the 
arrows represent phosphorylation sites in Bcl-2. BHRF1 has been shown to harbour a 
BH3 domain, which is unexposed (From Adams and Cory, 1998).  
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The pro-apoptotic family members Bax and Bak are critical in the permeabilisation of 
the outer mitochondrial membrane (OMM) and the subsequent release of apoptogenic 
molecules such as cytochrome c and SMAC/DIABLO into the cytosol, which 
ultimately leads to caspase activation. The anti-apoptotic family members, such as 
Bcl-2 and Bcl-XL, are known to inhibit the activity of Bax and Bak. A growing body 
of evidence indicates that BH3-only proteins de-repress Bax and Bak by directly 
binding and inhibiting Bcl-2 and other anti-apoptotic family members (Willis et al, 
2007) or alternatively that they may directly activate Bax and Bak (Hacker and 
Weber, 2007) (Figure 1.12.2). 
It has been established that both Bax and Bak promote caspase activation by their 
effects on mitochondria. These two pro-apoptotic proteins induce the release of 
proteins from the space between the inner and outer mitochondrial membranes 
(Newmeyer and Ferguson-Miller, 2003). This process of mitochondrial outer 
membrane permeabilisation (MOMP) leads to the release of cytochrome c and other 
soluble proteins. While it is generally believed that Bax and Bak form integral 
membrane pores, the biochemical nature of such pores and how anti-apoptotic Bcl-2 
family proteins might regulate them remains to be seen (Chipuk et al, 2006). During 
cytochrome c release into the cytosol, Bax and Bak induce mitochondria to fragment 
into more numerous and smaller units (Martinou and Youle, 2006). 
Once the OMM has been permeabilised, soluble proteins diffuse from the 
intermembrane space into the cytosol, where they promote caspase activation. The 
best studied of these proteins is cytochrome c, which binds to Apaf-1 and leads to the 
assembly of the apoptosome, which can bind pro-caspase-9 or and thereby induce its 
activation through a conformational change in the molecule (Wang, 2001; Shi, 2006). 
Cytochrome c–Apaf-1-dependent activation of caspase-9 is absolutely required for 
neuronal and fibroblast cell-death processes (Hao et al, 2005). However, lymphocytes 
may use alternative Apaf-1-, caspase-9- and cytochrome c-independent, but pro-
apoptotic Bcl-2-family-member-dependent, pathways for caspase activation (Marsden 
et al, 2002; Hao et al, 2005). One such pathway which is Apaf-1-independent, 
involves the relief of caspase inhibition by inhibitor of apoptosis proteins (IAPs), such 
as XIAP, which bind and neutralise certain caspases (such as caspase-9 and caspase-
3). This inhibitory action of IAPs can be antagonised by the binding of 
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SMAC/DIABLO, which is released from mitochondria after the activation of Bax 
and/or Bak (Youle and Strasser, 2008). 
Members of the Bcl-2 family are expressed to varying degrees in different cell types. 
In particular B-cells are known to express a battery of both apoptotic and anti-
apoptotic Bcl-2 family members, including Bcl-2, Bcl-xl, Bfl-1, Mcl-1, Bcl-w, Bim, 
Bax, Hrk, Bid, Noxa, Bak and Puma (Garrison et al, 2008) and Bik (Arena et al,  
2003). 
1.14 BH3-only proteins 
 
BH3-only proteins are essential for cell death initiation (Labi et al, 2006). A growing 
body of evidence indicates that different apoptotic stimuli can activate distinct but 
sometimes overlapping sets of BH3-only proteins (Strasser, 2005). The pro-apoptotic 
activity of BH3-only proteins is tightly controlled by diverse transcriptional and post-
translational mechanisms to prevent inappropriate cell death (Huang and Strasser, 
2000). For example, Puma and Noxa are transcriptionally induced in response to 
DNA damage by p53 whereas other BH3-only proteins, such as Bid or Bad, are 
thought to be mainly regulated at the post-translational level (Cory and Adams, 2002). 
While the molecular basis of BH3-only protein activity is still under investigation, it 
is clear that BH3-only proteins have the ability to bind to a hydrophobic groove on the 
surface of Bcl-2-like molecules, formed by their BH1, BH2 and BH3 domains thereby 
antagonising their pro-survival function (Willis and Adams, 2005). This physical 
interaction is dependent on a functional BH3-domain within the BH3-only protein. It 
has been suggested that BH3 only proteins can function via at least three separate 
modes of action (Letai et al, 2002; Kuwana et al, 2005; Strasser, 2005) and since the 
signaling pathways that mediate apoptosis seem to proceed through a succession of 
interconnected amplification loops, it is conceivable that more than one of these 
processes takes place (Strasser, 2005).  
In one model of BH3-only protein function, this interaction is thought to block the 
ability of Bcl-2-like pro-survival proteins to regulate the pro-apoptotic Bax/Bak, 
preventing them from undergoing oligomerisation and causing loss of mitochondrial 
outer membrane integrity and cell death (Strasser, 2005; Willis et al, 2007) (Figure 
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1.14.1A). It is also been suggested that the BH3-only proteins and Bax/Bak-like 
proteins function in parallel in a mutually dependent manner (Strasser, 2005) (Figure 
1.14.1B). In an alternative model, the BH3-only proteins activate Bax/Bak directly. In 
support of this model tBid and Bim have this ability. Bid and Bim directly activate 
Bax, causing its insertion into the mitochondrial membrane where it becomes active. 
However, Bim and tBid can be bound and neutralised by Bcl-2-like proteins, by 
sequestration, and the role of other BH3-only proteins in this model is to occupy Bcl-
2-like proteins and stop them from sequestering Bim/tBid. Accordingly, these BH3-
only proteins (e.g. Bad and Bik) are called sensitisers (Strasser, 2005; Hacker and 
Weber, 2007) (Figure 1.14.1C). 
Additionally a further possibility is that, to keep cells from dying, Bcl-2 (and/or its 
pro-survival homologues) might bind and inhibit a protein, perhaps a caspase 
activator (such as Apaf-1), and that apoptotic stimuli might trigger both BH3-only 
proteins and Bax/Bak-like proteins, which together would disrupt this binding 
(Strasser, 2005) (as depicted in Figure 1.15.5) 
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Figure 1.14.1: Models for interaction between BH3-only proteins, Bax/Bak-like 
proteins and pro-survival Bcl-2-family members in signaling in 
apoptosis.  
Three possible models are illustrated above. (A) BH3-only proteins might inactivate 
Bcl-2-like pro-survival proteins, which keep cells alive by inactivating Bax/Bak-like 
proteins. (B) Death stimuli might simultaneously activate BH3-only proteins and 
Bax/Bak -like proteins, which both block the pro-survival function of Bcl-2 and its 
homologues. (C) BH3-only proteins might activate the pro-apoptotic activity of 
Bax/Bak-like proteins directly, and pro-survival Bcl-2-family members might 
function by binding and inactivating BH3-only proteins and/or Bax/Bak-like proteins. 
(From Strasser, 2005). 
BH3-only proteins have distinct, only partially overlapping, binding preferences for 
their pro-survival Bcl-2-like relatives (Chen et al, 2005), indicating that certain BH3-
only proteins can only antagonise a very distinct subset of Bcl-2-like molecules in 
vivo (e.g. Noxa can only block Mcl-1 and A1), while others, such as Bim and Puma, 
are able to bind with similar affinities to all known Bcl-2 pro-survival proteins and, 
therefore, may have broader physiological functions than other BH3-only proteins 
(Labi et al, 2006).   
Since these proteins are essential initiators of cell death pathways, understanding their 
regulation may provide novel therapeutic targets to prevent pathological cell death. 
Inhibitors of BH3-only proteins may alleviate degenerative disorders, whereas small 
molecule mimetics may be used to kill cancer cells or self-antigen-specific 
lymphocytes in autoimmune disease (Huang and Strasser, 2000). 
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1.15  Bik  
 
The regulation of bcl-2 family members by EBV is a significant research interest the 
laboratory. Bik, in particular, was a major interest in the present study and will now 
therefore be discussed in detail.  
 
The human Bcl-2 interacting killer (bik/nbk) gene formerly known as BP4 (Han et al, 
1996b), and BIP1 (Chittenden et al, 1995), encodes the 160 amino acid pro-apoptotic 
Bik protein. Bik was the naissance member of the BH3-only proteins sharing a 
distinct sequence motif with the Bcl-2 family and a characteristic C-terminal trans-
membrane segment (Boyd et al, 1995; Han et al, 1996b) which determines its sub-
cellular localisation (Elangovan and Chinnadurai, 1997). Originally identified as a 
binding partner and antagonist of anti-apoptotic Bcl-2 and its adenovirus homolog, 
E1B 19K, Bik also displayed affinity for Bcl-XL, Bcl-XS and the EBV BHRF1 (Boyd 
et al, 1995; Han et al, 1996b; Han et al, 1996a). Subsequent sequence analysis 
indicated that Bik shares only the short BH3 signature domain with other members of 
the Bcl-2 family and had no homology for the other Bcl-2 signature domains BH1, 
BH2 and BH4 (Boyd et al, 1995). Bik is localised to the endoplasmic reticulum from 
where it elicits pro-apoptotic signals and, given sufficient time, these signals lead to 
cell death (Germain et al, 2002; Mathai et al, 2002; Zhao et al, 2008). 
  
1.15.1  Expression 
 
The bik transcript has a tissue-specific expression profile (Boyd et al, 1995; Han et al, 
1996a) with strong expression
 
in the kidney (Daniel et al, 1999). The gene is also 
expressed in many tumour lines and in B-cells following antigen receptor stimulation 
(Verma et al, 2000; Jiang and Clark, 2001).  
 
1.15.2  Structure 
 
Bik is localised on chromosome 22q13 and consists of five exons and four introns, 
spanning a region of 19kb. The translational start site and BH3 domain are located in 
exon 2 and 3, respectively (Figure 1.15.1). The alpha-helical BH3 region is required 
 58 
for both death promoting activities and dimerisation with anti-apoptotic proteins 
(Boyd et al, 1995; Tong et al, 2001; Letai et al, 2002). The C-terminal trans-
membrane hydrophobic domain and the stop codon are contained within exon 5. The 
transcriptional initiation site was identified as a G residue (marked as +1, Figure 
1.15.1) located approximately 13kb from the translational start site. The gene has a 
long un-translated sequence in exon 1. No canonical TATA or CCAAT boxes were 
identified near the transcriptional initiation site (Verma et al, 2000).  
 
 
 
 
Figure 1.15.1: Arrangement and sizes of exons and introns in the bik gene.  
Genomic organisation of the Bik gene indicating arrangement and sizes of exons and 
introns (From Verma et al, 2000). 
 
1.15.3 Function 
 
Bik is one of the pro-apoptotic members of Bcl-2 family with a death-promoting 
activity (Boyd et al, 1995; Tong et al, 2001). Early reports indicated that Bik exhibits 
death-promoting activities similar to the pro-apoptotic Bax and Bak in that it binds to 
pro-survival proteins and kills when over-expressed (Boyd et al, 1995). Indeed Bik 
protein is induced in response to a variety of cell stress stimuli, including genotoxic 
agents (Paquet et al, 2004; Mathai et al, 2005; Real et al, 2006), oncogenic stress 
(Mathai et al, 2002) and hypoxia (Koong et al, 2000) and has been shown to induce 
mitochondrial permeability transition, release of cytochrome c, caspase-12, -9, -7 and 
-3 processing, poly(ADP-ribose) polymerase (PARP) cleavage, and DNA 
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fragmentation;  all of which are indicative of cell death by apoptosis (Tong et al, 
2001; Germain et al, 2002; Zhao et al, 2007).  
 
Bik has been implicated in several cancers including human colorectal, prostate, lung 
and breast cancers, leukaemia, malignant glioma and renal cell carcinoma (Castells et 
al, 1999; Castells et al, 2000; Marshansky et al, 2001; Tong et al, 2001; Naumann et 
al, 2003; Hur et al, 2004; Germain et al, 2005; Sturm et al, 2006; Fu et al, 2007) and 
also displays abnormal expression in acute myeloid leukaemia (AML) compared to 
normal hematopoietic cells indicating that Bik expression may contribute to the 
biology of AML (Stirewalt et al, 2008). 
 
There is increasing evidence to suggest that repression of bik or inactivation of its 
product may play a role in tumour development. Consistent with this premise, is the 
evidence that bik mutations are a frequent feature of human lymphomas (Arena et al, 
2003), and the chromatin locus 22q13.3, which contains Bik coding sequence, 
exhibits deletions in human breast and colorectal cancers (Castells et al, 2000). 
Moreover, loss of bik, due to genomic deletion and transcriptional silencing by 
hypermethylation, is associated with renal cell carcinoma (RCC), suggesting a 
putative role in the acquisition of apoptosis resistance in tumour cells and 
significantly, restoration of Bik expression led to apoptotic death in RCC cells but not 
in non-malignant renal epithelial cells (Sturm et al, 2006; Zantl et al, 2007). In 
addition, bik down-regulation may contribute to Busulfan (Bu) resistance in 
hematopoietic stem cell transplantation (HSCT) of patients with chronic or acute 
myelogenous leukemia (CML or AML) (Valdez et al, 2008). Exogenous Bik can 
sensitise tumour cells to apoptosis (Daniel et al, 1999; Panaretakis et al, 2002; 
Oppermann et al, 2005) making bik a potential
 
therapeutic gene in cancer treatment 
(Zou et al, 2002).  
1.15.3.1 A role for Bik in B-cells  
 
Several lines of evidence suggest that the balance between pro-apoptotic Bik and the 
anti-apoptotic Bcl-XL
 
protein plays a key role in determining B-cell fate and that 
apoptosis activation signals the up-regulation of Bik protein in order to antagonize
 
the 
function of Bcl-XL. Consistent with this hypothesis, cell surface IgM
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B104 B-cell lymphoma cells induces Bik accumulation and increases the amount of 
Bik associated with Bcl-XL ultimately leading to apoptosis through the activation of 
caspases (Jiang and Clark, 2001). Furthermore, the cytokine transforming growth 
factor-β (TGF-β)-mediated apoptosis in the Ramos B-lymphoma cell line involves the 
activation of caspases and is accompanied by Bik up-regulation and a simultaneous 
loss of Bcl-XL expression (Saltzman et al, 1998). The involvement of Bcl-XL in 
regulating immature B-cell apoptosis is well established (Motoyama et al, 1995; Fang 
et al, 1998) and indeed the ability of Bcl-XL to rescue Bik induced apoptosis is also 
recognised (Boyd et al, 1995). Findings have shown that Bik binds to and can 
antagonise anti-apoptotic Bcl-XL under physiological conditions (Jiang and Clark, 
2001; Shimazu et al, 2007). Thus it may be the relative proportion of Bcl-XL not 
associated with Bik that determines whether B-cells survive.  
 
Bik is also
 
weakly down-regulated following CD27 ligation, whereas CD40 ligation 
(both belong to the TNF/TNFR family) resulted in a similarly weak increase in
 
Bik 
expression in B-cell receptor (BCR)-mediated apoptosis of Ramos cells. Thus, it is 
possible that CD27
 
signals regulate BCR-mediated apoptosis at the mitochondrial 
level
 
in a manner different from CD40 signals through the alteration
 
of the balance 
among Bcl-2 family members to regulate mitochondrial
 
permeability. In addition, 
since CD27 and CD40 inhibit p53 activation it is conceivable that Bik might be 
involved in the p53-dependent apoptosis pathway in B-cells (Hase et al, 2002).
 
The 
possible involvement of other pro-apoptotic
 
Bcl-2 members such as Bax or Bak in B-
cell apoptosis can also not be ruled out.  
1.15.4  Mechanism of bik-induced apoptosis 
 
It has been well established that Bcl-2 family proteins function at the mitochondria to 
prevent or promote the release of apoptogenic factors such as cytochrome c, AIF and 
SMAC/Diablo. In addition to their mitochondrial localisation, some anti-apoptotic 
members of the Bcl-2 family have also been found to be present at the endoplasmic 
reticulum (ER) and perinulcear membrane regions, suggesting a role of the Bcl-2 
family proteins at sites other than mitochondria (Zong et al, 2003; Zhao et al, 2007). 
The evidence suggests that Bik may act from the ER, coupling upstream death signals 
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to events at the surface of the mitochondria via activation of the death effectors Bax 
and Bak, resulting in cell death (Wei et al, 2001; Zong et al, 2001).  
The ER is well characterised as a calcium (Ca
2+
) store that sequesters excess cytosolic 
Ca
2+ 
and a reservoir for Ca
2+ 
signaling to maintain intracellular calcuim
 
homeostasis 
(Sambrook, 1990). A growing body of evidence suggests that changes in intracellular 
Ca
2+ 
homeostasis plays a significant role in the modulation of apoptosis (Pinton et al, 
2001). Indeed, evidence indicates that Bcl-2 family proteins might regulate apoptosis 
via a mechanism that affects the Ca
2+
 stores within the ER (Foyouzi-Youssefi et al, 
2000), or alternatively via a mechanism that controls the apoptotic cross talk between 
the ER and the mitochondria (Hacki et al, 2000). Members of the Bcl-2 family appear 
to differentially regulate intracellular Ca
2+
 level. Translocation of Bax, an apoptotic 
signaling protein, from the cytosol to the mitochondrial membrane is another step in 
this apoptosis signaling pathway (Smaili et al, 2003). 
Bik is exclusively localised to ER rather than mitochondria through its trans-
membrane domain (Germain et al, 2002; Zhao et al, 2008). Bik can induce changes in 
the content of cytosolic as well as ER Ca
2+
 stores (Mathai et al, 2005; Zhao et al, 
2008) and this process is thought to be mediated through a Bax/Bak regulated 
mechanism (Mathai et al, 2005). Recent findings have further revealed that the 
depletion of ER Ca
2+
 stores rather than the elevation of intracellular Ca
2+
 or the extra-
cellular Ca
2+
 influx play an important role in Bik-induced apoptosis (Zhao et al, 
2008). Furthermore, it has previously been demonstrated that ER Bik initiates 
dynamin-related protein-1 (DRP1)-regulated remodelling of mitochondrial cristae 
during apoptosis in a manner dependent on the transmission of Ca
2+ 
to the 
mitochondria (Germain et al, 2005) further supporting a role for Bik in the regulation 
of the ER Ca
2+
 stores.  
Exactly how the over-expression of Bik affects the intracellular Ca
2+
 homeostasis is 
presently unknown. Bik may oligomerise with the other Bcl-2 member proteins and 
create a non-selective or selective ion pore across the ER membrane causing leakage 
of Ca
2+
 from the ER Ca
2+
 stores (Zhao et al, 2008). Alternatively, Bik protein may 
interact directly or indirectly with the ER Ca
2+
 pump, or other Ca
2+
 channels.  
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Upon induction of apoptosis Bax molecules translocate from the cytosol to 
mitochondrial membranes where it is thought to oligomerise into an active trans-
membrane pore (Hsu et al, 1997; Wolter et al, 1997; Desagher et al, 1999). Bik is 
reported to function through the initiation of cell death signaling, whereas Bax/Bak-
like proteins function further downstream (Zong et al, 2001; Lindsten and Thompson, 
2006). Further reiterating this point is the finding that Bik induces exposure of an N-
terminal Bax epitope mediating its insertion into the outer mitochondrial membrane, 
release of cytochrome c, and cell death in H1299 cells (Gillissen et al, 2003). Since 
the interaction of Bik with Bax is associated with a change in conformation of Bax 
leading to cytochrome c release (Gillissen et al, 2003), it would appear then, that Bik 
functions as a positive death effector, engaging downstream components of the cell 
death pathway. Furthermore, Bik can co-operate with Noxa, another BH3 protein, to 
release cytochrome c from the mitochondria and this pathways involves 
conformational changes in Bax leading to its activation and ultimately caspase 
activation (Germain et al, 2005) 
Thus it appears that Bik initiates a pathway from its location at the ER that stimulates 
the release of Ca
2+
 from the ER via activation of the death effectors Bax and Bak, 
which leads to cytochrome c release and signaling of apoptosis from mitochondria 
(Germain et al, 2002; Germain et al, 2005). The collapse of membrane potential along 
with the release of cytochrome c from mitochondria is followed by the activation of 
caspases (Smaili et al, 2003). Accordingly Bik, is known to elicit pro-apoptotic 
signals which lead to cell death by pathways which involve the activation of caspases 
(Germain et al, 2002; Gillissen et al, 2003; Mathai et al, 2005; Zhao et al, 2007) 
which can  be inhibited by the broad range caspase inhibitor "-benzyloxycarbonyl-
Val-Ala-Asp(OMe)-fluoromethyl ketone (zVAD-fmk) (Mathai et al, 2002; Naumann 
et al, 2003; Hur et al, 2004). In one study Bik induced the depolarisation of 
mitochondrial membrane potential (MMP) through a caspase-12-dependent pathway, 
leading to the activation of initiator caspase-9 and ultimate cell death in 293 and 
Hep3B cells suggesting that caspase-12 may directly or indirectly influence the 
intrinsic apoptosis signal transduction pathways triggered by Bik at the ER (Zhao et 
al, 2007). Bik has also been shown to induce the catalytic activation of caspase-9, 
caspase-7 and caspase-3 processing in chemoresistant human tumour prostate and 
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colon cell lines (Tong et al, 2001). A model for caspase-dependent Bik-induced 
apoptosis can be seen in Figure 1.15.2. 
 
Figure 1.15.2: The caspase-dependent bik-induced apoptotic pathway.  
 
Upon apoptotic stimulation Bik induces the depletion of ER Ca
2+
 stores, exposure of 
an N-terminal Bax epitope mediating its insertion into the outer mitochondrial 
membrane, release of cytochrome c, and activation of a caspase-12-dependent 
pathway, leading to the activation of initiator caspase-9 and ultimately cell death. 
Adapted from Hunot and Flavell, 2001. 
 
Further evidence for the involvement of caspases in Bik-induced apoptosis is 
presented in a model in which Bik triggers apoptosis through the activation of 
caspases distal to the CrmA block (which preferentially inhibits proximal components 
of the
 
caspase protease cascade, including caspase-8 Muzio et al, 1997)
 
but upstream 
of the IAPs (the inhibitors of apoptosis molecules, that block caspase catalytic 
activity, Cp-IAP and Op-IAP (Clem and Miller, 1994; Orth and Dixit, 1997). A 
representation of this model is seen in Figure 1.15.3. 
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Figure 1.15.3: Relative order of Bik in the death pathway.  
 
At the apex of the cascade is the death signals that are susceptible to CrmA inhibition. 
Downstream
 
of this block, other Bcl-2-inhibitable death stimuli can enter
 
the death 
pathway. Bik and Bak/Bax may inhibit Bcl-2/Bcl-XL directly to release
 
an unidentified 
cytotoxic factor. Alternatively, Bik and Bak/Bax may
 
activate the pathway directly. 
Regardless, IAPs function downstream
 
of Bik and Bak/Bax. Activation of distal 
caspases results in cell
 
death (Adapted from Orth and Dixit, 1997). 
Interestingly it has also been reported that Bik can induce cell death in a caspase-
independent fashion in human melanoma cells (Oppermann et al, 2005) and that 
inhibition of caspases by treatment with zVAD-fmk in the absence of Bcl-2 actually 
enhances Bik-induced cell death in mouse embryonic fibroblasts (MEFs) (Rashmi et 
al, 2007). Interestingly a pathway in which Bik-mediated cell death induces the 
release of cytochrome c but not mitochondrial membrane potential loss and without 
modulating voltage-dependent anion channel activity (VDAC), (an important 
component of the PTP), has also been reported, suggesting that Bik may target 
molecules other than the PTP or act alone to induce cytochrome c release (Shimizu 
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and Tsujimoto, 2000). Furthermore, findings have suggested that Bik can induce 
cytochrome c release from
 
mitochondria independently
 
of Bax in H1299 cells. This 
report favoured a direct induction of the mitochondrial apoptotic signaling cascade by 
bik and subsequent activation of caspases (Germain et al, 2002). It is conceivable that 
bik could be acting on separate distinct pathways, in response to different stimuli.  
 
A mechanism of Bik-induced apoptosis regulated by Bcl-2 family members, such as 
Bax or Bcl-2/Bcl-XL cannot be excluded. The pro-apoptotic
 
activity of BH3-only 
proteins is proposed to be governed by their propensity
 
to interfere with at least a dual 
layer of protection of cells from the pro-apoptotic activity of Bak
 
(Willis and Adams, 
2005). It has previously been shown that binding of Bik inactivates
 
Bcl-XL and 
releases both Bax and Bak. While the interaction
 
between Bik and Bcl-XL seems to be 
stronger, Bik is also known to bind
 
to Bcl-2 (Elangovan and Chinnadurai, 1997; 
Verma et al, 2001; Gillissen et al, 2003), indicating that Bcl-2 is at least in part
 
inhibited by Bik. Once the capacity of Bcl-2 to bind Bax has been surpassed, the 
liberated Bax protein becomes activated. Notably,
 
the Bax inhibitors Bcl-2 and Bcl-XL 
are not stabilised by Bik.
 
In contrast, Bak, released from Bcl-XL upon Bik expression,
 
is still kept in check by Mcl-1, and this is enforced by
 
the up-regulation of the Bak 
inhibitor Mcl-1 by Bik. Mcl-1-mediated
 
repression of Bak thereby provides a 
molecular rationale for
 
the strict Bax dependency of Bik-induced cell death. Thus it 
appears that Mcl-1 determines the Bax dependency of Bik-induced apoptosis 
(Gillissen et al, 2007). In this instance Bik appears to act
 
as de-repressor molecule 
binding to distinct anti-apoptotic proteins. The consequently de-repressed pro-
apoptotic multi-domain proteins
 
can then be counteracted by a second set of anti-
apoptotic proteins.
 
This adds a higher degree of specificity and the outcome of 
triggering
 
this tightly balanced interaction network would be determined
 
by both the 
specific BH3-only proteins induced by a given death
 
stimulus and the abundance of 
their anti-apoptotic counterparts
 
forming this second obstacle to apoptosis (Gillissen 
et al, 2007). A diagram depicting a model for the regulation of Bik-induced apoptosis 
by Bcl-2 family members can be seen in Figure 1.15.4. 
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Figure 1.15.4: Model for the regulation of Bik/+bk-induced apoptosis by Bcl-2 
family members. 
 
(A) In healthy cells, Bax is inactivated by Bcl-2 and Bcl-XL, whereas Bak is 
sequestered by Bcl-XL and Mcl-1. (B) Bik/Nbk activates the pro-apoptotic Bax 
through neutralisation of the anti-apoptotic Bcl-XL. In contrast, increased levels of the 
anti-apoptotic Mcl-1 keep in check Bak that was released from Bcl-XL upon 
competition with Nbk. From Gillissen et al, 2007. 
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1.15.5  Regulation 
 
Regulation of bik on several different levels has been reported. Evidence of roles for 
transcriptional regulation, methylation, phosphorylation and protein degradation by 
the proteasome have all been indicated. Additionally, the specificity of the interplay 
between hetero-dimerising partners is also thought to be associated with bik control.  
Indeed stringent regulation of bik gene expression at various steps is probably 
essential, given the fact that Bik is predicted to possess an already exposed
 
BH3 
domain and is thus considered constitutively active (McDonnell et al, 1999). It is 
clear that external and internal stimuli lead to regulation of bik at several different 
levels, including tissue-specific expression (Daniel et al, 1999), transcriptional and 
translational control and intracellular localisation (Germain et al, 2002; Mathai et al, 
2002; Zhao et al, 2008). Evidence that bik is transcriptionally regulated by a number 
of transcription factors including p75NTR, SFRP1, IgM, E4orf6, E1A, GRP78/BiP, the 
E2F transcription factors and TGF-β has been demonstrated (Saltzman et al, 1998; 
Jiang and Clark, 2001; Mathai et al, 2002; Tabassum et al, 2003; Han and Amar, 
2004). Furthermore, apoptosis triggered by bik can be either p53-dependent or 
independent depending on the induction stimulus (Han et al, 1996a; Bartke et al, 
2001; Mathai et al, 2002). 
  
The regulation of Bik function by phosphorylation has also been verified (Verma et 
al, 2001). Bik is phosphorylated on consensus
 
CKII phosphorylation sites (Thr-33 
and/or Ser-35) (Verma et al, 2001) an event that appears to result in a gain in function 
(Verma et al, 2001). Mutation of the phosphorylation sites, in which the threonine and 
serine residues were changed to alanine residues, indicated that phosphorylation of 
Bik is required for its apoptotic activity, without significantly affecting its ability to 
hetero-dimerise with Bcl-2 and Bcl-XL (Verma et al, 2001). The precise mechanism 
by which phosphorylation plays
 
a role in the apoptotic activity of Bik is not known, 
although it is possible that phosphorylation of Bik may play role in interaction
 
with 
other potential cellular targets or that the activity of Bik may be activated by 
phosphorylation in response to different
 
apoptotic stimuli in various human tissues 
(Verma et al, 2001). 
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The methylation status of bik remains uncertain. While treatment with the DNA 
methylation inhibitor, zebularine induced genomic de-methylation of a multiple 
myeloma cell line KAS-6/1, and induced the expression
 
of Bik (Pompeia et al, 2004), 
conflicting reports argue that DNMT1 mediated bik suppression does not involve a 
change in the DNA
 
methylation state or histone modification, maintaining that 
DNMT1 is capable of regulating gene expression by a DNA methylation independent 
pathway (Milutinovic et al, 2004). A closer look at the mechanism of action of 
zebularine, reveals that this drug acts by forming a complex with DNMT1 in the 
position normally incorporated by the base targeted for methylation (Zhou et al, 
2002). Thus, the gene targeted to disrupt methylation may also suppress Bik 
independently of the DNA
 
methylation state (Pompeia et al, 2004). Other studies have 
indicated a role for DNA methylation in transcriptional silencing of the bik gene. 
Exposure to 5'-aza-2'-deoxycytidine resulted in strong up-regulation of bik mRNA in 
renal cell carcinoma (RCC) cell lines (Sturm et al, 2006) and was shown to be 
induced by the histone deacetylase inhibitor, sodium butyrate in human hepatoma 
cells (Ogawa et al, 2004). Increases in bik mRNA expression were observed in both 
HepG2 and Hep3B cells following treatment with 5-aza-2′-deoxycytidine or histone 
deacetylase inhibitor sodium butyrate given separately. Bik protein however was 
undetectable (Wang et al, 1998). A combination treatment of both 5-aza-2′-
deoxycytidine plus depsipeptide has shown a synergistic effect on bik gene induction 
in a variety of cancer cell lines (Dai et al, 2006). It may be the case that control of bik 
expression by epigenetic mechanisms occurs in a cell type-specific manner. 
 
The realisation that Bik may rapidly turnover during apoptosis suggests another level 
of control by means of Bik degradation (Marshansky et al, 2001). It has been 
postulated that the accumulation of Bik protein may be a direct result of its reduced 
degradation in the cell (Marshansky et al, 2001). Indeed, reports suggest that Bik is 
one of the mediators of proteasome inhibitor-induced apoptosis and that the 
proteasome inhibitors Bortezomib (Nikrad et al, 2005) and lactacystin (Marshansky et 
al, 2001) can regulate Bik expression, through stabilisation of the protein. This 
accumulation of Bik is sufficient to induce apoptosis indicating that it maybe the 
accumulation
 
of Bik rather than the expression per se that determines
 
whether a cell 
undergoes apoptosis (Jiang and Clark, 2001).   
 
 69 
Akin to other BH3-only proteins, Bik binds to pro-survival family members, killing 
cells when over-expressed (Boyd et al, 1995). Not unlike other pro-apoptotic 
members of the Bcl-2 family the BH3 domain of bik has proven critical for
 
pro-
apoptotic activities; dimerisation as well as for cytochrome c release and apoptosis 
(Boyd et al, 1995; Cosulich et al, 1997; Hegde et al, 1998; Germain et al, 2002). 
Since BH3-only pro-apoptotic
 
proteins share only the BH3 domain
 
in common 
(Bouillet and Strasser, 2002), it has been postulated as to whether the BH3 domain is 
a death
 
effector module eliciting its cell death activity
 
through the inactivation of the 
anti-apoptotic proteins by hetero-dimerisation, thus disrupting the complex of the 
death suppressor with a caspase activating molecule such as Apaf-1, which in turn 
results in the activation of caspases and eventually death of the cell (Boyd et al, 1995; 
Kelekar and Thompson, 1998; Lutz, 2000; Chittenden, 2002) as represented in Figure 
1.15.5.  
 
Accordingly then, regulatory control could be directly associated with the specificity 
and nature of the interplay between Bik and its hetero-dimerising partners (Han et al, 
1996a; Elangovan and Chinnadurai, 1997). In this regard, the death promoting activity 
of Bik can be suppressed by co-expression of Bcl-2, Bcl-XL and BHRF1, and E1B-19k 
(Boyd et al, 1995; Elangovan and Chinnadurai, 1997). Bik also binds with Bcl-XS, a 
death-promoting protein that lacks the BH1 and BH2 domains, possibly indicative of 
a co-operation effect between the two proteins (Boyd et al, 1995). It has long been 
recognised that the relative levels of available Bcl-2 family dimerisation partners in 
the cell may shift the balance of cell fate either in favour of viability or of cell death, 
following exposure to an appropriate stress (Han et al, 1996a). The assumption that 
certain BH3-only ligands possess a degree of specificity for their pro-survival 
receptors would render apoptosis of the Bcl-2 family a sophisticated affair, with Bik
 
functioning as a naturally dominant negative antagonist
 
whose role in the cell is to 
sequester and inactivate anti-apoptotic
 
proteins.  
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Figure 1.15.5: Model for Apaf-1 regulation by the Bcl-2 family.  
 
A pro-survival member Bcl-2 family member such as Bcl-xL may bind Apaf-1 and 
prevent it from activating procaspase-9 (or another initiating pro-caspase). A death 
signal may, for example, provoke interaction of a BH3 family member such as Bik, or 
perhaps a Bax family member with Bcl-XL, preventing it from neutralising Apaf-1. In 
the presence of cytochrome c released from mitochondria and ATP, Apaf-1 can then 
bind to procaspase-9 and promote its dimerisation and activation by autocatalysis. 
Caspase-9 subsequently activates effector caspases (Adapted from Adams and Cory, 
1998).  
 
Association of Bik with anti-apoptotic proteins indeed hinders Bik function (Boyd et 
al, 1995). However, mutational
 
analysis of the BH3 domain in bik, suggests that 
hetero-dimerisation via
 
the BH3 domain with survival proteins alone is insufficient to
 
explain their cell death inducing activity (Elangovan and Chinnadurai, 1997). It has 
also been hypothesised that sequences in the C-terminal region of Bik might also be 
required for the pro-apoptotic activity of Bik, in addition to the activity of the BH3 
domain. The
 
precise biochemical activity of the C-terminal region of Bik is
 
not known 
but it is conceivable that the C-terminal sequences
 
may function in concert with the 
BH3 domain to enforce apoptosis. Another, simpler rationalisation may be that the C-
terminal region
 
plays a role in Bik protein folding is also possible (Elangovan and 
Chinnadurai, 1997). Interestingly, this region is known to contain a sequence motif 
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similar
 
to the substrate binding motif of the caspase family, and it was postulated that 
this motif could modulate the substrate-caspase
 
complexes. Indeed a very recent study 
demonstrated that the trans-membrane domain not only decided the sub-cellular 
localisation of Bik, but also had an important role in Bik-induced apoptosis in Hep3B 
cells (Zhao et al, 2008).  
 
Thus the regulation of Bik appears complex. It may be that distinct regulatory 
mechanisms involving phosphorylation, turnover and altered mRNA levels, may be 
engaged in response to an array of different signaling molecules, such as survival 
factors, growth factors and death inducers, including viral infection (Lutz, 2000) and 
perhaps dependent on the cellular context (Mathai et al, 2002) providing multiple 
means to regulate this pro-apoptotic protein.   
 
1.15.6 EBV regulation of the Cellular Apoptotic Programme  
 
 
A central component of the overall EBV strategy and its role in the development of 
related malignant disease is the ability of the viral proteins to suppress the cellular 
apoptotic program. In this regard, EBV has developed mechanisms that suppress the 
apoptotic programme of the host in order to delay cell death during the lytic stage of 
infection, until virion numbers have been sufficiently amplified to transmit infection 
to other individuals via saliva, and also to ensure persistence in the host memory B-
cell compartment. EBV genes have been shown to manipulate the cell survival 
machinery of the infected cell by directly regulating the apoptotic death machinery, 
specifically by inducing the expression of several anti-apoptotic proteins such as Bcl-
2, Bfl-1, Mcl-1, A20, c-IAP-2 and also through the down-regulation of expression of 
pro-apoptotic proteins such as Bax and Bim (Laherty et al, 1992; Fries et al, 1996; 
Wang et al, 1996; D'Souza et al, 2000; Clybouw et al, 2005; Grimm et al, 2005; 
Pegman et al, 2006; Anderton et al, 2007).  
 
Group I BL cell lines which display type I latency, only expressing EBNA1, EBERs 
and BARTs and many EBV-negative BL lines can readily be triggered into apoptosis, 
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whereas Group III BL cell lines, which express the complete set of EBV latent 
proteins, are relatively resistant to a variety apoptotic triggers, including growth factor 
withdrawal, Ca
2+
 ionophore treatment and over-expression of the p53 tumour 
suppressor gene (Henderson et al, 1991; Okan et al, 1995).  EBV-negative BL cells 
converted to the type III latency state by infection with the B95-8 strain of EBV also 
display elevated thresholds of resistance to apoptotic stimuli (Gregory et al, 1991), 
thus implicating EBV latent genes in cell survival.   
 
1.15.6.1  EBV up-regulates bcl-2   
 
Type I BLs express little or no Bcl-2, group III BL cells lines display high levels of 
the Bcl-2 protein (Henderson et al, 1991). Bcl-2 is a prototype anti-apoptotic protein 
that interacts with the mitochondrial membrane and inhibits the action of caspases 
(Adams and Cory, 1998).  Transfection of individual EBV latent genes into EBV-
negative BL cell lines has shown that up-regulation of Bcl-2 expression correlates 
with the expression of three EBV proteins; LMP1, (Henderson et al, 1991; Rowe et 
al, 1994) EBNA2, (Finke et al, 1992) and EBNA3B (Silins and Sculley, 1995). 
Significantly, over-expression of Bcl-2 in group I BL cell lines following gene 
transfer results in reduced apoptosis in response to a number of stimuli compared with 
group III cell lines, and the inhibition of cell death was correlated to the amount of 
Bcl-2 expressed (Henderson et al, 1991; Milner et al, 1992).  Indeed, transfections 
with EBV LMP1 also resulted in enhanced survival of these cells and the ability of 
LMP1 to confer resistance to apoptosis to the type I BLs resulted from its ability to 
induce endogenous Bcl-2 expression (Gregory et al, 1991; Henderson et al, 1991). 
While LMP1 and EBNA2 appear to up-regulate Bcl-2 expression in vitro, the 
recirculating B-cells of peripheral blood which are a target of EBV, already express 
relatively high levels of Bcl-2 and EBV infection and so expression of LMP1 or 
EBNA2 or the combined expression of both, does not significantly impact Bcl-2 
expression. Thus it may be that the role of LMP1/EBNA2 in vivo is to maintain the 
high constitutive level of Bcl-2 rather than to induce it (Martin et al, 1993). 
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1.15.6.2  EBV up-regulates A20  
 
A20 is an inducible zinc finger protein that confers resistance to TNFα cytoxicity 
(Laherty et al, 1992) and is induced in response to a wide variety of stimuli, including 
cytokines such as TNF, IL-1, and CD40, as well as bacterial and viral products such 
as lipopolysaccharide (LPS), and human T-cell leukemia virus type I Tax in many cell 
types, including fibroblasts, lymphocytes and endothelial cells (Beyaert et al, 2000). 
A20 is constitutively expressed in EBV-immortalised B-cells and transfection 
experiments have demonstrated that LMP1 induces the expression of A20 in both 
lymphocytes and epithelial cells (Laherty et al, 1992; Fries et al, 1996; Spender et al, 
1999). Studies of the A20 promoter have shown that LMP1 transcriptionally activates 
the A20 gene through cis-acting NF-κB binding sites with a role for LMP1-inducible 
binding of an NF-κB-like factor to a consensus binding sites within the A20 promoter. 
A20 has also been identified as functioning in a negative feedback loop by inhibiting 
the activation of NF-κB from both CTAR1 and CTAR2 of the LMP1 protein. This 
effect is mediated by the binding of A20 to TRAF2 (Eliopoulos et al, 1999a).   
 
1.15.6.3  EBV up-regulates mcl-1 
Maximal Bcl-2 up-regulation by LMP1 requires 48 to 72 hours (Rowe et al, 1994). 
Up-regulation of the Bcl-2 homologue Mcl-1 by LMP1 precedes the induction of Bcl-
2 and is transient; and levels of Mcl-1 decrease when Bcl-2 levels begin to increase. 
Mcl-1 is an anti-apoptotic protein that has been shown to contribute to the prolonged 
existence of chronic lymphotrophic leukaemia B-cells and its higher expression is 
correlated with resistance to chemotherapy treatment (Moshynska et al, 2004). It is 
thought that Mcl-1 functions as a rapidly inducible, short-term effector of cell 
viability (Chao et al, 1998). LMP1 also blocked the decline in Mcl-1 levels in 
response to apoptotic stimulation triggered by elevated cyclic AMP. This effect of 
LMP1 was associated with a delayed cell death in the EBV-negative BL cell line 
BL41. The maintenance of Mcl-1 expression by LMP1 is likely to be a crucial 
immediate-early response that enables cells to survive until Bcl-2 can be up-regulated 
(Wang et al, 1996). 
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1.15.6.4  EBV up-regulates c-IAP2 
 
c-IAP2 is a member of the cellular inhibitor of apoptosis protein family (c-IAP), and 
was originally identified as a molecule recruited to the TNF receptor complex 
receptor via TRAF1 and TRAF2 (Rothe et al, 1995). Its expression is preferentially 
up-regulated by TNF and other stimuli activating NF-κB including IL-1, LPS, and 
CD30 stimulation (Craxton et al, 1998; Stehlik et al, 1998). Transcriptional activation 
by TNF or IL-1 is mediated
 
co-operatively by two NF-κB binding sites bound by the 
NF-κB p50/p65 hetero-dimer. In addition, over-expression of CD40 or LMP1 resulted 
in the c-IAP2 promoter-driven reporter
 
gene activation (Hong et al, 2000). It has been 
postulated that the LMP1-inducible c-IAP2
 
protein functions as a pro-survival factor 
during EBV-infection, acting independently
 
or in concert with TRAF1 or other 
LMP1-inducible anti-apoptotic
 
proteins such as A20 and Bcl-2 (Hong et al, 2000).   
1.15.6.5  EBV up-regulates bfl-1 
 
Studies in our laboratory have revealed the up-regulation of another anti-apoptotic 
gene, bfl-1/A1 during EBV infection. The pro-survival Bcl-2-family member Bfl-1/A1 
is a transcriptional target of NF-κB that is over-expressed in many human tumours 
and is a means by which NF-κB is known to inhibit apoptosis (Karsan et al, 1996; 
Grumont et al, 1999; Somogyi et al, 2001). Two EBV proteins LMP1 and EBNA2 
have been shown to up-regulate expression of this cellular gene in the laboratory 
(D'Souza et al, 2000; D'Souza et al, 2004; Pegman et al, 2006). In this regard, 
expression of LMP1 in EBV-negative BL cell lines coincides with a dramatic increase 
in bfl-1 mRNA (D'Souza et al, 2000) and bfl-1 expression was found to protect EBV-
positive cells against serum depletion-induced apoptosis. Moreover, expression of 
LMP1 in EBV-negative cell lines was found to trans-activate the bfl-1 promoter 
through interactions with components of the tumour necrosis factor receptor 
(TNFR)/CD40 signaling pathway. This process is NF-κB dependent, and involves the 
recruitment of TNFR-associated factor 2, and is mediated to a greater extent by 
CTAR2 relative to the CTAR1 domain of LMP1 (D'Souza et al, 2004).  EBNA2 also 
up-regulates bfl-1 expression. EBNA2 trans-activation of bfl-1 requires CBF1, and 
there is an essential role for a core consensus CBF1-binding site on the bfl-1 
promoter. Interestingly bfl-1 expression is induced and maintained at high levels by 
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the EBV growth program in an LCL, and withdrawal of either EBNA2 or LMP1 does 
not lead to a reduction in bfl-1 mRNA levels in this context, whereas the simultaneous 
loss of both EBV proteins results in a major decrease in bfl-1 expression (Pegman et 
al, 2006).  
 
1.15.6.6  EBV down-regulates bax.  
 
Bax is a member of the Bcl-2 family that, together with Bak, is required for 
permeabilisation of the OMM (Wei et al, 2001). EBV LMP1 inhibits bax promoter 
activity
 
through activation of NF-κB signaling via CTAR-1 and CTAR-2. The bax 
promoter harbours 3 κB consensus sites (Bentires-Alj et al, 2001) of which LMP1 is 
known to activate 2, namely κB2 and κB3. LMP1 induced binding of the NF-κB 
hetero-dimer p65/p50 to the κB2 site and of the p50/p50 homo-dimer to the κB3 site. 
Promoter mutation analysis revealed that the κB2 site is necessary for inhibition of 
bax promoter activity and the κB3 site, for its activation. However, the activation of 
the bax promoter by LMP1 was observed only in the presence of specific inhibitors of 
p65/p50. In all other cases, LMP1 inhibited bax promoter activity. Moreover, in cells 
with impaired Bax function or expression the
 
anti-apoptotic activity of LMP1 is 
significantly reduced indicating that Bax is an important target of the anti-apoptotic
 
activity of LMP1 (Grimm et al, 2005). 
 
1.15.6.7  EBV down-regulates bim.  
 
Bim is a BH3-only protein whose over-expression in cells leads to cytochrome c 
release through the activation of Bax (Hacker and Weber, 2007). All mature B-cells 
express significant amounts of BH3-only Bim (O'Reilly et al, 2000; Strasser, 2005). 
Infection of BL cells with EBV results in a significant down-regulation in the 
expression of all three isoforms of the bim gene (Clybouw et al, 2005; Leao et al, 
2007). Moreover, this down-regulation appears not to require expression of EBNA2 
or the LMP proteins (Leao et al, 2007) and is in fact dependent on the co-operation of 
EBNA3A and EBNA3C (Anderton et al, 2007). It has been reported that EBV 
infection may lead to post-translational modulation of Bim expression, involving the 
phosphorylation of BimEL by the EBV-activated kinase ERK1/2, followed by its 
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degradation through the proteasome pathway (Clybouw et al, 2005). However, a 
pathway in which EBNA3A and EBNA3C co-operate to regulate Bim expression at 
the level of transcription has also been described (Anderton et al, 2007). 
 
1.15.7  EBV lytic proteins encode anti-apoptotic functions. 
 
During the lytic cycle of virus replication, repressors of apoptosis can provide a 
selective advantage by protecting the cell from death. EBV encodes its own gene 
products which can delay apoptosis in order to maximise viral production and spread 
of virus progeny to other individuals. These genes include BHRF1, BZLF1 and 
BALF1 (Henderson et al, 1993; Tarodi et al, 1994; Dawson et al, 1995; Marshall et 
al, 1999).  As indicated earlier, EBV also encodes a viral homologue of IL-10 (Stuart 
et al, 1995) 
 
BHRF1 promotes the survival and
 
proliferation of lytically infected cells (Dawson et 
al, 1998) and the highly conserved nature of BHRF1 amoung different EBV
 
isolates 
at both the sequence and functional level supports the proposed
 
vital role of BHRF1 in 
delaying cell death, thereby maximising the
 
production of progeny virus and 
facilitating the establishment of virus
 
persistence (Khanim et al, 1997). BZLF1 has 
been shown to interact with p53 and inhibit its trans-activating function in lymphoid 
cells, thereby providing a mechanism for preventing p53-mediated apoptosis (Cayrol 
and Flemington, 1996). The BALF1 ORF in EBV possesses significant sequence 
similarity to other anti-apoptotic viral Bcl-2 homologs and the cellular Bcl-2 and Bcl-
XL. A recombinant GFP-BALF1 fusion protein co-localises with mitochondrial dyes, 
suppresses apoptosis, and hetero-dimerises with Bax and Bak (Marshall et al, 1999).  
 
While the growth stimulatory and anti-apoptotic genes induced by the initial EBV 
infection almost certainly prolong survival in the lytic stage of the lifecycle, it is also 
likely that they may augment the likelihood of the virus-infected cell progressing into 
the memory B-cell pool. Taken together, these interactions account, at least in part, 
for the ability of EBV to induce cell proliferation and survival, which is essential for 
both EBV-induced immortalisation of B-cells and establishment of life-long 
persistence in the memory B-cell compartment.   
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1.16  Objectives of the study 
 
The modulation of anti- and pro-apoptotic proteins by EBV plays a central role in the 
overall virus strategy, and in the development of virus-associated malignancies.  
Previous work in our laboratory has demonstrated that the cellular bfl-1 gene plays an 
important role in regulating the survival of EBV-infected B-cells (D'Souza et al, 
2000; D'Souza et al, 2004; Pegman et al, 2006). In a related study in our laboratory, it 
was observed, that bfl-1 is expressed in H/RS cells in vivo and that its expression is 
regulated by NF-κB. Bfl-1 protected H/RS cells from apoptosis induced by NF-κB 
inhibitors and knockdown of bfl-1 expression significantly increased the 
chemosensitivity of cultured H/RS cells (Loughran, S.T. manuscript in preparation). 
 
Preliminary results in the laboratory had indicated that repressed levels of bik mRNA 
appeared to be a feature of the BL cell line
 
expressing a group III phenotype but not 
the BL group I
 
phenotype, indicating that the pro-apoptotic bik gene could potentially 
be an important target for down-regulation by EBV latent genes in the mediation of an 
increased anti-apoptotic threshold of EBV infected cells. 
 
The down-regulation of bik by EBV in B-cells would have implications for the 
biology of EBV, as EBV-mediated down-regulation of this gene may contribute to the 
survival of EBV-infected B-cells, since cells similar to LCLs are present in the 
circulation and during primary infection by the virus (Qu and Rowe, 1992; Tierney et 
al, 1994).  Additionally, the suppression of bik may contribute to the development of 
EBV-associated B-cell malignancies, such as post-transplant lymphoproliferative 
disorders and BL tumours. Mechanistic studies into the contribution of bik to cell 
survival will provide important information about both normal B-cell development 
and potential routes to B-cell malignancy.   
 
The main focus of the current study was thus to  
 
• Establish a role for EBV in the regulation of the cellular bik gene.  
• Elucidate the mechanisms by which this pro-apoptotic gene is regulated and in 
particular to determine if EBNA2 is involved in its regulation. 
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• Determine the significance of the loss of Bik expression to the survival of 
EBV-infected cells in culture. 
 
In summary, this thesis presents the novel finding that EBV down-regulates the 
cellular bik gene in B-cells proliferating due to the EBV growth programme, with a 
key role for EBNA2 and possibly c-Myc in this regulation. Significantly, restoration 
of Bik expression in LCLs leads to apoptotic cell death. The down-regulation of bik 
by EBNA2 highlights the protective effect of EBNA2 in EBV-infected cells and 
which may complement the LMP1-induced survival signals mediated through NF-κB.  
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2.1.1 Biological Materials 
 
 
2.1.1.1 Cell lines 
 
Table 2.1-1: Cell lines used in the study 
 
Cell Lines 
 
EBV Status Cell Classification Description 
AG876  + Type III BL Type III BL cell line expressing all of the 
EBV latent genes. 
Akata-4E3 - Type I BL During cultivation of the Epstein-Barr 
virus (EBV)-positive
 
Burkitt's lymphoma 
(BL) line Akata, EBV DNA
 
was lost from 
some of the cells and EBV-negative 
clones were isolated (Shimizu et al, 
1994). 
BJAB 
 
- Burkitt-like 
lymphoma cell line 
BJAB is
 
a B-cell derived from a patient 
with EBV-negative
 
African Burkitt's 
lymphoma. The cells do not contain 
detectable amounts of EBV DNA, nor do 
they express the EBV-determined nuclear 
antigen EBNA. However the cells have 
the characteristics of B-type lymphocytes 
and carry receptors for EBV (Menezes et 
al, 1975).  
BJAB-ER/EBNA2(K3) 
(BJABK3) 
- Stable transfectant EBV negative BL-like cell line stably 
transfected with an EBNA2 expression 
plasmid in which EBNA2 activation 
domain is fused to the estrogen binding 
domain, rendering the activation of  
EBNA2  dependent on the presence of 
estrogen (Kempkes et al, 1996) 
BL41 
BL41-B95.8 
IARC 171 
 
+ 
+ 
+ 
 
Type I 
Type III 
LCL 
 
These cells are a matched set. BL41 is an 
early passage BL cell line expressing 
EBNA1 as the only viral protein, BL41-
B95.8 is the cell line stably transformed 
with the EBV strain B95.8 expressing all 
the EBV latent genes (Calender et al, 
1987).  
 
IARC 171 is a spontaneously transformed 
Lymphoblastoid Cell Line derived from 
the same patient. 
BL41-P3HR1 + Type I BL41-P3HR1 is the BL41 cell line stably 
transformed with the EBV strain P3HR1 
expressing all the EBV latent genes 
except EBNA2 and EBNA-LP (Calender 
et al, 1987).  
 
 
 
BL41-ER/EBNA2 (K3) 
(BL41K3) 
 
 
 
 
 
 
- 
 
 
 
 
 
BL (stable 
transfectant) 
 
 
 
EBV negative BL cell line stably 
transfected with an EBNA2 expression 
plasmid in which the EBNA2 activation 
domain is fused to the estrogen binding 
domain, rendering the activation of 
EBNA2 dependent on the presence of 
estrogen (Kempkes et al, 1996). 
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BL41P3HR1-ER/EBNA2 
(9A) 
(BL419A) 
 
 
+ 
 
EBV Positive BL 
(Stable transfectant) 
 
 
EBV negative BL infected with the 
P3HR1 strain of EBV and subsequently 
transfected with an EBNA2 fusion protein 
where EBNA2 activation is dependent on 
the presence of estrogen as above 
(Kempkes et al, 1996) 
DAUDI 
 
 
+ EBV positive BL 
Type III 
DAUDI, described by (Klein et al, 1968), 
is deleted for EBNA-2 and does not 
express LMP1. This cell line expresses 
only EBNA1 and LMP2A. The EBV 
genome in Daudi cells has a deletion 
similar to that observed in a non-
transforming strain (P3HR-1) of the virus 
(Jones et al, 1984). 
DG75 
 
 
 
DG75-tTA-EBNA2 
 
 
 
 
 
DG75-tTA-LMP1 
 
- 
 
 
 
- 
 
 
 
 
 
- 
EBV negative BL 
 
 
 
Stable transfectant 
 
 
 
 
 
Stable transfectant 
 
Lymphoid B-cell line derived from an 
Israeli Burkitt-like lymphoma case (Ben-
Bassat et al, 1977). 
 
Tetracycline regulated system whereby 
the expression of EBNA2 can be induced 
by the removal of tetracycline from the 
growth media (Floettmann et al, 1996). 
 
Tetracycline regulated system whereby 
the expression of LMP1 can be induced 
by the removal of tetracycline from the 
growth media (Floettmann et al, 1996). 
EREB 2.5 + 
 
LCL An LCL established by co-infecting B-
cells with a 28kb mini-EBV plasmid that 
only expresses estrogen-responsive 
EBNA2, together with the EBV P3HR1 
strain in which it’s own EBNA2 gene is 
deleted (Kempkes et al, 1995a). 
 
HEK-293 
 
- 
  
Human embryonic kidney cell line 
(Graham et al, 1977). 
IARC 290B - LCL IARC 290B is a spontaneously 
transformed LCL. 
IB4 - LCL An LCL established by infection of 
umbilical cord blood lymphocytes with 
the EBV strain B95.8 (King et al, 1980) 
KEM BL 
 
+ 
 
 
Type I BL 
 
Early passage BL cell lines expressing 
EBNA1 as the only viral gene. 
 
L428 
 
 
 
 
LCL 327 
- 
 
 
 
 
+ 
EBV negative HL 
 
 
 
 
LCL 
Established from the pleural effusion of a 
37-year-old woman with HL (stage IVB,  
nodular sclerosis, refractory, terminal) in 
1978 (Schaadt et al, 1979). 
 
An EBV immortalised B-cell line (Allday 
et al, 1995). 
 
 
Mutu I 
 
 
 
 
 
+ 
 
 
 
 
 
Type I 
 
 
 
 
 
Early passage BL cell expressing EBNA1 
as the only viral gene (Gregory et al, 
1990).  
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All BL cell lines and LCLs were obtained from Professor Martin Rowe, University of 
Wales, Cardiff, Wales.  The estrogen-responsive cell line EREB 2-5 was a gift from Dr. 
Ursula Zimber-Strobl, GSF-National Research Centre for Environment and Health, 
Munich, Germany.  The EREB 2-5-derived
 
cell line, P493-6 was a gift from Prof. Dr. med. 
Georg W. Bornkamm, Institute of Clinical Molecular Biology and Tumor Genetics 
Munich, Germany.  The estrogen responsive cell lines BL41K3, BL419A and BJABK3 
were gifts from Dr. Bettina Kempkes GSF-National Research Centre for Environment and 
Health, Munich, Germany. Akata-4E3 was received from Professor Diane Hayward, Johns 
Hopkins School of Medicine, Baltimore, Maryland 21231, USA. 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
Mutu III 
 
+ 
 
Type III 
 
Stable clone of early passage BL cell line  
Mutu I which has upon serial passage 
drifted to express the full compliment of 
EBV latent genes (Gregory et al, 1990). 
 
OKU BL 
OKU LCL 
+ 
+ 
 
Type I 
 LCL 
 
These cells are a matched pair. OKU BL 
is a group I BL cell line expressing only 
EBNA1.  
 
OKU LCL was established upon infection 
of peripheral lymphocytes from the same 
patient from whom OKU BL was derived 
with the EBV strain B95.8. 
P493-6 + 
 
LCL An EREB 2-5-derived
 
cell line, P493-6, 
in which c-Myc is expressed under the 
control
 
of a tetracycline-regulated 
promoter (Pajic et al, 2000).  
RAEL BL 
 
+ 
 
Type I BL Early passage BL cell lines expressing 
EBNA1 as the only viral gene. 
X50-7 
 
- LCL 
 
X50-7 is a spontaneously transformed 
LCL. 
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2.1.1.2 Antibodies used in the study 
 
 
Table 2.1-2: Antibodies used in the study 
 
Antibody +ame/Code Description Supplier 
Goat Anti-BIK NBK (N-19): sc-
1710 
 
An affinity purified Goat 
Polyclonal IgG raised against a 
peptide mapping at the N-
terminus of Bik/NBK of 
human origin 
 
Santa Cruz 
Mouse Anti-Bik Mouse Anti-Human 
Bik Clone C33-1 
(557040) 
Monoclonal IgG raised against 
amino acids 40-114. 
BD Biosciences 
Rabbit Anti-Bax-
Horseradish 
Peroxidase (HRP)  
 
Bax (N-20): sc-493 
 
Affinity purified rabbit 
polyclonal antibody raised 
against a peptide mapping at 
the  
 
N-terminus of Bax of human 
origin. 
 
Santa Cruz 
 
Rabbit-Anti c-Myc 
 
c-Myc (N-262) :sc-
764 
Rabbit Polyclonal IgG raised 
against amino acids 1-262 
mapping at the N-terminus of 
c-Myc of human origin. 
 
Santa Cruz 
 
Mouse Anti- β - Actin 
Clone AC-15 
 
Anti- β – Actin 
A1978 
 
Monoclonal IgG Raised 
against β-cytoplasmic actin N-
terminal peptide. 
 
Sigma 
Donkey Anti-Goat 
IgG-HRP 
 
Anti-Goat IgG-HRP 
V8051 
 
Secondary antibody developed 
in donkeys against goat IgG; it 
has been affinity-purified and 
conjugated to HRP. 
 
Promega 
Goat Anti-Mouse IgG 
Alkaline Phosphatase 
(AP) Conjugate 
Anti-Mouse IgG 
(AP) Conjugate 
S3721 
 
Affinity-purified goat anti-
mouse antibody 
 
Promega 
Mouse anti-EBNA2 PE2 An affinity purified 
monoclonal antibody that 
reacts with the latent gene 
product EBNA2. 
Professor Martin 
Rowe, University of 
Cardiff, Wales 
 
Mouse anti-LMP1 CS1-4 An affinity purified 
monoclonal antibody that 
reacts with EBV-encoded 
latent gene product LMP1. 
Professor Martin 
Rowe, University of 
Cardiff, Wales 
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Rat Anti-HA-HRP Anti-HA-peroxidase 
high affinity 
(12013819001) 
HRP-conjugated rat 
monoclonal antibody that 
recognises the HA peptide 
sequence (YPYDVPDYA) 
derived from the influenza HA 
protein. 
Roche. 
 
Mouse anti-p53 
 
Anti-p53 (OP43) 
Monoclonal IgG raised against 
amino acids 21-25 of human 
p53 
Merck 
 
 
 
2.1.1.3 Bacterial strains used in the study 
 
Table 2.1-3: Bacterial strains used in the study 
 
Bacterial Strain Genotype 
 
E. coli JM109 
endA1, recA1, gyrA96, thi, hsdR17 (rk
-
, mk
+
), relA1, supE44, λ-, ∆(lac-
proAB), [F´, traD36, proA + B + , lacl 
q
 Z∆M15] 
 
 
2.1.1.4 Expression and Reporter Constructs 
 
Table: 2.1-4: Plasmids used in this study 
 
Plasmid Source Description 
pSG5  
 
 
 
 
pSG5-EBNA2 
 
 
 
 
pSG5EBNA2ww323sr 
Stratagene 
 
 
 
 
Lindsey Spender, Ludwig Institute 
for Cancer Research, Imperial 
College School of Medicine, 
London.   
 
Professor Diane Hayward, Johns 
Hopkins School of Medicine, 
Baltimore, Maryland 21231, USA. 
The pSG5 Vector is a eukaryotic 
expression vector, harbouring the 
SV40 promoter and the ampicillin 
resistance gene. 
 
pSG5EBNA2 expresses the wild 
type EBNA2 gene (from the EBV 
strain B95.8) cloned into pSG5. 
  
 
pSG5EBNA2ww323sr is identical to 
pSG5-EBNA2 except that EBNA2 
has had two tryptophan residues 
mutated to serine and arginine 
residues at positions 323 and 324 
respectively.  pSG5EBNA2ww323sr 
therefore, does not bind RBP-
Jκ/CBF1 (Ling et al, 1993a). 
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pGL2-Basic 
 
 
 
 
 
 
-1374/+81- bfl1-Luc 
 
 
 
 
 
 
 
-1710/+203-bik-Luc 
 
-855/+203-bik-Luc 
 
-191/+203-bik-Luc 
Promega 
 
 
 
 
 
 
Dr. Brendan D'Souza, Laboratory 
for molecular and cellular biology. 
Dublin City University, Glasnevin, 
Dublin 9. 
 
 
 
 
This study 
 
The pGL2-Basic Vector
 
is a reporter 
construct lacking eukaryotic 
promoter and enhancer sequences, 
The vector carries the coding region 
for firefly (Photinus pyralis) 
luciferase. 
 
–1374/+81 Bfl-1 is a reporter 
construct for bfl-1 in which the bfl-1 
promoter from the -1374/+81 Bfl-1 
CAT  construct was inserted into the 
pGL2 basic vector which contains 
the luciferase  reporter (D'Souza et 
al, 2000). 
 
Reporter construct for bik in which 
the full length 1.9kb bik promoter 
from the -1710/+203 Bik CAT 
construct was cloned into the 
promoterless vector pGL2-basic 
which expresses the luciferase 
reporter gene. -855/+203-bik-Luc 
and -191/+203-bik-Luc are 
progressive deletion fragments of the 
bik promoter region containing the 
regions –855 to +203 and  -191 to 
+203 cloned into pGL2-basic. 
 
pGL3-Basic 
 
 
 
 
 
 
 
 
 
 
 
pGL3-1710/+203-bik-Luc 
 
pGL3-855/+203-bik-Luc 
 
pGL3-191/+203-bik-Luc 
Promega 
 
 
 
 
 
 
 
 
 
 
 
This study 
 
The pGL3-Basic is a reporter 
construct containing the backbone of 
the pGL2-Basic with increased 
expression, and contains a modified 
coding region for firefly luciferase 
that has been optimised for 
monitoring transcriptional activity in 
transfected eukaryotic cells. pGL3-
Basic lacks eukaryotic promoter and 
enhancer sequences. 
 
Full length 1.9kb reporter construct 
for bik as above but in the pGL3-
basic background. pGL3-855/+203-
bik-Luc and pGL3-191/+203-bik-Luc 
are progressive deletion fragments in 
pGL3-basic also as above.  
 
pcDNA3 
 
 
 
 
pcDNA3-Myc-bik 
 
Invitrogen 
 
 
 
 
Professor Eileen White, Department 
of Molecular Biology and 
Biochemistry, and Cancer Institute 
of New Jersey, Rutgers University, 
Piscataway, New Jersey 08854 
 
 
 
 
The pcDNA3 Vector is a eukaryotic 
expression vector, harbouring the 
CMV promoter and the ampicillin 
and G418 resistance gene. 
 
Expresses the Bik protein tagged to 
the Myc-epiptope in pcDNA3. 
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pcDNA3-HA-bik 
 
 
 
pcDNA3-HA-bik-∆BH3 
 
 
Dr. G. Chinnadurai, Saint Louis 
University School of Medicine, 
Missouri. U.S.A. 
 
Dr. G. Chinnadurai, Saint Louis 
University School of Medicine, 
Missouri. U.S.A. 
 
Expresses Bik protein tagged to the 
influenza virus hemaglutinin (HA) 
epitope in pcDNA3. 
 
pcDNA3-HA-bik-∆BH3 is an 
expression vector for Bik protein as 
before but containing a deletion in 
the BH3 domain which abrogates the 
death promoting activity of this 
protein. 
 
pcDNA3-HA-bfl-1 Dr. G. Chinnadurai, Saint Louis 
University School of Medicine, 
Missouri, U.S.A. 
Expresses Bfl-1 protein tagged to the 
influenza virus HA epitope in 
pcDNA3 (D'Sa-Eipper et al, 1996). 
pcDNA3-HA-Myc 
 
 
Prof. Dr. med. Georg W. 
Bornkamm, Institute of Clinical 
Molecular Biology and Tumor 
Genetics (München, Germany)  
 
Expresses the Myc protein tagged to 
the HA-epiptope in pcDNA3. 
 
pCMV-LacZ Clontech pCMV-LacZ contains E.coli β-
galactosidase gene under the control 
of the CMV promoter-enhancer.   
 
pGa50-7 
 
pGa981-6 
Dr. Bettina Kempkes, Institute of 
Clinical Molecular Biology and 
Tumour Genetics, GSF, Munich, 
Germany. 
pGa50-7 is  a β-globin minimal 
promoter construct. 
 
pGa981-6 is a reporter construct 
(Minoguchi et al, 1997) which was 
generated using a 50bp 
oligonucleotide containing both 
CBF1 binding sites of the EBV TP1 
promoter, which was then ligated as 
a hexamer into pGa50-7 (Laux et al, 
1994b). 
 
p-1710/+203-BikCAT 
 
 
 
 
 
 
 
Dr. G. Chinnadurai, Saint Louis 
University School of Medicine, 
Missouri. U.S.A. 
 
 
 
p-1710/+203Bik CAT contains the 
region –1710 to +203 of the human 
bik gene cloned into the pBLCAT-2 
∆TK vector (in which the tk 
promoter has been deleted) (Verma 
et al, 2000), expressing a CAT 
reporter gene.  
pJT125 
 
 
 
pRSP 83 
 
Professor Elliot Kieff. Department 
of microbiology and molecular 
genetics, Harvard Medical School, 
Massachussetts. 
 
Dr. Paul Ling, Department of 
Molecular Virology and 
Microbiology, Baylor College of 
Medicine. Baylor Plaza, Houston, 
Texas. 
 
pSG5LP expression plasmid 
containing two W repeats  is also 
known as pJT125 and the non 
functional partner for this (pRSP83) 
also consists of the EBNA-LP 
isoform with  2 W repeats however 
site directed mutagenesis changed 
three serine residues in each of the 
W2 repeats to alanine residues. The 
EBNA-LP expression plasmids are 
cloned into the pSG5 vector 
(Harada,and Kieff; Peng et al., 2000. 
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pRTS-1 
 
Prof. Dr. med. Georg W. 
Bornkamm, Institute of Clinical 
Molecular Biology and Tumor 
Genetics (München, Germany)  
 
Novel tetracycline-inducible vector 
carrying all the elements for 
conditional gene expression 
including the gene of interest on one 
EBV-derived episomally replicating 
plasmid (Bornkamm et al, 2005).  
 
pRTS-1-HA-bik 
pRTS-1-HA- bik-∆BH3 
 
This Study 
 
 
 
 
 
 
 
 
 
 
 
Generated by insertion of, HA-bik 
ORF from pcDNA3-HA-bik into 
pRTS-1, generating a tetracycline 
regulatable vector capable of 
conditional expression of HA-tagged 
Bik protein. 
 
pRTS-1-HA-bik-∆BH3 was 
generated by insertion of HA-bik-
∆BH3 ORF from pcDNA3-HA-bik-
∆BH3 into pRTS-1. 
 
pRTS-1-Myc-bik 
 
This Study Generated by insertion of, Myc-bik 
ORF from pcDNA3-Myc-bik into 
pRTS-1, generating a tetracycline 
regulatable vector capable of 
conditional expression of Myc-
tagged Bik protein. 
 
pRTS-1-HA-bfl-1 Dr. Sinead Loughran Laboratory for 
molecular and cellular biology. 
Dublin City University, Glasnevin, 
Dublin 9. 
Generated by insertion of, HA-bfl-1 
ORF into pRTS-1, capable of 
conditional expression of HA-tagged 
Bfl-1 protein. 
 
 
 
2.1.1.5 Oligonucleotides 
Table 2.1-5: Oligonucleotides used in this Study 
 
 
Target Primer Sequence 
 
BIK ORF F 
BIK ORF R 
(Sequencing) 
 
 
5’-GGT ACC ATG GAG CAA AAG CT-3’ 
5’-CTC GAG CCT CCA GGG CAG TG-3’ 
 
BikPromFor 
BikPromRev 
 
5’-CGC GGA TCC ACC CAC TCT GCC CTT GA-3’ 
5’-CGC GGA TCC TGG CAG CGT CTG TAA GC-3’ 
 
BikPromFor2 
BikPromRev2 
5’-CCG CTC GAG CAC CCA CTC TGC CCT TGA-3’ 
5’-CGG GGT ACC CAC CCA CTC TGC CCT TGA-3’ 
 
 
MycBikForSfiI 
MycBikRevSfiI 
 
 
5’-TCT ATG GGC CTC ACT GGC CGG TAC CAT GGA GCA AAA GCT-3’ 
5’-TCT ATG GGC CTC ACT GGC CCT CGA GCC TCC AGG GCA GTG-3’ 
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HABikForSfiI 
HABikRevSfiI 
 
5’-TCT ATG GGC CTC ACT GGC CAT GTA CCC ATA CGA TGT T-3’ 
5’-TCT ATG GGC CTC ACT GGC CTC ACT TGA GCA GCA GGT-3’ 
 
 
pEBNAseqFor 
(Sequencing primer) 
 
 
5’-CAA GCT TTT CGG CCT CAC TGG CC-3’ 
 
GAPDH-F 
GAPDH-R  
5’-TGC ACC ACC AAC TGC TTA-3’ 
5’-GAT GAT GTT CTG GAG AGC-3’ 
 
pGL2-F  
pGL2-R  
(sequencing primers) 
5’-GTA TCT TAT GGT ACT GTA ACT G-3’ 
5’- CTT TAT GTT TTT GGC GTC TTC C-3’ 
pcDNA3-For 
pcDNA3-Rev 
(sequencing primers) 
5’-GGC TAA CTA GAG AAC CCA CTG-3’ 
5’-GGC AAC TAG AAG GCA CAG TC-3’ 
 
 
All oligonucleotides were synthesised by and obtained from MWG-Biotech, 
Ebersberg, Germany. 
   
2.1.2 Bioinformatics software 
A number of web-based bioinformatics tools listed in Table 2.1-6 were used routinely 
in this study. 
Table  2.1-6: Web-based bioinformatics tools used in this study 
 
Tool Source Use 
BLAST http://www.ncbi.nlm.nih.gov/
BLAST 
Comparison of nucleotide or protein 
sequences to GenBank sequence database. 
Statistical significance of matches 
calculated. 
BioSeq File Format 
converter 
http://bioinformatics.org/JaM
BW/1/2/index.html 
Conversion of nucleotide sequences to 
other formats including FASTA and 
GenBank.   
 
CpG Island Searcher http://cpgislands.usc.edu/cpg.a
spx 
The CpG island searcher screens for CpG 
islands which meet the criteria selected in 
submitted DNA sequences 
 
MatInspector http://www.genomatix.de/prod
ucts/MatInspector/MatInspect
or1.html 
Nucleic Acid Sequence Searches, to 
identify putative transcription factor 
binding sites. 
NEBcutter V2.0 http://tools.neb.com/NEBcutte
r2/index.php 
Identification of restriction enzymes sites 
along a DNA sequence, and prediction of 
fragment sizes. 
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NetPrimerLaunch http://www.premierbiosoft.co
m/netprimer/netprlaunch/netpr
launch.html 
Primer analysis software for prediction of 
primer properties including, Tm, GC 
content, probability of primer-
dimers/hairpins formation. 
TESS http://dot.imgen.bcm.tmc.edu/ 
 
Nucleic Acid Sequence Searches, to 
identify putative transcription factor 
binding sites. 
Translate tool http://www.expasy.org/tools/d
na.html 
Translation of a nucleotide (DNA/RNA) 
sequence to a protein sequence. 
 
2.1.3 Chemical and Molecular Biology Reagents  
 
Table 2.1-7: Chemical and molecular biology reagents used in this study 
 
Supplier Product/Code 
Amersham Rainbow Molecular Weight Markers (RPN800) 
Amaxa GmBH Cell Line Nucleofector Kit T (VCA-1002), Kit V (VCA-1003) 
Applied Biosystems AmpliTaq Gold DNA Polymerase (N8080240), Bax Real Time Assay 
(Hs00180269_m1), Bik Real Time Assay (Hs00154189_m1), Gapdh 
Real Time Assay (Hs99999905_m1), Taqman 2X Universal PCR 
Master Mix No AmpErase UNG (58004008-01). 
ASP Presept Disinfectant Tablets (SPR25) 
BD Biosciences Annexin V-PE kit code 559763, FACS flow (342003). 
BDH Bromophenol blue (44385), EDTA (280254D), Glycine (444495D), 
Hydrochloric acid (28507BF), Isopropanol (296946H), Magnesium 
sulphate (29117), Methanol (29192BL), Nitrocellulose membrane 
(436107E), Potassium acetate (295814P), Sodium dihydrogen 
orthophosphate (30716), Sucrose (102745C), 
Tris(hydroxymethyl)methylamine (271195Y). 
Eppendorf Perfectprep Gel Cleanup (955152000) 
Invitrogen 
 
 
1 Kb DNA ladder (15615-016),100 bp DNA ladder (15628-019), 
Foetal calf serum (10270-106),  HEPES (15630-056), Glutamax 1640 
(61870-010), RPMI 1640 (31870-025), Trypan blue (15250-061), 
Trypsin (25090-028), Sodium Pyruvate (11360-039), SYBR Gold 
Nucleic Acid Gel Stain (S11494), Lipofectamine (18324-012).    
Kodak X-ray film (FS388). 
Labkem  Nitrocellulose Membrane (436107E) 
Labscan Chloroform (A3505E).  
Lennox Chemicals IMS (B0982) 
 
Merck 
 
Calcium chloride (23821000), Glacial acetic acid (100632511), 
Magnesium chloride (1058321000), Potassium Hydroxide 
(50321000), Sodium carbonate (A654792), di-Sodium hydrogen 
phosphate (1065860500), 5-aza-2’-Deoxycytidine (189825), zVAD-
FMK (219007), Anti-p53 (OP43). 
National diagnostics Acrylagel (EC810), Bis-acrylagel (EC820). 
Millipore Amicon Ultrafilter (UFC8 00508) 
New England Biolabs 
 
Alkaline Phosphatase (CIP) & 10X dephosphorylation buffer 
(M0290S). T4 DNA Ligase & 10X ligation buffer (M0202L), 
Restriction enzymes. 
Oxoid 
 
Agar (L13), PBS tablets (BR14), Tryptone (L42), Yeast extract (L21), 
PBS (Br14A) 
Pierce 
 
BCA Protein assay kit (23227), SuperSignal® West Pico 
Chemiluminescent Substrate (34080). 
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Promega 
 
dNTPs (U1330), Luciferase Assay System (E1501), Magnesium 
chloride 25mM (A3511), M-MLV reverse transcriptase & RT buffer 
(M1701), 5X Reporter lysis buffer (E3971), RNasin (N2111), 
Wizard
® 
PCR Preps DNA purification system (A7170), Donkey Anti-
Goat HRP V8051, Goat Anti-mouse Alkaline phosphatase conjugate 
S3721. 
Roche Rat Anti-HA-HRP (12013819001), Taq polymerase & 10 X enzyme 
buffer (1146173), Hygromycin B (843555), Leupeptin (1017128).  
Qiagen 
 
Qiagen
®
 Plasmid Purification Kit (12143), Quantitect 
TM
 SYBR
®
 
Green PCR Kit (204143). 
Santa Cruz Biotechnology Goat Anti-Bik sc1710, Rabbti Anti-Bax-HRP sc493, Rabbit Anti-c-
Myc sc764 
Sigma-Aldrich Chemical Co.  
 
3M sodium acetate, pH5.2 (S7899), Agarose (A5093), Ampicillin 
(A9518), Aprotinin (A4529), Ammonium Persulfate (215589), BCIP-
NBT (B1911), Bovine serum albumin (A9647), Chlorofrom:isoamyl 
alcohol (24:1) (C0549), Colorburst electrophoresis markers (C4105), 
Coomassie Brilliant Blue R (B0149), Copper (II) Sulphate 
pentahydrate (31293), DEAE-dextran (D9855), DEPC (D5758), 
DMSO (D8779), β-estradiol (E8875), Ethidium bromide (E4391), 
Geneticin (G418) (A1720), Glucose (G7528), Glycerol (G5516), 
Hydrogen peroxide (H1009), Hydroquinone (H9003), L-glutamine 
(G7513), Manganese Chloride (M3634), MOPS (M3183), ONPG 
(N1127), Penicillin/streptomycin (P0781), Phenol:chloroform:isoamyl 
alcohol (25:24:1) (P3803), PMSF (P7626), Ponceau S (P7170), 
Potassium chloride (P4504), Puromycin (P8833), RedTaq (D4309), 
RNase A (R6513), Rubidium chloride (R2252), Lauryl Sulfate 
(L6026), Sodium Butyrate (B5887), Sodium chloride (S3014), Sodium 
hydroxide (S5881), α-Thioglycerol (M1753 ),Tetracycline (T7660), 
TEMED (T7024), Tri reagent (T9424),3,3’,5,5’-Tetramethylbenz 
idine (TMB) (T0565), Triton
®
 X-100(T8787), Trizma
®
 Base (T1503), 
Trichostatin A (T8552) Tween 20 (P1379), Water (Molecular Grade) 
(W4502), Mouse Anti-β-Actin A1978, Sodium Citrate (S1804) 
MG132 (C2211), Actinomycin D (A1410). 
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2.2 Methods 
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2.2.1  D+A Manipulation
*
 
 
2.2.1.1  D+A Storage 
 
DNA samples were stored in Tris-EDTA (TE) buffer (pH 8.0) at 4˚C.  EDTA was 
used to chelate heavy metal ions that are needed for DNase activity while storage at 
pH 8.0 minimises deamidation.  DNA was also stored in sterile distilled H2O (dH2O) 
at -20˚C.  
 
2.2.1.2  Phenol/chloroform extraction and ethanol precipitation 
 
The standard method to concentrate nucleic acid samples, remove proteins or change 
the buffers in which a sample was dissolved is a Phenol/chloroform extraction 
followed by ethanol precipitation. DNA partitions into the aqueous phase, denatured 
proteins collect at the interface, and lipids partition into the organic phase. Nucleic 
acids are routinely recovered from aqueous solutions using ethanol precipitation in the 
presence of sodium acetate.  
 
An equal volume of phenol/chloroform/isoamyl alcohol (25:24:1) was added to the 
DNA solution, mixed by vortexing and centrifuged for 5 mins at 13,000 x g at room 
temperature.  The upper aqueous phase was removed, avoiding any material at the 
interphase, and placed in a sterile microfuge tube.  An equal volume of 
chloroform/isoamyl alcohol (24:1) was added to the aqueous phase (to remove any 
residual phenol), vortexed as before, and centrifuged for 5 mins at 13,000 x g at room 
temperature.  Again the upper aqueous phase was removed to a fresh tube.  One-tenth 
volume of 3M sodium acetate (pH 5.2) was added to the solution of DNA to aid 
precipitation, mixed and followed by 2 and a half volumes of 100% (v/v) ethanol.  
This mixture was vortexed and incubated at -20˚C for a minimum of 20 mins. When 
dealing with very small quantities of DNA samples were precipitated in ethanol at -
20
o
C overnight. The DNA samples were then centrifuged for 20 mins at 12,000 x g at 
4˚C, the supernatant was removed and pellets were washed with 300µl 70% (v/v) 
ethanol to remove excess salts.  The tube was centrifuged for 5 mins at 10,000 x g, the 
                                                 
*
 Preparations of all solutions used in DNA manipulation are outlined in Appendix I.  
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supernatant was removed and pellets were air dried for approximately 10 mins.  
Pellets were re-suspended in an appropriate volume of sterile TE (pH 8.0) or dH2O 
and were stored at 4˚C or -20˚C respectively. 
 
2.2.1.3  Restriction digestion of D+A 
 
Restriction enzymes specifically bind and cleave double-stranded DNA at specific 
sites within or adjacent to a particular sequence, which is known as the recognition 
site. Restriction digestion of DNA was carried out for identification purposes, plasmid 
linearisation or to excise fragments from plasmid DNA. Restriction digestion patterns 
were predicted for DNA sequences using the NEBCutter or the WebCutter 2.0 
bioinformatics tool (Table 2.1-6). All restriction enzymes used were supplied with 
incubation buffers at a concentration of 10X (working concentration 1X).  Some 
enzymes required the addition of Bovine Serum Albumin (BSA) to the reaction to 
stabilise the enzyme, (working concentration 1X). DNA digestion reactions were 
performed according to manufacturers’ instructions (New England Biolabs) and 
incubated for 3 hours at the optimum enzyme temperature (between 37˚C and 50˚C, 
usually 37˚C).  
 
2.2.1.4 Dephosphorylation of linearised plasmid D+A 
 
T4 DNA ligase catalyses the formation of a phosphodiester bond between juxtaposed 
5' phosphate and 3' hydroxyl termini in duplex DNA during ligation reactions. Calf 
intestinal phosphatase (CIP) is an enzyme that catalyses the removal of 5´ phosphate 
groups from DNA.  Since CIP-treated fragments lack the 5´ phosphoryl termini 
required by ligases, they cannot self-ligate. Therefore in order to minimise re-
circulisation of linearised DNA required for ligation and thus decreased the vector 
background in cloning strategies, treatment with CIP is required.  
 
Digested DNA (<100 ng/µl) was de-phosporlylated using CIP in a 100µl volume (CIP 
was added 1 unit/100 pmoles for cohesive termini).  The solution was mixed by 
pipetting, centrifuged briefly and incubated for 1 hour at 37˚C. This was followed by 
an enzyme denaturation step achieved by heating to 75˚C for 10 mins.  The DNA was 
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then purified by phenol/chloroform extraction and ethanol precipitation, or gel 
purification. The purified linearised, CIP-treated DNA was stored at 4˚C until 
required for ligation. 
 
2.2.1.5  Polymerase chain reaction (PCR) 
 
The polymerase chain reaction (PCR) uses short synthetic primers to amplify a 
specific region of DNA through multiple rounds of denaturation, annealing and 
elongation.  PCR was used to amplify fragments of DNA for subsequent sub-cloning, 
for identification purposes and also for screening and sequencing. Primers are 
designed to allow polymerisation of both strands of the DNA using the thermostable 
enzyme DNA polymerase.   
 
 PCR reactions were set up by the addition of reagents in the following order: 
 
 
Table 2.2-1: PCR Reaction Components 
 
Component Volume 
dH2O 37µl 
Template DNA (~500ng) 1µl 
Forward primer (40pmole) 2.5µl 
Reverse primer (40pmole) 2.5µl 
10X enzyme buffer 
(+MgCl2) 
5µl 
dNTP mix (each at 
10mM) 
1µl 
Taq polymerase (5 U/µl) 1µl 
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All PCR reactions were carried out in a Hybaid thermocycler under the following 
conditions: 
 
Table 2.2-2: PCR Reaction Conditions 
 
Stage                                           Step                                 +umber of cycles 
Denaturation   95 ˚C, 5 mins  1 Cycle 
 
Denaturation   95 ˚C, 45 seconds 
Annealing                                          X ˚C, 45 seconds 35 Cycles 
Extension                                     72 ˚C, 1 min 
 
Extension   72 ˚C, 15 mins  1 Cycle 
 
X = Annealing temperature was calculated by subtracting 5 ˚C from the melting 
temperature (Tm
*
) of a primer pair. Annealing temperatures and primers are listed in 
Table 2.1-5. 
  
 
2.2.1.6  Purification of PCR products 
 
PCR products were purified using the Promega Wizard
®
 PCR Preps DNA Purification 
System to remove contaminants including primer-dimers and primers used for 
amplification according to the manufacturers protocol (Wizard
®
 PCR Preps DNA 
Purification System, Technical Bulletin, 2005). The purified DNA was stored at 4˚C 
until required for further use.     
 
2.2.1.7  Ligation of D+A molecules 
 
T4 DNA ligase catalyses the formation of a phosphodiester bond between juxtaposed 
5' phosphate and 3' hydroxyl termini in double-stranded DNA. This enzyme joins 
blunt end and cohesive end termini. Cohesive end ligations of equimolar 
concentrations of vector and insert DNA (final concentration 1µg), used in the cloning 
reactions were generally carried out overnight at 16˚C (or alternatively for 3 hours at 
room temperature (20-25°C) in a commercial ligation buffer (containing 5mM ATP) 
                                                 
*
 Tm = [2*(A/T content) + 4*(G/C content)]. 
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with 10 units of T4 DNA ligase/ml in a total volume of 10µl.  After ligation, the 
samples were heated at 65˚C for 10 mins to inactivate the ligase and stored at -20˚C 
until required for transformation. 
 
2.2.1.8  Preparation of competent cells 
 
Competence is the ability of a cell to take up extracellular DNA from its environment. 
E. coli cells are more likely to incorporate foreign DNA if the cultures are treated to 
make them transiently permeable to DNA. In this regard, a modified Rhubidium 
chloride (RbCl2) method was employed to prepare competent cells.  A JM109 E.coli 
strain was streaked from a glycerol stock on to a Luria-Bertani (LB) (Appendix I) 
agar plate and incubated at 37˚C overnight.  An isolated colony was then picked using 
a sterile inoculating loop and used to inoculate 2.5ml of LB broth which was 
incubated at 37˚C in a shaking incubator at 200 rpm overnight.  This culture was then 
used to inoculate 250 ml of sterile LB broth supplemented with 20mM MgSO4.  The 
250 ml culture was incubated in a 1L flask at 37˚C until the O.D. of the culture was 
between 0.4 and 0.8, at 640 nm (approximately 4-5 hours).  The cells were then 
transferred to two sterile 250ml centrifuge tubes and collected by centrifugation at 
4,500 x g, 4˚C for 5 mins.  The cells were then gently re-suspended in 0.4 of their 
original volume in ice cold TFB1 (Appendix I) (100ml for 250ml culture). Cells were 
kept on ice for all subsequent steps and pipettes, tubes and flasks were chilled. The re-
suspended cells were then incubated on ice at 4˚C for 5 mins followed by 
centrifugation at 4,500 x g at 4˚C for 5 mins. Cells were then gently re-suspended in 
1/25 of the original volume of ice-cold TFB2 (Appendix I) (10ml for a 250ml 
culture). These cells were then dispensed into 100µl aliquots and incubated on ice for 
1 hour.  Prior to storage the aliquoted cells were snap frozen in a dry ice/isopropanol 
bath. JM109 competent cells prepared by this method and stored at -80˚C are stable 
for 1 year.  
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2.2.1.9  Transformations 
 
A 95µl aliquot of competent cells was placed in a pre-chilled microfuge tube 
containing 5µl DNA (~100ng/10µl).  The contents of the tube were mixed gently by 
flicking, and incubated on ice for 30 mins, during which time an aliquot of SOC 
medium (Appendix I) was pre-heated to 37˚C.  After 30 mins on ice the cells were 
heat-shocked in a water bath at 42˚C for 55-65 seconds, and were then removed 
immediately to ice for a further 2 mins.  A 900µl aliquot of preheated SOC was added 
to the cells which were then incubated at 37˚C in a shaking incubator for 1 hour 30 
mins.  The cells were then collected by centrifugation for 3 mins at 6,000 x g 
following which, and 900µl of supernatant was removed and discarded.  The cells 
were re-suspended in the remaining supernatant and plated out, along with the 
controls, on LB plates containing antibiotic at the appropriate concentration, and 
incubated overnight at 37˚C.  Plasmids carrying the antibiotic resistance gene confer 
this resistance to the transformed cells and thus only transformed cells will yield 
colonies.  These colonies were subsequently used to prepare broth cultures for DNA 
mini-preparations. 
 
2.2.1.10  Small scale preparation of plasmid D+A (Miniprep) 
 
A single bacterial colony was used to inoculate 5ml of LB medium containing the 
appropriate antibiotic and incubated with shaking (200rpm) overnight at 37˚C.  An 
aliquot (1.5ml) of this culture was transferred to a sterile microfuge tube and 
centrifuged for 30 seconds at room temperature; the remainder was stored at 4˚C.  The 
supernatent was removed from the tube using pipettes, leaving the cells as dry as 
possible.  The cells were then re-suspended in 100µl of Buffer P1 (Appendix I) by 
vortexing.  200µl of freshly prepared Lysis solution; Buffer P2 (Appendix I) was then 
added, the tube contents were mixed by inverting the tube rapidly a number of times.  
150µl of ice-cold neutralisation Buffer P3 (Appendix I) was added to stop the reaction 
and the tubes were vortexed gently for 10 seconds. 
 
The lysate was centrifuged for 5 mins at 12,000 x g, the supernatant was transferred to 
a fresh tube, taking care not to carry over any of the white precipitate.  A phenol 
chloroform extraction and ethanol precipitaion was carried out as described 
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previously in Section 2.2.1.2. The pellet was air-dried, then resuspended in 20µl of 
dH20. 1µl of DNase-free RNase A (20µg/ml) was also added, and the mixture was 
vortexed, incubated at 37˚C for 1 hour and then stored at 4˚C (Adapted from Maniatis 
et al, 1982). 
 
2.2.1.11 Glycerol Stocks 
 
Glycerol stocks enable long term storage of bacteria since glycerol prevents water in 
the broth from forming ice crystals that can puncture and kill the bacterial cells. 
Glycerol stocks of bacterial cultures were prepared by the adding 0.5ml of a 50% 
(v/v) glycerol solution to 0.5ml of the overnight bacterial culture of interest, mixing 
and storing at -80˚C for future use. 
 
2.2.1.12 Qiagen
® 
plasmid D+A purification protocol (Midiprep) 
 
Plasmid DNA was isolated and purified using the Qiagen
®
 Plasmid Midi Kit.  The 
process of plasmid isolation involves the lysis of the cells by a treatment with 
lysozyme followed by SDS which denatures proteins after the lysis of the membranes. 
The precipitation of the SDS-protein complex with high-molarity salt specifically 
subtracts the chromosomal DNA from the supernatant, since it remains attached to the 
mesosome. 
 
A glycerol stock of the bacteria of interest was streaked on an LB agar plate 
(containing the appropriate antibiotic) and incubated overnight at 37˚C.  An isolated 
colony from this plate was used to inoculate a 5ml starter culture (with the appropriate 
antibiotic) and incubated in a shaking incubator at 225rpm 37˚C for 8 hours.  100µl of 
the starter culture was used to inoculate 50ml of LB (containing the appropriate 
antibiotic) in a 250ml sterile flask and incubated overnight in a shaking incubator at 
37˚C.  It was important that the O.D. of the culture was between 1 and 1.5 at 600nm.  
The bacteria culture was transferred to a centrifuge tube and the bacterial cells were 
harvested by centrifugation at 6,000 x g for 15 mins at 4˚C using a JA-20 rotor in a 
Beckman centrifuge.  The supernatant was decanted and the cells were re-suspended 
completely in 4ml of Buffer P1 containing RNase A (100µg/ml).  The bacterial cells 
were then lysed by addition of 4ml Buffer P2 and incubation at room temperature for 
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5 mins.  Following incubation, 4ml of pre-chilled Buffer P3 was added (to precipitate 
genomic DNA, protein, cell debris and SDS), mixed gently by inverting the tube 5-6 
times and incubated on ice for 15 mins.  The mixture was then centrifuged for 1 hour 
30 mins at 16,000 x g at 4˚C and the supernatant saved. 
 
The Qiagen-tip 100 was equilibrated by applying 4ml of QBT buffer and allowing the 
column to empty by gravity.  The column does not dry out at this stage, as the flow of 
buffer will stop when the buffer reaches the upper filter.  Following equilibration, the 
supernatant from the previous centrifugation step was applied to the filter and allowed 
to flow through.  The Qiagen-tip was washed with 2 x 10ml of Buffer QC.  DNA was 
then eluted with 5ml of Buffer QF.  DNA was precipitated by adding 0.7 volumes of 
room-temperature isopropanol. The DNA/isopropanol mixture was then aliquoted and 
centrifuged immediately at 13,000 x g for 45 mins at 4˚C and the supernatant was 
carefully removed using pipettes.  The resulting pellet was washed with 70% (v/v) 
ethanol (13,000 x g for 15 mins at 4˚C), allowed to air dry for 5 mins and re-dissolved 
in 30µl of TE or dH2O.  DNA was then quantified by spectrophotometric analysis, 
and quality of the DNA was checked by Agarose gel electrophoresis (Adapted from 
the manufactures protocol Qiagen
®
 Plasmid Purification Handbook, 2005). 
 
2.2.1.13 Qiagen®  EndoFree plasmid purification protocol (Maxiprep) 
 
Endotoxins are frequent contaminants in plasmid DNA prepared from bacteria. In 
order to improve transfection efficiency endotoxin free plasmid DNA was isolated 
and purified using the Qiagen
®
 EndoFree Plasmid Midi Kit from Promega according 
to the manufacturers protocol (EndoFree
®
 Plasmid Purification Handbook, 2005). 
Endotoxin free DNA was then quantified by spectrophotometric analysis, and quality 
of the DNA was checked by Agarose gel electrophoresis. 
Maxi Kit 
2.2.1.14 Determination of +ucleic Acid Sample Concentration. 
 
The concentration of isolated nucleic acids can be determined spectrophotometrically. 
Nucleic acids absorbs UV light maximally at an abosorbance of 260nm thus, optical 
absorbance can be used as an accurate measurement of its concentration. Pure DNA at 
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50µg/ml in aqueous solution has an A260 of 1, while 40µg/ml of pure RNA also has an 
absorbance reading of 1 at this wavelength.    
 
Absorbance is also useful as a measure of the purity of DNA. The ratio of A260/A280 of 
a pure dsDNA preparation should be between 1.65 and 1.85. Higher values are often 
due to RNA contamination and lower values to protein and phenol contamination.  
Pure DNA and RNA have A260/A280 ratios of 1.8 and 2.0 respectively.   
 
Shimadzu UV-160A Spectrophotometer 
 
Absorbances were read on the Shimadzu UV-160A spectrophotometer using a quartz 
cuvette and nucleic acid concentrations were determined according to the following 
equations: 
 
Concentration of DNA (µg/µl) =  Absorbance (260nm) x 50 x dilution 
factor 
            1000 
 
Concentration of RNA (µg/µl) = Absorbance (260nm) x 40 x dilution 
factor             1000 
 
The +anoDrop
®
 +D-1000 Spectrophotometer 
 
The NanoDrop
®
 ND-1000 Spectrophotometer was also used to determine nucleic acid 
sample concentrations. An undiluted 1µl sample was pipetted onto the end of a fibre 
optic cable (the receiving fibre). A second fibre optic cable (the source fibre) was then 
brought into contact with the liquid sample causing the liquid to bridge the gap 
between the fibre optic ends. (The gap is controlled to both 1mm and 0.2mm paths by 
the computer). A pulsed xenon flash lamp provided the light source and a 
spectrometer was used to analyse the light after passing through the sample. The 
instrument is controlled by special software run from a PC, and the data was logged in 
an archive file on the PC. 
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2.2.1.15 Agarose gel electrophoresis of D+A 
 
DNA has a negative charge in solution, and the magnitude of this charge is relative to 
the DNA fragment length. DNA will migrate to the positive pole in an electric field 
and thus DNA fragments can be separated based on size by passing through a porous 
gel under an electrical current. This is the basis for agarose gel electrophoresis and it 
is the standard method used to separate, identify, and purify DNA fragments.  
 
The appropriate quantity of agarose was added to 100ml 1X TAE buffer based on the 
percentage agarose gel required.  Increasing the percentage agarose (1.8-2.0%) in the 
gel was generally used to improve resolution of smaller DNA fragments while 
separation of larger DNA molecules was best achieved by using lower percentage gels 
(0.7-1.0%).  The agarose was completely dissolved by boiling with intermittent 
mixing and after sufficient cooling (~60˚C) the gel was cast into the Hybaid 
horizontal gel electrophoresis system.  A comb was inserted for formation of the 
wells.  The gel was left to polymerise before filling the chamber with 1X TAE and 
removing the comb.  Sample buffer, containing bromophenol blue as a tracking 
marker (Appendix I), was added to each sample before loading up to 20µl of the 
sample containing the nucleic acid per well.  DNA sample buffer was also added to 
500ng of a 1Kb or 100bp ladder, which was loaded as a size marker.  The gel was run 
at constant voltage (5V/cm, usually 100V), for 1 to 2 hours.  After completion, the gel 
was stained in ethidium bromide (0.5mg/ml) for 30 mins, destained in dH2O for 15 
mins and viewed under UV illumination. 
 
2.2.1.16 Isolation of D+A from Agarose Gels. 
 
Agarose gels were prepared in 1X TAE buffer as described previously in 2.2.1.15. 
Ethidium Bromide was added to the samples before electrophoresis so as to minimise 
manipulation with the gel. After electrophoresis, the gel was viewed in a dark-room 
under 70% UV illumination. The time of exposure to UV light was kept to a 
minimum, as overexposure to UV leads to DNA damage. The DNA band of interest 
was excised from the gel using a clean scalpel blade, excess agarose was cut away 
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(without disrupting the fragment), to minimise the size of the gel slice, which was 
then placed in a pre-weighed sterile microfuge tube. 
 
2.2.1.17 Eppendorf Perfectprep
® 
Gel Cleanup 
 
Extraction and Purification of dsDNA fragments from TAE agarose gels was 
achieved using the eppendorf Perfectprep
®
 Gel Cleanup kit following the 
manufacturers’ protocol (Perfectprep
®
 Gel Cleanup Manual, 2002). The purified 
DNA was eluted in 30µl of molecular biology grade water and stored at 4˚C or -20˚C. 
 
2.2.1.18 D+A Sequencing 
 
Sequencing of plasmid DNA was performed to ensure the nucleic acid fidelity and 
‘in-frame’ insertion of DNA fragments following cloning. Plasmid DNA as prepared 
in Section 2.2.1.12 was quantified (Section 2.2.1.14) and 1-2µg (typically 1-2µl) was 
transferred to a sterile 1.5ml eppendorf. The DNA was lyophilised in a Savant 
DNA110 speed vac on the low heat setting for 15-20 mins or until the solvent had 
evaporated. The lyophilised DNA was sent to MWG-Biotech, Ebersberg, Germany 
for sequencing. Sequencing forward and reverse primers were supplied by MWG-
Biotech for most commercially available cloning systems. In the absence of existing 
sequencing primers (as in the case of the pRTS-1 vectors), a forward and/or reverse 
primer was designed and purchased and 100pmol of primer was transferred to a sterile 
eppendorf and sent with each sequencing reaction to MWG-Biotech. Sequencing 
results were obtained electronically as linear nucleotide sequences. 
 
 
 
 
 
 
 
 
 104 
2.2.2 Cell Culture Methods 
 
All cell culture techniques were performed in a sterile environment using a Holten 
laminar flow cabinet.  Cells were visualised with an Olympus CK2 inverted phase 
contrast microscope. 
 
2.2.2.1 Culture of cells in suspension 
 
All media compositions and media supplements are given in Appendix I.  The cell 
lines AG876, BJAB, BJABK3, BL41, BL41-B95.8, BL41K3, BL419A, BL72, DG75, 
DG75-tTA-EBNA2, DG75-tTA-LMP1, EREB 2.5, MUTU I, MUTU III, X50-7, 
IARC 171, IARC 290B, IB4, KEM BL, OKU BL, OKU LCL, RAEL BL were 
maintained in RPMI 1640 supplemented with 10% foetal bovine serum (FBS), 2mM 
L-glutamine, 100µg/ml streptomycin and 100U/ml penicillin. Cultures were seeded at 
a density of 2 X 10
5 
to
 
5 X 10
5 
cells per ml in 25cm
2 
flasks and expanded in 75cm
2 
flasks.  P493-6 was maintained in RPMI 1640 supplemented with 10% FBS, 2% L-
glutamine, and 1% Sodium Pyruvate. These cells were seeded at a density of 2 X 10
5 
to
 
5 X 10
5 
cells per ml in 25cm
2 
flasks. Additional supplements were added to some 
culture media as described in Section 2.2.2.3.  Cells were sub-cultured two or three 
times per week by harvesting the cells into a sterile centrifuge tube and centrifuging at 
1000 x g for 5 mins at room temperature.  The cells were gently re-suspended in a 
suitable volume of fresh supplemented media and replaced into the tissue culture 
flask.  All cell lines were incubated in a humid 5% CO2 atmosphere at 37˚C in a 
Heraeus cell culture incubator. 
 
2.2.2.2 Culture of adherent cells 
 
The HEK293 cell line (Table 2.1-1; Human embryonic kidney cell line) was 
maintained in minimum essential medium (Eagle) with 2mM L-glutamine and 
Earles’s BSS adjusted to contain 1.5g/L sodium bicarbonate, 0.1mM non-essential 
amino acids, and 1.0mM sodium pyruvate, 100µg/ml streptomycin and 100U/ml 
penicillin, 10% (v/v) FBS. HEK293 cells were seeded into 25cm
2 
and 75cm
2 
tissue 
culture flasks. Adherent cells were detached by treatment with Trypsin solution 
(Invitrogen). For trypsinisation the medium was decanted and the cells were washed 
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with 2ml of sterile 1X PBS to remove any residual serum. A volume of 2ml of 1X 
tyrpsin solution was added to each flask and the flasks incubated at 37˚C for 5 mins or 
until all the cells could be visualised as having detached form the flask surface. The 
cell suspension was then decanted into a sterile centrifuge tube containing 8ml of 
sterile supplemented media and centrifuged at 100 x g for 5 mins. Cells were 
resuspended in supplemented media at 2 to 5 X 10
5 
cells/ml, using 5ml per 25cm
2 
flask and 15ml per 75cm
2
 flask and incubated in a humidified 5% CO2 atmosphere at 
37˚C in a Heraeus cell culture incubator. 
 
2.2.2.3 Media supplements 
 
Supplements were added to the growth media of certain cell lines either to select cells 
containing transfected plasmids, activate the function/or induce expression of a gene 
of interest or to improve cellular proliferation. 
 
L-cysteine is essential for the proliferation and survival of the majority group 1 BL 
cell lines.  However, L-cysteine is quickly oxidated under normal culture conditions.  
To improve proliferation of the group I Burkitt lymphoma cell lines α-thioglycerol 
was added to the growth media as a stable substitute for L-cysteine.  The α-
thioglycerol was dissolved in bathocuprine disulfonic acid (BCS). BCS inhibits 
autoxindation of thiols in liquid solutions.  Sodium pyruvate was also added to the 
media to protect against any H2O2 which may be generated.   
 
The DG75-tTA-EBNA2 and DG75-tTA-LMP1 cell lines were maintained in 
supplemented RPMI containing 1µg/ml of tetracycline.  Every three weeks the 
transfected cells were reselected by the addition of 500µg/ml of hygromycin and 
1,000µg/ml of geneticin (G418) to DG75-tTA-EBNA 2 and 800µg/ml of hygromycin 
and 2,000µg/ml of G418 to DG75-tTA-LMPI. 
The stably transfected cell lines BL41K3, BL419A and BJABK3 were maintained 
under permanent selection with the addition of 800ug/ml geneticin to BL41K3 and 
BJABK3, and 1200ug/ml of geneticin to BL419A. In experiments where EBNA2 
activation was required, cells were washed twice in PBS and placed in fresh 
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supplemented RPMI with the appropriate antibiotics for selection,) estrogen was then 
added to a final concentration of 1µM.   
 
The estrogen responsive EREB 2-5 cell line was maintained in supplemented medium 
containing 1µM estrogen. To abolish functional EBNA2 activity, EREB 2-5 cells 
were washed 4 times in PBS, with a further 2 washes 24 hours later and replaced in 
estrogen-free supplemented medium.    
 
In the P493-6, functional EBNA2 activity was induced by culturing the cells in 
supplemented medium containing 1µM estrogen. To abolish functional EBNA2 
activity, cells were washed 4 times in PBS, with a further 2 washes 60 hours later and 
replaced in estrogen-free medium.   Expression of c-myc, was repressed by treatment 
with 0.1µg/ml tetracycline was added to culture medium. For myc reinduction, cells 
were washed 3 times with tetracycline-free culture medium and reseeded in 
tetracycline-free medium. 
 
2.2.2.4  Cell counts 
 
Cell counts were carried out using an improved Neubauer haemocytometer slide.  
Trypan blue exclusion dye was used to establish cell viability. A volume of 10µl of 
trypan blue was added to 90µl of a cell suspension and mixed.   A sample of this 
mixture was added to the counting chamber of the haemocytometer and cells were 
visualised by light microscopy.  Viable cells excluded the dye and remained clear 
while dead cells stained blue.  Cell numbers were determined by multiplying the 
average cell count (of 3-5 individual counts) by the dilution factor (usually 1.1) and 
again by the volume of the haemocytometer chamber (1 X 10
4 
cells/ml).  Thus, cell 
counts were expressed as the number of cells per ml. 
2.2.2.5  Cell storage and recovery 
 
In order to prepare stocks of suspension cells for long-term storage, 1 X 10
7 
cells in 
exponential phase were centrifuged, the excess media was discarded and the cells 
were re-suspended in 750µl of supplemented RPMI to which 150µl of FBS was 
added, and then placed on ice for 10 mins. DMSO was added to a final concentration 
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of 10% (v/v), mixed gently and transferred to a sterile cryotube. In the case of 
adherent cells, one confluent 75cm
2 
flask of cells was used per cell stock. Adherent 
cells were washed with 1X PBS followed by trypsinisation and re-suspended in 900µl 
of FBS and 100µl of DMSO. The cells were mixed gently and added to a sterile 
cryotube. The cryotubes were slowly lowered into the gas phase of liquid nitrogen and 
then immersed in liquid nitrogen in a cryofreezer (Cooper Cryoservices).   
 
Cells were recovered from liquid nitrogen by thawing rapidly at 37˚C and transferring 
to a sterile centrifuge tube containing 5ml of pre-warmed supplemented media. The 
cells were centrifuged at 100 x g for 5 mins, the cells were re-suspended in 5-10ml of 
fresh supplemented media, transferred to a culture flask and incubated at 37˚C in 5% 
CO2. 
2.2.2.6  Transient transfections 
 
Transient transfection of cells was performed by electroporation, nucleofection, 
Lipofectamine or using the DEAE-dextran method. In all cases, cells were seeded at a 
density of 2-5 X 10
5
 per ml of media 24 hours prior to transfection. After this time in 
culture, cells were counted again as it was essential for cell numbers to have almost 
doubled before beginning the transfection, thus ensuring that cell growth was in 
logarithmic phase, allowing for optimal DNA uptake during transfection. The same 
quantity of total DNA was used per transfection.  
 
2.2.2.7  Electroporation of B lymphocytes 
 
Transfection of AG876, IB4, BL41-K3, BJAB and P493-6 cell lines (Table 2.1-1) was 
carried out by electroporation. During the electroporation method of transfection, the 
application of brief high voltage electric pulses to the cells leads to the formation of 
nanometer-sized pores in the plasma membrane. DNA is taken directly into the cell 
cytoplasm either through these pores or as a consequence of redistribution of 
membrane components that accompanies the closure of the pores.   
 
Total DNA (10-20µg per transfection) dissolved in 30µl TE buffer (pH 8.0) was 
transferred into a sterile electroporation cuvette. A total of 1 X 10
7
 cells were used per 
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transfection. Cells were centrifuged at 100 x g for 5 mins and the supernatant 
discarded. The cells were then washed in PBS, centrifuged at 100 x g for 5 mins and 
the supernatant again discarded. For each 1 X 10
7
 cells, 220µl of serum-free media 
was used for re-suspension and the cells transferred to the DNA-containing 
electroporation cuvettes. The cell/DNA mix was incubated at room temperature for 5 
mins. Each cell/DNA mix was then pulsed at 220-250V (BJAB, 250V; P493-6, 
AG876, IB4 and BL41K3 220V) with a capacitance of 960µF (using a capacitance 
extender) and resistance set to infinity using a Biorad Gene Pulser. Immediately after 
electroporation the cuvettes were placed on ice until the cell/DNA mix was 
transferred into 5ml supplemented media in a 6 well dish, and the contents were 
mixed by gently rocking back and forth.  Care was taken to ensure cells were stored 
no longer than 10 mins after electroporation to avoid reduction in cell viability/gene 
transfer efficiency.  Transfected cells were harvested 48 hours later.  
 
2.2.2.8 +ucleofection of B lymphocytes 
 
The Nucleofector technology is based on electroporation. It consists of the 
Nucleofector device II (Amaxa), which delivers a cell-specific combination of 
electrical parameters, and Nucleofector Solutions, in which the cells are contained 
while the unique electrical program is executed. Optimised conditions for 
nucleofection of BJAB and IB4 cells yielded higher percentage transfection 
efficiency, when compared to cells transfected using the electroporation technique.  
 
The nucleofector solution specific to the particular cell line under investigation 
(Solution T/V for BJAB/IB4) was pre-warmed to room temperature and 50ml of 
supplemented media was pre-warmed to 37ºC. Supplemented medium (2ml) was 
aliquoted into the appropriate number of wells of a 6 well plate and pre-incubated at 
37˚C/5% CO2/humidified atmosphere. A total of ~7µg DNA was prepared in sterile 
1.5ml eppendorfs for each sample. For each transfection, 2.5 X 10
6
 (IB4)/ 5 X 10
6
 
(BJAB) cells were collected by centrifugation at 90 x g for 10 mins and the 
supernatant was discarded completely so that no residual medium remained. The cells 
were resuspended in room-temperature solution in question to a final concentration of 
2.5 x 10
6
 cells/100µl (IB4) or 5 X 10
6
 /100µl (BJAB). Care was taken to ensure cells 
were stored in nucleofector solution no longer than 15 mins to avoid reduction in cell 
 109 
viability/gene transfer efficiency. A volume of 100µl of cell suspension was mixed 
with the DNA and the nucleofection sample was transferred to an Amaxa-certified 
cuvette, taking care to avoid bubbles. The cuvette was placed in the nucleofection 
chamber and pulsed on program T-016 (IB4 and BJAB). Immediately after this, 500µl 
of pre-warmed medium was added to the cuvette. The contents were then gently 
transferred to the prepared 6-well plates, mixes gently and incubated at 37˚C/5% 
CO2/humidified atmosphere until cells were harvested. 
 
2.2.2.9 Lipofectamine-mediated transfection  
 
Lipofectamine transfection reagent (Invitrogen) is a 3:1 (w/w) liposome formulation 
of the polycationic lipid 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-
N,Ndimethyl-1-propanaminium trifluoroacetate (DOSPA) and the neutral lipid 
dioleoyl phosphatidylethanolamine (DOPE) in membrane-filtered water was used to 
deliver DNA into the HEK293 cell line. Lipofectamine treatment alters the cellular 
plasma membrane, allowing nucleic acids to cross into the cytoplasm. 
 
One day before transfection, 1 X 10
6
 HEK293 cells were seeded in 2ml of 
supplemented growth medium in a six well plate to ensure that cells would be 90-95% 
confluent on the day of transfection. Antibiotics were excluded from the medium 
during transfection as they would be taken up with the lipofectamine, and thus cause 
cell death. On the day of transfection 4µg of DNA was diluted in 250µl of OptiMem 
medium and was mixed gently. Following this, 10µl of the Lipofectamine reagent was 
diluted in 250µl OptiMem and incubated for 5 mintues at room temperature. Care was 
taken to proceed to the next step with in 25 mins. The diluted DNA was then 
combined with the diluted lipofectamine and the mixture was incubated at room 
temperature for a further 20 mins. Following this, 500µl of the DNA:lipofectamine 
mix was added to the appropriate well of the six well plate and the contents were 
mixed gently by rocking the plate back and forth. Plates were left overnight at 37˚C 
under a 5% CO2/humidified atmosphere. After 4-6 hours the medium was replaced 
with fully supplemented medium. Transfected cells were harvested 48 hours later. 
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2.2.2.10 DEAE-Dextran-mediated transfection 
 
Transfection of DG75 and BJAB cells was performed using this method of 
transfection. During transfection, positively charged DEAE-dextran binds to the 
negatively charged phosphate groups of the DNA, forming aggregates. These 
complexes, when applied to cells, subsequently bind to the negatively charged plasma 
membrane. It is believed that cellular uptake of DNA is mediated by endocytosis, and 
further assisted by osmotic shock.   
 
A maximum of 25µg of DNA dissolved in dH2O was used per transfection. Total 
DNA was prepared in a sterile microfuge tube and brought to a volume of 600µl with 
TBS (Appendix I). Following this, 600µl of 1mg/ml DEAE-dextran solution 
(Appendix I) was mixed with the DNA solution. Meanwhile, 1 X 10
7
 
cells/transfection were centrifuged at 100 x g for 5 mins and the supernatant was 
discarded. The cells were then washed in PBS, centrifuged at 100 x g for 5 mins and 
the supernatant again discarded. The cells were then gently re-suspended in the 
DNA/DEAE-dextran mix. The transfection cocktails were incubated at 37 ˚C for 30 
mins with gentle swirling every 5-10 mins to promote homogenisation. Transfections 
were terminated by the addition of 10ml supplemented medium to the tube and the 
cells were collected by centrifugation at 100 x g for 5 mins, washed in PBS as before 
and transferred to 6 well plates containing 10ml supplemented media for incubation. 
Cells were harvested at 48 hours post transfection.   
 
2.2.2.11 Microscopic analysis following gene transfer 
 
Following some transfections gene transfer efficiency was monitored by fluorescence 
microscopy for green fluorescent protein (GFP)-expressing cells at 4-72 hours post 
transfection. A volume of 600µl of suspension cells was removed to a 1.5 ml sterile 
eppendorf and centrifuged at 100 x g for 5 mins. The supernatant was discarded and 
the cells were resuspended in 20µl of PBS/0.5% BSA and applied to a glass 
microscope slide. A coverslip was applied with care taken to avoid air bubbles and the 
slide was examined under bright field and fluorescent field microscopy using an 
Olympus DP-50 fluorescent microscope [excitation 450–500 nm, emission 515–565 
nm] with a camera and StudioLife software (Olympus Optical Company).  
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2.2.2.12 Harvesting cells post-transfection for luciferase/β-gal assays 
 
Suspension Cells 
 
Cells were collected by centrifugation at 100 x g for 5 mins at room temperature. The 
cells were washed once in sterile PBS and centrifuged again at 100 x g for 5 mins.  
The supernatant was discarded, insuring all traces of PBS were removed using 
pipettes. The cells were re-suspended in 50µl of 1X reporter lysis buffer (diluted with 
dH2O from a 5X stock, Promega) and the cell suspension transferred to a microfuge 
tube. The tubes were vortexed for 10-15 seconds.  The lysates were clarified by 
centrifugation at 13,000 x g for 5 mins and the supernatant saved in a fresh tube.  
Samples were stored at –80 ˚C until luciferase/β-galactosidase assays were performed. 
Transfected cells were also harvested for the purposes of FACS analysis and Western 
Blotting. Details pertaining to the protocol followed in each case is given in Sections 
2.2.2.16  and 2.2.4.3 respectively.  
 
Adherent Cells 
 
The supernatant was removed from each well and placed in a universal tube. 1ml of 
PBS was added to each well and the cells were scraped. The cell suspension was 
transferred into the corresponding universal tube containing the supernatant. Each 
well was rinsed with 2ml PBS and added to the corresponding universal tube. Cells 
were collected at 1,800rpm for 5 mins at room temperature. The cells were washed 
once in sterile PBS and centrifuged again at 1,800rpm for 5 mins.  From this point the 
samples were processed as for suspension cells above.  
 
2.2.2.13 Luciferase assay 
  
Following transfection, promoter activity was determined by means of the luciferase 
assay. Firefly luciferase from the firefly Photinus pyralis, a monomeric 61 kDa 
protein, catalyses luciferin oxidation using ATP-Mg
++
 as a co-substrate. In this 
luminescent reaction light is produced by converting the chemical energy of luciferin 
oxidation through an electron transition, forming the product molecule oxyluciferin.  
 112 
In the conventional assay for luciferase, a flash of light is generated that decays 
rapidly after the enzyme and substrates are combined.   
 
Luciferase assay reagent was prepared by reconstituting luciferase assay substrate 
with luciferase assay buffer (Promega) and stored in aliquots in the dark at –70 ˚C. At 
the time of assay, it was important to allow sufficient time for the luciferase detection 
reagent to equilibrate to room temperature. A volume of 20µl of cell lysate was 
dispensed into individual wells in a white 96 well plate, along with 20µl of 1X lysis 
buffer to act as a blank. Subsequently, 100µl of detection reagent was added to the 
lysate immediately prior to measuring, in order to initiate enzyme activity, mixed by 
repetitive pipetting (3 times) and light emission integrated over a period of 60 
seconds, after lag period of 10 seconds, was measured on a luminometer (Labsystems 
Luminoskan 391A). Luciferase activity levels were adjusted for transfection 
efficiencies, estimated using β-galactosidase assay.    
 
2.2.2.14 β-Galactosidase assay  
 
When measuring the effect of promoters or enhancers on gene expression, it is 
essential to include an internal control that will distinguish differences in the level of 
transcription from differences in the efficiency of transfection or in the preparation of 
extracts. This is best achieved by co-transfecting the cells with two plasmids: one that 
carries the construct under investigation, and another that constitutively expresses an 
activity that can be assayed in a separate experiment. An enzyme frequently used for 
this is E. coli β-galactosidase (β-gal). This assay is a convenient method for assaying 
β-gal activity in lysates prepared from cells transfected with β-gal reporter vectors, in 
this case pCMV-LacZ.  
 
The β-gal assay was performed using a sample from the same lysates assayed for 
luciferase activity. Cell extract (30µl) was added to 3µl 100X Mg solution, 66µl 1X o-
nitrophenyl-β-D-galactopuranoside (ONPG) and 201µl 0.1M sodium phosphate (all 
described in Appendix I) and incubated at 37˚C for >30 mins or until a faint yellow 
colour developed. This yellow colour development is the result of hydrolysis of 
ONPG by β-gal to form o-nitrophenyl. A reaction tube was included containing 1X 
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lysis buffer instead of cell lysate in order to obtain a background reading. Reactions 
were terminated by addition of 500µl 1M Na2CO3 (Appendix I). Optical densities 
were read at 420nm using a Shimadzu spectrophotometer over a linear range of 0.2-
0.8. 
2.2.2.15 Stable Transfections 
 
Stable cells lines were established by transfection (as in Section 2.2.2.15) followed by 
selection with the appropriate drug 48 hours later. Within 2-4 weeks drug resistant 
cells grew out. In some cases, specific drug concentrations for selection in individual 
cell lines were known from previous publications/projects, otherwise drug curves 
were prepared in advance of transfection to determine the minimum drug 
concentration to cause cell death.  
2.2.2.16 Flow cytometric analysis 
 
Flow cytometry may be defined as a technology to measure properties of cells as they 
move, or flow, in liquid suspension. Most flow cytometers can measure two kinds of 
light from cells, light scatter and fluorescence. Light scatter is the interaction of light 
and matter. All materials, including cells, will scatter light. In the flow cytometer, 
light scatter detectors are located opposite the laser (relative to the cell), and to one 
side of the laser, in-line with the fluid-flow/laser beam intersection. The 
measurements made by these detectors are called forward light scatter and side light 
scatter, respectively. Forward light scatter provides information on the relative size of 
individual cells, whereas side light scatter provides information on the relative 
granularity of individual cells. Fluorescence is the property of a molecule to absorb 
light of a particular wavelength and re-emit light of a longer wavelength. The 
wavelength change relates to an energy loss that takes place during the process.  
 
2.2.2.17 Annexin V/ vital dye staining 
 
In normal live cells, phosphatidyl serine (PS) is located on the cytoplasmic surface of 
the cell membrane. However, in apoptotic cells, PS is translocated from the inner to 
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the outer leaflet of the plasma membrane, thus exposing PS to the external cellular 
environment. The human anticoagulant, annexin V, is a 35–36 kDa Ca2+-dependent 
phospholipid-binding protein that has a high affinity for PS and can be used to 
identify apoptotic cells by binding to PS. Fluorescent dyes that bind to nucleotides 
and penetrate only damaged cellular membranes were used (vital dyes). Intercalation 
complexes are formed by propidium iodide or 7-Amino-actinomycin (7-AAD) with 
double-stranded DNA, which effect an amplification of the fluorescence. 
 
2.2.2.18 Annexin V-PE/7-AAD 
 
The Annexin-PE Apoptosis Detection Kit (Becton Dickinson) contains recombinant 
annexin V conjugated to the fluorochrome, phycoerythrin (PE) and the vital dye 7-
AAD. Viable cells with intact membranes exclude 7-AAD, whereas the membranes of 
dead and damaged cells are permeable to 7-AAD. Cells that stain positive for 
Annexin V-PE and negative for 7-AAD are undergoing apoptosis. Cells that stain 
positive for both Annexin V-PE and 7-AAD are either in the end stage of apoptosis, 
are undergoing necrosis, or are already dead. Cells that stain negative for both 
Annexin V-PE and 7-AAD are alive and not undergoing measurable apoptosis. 
 
To perform the assay, cells were harvested and washed twice in ice-cold PBS. The 
cells were resuspended in 1X annexin-binding buffer at a concentration of ~1 X 10
6
 
cells/ml. A volume of 5µl of Annexin V-PE solution and 5µl of 7-AAD solution were 
added to 100µl of cell suspension. The cells were incubated at room temperature for 
15 mins in the dark and 400µl of 1X annexin-binding buffer was then added and the 
samples were analysed within one hour by flow cytometry. 
 
2.2.2.19 PI/FACS (cell cycle) analysis 
 
Cells were harvested and washed in ice-cold PBS (typically 1-5 X 10
6 
cells). The cells 
were resuspended in 500µl 1X PBS containing 0.1% Glucose. A volume of 5ml of ice 
cold 70% ETOH was added immediately, by slowly running down the side of the tube 
and the solution was mixed promptly. The cells were then stored at 4
o
C for between 1 
hour and 1 week to fix. Two to three hours prior to FACS analysis the cells were 
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collected by centrifugation at 1,800rpm for 5 mins, and washed once in 1X PBS. The 
cells were then centrifuged for 2 mins and any residual PBS was removed using 
pipettes. The cells were suspended in 300µl propidium iodide solution (Appendix I) 
and 20µl of 10mg/ml RNase was added. The cells were mixed gently and incubated at 
37
o
C for 30-45 mins. Samples were then analysed by flow cytometry. 
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2.2.3 R+A Analysis 
 
2.2.3.1 R+ase-free environment 
 
Because RNA is easily degraded by ubiquitous RNases, standard procedures were 
employed to avoid this potential hazard (Sambrook et al, 1989). Prior to working with 
RNA, any apparatus or surfaces to be used were treated to remove RNase. The 
apparatus/surface was washed in detergent and rinsed well in DEPC-treated H2O, then 
in 100% (v/v) ethanol and finally allowed to air dry. Any apparatus to be used were 
also immersed in a 3% (v/v) solution of hydrogen peroxide (Sigma-Aldrich) for 15 
mins, and were then rinsed thoroughly in DEPC treated upH2O and allowed to dry.  
Because hands are a major source of RNase contamination, gloves were used at all 
times and changed frequently. 
 
2.2.3.2  R+A analysis by gel electrophoresis 
 
In order to examine RNA transcripts/ascertain the integrity of RNA, isolated samples 
were run on 1.5% (w/v) agarose gels. The appropriate amount of agarose was 
dissolved in DEPC-treated H2O and prepared according to Section 2.2.1.15. The RNA 
samples (1µl) were prepared for electrophoresis by adding 3µl of RNA sample buffer 
(Appendix I) and made up to 15µl in DEPC-treated H2O. The samples were heated to 
65 °C for 10 mins prior to loading on the gel.  The gel was run in 1X TAE as 
described in Section 2.2.1.15. As ethidium bromide is included in the RNA sample 
buffer the gels did not require further staining and could be visualised directly on a 
UV trans-illuminator.   
 
2.2.3.3 R+A extraction from cultured cells 
 
Prior to RNA isolation the condition of cells was reviewed by phase contrast 
microscopy.  A cell count was performed as described in Section 2.2.2.4.   
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2.2.3.4 R+A extraction using Tri-reagent   
 
Cells grown in suspension were centrifuged at 100 x g for 5 mins, washed once in 
PBS and the cells were lysed by repeat pipetting in Tri Reagent (Sigma-Aldrich). A 
volume of 1ml of Tri reagent was used per 1 X 10
7 
cultured cells.  The lysate was left 
at room temperature for 5 mins after which time the procedure could be halted by 
storing samples at –80 ˚C.  
Phase separation was achieved by adding 200µl of chloroform per 1ml of lysate.  The 
samples were covered and shaken gently but thoroughly for 15 seconds or until 
completely emulsified.  Samples were incubated at room temperature for 15 mins.  
The resulting mixture was centrifuged at 13,000 x g for 20 mins at 4 ˚C.  During 
centrifugation the mixture separated into a lower red, phenol-chloroform phase, an 
interphase and a colourless upper aqueous phase. The aqueous phase, which contained 
the RNA, was removed to a fresh tube and RNA was precipitated by addition of 500µl 
of ice-cold isopropanol per ml of Tri-reagent used initially. The samples were 
incubated for 10 mins on ice and then centrifuged at 13,000 x g for 15 mins at 4 ˚C. 
The resulting RNA pellet was washed using 1ml of 75% (v/v) ethanol by inverting the 
tube 5 times.  The pellets were then centrifuged at 13,000 x g for 5 mins at 4 ˚C, and 
the 75% (v/v) ethanol was aspirated.  Pellets were air dried and dissolved in DEPC 
treated upH2O.  The resulting RNA preparation was heated at 60˚C and mixed gently 
to ensure a homogeneous solution prior to aliquoting. An aliquot was removed for 
spectrophotometric (Section 2.2.1.14) and gel electrophoretic analysis (Section 
2.2.3.2) and the remainder of the purified RNA was stored at – 80˚C.  
 
2.2.3.5 Total R+A isolation from cells using QIAgen R+easy™ kit  
 
RNA was extracted from small numbers of cultured cells (<5 X 10
5
) using an RNeasy 
kit (QIAgen) according to the manufacturer’s protocol (RNeasy Mini Handbook, 
2006). An aliquot of purified RNA was removed for spectrophotometric (Section 
2.2.1.14) and gel electrophoretic analysis (Section 2.2.3.2 ) prior to RT-PCR. 
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2.2.3.6 Quantification of mR+A from cultured cells by RT-QPCR 
 
The quantification of mRNA purified from cultured cells was performed in a two-step 
procedure.  In the first step, cDNA was prepared from RNA by reverse transcription 
(RT) with random hexamers serving as primers.  During the second step, cDNA was 
amplified by real time quantitative PCR (QPCR). Real-time QPCR is increasingly 
being adopted for RNA quantification based on its ability to detect the amount of PCR 
product present at every cycle (i.e. in real time), as opposed to the endpoint detection 
by conventional PCR methods, thus allowing the real-time progress of the reaction, 
especially its exponential phase, to be viewed.  The real-time PCR approach is based 
on the detection and quantification of a fluorescent reporter, where the signal 
increases in direct proportion to the amount of PCR product in a reaction.  TaqMan 
gene expression assays were used in this study for comparative gene expression 
analysis, normalising with gapdh endogenous control mRNA levels (Applied 
Biosystems, Table: 2.1-7).  
2.2.3.6.1 Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase 
 
In this process mRNA was transcribed into cDNA using Moloney Murine Leukemia 
Virus (M-MLV) reverse transcriptase.  Initially, 2µl of random hexamers was added 
to 2µg RNA and the volume brought up to 10µl with DEPC H2O. The mixture was 
heated to 70˚C for 5 mins, to destabilise secondary mRNA structures, and then placed 
on ice. Then, the RT reactants were added in the order listed in Table 2.2-3.  
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Table 2.2-3 MMLV RT reactants  
Component Volume 
Reverse Transcriptase buffer (5X) 
dNTP mix (20mM) 
MgCl2 (25mM) 
BSA (4µg/µl) 
DEPC H2O  
RNasin ribonuclease inhibitor 
M-MLV reverse transcriptase (200U/µl) 
8µl 
1µl 
4µl 
1µl 
     13µl 
2µl 
  1µl 
    
The reactions were placed in a Hybaid thermocycler at 37˚C for 1 hour and 95˚C for 2 
mins followed by storage at 4˚C. 
2.2.3.6.2 Real time relative PCR (QPCR) 
 
cDNA generated by RT was quantified by real time PCR using the TaqMan gene 
expression assays (Applied Biosystems), which consisted of  two unlabeled primers 
for amplifying the sequence of interest (final concentration of 900nM each) and one 
dual-labeled TaqMan MGB probe (6-FAM dye- and TAMRA-labeled) for detecting 
the sequence of interest (final concentration of 250nM). PCR exploits the 5’-3’ 
nuclease activity of the DNA polymerase system to cleave a TaqMan probe during 
PCR as illustrated in Figure 2.2.1.  
 
Quantification of a cDNA target was normalised for differences across 
experiments/samples using an endogenous control as an active reference (gapdh). The 
PCR reaction mix was prepared for each sample (in triplicate) by addition of the 
reagents listed in Table 2.3-2 to the individual wells of a 96-well reaction plate 
(Applied Biosystems) followed by the addition of 2µl of cDNA to give a total reaction 
volume of 25µl. 
 
 
 
 
 
 
 120 
 
 
Figure 2.2.1 Principles of the TaqMan assay primers and probes  
 
When the probe is intact, the proximity of the reporter dye to the quencher dye results 
in suppression of the reporter fluorescence primarily by Förster-type energy transfer 
(Lakowicz, 1983). During PCR, if the target of interest is present, the probe 
specifically anneals between the forward and reverse primer sites. The 5’–3’ 
nucleolytic activity of the DNA polymerase system cleaves the probe between the 
reporter and the quencher only if the probe hybridises to the target. The probe 
fragments are then displaced from the target, and polymerisation of the strand 
continues. The 3´ end of the probe is blocked to prevent extension of the probe during 
PCR. This process occurs in every cycle and does not interfere with the exponential 
accumulation of product. The increase in fluorescence signal is detected only if the 
target sequence is complementary to the probe and is amplified during PCR. Because 
of these requirements, any non-specific amplification is not detected (From Applied 
Biosystems White Paper on TaqMan gene expression assays 
http://docs.appliedbiosystems.com/pebiodocs/00106737.pdf). 
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Table 2.2-4 Real time QPCR reactants 
Component Volume/Reaction 
Assay 1.25µl 
20X TaqMan PCR master mix
*
 12.5µl 
Nuclease Free H2O 9.25µl 
Total 23µl 
 
The plate was covered with an optical adhesive cover and centrifuged at 2,000 x g for 
2 mins to eliminate air bubbles. Amplification and detection were performed with an 
ABI Prism 7500 sequence detection system under the following conditions: 10 mins 
at 95 °C to activate AmpliTaq Gold DNA polymerase, and 45 cycles of 15 seconds at 
95 °C and 1 min at 60 °C. Following QPCR, the products were analysed by agarose 
gel electrophoresis according to Section 2.2.1.15 to check for migration of fragments 
at the expected size. 
 
During amplification, the ABI Prism sequence detector monitored real-time PCR 
amplification by quantitatively analysing fluorescence emissions. The reporter dye 
(FAM) signal was measured against the internal reference dye (ROX) signal to 
normalise for non-PCR-related fluorescence fluctuations occurring from well to well. 
The threshold cycle represented the refraction cycle number at which a positive 
amplification reaction was measured and was set at 10 times the standard deviation of 
the mean baseline emission calculated for PCR cycles 3 to 15. The results were 
analysed the Comparative CT method (∆∆CT) as described by (Livak and Schmittgen, 
2001).  
 
The equation below shows the 2
- ∆∆CT 
equation, which was used to compare the gene 
expression in two different samples (e.g. samples A and B); and in every case each 
sample was related to an internal control gene (gapdh). During analysis the treated 
sample was designated as ‘sample A’ and the untreated control as ‘sample B’.  
 
 
                                                 
*
 TaqMan universal PCR Master mix contained AmpliTaq gold polymerase, dNTPs and the passive     
reference, ROX 
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Fold Change = 2
- ∆∆CT 
= [(CT of the gene of interest- CT internal control gene) sample 
A – 
(CT of the gene of interest- CT internal control gene) sample B] 
 
Equation used for analysis of real-time PCR data by the comparative CT method.  
 
Results were interrupted as the expression of the gene of interest (relative to the 
internal control) in the treated sample compared to the untreated control. 
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2.2.4 Protein Analysis  
2.2.4.1 Preparation of cellular protein 
 
Proteins were isolated from both suspension and adherent cells for analysis by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) and by western blotting. Prior to 
isolation, cells were washed in PBS. Suspension cells were centrifuged at 100 x g for 
5 mins and the supernatant removed. Ice-cold PBS (10ml) was added; the cells were 
centrifuged again at 100 x g and all of the supernatant removed. Adherent cells were 
washed twice with 10ml of ice-cold PBS, and the cells were scraped into 1ml of PBS.  
The crude cell suspension was centrifuged at 100 x g for 5 mins. For both suspension 
and adherent cells, the cells were re-suspended in ice-cold suspension buffer 
(Appendix I) using 200µl of suspension buffer for every 1 X 10
7 
cells and the cell 
suspension transferred to a microfuge tube. An equal volume of 2X SDS gel loading 
buffer (Appendix I) was immediately added to the cell suspension, after which the 
sample became extremely viscous. The sample was then subjected to sonication for 1 
min on full power (using a Vibra Cell Sonicator) to shear the DNA.  The lysate was 
clarified by centrifugation at 12,000 x g for 10 mins at room temperature. The 
supernatant was aliquoted and stored at –20 ˚C until required for analysis.   
2.2.4.2 SDS-polyacrylamide gel electrophoresis of proteins 
 
During polyacrylamide gel electrophoresis (PAGE), proteins are driven by an applied 
current through a polyacrylamide gel. PAGE is carried out in the presence of the 
negatively charged detergent sodium dodecylsulphate (SDS), which binds to all types 
of protein molecules. Electrostatic repulsion between the bound SDS molecules 
causes the proteins to unfold into a similar rod-like shape, and since the amount of 
SDS bound is proportional to the molecular weight of the polypeptide and is sequence 
independent, SDS-polypeptide complexes migrate through polyacrylamide gels in 
accordance with the size of the polypeptide. 
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2.2.4.2.3 Preparation of SDS-polyacrylamide gels 
 
SDS-PAGE was performed using 10% (v/v) resolving gels and 5% (v/v) stacking 
polyacrlyamide gels prepared as detailed in Appendix I.  
        
An ATTO protein gel electrophoresis system was used in this study. Glass plates were 
washed with detergent, rinsed first with tap water, then with dH2O and finally wiped 
in one direction with tissue soaked in 100% (v/v) ethanol. The gasket was placed 
around the ridged plate; the plates were assembled and secured with clamps. The 
resolving gel was then poured to within 2cm of the top of the larger plate and overlaid 
with 100% (v/v) ethanol. When set, the ethanol was removed and the stacking gel was 
poured. A clean comb that had been wiped in 100% (v/v) ethanol was inserted and the 
gel was allowed to polymerise for at least 20 mins. The electrophoresis tank was filled 
with 1X Tris-glycine running buffer (Appendix I) to a level of about 5cm deep. After 
polymerisation, the gaskets and clamps were removed and the pre-poured gels were 
lowered into the buffer at an angle to exclude air bubbles from the gel-buffer 
interface.  The tank was completely filled with 1X running buffer and the comb 
removed from the gel. Un-polymerised gel was removed by gently rinsing the wells 
with 1X running buffer and the wells were then straightened using a loading tip. The 
gel plates were fixed firmly in place with the pressure plates. The chamber formed by 
the inner plates (notched plate facing inwards) was filled with 1X running Buffer, the 
samples were loaded and the electrodes attached. The gels were electrophoresed at a 
constant current of 30mA per gel until the blue dye front had reached the bottom of 
the gel. When complete the plates were removed, separated and the gel was placed in 
transfer buffer prior to Western blotting (Section 2.2.4.3).  
2.2.4.3 Western blotting 
 
During western blotting, electrophoretically separated proteins were transferred from 
the polyacrylamide gel to a solid support, usually a nitrocellulose membrane, and 
probed with antibodies that reacted specifically with antigenic epitopes displayed by 
the target protein attached to the solid support. The bound antibody, unless 
conjugated, was detected by a secondary immunological reagent, conjugated to either 
the alkaline phosphatase (AP) or horseradish peroxidase (HRP) enzyme for detection. 
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2.2.4.3.4 Transfer of protein to nitrocellulose filters 
 
Following gel electrophoresis, gels were equilibrated in transfer buffer (Appendix I) 
for at least 15 mins. Equilibration facilitated the removal of electrophoresis salts and 
detergents. Salts if not removed, increase the conductivity of the transfer and the 
amount of heat generated during transfer. Nitrocellulose membrane was cut to the 
dimensions of the gel, along with 6 pieces of 3MM filter paper that were required for 
the gel/membrane sandwich. Protein transfer was carried out on the Bio-Rad Trans-
Blot
®
 SD semi-dry electrophoretic transfer cell. A pre-soaked sheet of filter paper was 
placed onto the platinum anode. A pipette was rolled over the surface of the filter 
paper to exclude all air bubbles. This step was repeated with two more sheets of filter 
paper.  Then, the pre-wetted blotting membrane was placed on top of the filter paper 
and all bubbles rolled out. The equilibrated gel was carefully placed on top of the 
nitrocellulose membrane, aligning the gel on the centre of the membrane. Any air 
bubbles were again rolled out. Another 3 sheets of pre-wetted filter were placed on 
top of the gel, with care taken to remove air bubbles. The cathode was placed on top 
of the stack and the safety cover replaced on the transfer unit. Gels were transferred 
for 30 mins at 17V.    
2.2.4.3.5 Staining of proteins immobilised on nitrocellulose filters 
 
Ponceau S is a negative stain, which binds to positively charged amino acid groups of 
proteins. It also binds non-covalently to non-polar regions of proteins. Ponceau S 
staining was employed to determine whether uniform transfer of proteins to the 
nitrocellulose membrane had taken place. Transferred protein was detected as red 
bands on a white background. This staining technique is reversible to allow further 
immunological analysis. Following electrophoretic transfer, the nitrocellulose 
membrane was immersed in 20ml Ponceau S solution (Sigma-Aldrich) and stained for 
5 mins with constant agitation.  After proteins were visualised, the membrane was 
washed in several changes of dH2O until all the stain had been washed away. The 
membrane was then used for immunological probing.   
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2.2.4.3.6 Immunological probing 
 
Following Ponceau S staining, the membrane was incubated in blocking buffer 
(Appendix I) for 3 hours at room temperature followed by incubation with the 
appropriate primary antibody (diluted in blocking buffer, see Table 2.2-5) at 4 ˚C 
overnight.   
Table 2.2-5 Incubation Conditions for Antibodies Used in Western Blotting 
 
Primary 
Antibody 
+ame Dilution 
In Blocking Buffer 
Secondary Antibody Dilution 
In Blocking 
Buffer 
Anti-β-actin Anti-actin 
AC-15 
1/10,000 AP-conjugated Anti-
mouse IgG 
1/20,000 
Goat-Anti-Bik 
 
Mouse-Anti-
Bik 
NBK (N-19): 
sc-1710 
 
Mouse Anti-
Human Bik 
Clone C33-1 
(557040) 
 
1/200 
 
1/500 
Anti-Goat-HRP 
 
AP-conjugated Anti-
mouse IgG 
1/5000 
 
1/5000 
 
 
Anti-Bax-HRP Bax (N-20): 
sc-493 
1/100 n/a n/a 
Anti-cMyc c-Myc (N-
262) :sc-764 
1/1000 Anti-Rabbit-AP 1/1000 
Anti-HA-
peroxidase 
Anti-HA-
peroxidase, 
high affinity 
1/1000 n/a n/a 
Anti-p53 Anti-P53 
OP43 
1/500 AP-Conjugated Anti 
Mouse IgG 
1/1000 
Anti-EBNA2 PE2 1/100 AP-Conjugated Anti 
Mouse IgG  
1/5000 
Anti -LMP1 CS1-4 1/1000 AP-Conjugated Anti 
Mouse IgG  
1/5000 
  
 
After overnight incubation, the membrane was washed three times in TBS-T (0.1% 
(v/v) Tween-20 in TBS (Appendix) for 15 mins. The filter was then incubated with 
the appropriate secondary antibody (Table 2.2-5) for 1 hour 30 mins at room 
temperature, followed by three 15-min washes in TBS-T. (Conjugated primary 
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antibodies were developed following three washes in TBS-T, and needed no further 
incubation step).  All of the above incubations were carried out with constant 
agitation.  The membrane was then placed in a clean container and covered with 5-
Bromo-4-chloro-3-indolyl phosphate/Nitro Blue Tetrazolium (BCIP/NBT, Sigma) or 
3,3’,5,5’-tetramethylbenzidine (TMB, Sigma), which are used for the colourimetric 
detection of alkaline phosphatase- or hydrogen peroxidase-conjugated molecules 
respectively. When incubated with alkaline phosphatase or hydrogen peroxidase, 
bound enzyme catalysed the production of a coloured product that was easily 
observable.  The membrane was then rinsed in distilled water to stop the reaction and 
photographed.  
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CHAPTER 3 : 
EBV-associated changes in bik expression in  
BL-derived and Lymphoblastoid cell lines. 
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3.1 Introduction 
 
Central to the infection strategy of EBV is its ability to inhibit the cellular apoptotic 
programme (Klein, 1994). Suppression of apoptosis in vivo is an essential feature 
contributing to the persistence of the latent virus in infected B-cells (Gregory et al, 
1991). The manner in which EBV can protect B-cells from apoptosis has long been 
attributed to cellular alterations caused by the interactions between the virus and the 
various members of the cellular apoptotic programme (Gregory et al, 1991; Snow et 
al, 2006). To this end, EBV encodes genes that can prevent or delay the death of a 
host cell (Henderson et al, 1993).  
 
There are two phenotypically distinct EBV-carrying B-cell types that can be grown in 
culture, exhibiting different patterns of EBV gene expression and regulation (Figure 
3.1.1). In studies of freshly isolated BL tumour cells and cell lines from cases of 
EBV-positive African BL, the tumour biopsy cells were found to display a group I 
phenotype and were found to express only the EBNA1 protein plus the EBERs 
(Middeldorp et al, 2003). These cells readily undergo apoptosis in response to various 
triggers (Gregory et al, 1991). In some cell lines following their establishment in vitro 
the group I phenotype is either retained or the cell populations fluctuate between 
group I and its subcategory group I/II, during continuous culture.  Other cell lines, 
however, undergo a spontaneous ‘drift’ or phenotypic change from group I, through 
the transient group II stage to group III.  This propensity for phenotypic change was 
found to be a feature of EBV-positive, rather than EBV-negative cases of BL (Perera 
et al, 1999). These cells (group-III BL cells and LCLs) are phenotypically altered due 
to the presence of the EBV genome and express the complete viral repertoire 
including six EBV nuclear antigens (EBNA1, EBNA2, EBNA3A, EBNA3B, 
EBNA3C, EBNA-LP) three virus-encoded latent membrane proteins (LMP1, 
LMP2A, LMP2B) and the EBERs (Middeldorp et al, 2003). Type III cells also 
display enhanced cell survival (Gregory et al, 1991). A comparison of the phenotype 
of BL type I cells directly to that of the proliferating EBV-immortalised LCL or BL 
cells with group III latency, reveals that the virus induces dramatic changes in the 
gene expression programme of the cell during infection.  
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Figure 3.1.1:Type I and Type III latency 
 
Phenotypically distinct human B-cell lines display three transcriptionally distinct 
forms of EBV latency frequently described as  Type I (or latency I/group I or the 
latency programme), Type II (or latency II/group II) and Type III (or Latency 
III/group III, or the growth programme) (Kerr et al, 1992). In BL Type I, only 
EBNA1 and BARF-0, as well as large copy numbers of EBER1 and EBER2 are 
expressed. EBV-infected LCLs express six EBV nuclear antigens [EBNAs -1, -2, -
3A, -3B, -3C and –LP] and three latent membrane proteins [LMPs 1, 2A and 2B] and 
show high levels of expression of the B-cell activation markers CD23, CD30, CD39 
and CD70, and of the cell adhesion molecules lymphocyte-function-associated 
antigen 1 (LFA1; also known as CD11a/18), LFA3 (also known as CD58) and 
intercellular cell adhesion molecule 1 (ICAM1; also known as CD54) (Young and 
Rickinson, 2004).  The cell surface changes that characterise the Type I and Type III 
phenotypic drift are accompanied by changes in morphology (Rowe et al, 1987; 
Gregory et al, 1990). Adapted from Middeldorp et al, 2003. 
  
The apoptotic threshold of a cell is determined by the balance in the expression of the 
levels of pro- and anti-apoptotic dimerisation partners available and in this regard the 
ability of EBV to regulate various members of the Bcl-2 family to shift the balance of 
cell fate has long been realised (Henderson et al, 1991). Suppression of apoptosis in 
EBV-infected cells has been associated with
 
the induction of anti-apoptotic factors 
including Bcl-2, A20, and Mcl-1 (Henderson et al, 1991; Finke et al, 1992; Laherty et 
al, 1992; Rowe et al, 1994; Silins and Sculley, 1995; Wang et al, 1996; Kenney et al, 
1998; Sheng et al, 2003) and the inhibition of pro-apoptotic molecules such as Bax 
and Bim (Clybouw et al, 2005; Grimm et al, 2005; Anderton et al, 2007). The 
regulation of the cellular bfl-1 gene has been studied extensively in our laboratory, 
and findings indicate that, bfl-1 is anti-apoptotic in BL cells and is regulated by EBV 
via two different pathways with roles for both NF-κB and Notch nuclear proteins 
(D'Souza et al, 2000; D'Souza et al, 2004; Pegman et al, 2006). While the expression 
pattern of viral genes during EBV infection is well defined, the spectrum of cellular 
Type I Type III 
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target genes and the potential contribution of these
 
target genes to B-cell 
immortalisation and EBV pathogenesis
 
remains an interesting area of research which 
has implications for the biology of EBV and malignant disease.  
 
Preliminary experiments in our laboratory, examining EBV-associated changes in the 
level of expression of apoptosis-related genes indicated that the pro-apoptotic bik 
gene may be a target of EBV regulation. Thus, these observations prompted an 
investigation to further current understanding of the molecular mechanisms that cause 
EBV-infected cells to survive by elucidating the status of the bik gene during EBV-
infection.  
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3.2  EBV associated down-regulation of the bik gene.  
 
3.2.1 Expression of bik gene in EBV-infected cell lines. 
 
A preliminary experiment was undertaken in the lab to examine previously unreported 
EBV-associated changes in the expression of bcl-2 related genes using two 
established isogenic EBV-positive BL cell lines, group I MUTU-BL (MUTU I) and 
group III MUTU-BL (MUTU III). MUTU I cells are an early passage BL cell line 
expressing EBNA1 as the only viral gene (Gregory et al, 1990). MUTU III cells are a 
stable clone of MUTU I which has drifted upon serial passage to express the full 
compliment of EBV latent genes (Gregory et al, 1990). mRNA levels from the 
apoptosis related genes bclXL/S, bfl-1, bik, bak, bax, bcl-2 and mcl-1 were analysed by 
Ribonuclease Protection Assay (RPA) and it can be seen in Figure A (Appendix II) 
that significantly elevated expression of bfl-1 and bcl-2 were present in MUTU-III 
cells relative to MUTU-I cells, as has been previously reported (Henderson et al, 
1991; D'Souza et al, 2000). It is also evident that repression of bik mRNA appears to 
be a feature of the BL cell line
 
expressing a group III phenotype (MUTU-III) but not 
the BL group I
 
phenotype (MUTU-I). These cell lines are isogenic clones, allowing 
the study of phenotypic differences in an identical genetic background. The result 
seems concurrent with a model for a differential expression of bik, with decreased 
levels of bik mRNA expressed in EBV-infected cell lines expressing the full 
compliment of EBV latent genes.  Thus, it was indicated for the first time that the pro-
apoptotic bik gene could potentially be an important target for down-regulation by 
EBV latent genes in the mediation of an increased anti-apoptotic threshold of EBV 
infected cells.  
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This novel finding prompted an investigation to elucidate if bik down-regulation is a 
general feature of EBV-infected B-cells, and to this end bik expression was examined 
in a range of Burkitt’s lymphoma (BL)-derived cell lines and B lymphoblastoid cell 
lines (LCLs).  
 
On this basis total protein and RNA were prepared simultaneously from a range of 
cell lines and were used in Western blot analysis and Reverse Transcription (RT) Real 
Time PCR (QPCR) respectively (Section 2.2.4.3 and 2.2.3.6). The level of Bik protein 
was detected by Western blot analysis using an affinity purified goat polyclonal IgG 
raised against a peptide mapping at the N-terminus of Bik and each lane was 
normalised for β-Actin expression levels (endogenous control) using a mouse 
monoclonal IgG generated from an N-terminal peptide of β-Actin.  
 
Bik protein expression was studied in 7 BL-derived cell lines with group I phenotype 
[BJAB, AKATA-4E3, MUTU I, DG75, OKU BL, KEM BL and BL41K3], 5 EBV 
positive cell lines with a group III phenotype [AG876, MUTU III, BL41-B95.8, 
DAUDI and BL41-P3HR1] and in 6 EBV-immortalised LCLs [IB4, IARC 171, IARC 
290B, X50-7, OKU LCL, EREB2.5]. From this experiment it was clearly seen that 
Bik is highly expressed in the cells expressing the EBV latency programme (Lat I) 
and has little or no expression in those BL cells expressing the EBV growth 
programme (Lat III) and LCLs as indicated in Figure 3.2.1A. Two exceptions to this 
general observation were the DAUDI and BL41-P3HR1 cell lines, two long-
established BL Lat III cell lines. These cell lines contain EBV genomes that carry 
different deletions spanning the viral EBNA2 coding sequence, and both of which 
express high levels of Bik (Figure 3.2.1A). DAUDI, originally described by (Klein et 
al, 1968) contains a 7.4kb deletion corresponding to the EBNA2/EBNA-LP coding 
sequence, which is larger than but similar to the deletion found in a non-transforming 
strain of the virus; P3HR-1 (Jones et al, 1984). BL41-P3HR1 is a BL cell line infected 
with this EBNA2-deficient isolate (Jones et al, 1984; Kempkes et al, 1996). 
Consequently, since both cell lines are deficient for EBNA2 and both express elevated 
levels of Bik protein, in contrast to their EBNA2-expressing counterparts, a potential 
role for EBNA2 in the modulation of the bik gene in this B-cell background was 
considered.  
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Isogenic MUTU-BL clones show either a group I or a group III phenotype and thus 
allow the study of phenotypic differences due to EBV in an identical genetic 
background. Bik is expressed in group I clones of MUTU I and is not expressed in the 
isogenic group III counterpart, MUTU III (Figure 3.2.1A) thus confirming the 
correlation between Bik expression and EBV latent viral gene expression in an 
isogenic cell system. In addition to this, OKU BL is a group I BL cell line expressing 
only EBNA1 whereas OKU LCL was established upon infection of peripheral 
lymphocytes from the same patient from whom OKU BL was derived with the EBV 
strain B95.8. 
 
Having established that suppressed Bik protein levels was a consistent feature of 
LCLs and BL cells expressing a type III latency, QPCR was then used to ascertain if 
down-regulation was at the transcriptional level in this context. Firstly, RT reactions 
using random primers were carried out to generate cDNA, which was subsequently 
used in a QPCR assay to determine the level of bik mRNA present.  mRNA levels of 
the internal control gene gapdh were also monitored, and the resulting data obtained 
was used to normalise data acquired for bik.  The relative level of bik mRNA was 
calculated using the Comparative CT method [∆∆CT] as described by (Livak and 
Schmittgen, 2001). Bik mRNA level was studied in 6 BL cell lines with group I 
phenotype [BJAB, MUTU I, DG75, OKU BL, KEM BL and RAEL], 4 cell lines with 
a group III phenotype [AG876, MUTU III, BL41-B95.8, DAUDI and BL41-P3HR1] 
and in 5 EBV-immortalised LCLs [IB4, IARC 171, IARC 290B, X50-7, EREB2.5]. 
Overall it was found that significantly less levels of bik mRNA were present in BL 
cells expressing a group III phenotype and LCLs when compared to BL type I. 
(Figure 3.2.1B). Relative quantitation of the levels of bik transcript after normalising 
for gapdh mRNA levels in KEM BL cells had comparatively high bik expression at an 
approximately 100-fold greater level than that observed in the LCL X50-7, and at a 
level 63-fold above the mean expression level seen in LCLs. Bik expression was also 
relatively high in the RAEL, BJAB and DG75 BL cell lines with approximately 71, 
40 and 34-fold respectively increased mRNA levels observed than in LCL X50-7. The 
mean expression level for BL type I in general was 46-fold greater than that observed 
in LCLs and an average 3-fold more than that observed in Lat III cells. Bik mRNA 
levels observed in the MUTU I cell line were similar to those observed in MUTU III. 
This inconsistency is possibly an indication that these Type I BL cells had drifted on 
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serial passage to a group III phenotype, prior to RNA isolation in the QPCR 
experiment. In general however in the cell lines examined, bik mRNA was generally 
expressed to a greater extent in the BL cell lines with a group I phenotype than in 
those expressing a group III phenotype or in EBV-immortalised B-cells. However, 
upon closer examination of Figure 3.2.1, it can be seen that expression of bik in Type 
III cell lines is elevated relative to the expression level seen in LCLs. These results 
indicate that the bik gene may be down-regulated by EBV at a transcriptional level in 
LCLs, however transcriptional regulation of bik by EBV in BL type III cell lines is 
less in evidence.  
Interestingly, whereas the Bik protein expressed
 
in BL type I cells always appeared as 
27/26-kDa double
 
bands during Western blotting, any low levels of Bik detected in 
LCLs and in BL Type III cell lines was always evident as a single band. In principle 
there are a several possible explanations for this double band pattern. Assuming the 
correct specificity of the antibody, some form of post-tranlational modification may 
account for the two-band pattern observed, possibly phosphorylation or glycosylation. 
Since the regulation of Bik by phosphorylation has already been verified (Verma et al, 
2001) these observations may suggest that the phosphorylated form of Bik may 
predominate in BL Type I cell lines. However, in order to determine if 
phosphorylation accounts for this post-translational modification and if one of the
 
bands may represent the phosphorylated form of Bik, it would be necessary to 
determine whether Bik is a phosphoprotein and if it can serve as a substrate for 
protein kinases in this particular context. 
 
Thus, Bik repression appears to be a common feature of LCLs and BL cells 
expressing all the viral latency-associated proteins. Taken together these results 
suggest that bik is a negative transcriptional target of the EBV latent proteins.  
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Figure 3.2.1: Analysis of a range of EBV-related cell lines for Bik expression.  
 
(A) Protein extracts prepared from a range of BL cell lines with a group I phenotype, 
a group III phentotype, and LCLs (as indicated above) were analysed by Western blot 
analysis. The level of Bik protein was detected using an affinity purified goat 
polyclonal IgG (Santa Cruz, sc-1710) (Upper Panel) and was normalised for β-Actin 
expression levels (endogenous control) using a mouse monoclonal IgG (Lower 
Panel). (B) The level of bik mRNA expression present was quantitated by QPCR.  
DNA was monitored in real-time by detection of fluorescence intensity using FAM-
labeled TaqMan probes for bik and gapdh. Fluorescent signals were recorded using 
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the ABI Prism 7500 Sequence Detection System. Bik levels were assayed in triplicate 
and normalised using gapdh. Relative quantification levels were calculated relative to 
the control (X50-7; arbitrarily assigned a value of 1). (Data are Mean±SD, n=2). 
 
*
 Both cell lines carry deletions spanning the EBNA2 coding sequence. 
3.2.2    Bik is not mutated in EBV negative BL cell lines.  
 
Considering that Bik possesses an already exposed
 
BH3 domain and is thus predicted 
to be constitutively active (McDonnell et al, 1999) and also given the fact that Bik is 
known to trigger apoptosis in various cell types (Han et al, 1996a; Tong et al, 2001; 
Germain et al, 2002; Hur et al, 2004; Oppermann et al, 2005) the detection of Bik in 
BL type I cell lines was not consistent with a pro-apoptotic role for Bik in this cell 
context. Interestingly, inactivating mutations have been found in other lymphomas but 
no data has yet been reported for bik.  
 
In order to investigate the possibility that mutations leading to functionally redundant 
forms of Bik might be present in BL type I cells, bik cDNAs derived from two EBV-
positive (AKATA and MUTU I) and two EBV-negative BL-derived cell lines (BL41 
and DG75) were sequenced across the bik open reading frame (ORF) located on 
exons 2-5 of the gene (Verma et al, 2000). As LCLs are derived from normal B-
lymphocytes it was not deemed necessary to examine putative mutations in this 
context. Total RNA was prepared from all four cell lines (Section 2.2.3.4) and RT 
reactions were carried out to generate cDNA (Section 2.2.3.6.1), which was 
subsequently used for PCR (Section 2.2.1.5). Conditions used for PCR and the primer 
sequences used for the amplification of the bik ORF (BIKORF F, BIKORF R) from 
the four different cell lines are indicated in Table 2.1-5. Following PCR, the products 
were analysed by agarose gel electrophoresis (Section 2.2.1.15) to check for 
amplification of fragments of the expected size (Figure 3.2.2A). The PCR products 
were subsequently purified using the Promega Wizard
® 
DNA purification system 
(Section 2.2.1.6), and the individual, purified PCR products were then sequenced 
(Section 2.2.1.18). All stages of the process were carried out in isolation for each 
individual cDNA, ensuring no cross-contamination of cDNA or PCR products could 
occur. Sequencing results, which were obtained as linear nucleotide sequences, were 
compared with the nucleotide sequence of the human bik gene (accession number 
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U34584) using the multiple-sequence alignment program MultAlin (Table 2.1-6). The 
sequence of the four cDNAs for bik, demonstrated 100% homology with the 
published bik gene sequence. (Figure 3.2.2B). Thus, no mutations leading to changes 
in the primary amino acid sequence were found, implying that the selection of loss-of-
function mutations in the bik gene is unlikely to be a feature of BL cells.  
 
 
1         2          3           4         5           6
600bp►
1500bp►
2072bp►
 
 
 
Figure 3.2.2 Sequencing of bik cD+A from EBV-positive and EBV-negative BL-
derived cell lines. 
 
(A) PCR products amplified from two EBV-positive (AKATA and MUTU I) and two 
EBV-negative BL-derived cell lines (BL41 and DG75) using forward and reverse 
primers; BIKORF F and BIKORF R, were analysed by agarose gel electrophoresis on 
a 1.2% agarose-1X TAE gel and electrophoresis at 100V for 1 hour in 1X TAE. 
Amplification of the bik cDNA fragment resulted in a band at 483bp (lane 2 
ATG 
TGA 
A 
B 
◄
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[AKATA], lane 3 [BL41], lane 4 [negative control], lane 5 [DG75] and lane 6 
[MUTU I]). A 100bp DNA ladder (Invitrogen) is shown in lane 1. (B)Bik ORF 
sequencing results highlighting the ATG codon and the TGA Stop codon. The 
nucleotide sequence of bik cDNAs from (A) above were sequenced across the bik 
open reading frame using Bik ORF specific forward and reverse primers (BIKORF F 
and BIKORF R). Sequence results were aligned with the published bik sequence 
(GenBank Accession number: U34584) using MultAlin software. Sequences 
highlighted in red demonstrated 100% homology.  
 
3.2.3    Status of Bax in EBV derived cell lines 
 
Recent evidence has suggested that pro-apoptotic BH3 only members of the Bcl-2 
family couple upstream death signals to downstream activation of the death effectors 
Bax and Bak, resulting in cell death (Wei et al, 2001; Zong et al, 2001). Indeed, 
specifically in the case of bik, reports indicate that induction of cell death is mediated 
by an entirely Bax-dependent mitochondrial pathway (Gillissen et al, 2003; Mathai et 
al, 2005). The absence of Bax expression might therefore explain the failure of type I 
BL cells to succumb to apoptosis. Therefore in an attempt to indicate a role for bik in 
cells from EBV associated malignancies, bax expression was investigated in a range 
of cell lines including BL Type I, BL type III and LCLs. 
 
Total protein and RNA were prepared simultaneously from a range of cell lines and 
were used in Western blot analysis and RT Real Time PCR (QPCR) respectively as 
before. The level of Bax protein was detected by Western blot analysis using affinity 
purified rabbit polyclonal antibody raised against a peptide mapping at the N-terminus 
of Bax (Table 2.1-2). Bax protein expression was examined in 6 BL cell lines with 
group I phenotype [DG75, MUTU I, BL41K3, KEM BL, BJAB, and OKU BL], 5 
BL-derived cell lines with a group III phenotype [BL72 III, AG876, BL41-B95.8, 
DAUDI and BL41-P3HR1] and in 4 EBV-immortalised LCLs [IB4, X50-7, IARC 
171, and IARC 290B]. It can be seen that Bax was generally expressed in cells 
expressing the EBV latency programme (Lat I) and in those cells expressing the EBV 
growth programme (Lat III and LCLs) (Figure 3.2.3A). Bax expression in BL cell 
lines was independent of EBV status and, with the exception of DG75 cells, was 
expressed in every cell line examined and did not vary significantly (Figure 3.2.3A). 
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In addition it was found that bax mRNA was present in all BL cells expressing a 
group I phenotype (including DG75), in BL group III cell lines and in LCLs and no 
trend in expression levels was evident (Figure 3.2.3B). Interestingly, DG75 cells 
express bax mRNA, and the absence of Bax protein is due to single base deletions and 
additions in a poly-guanine tract within the bax ORF. These frameshift mutations are 
known to result in premature termination of translation (Brimmell et al, 1998). 
Overall, the expression of Bax protein and mRNA was confirmed in a range of cell 
lines including BL Type I (except DG75), BL type III and LCLs.  
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Figure 3.2.3: Analysis of a range of EBV-related cell lines for Bax expression.  
 
(A) Protein extracts were prepared from a range of BL cell lines with a group I 
phenotype, a group III phentotype and LCLs (as indicated above [panel A]), and were 
analysed by Western blot analysis as before. The level of Bax protein was detected 
using an affinity purified Rabbit polyclonal IgG. (B) RT-Real Time PCR analysis for 
bax expression. Total RNA was reverse transcribed using random primers 
oligonucleotides and amplification of DNA was monitored in real-time using FAM-
labelled TaqMan probes for bax and gapdh. Bax levels were assayed in triplicate and 
normalised using gapdh as before. Relative quantification level of bax mRNA was 
plotted as a function of the control (DG75; arbitrarily assigned a value of 1). (Data are 
Mean±SD). 
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3.2.4    Effect of culture conditions on Bik expression in the AG876 cell 
line. 
 
The results presented in Section 3.2.1, indicated bik mRNA was expressed at 
relatively elevated levels in Type III cells compared to LCL cells. It was therefore a 
possibility that bik levels may vary during serial passaging in BL Type III cell lines 
and it was decided to examine expression of Bik protein and mRNA in AG876 (Type 
III BL) during passaging. A time course experiment was performed in which cells that 
had been passaged three times a week were seeded into multiple flasks at a density of 
5 X 10
5
 cells/ml and were subsequently left unpassaged, or alternatively were 
passaged every 24 hours or every 48 hours. Total mRNA and protein were harvested 
simultaneously from cells at various time points after the initial passage and were 
used in Western blot analysis and QPCR respectively.  
 
Western blotting was used to examine the level of Bik protein over the course of the 
experiment and levels of the endogenous control β-Actin were also monitored and 
confirmed equal loading in each case (Figure 3.2.4A). A second Bik antibody was 
acquired from BD Biosciences (557040; Table 2.1-2) at a later stage in this study. In 
order to validate this antibody for use a control experiment was undertaken (see 
Chapter 4; Section 4.23). The BD antibody was used in the following experiment. 
Analysis of Bik protein revealed that no significant fluctuation in the level of Bik 
protein was evident over the course of the experiment (Figure 3.2.4A). Of note, 
whereas the Bik protein expressed
 
in DG75 (BL type I) appeared as 27/26-kDa double
 
bands during Western blotting, the low levels of Bik detected in the AG876 cell line 
(BL type III) were detected
 
as a single band at 26kDa (Figure 3.2.4A).   
 
QPCR was subsequently used to examine the expression of the bik gene during the 
same experiment. As shown in Figure 3.2.4B, fluctuations in the quantity of bik 
transcript were evident. The level of bik mRNA increased approximately 2-fold after 
96 hours of continuous culture without passaging, and bik mRNA levels approached 
the level of bik transcript seen in DG75 cells. The same observation was made in the 
cells that were passaged every 24 hours. In cells which were passaged every 48 hours 
however, a small transient increase was observed after 24 hours in culture, which 
dropped thereafter returning to a similar level that was observed at 0 hours. 
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Considering the level of protein evident in DG75 on the Western blot, a higher level 
of mRNA expression would have been expected.  
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Figure 3.2.4: Effect of passaging on Bik expression in the AG876 cell line. 
 
(A) AG876 cells were monitored for Bik expression during passaging. Total protein 
was prepared at various time points and used in Western blot analysis. The level of 
Bik protein  was detected using a monoclonal IgG (BD Biosciences 557040). DG75 
cells were used as a positive control. (B) RT-Real Time PCR analysis for the level of 
bik expression in (A) above was also examined. Isolated RNA was reverse transcribed 
using random primers and amplification of DNA was monitored by detection of 
fluorescence intensity using FAM-labelled TaqMan probes for bik and gapdh. 
Flourescent signals were detected using an ABI Prism 7500 Sequence detection 
system. After normalisation for gapdh, relative quantitation of bik mRNA was plotted 
as a function of the control (0h, no passage; arbitrarily assigned a value of 1). (Data 
are Mean±SD).  
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3.3 Discussion 
 
The results presented here identify bik as a possible target for down-regulation in 
EBV-infected B-cells. Elevated levels of bik mRNA and protein in two EBV-positive  
type III cell lines (DAUDI and BL41-P3HR1), which harbour different deletions 
spanning the viral EBNA2 coding sequence indicated a possible role for this viral 
protein and also identify EBNA2 as a possible candidate protein with the ability to 
mediate this effect. Since the apoptotic threshold of a cell is determined by the 
balance of protein expression partners, both pro- and anti-apoptotic, the ability of 
EBV to down-regulate the expression of a pro-apoptotic protein may raise the 
apoptotic threshold of the infected, EBNA2-expressing cell.   
 
The detection of Bik in BL type I cell lines, was not consistent with a pro-apoptotic 
role for this protein in this cell context. Considering Bik behaves as a pro-apoptotic 
component of the apoptosis machinery, this apparent resistance of Lat I cells to Bik 
expression is not clear. The detection of some somatic mutation that would impair its 
apoptotic function in BL cells may explain this inconsistency. However, no mutations 
leading to changes in the primary amino acid sequence were identified, (in 2 EBV 
positive and 2 EBV negative BLs) implying that the selection of loss-of-function 
mutations is unlikely to be a feature of BL cells. Inactivating mutations of the bik 
gene have previously been reported in human peripheral B-cell lymphomas (Arena et 
al, 2003). Interestingly, those mutations were only found in peripheral B–cell 
lymphomas with germinal centre/post-germinal centre origin in which a severe 
impairment in the control of apoptotic death plays an essential role in B-cell 
transformation. Another report rules out bik mutations in colorectal carcinomas 
(Abdel-Rahman et al, 1999), and yet another in Non-Hodgkins Lymphomas, gastric 
cancers, colon cancers and urinary bladder cancers (Lee et al, 2006). It is of interest 
that mutational inactivation of the gene is not observed in BL cells in which 
mutational events in other genes are common (Lindstrom and Wiman, 2002). Since 
Bik-induced apoptosis has been shown to be dependent on Bax, it was therefore 
confirmed that Bax was expressed in a range of cell lines including BL Type I (except 
DG75), BL type III and LCLs, and this is consistent with the findings of others 
(Brimmell et al, 1998). Of note, Bax in the DAUDI cell line is non-functional, 
expressing a mutant bax allele that contains a missense mutation
 
in the BH1 domain, 
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which leads to abnormal dimerisation characteristics and loss of pro-apoptotic activity 
(Meijerink et al, 1998). 
 
Interestingly, BL type I cells do not express high levels of Bcl-2 (Finke et al, 1992) 
which is known to inhibit Bik-induced apoptosis (Letai et al, 2002). However, several 
BL type I cells have been shown to express high levels of Bcl-XL and Mcl-1 (Wang et 
al, 1996; D'Souza et al, 2000), both of which are known to interfere with Bik-induced 
apoptosis (Shimazu et al, 2007). In particular, several lines of evidence suggest that 
the balance between pro-apoptotic Bik and the anti-apoptotic Bcl-XL
 
protein may play 
a key role in determining B-cell fate (Saltzman et al, 1998; Jiang and Clark, 2001). 
The relative proportion of Bik not associated with Bcl-XL may therefore be an 
important factor in the ability of these cells to tolerate the expression of this pro-
apoptotic molecule. 
 
In BL type I cells (which express only EBNA1), Bik appears as a doublet compared to 
LCLs and BL type III cells, (which express the full compliment of EBV latent genes). 
Since the regulation of Bik by phosphorylation has been verified elsewhere (Verma et 
al, 2001), these observations may be suggestive that constitutive phosphorylated Bik  
is the dominant form in BL type I,
 
but not in the BL type III or LCL cell lines. 
Dephosphorylation of Bik may provide an “off” switch for Bik function. Indeed, BH3 
proteins are known to be regulated by post-translational modifications, resulting in 
conformational changes to cause their release from an inactive complex and increased 
affinity for anti-apoptotic bcl-2 homologues (Huang and Strasser, 2000). In cells 
stimulated by growth factors, Bad is phosphorylated at several serine residues and this 
allows its sequestration in the cytoplasm by binding to the 14.3.3 chaperon protein 
(Zha et al, 1996). Phosphorylation of two residues, serine 112 and 136, depends on 
several kinases, including AKT, RSK, PKA or Raf-1 (Datta et al, 1997; Bonni et al, 
1999; Bertolotto et al, 2000). Studies have also established that Bim is regulated by 
phosphorylation (Shinjyo et al, 2001; Biswas and Greene, 2002) and incubation of 
Ramos cells with either anti-IgM or the phorbol ester PMA, two conditions that 
efficiently activate the Erk1/2 pathway, led to Bim-EL mobility shift, indicative of 
phosphorylation and correlated with induction of apoptosis (Luciano et al, 2003). 
Importantly as discussed in Chapter 1 phosphorylation of Bik is required for eliciting 
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efficient apoptotic activity and does not significantly affect its ability to 
heterodimerise with Bcl-2 (Verma et al, 2001).  
 
The levels of bik mRNA were found to be relatively stable when AG876 cells were 
passaged every 48 hours. The fluctuation in bik mRNA levels in cells which were left 
unpassaged and in cells which were passaged every 24 hours, may suggest that the 
available amounts or activities of cell factors required for synthesis varied during cell 
growth, possibly due to the effects of passaging/the addition of fresh serum to the 
cells.  The differences in bik mRNA levels between Type III cell lines and LCLs may 
indicate a dissimilarity of regulatory mechanisms involved in the expression of the bik 
gene between the different cell types. A potential role for EBNA2 in the regulation of 
the bik gene is to be considered (Section 3.2.1). Interestingly, EBNA2 has cell-context 
dependent effects on its target gene c-myc. In this regard EBNA2 negatively regulates 
c-myc causing a down-regulation in its expression in those BL-derived cell lines 
carrying the
 
t(8;14) chromosomal translocation (Maier et al, 2005) while in 
lymphoblastoid B-cell lines that do not carry this translocation, c-myc expression is 
transiently up-regulated in response to
 
EBNA2 (Maier et al, 2005). 
 
Thus, repression of bik at the level of transcription, with an associated loss of Bik 
protein appears to be a feature of LCLs relative to BL-derived cell lines. This 
indication that the bik gene may be regulated by EBV at the level of transcription is in 
line with the findings of others, since cytokine mediated changes in the level of 
expression of a number of the BH3 only proteins is regulated at a transcriptional level 
(as reviewed in Puthalakath and Strasser, 2002). 
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CHAPTER 4 : 
Regulation of bik by EB+A2 in BL-derived  
cell lines 
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4.1 Introduction 
 
Nine latent viral proteins act together to initiate and maintain B-cell proliferation upon 
EBV infection in vitro (Young and Rickinson, 2004). Of these LMP1, EBNA2 and 
EBNA3C have long be been realised to make the most significant contribution to the 
promotion of cell survival in EBV-infected cells (Wang et al, 1990). In BL-derived 
cell lines, LMP1 is known to activate many
 
of the phenotypic changes that are seen in 
the EBV infected B-cell, including
 
the up-regulation of B-cell activation markers and 
adhesion
 
molecules and an increased resistance to apoptosis (Wang et al, 1988; 
Cordier et al, 1990; Wang et al, 1990; Hatzivassiliou and Mosialos, 2002). EBNA2, is 
the first protein expressed after infection of primary B-cells (Alfieri et al, 1991) and 
all the viral genes expressed in immortalised B-cells (including LMP1) are under the 
control of this viral transcription factor (Zimber-Strobl and Strobl, 2001). In addition 
EBNA2 modulates the expression of many cellular genes, either directly or indirectly 
via c-Myc modulation (Kaiser et al, 1999; Zimber-Strobl and Strobl, 2001). In this 
way, EBNA2 instigates the transcription of a plethora of target genes, which regulate 
the activation
 
of the resting B-cell, cell cycle entry, and proliferation of
 
growth-
transformed cells (Cohen et al, 1989; Sinclair et al, 1994; Kempkes et al, 1995a; 
Kaiser et al, 1999; Zimber-Strobl and Strobl, 2001).
  
It has previously been demonstrated in our laboratory that both EBNA2 and LMP1 
can independently up-regulate the anti-apoptotic cellular bfl-1 gene (D'Souza et al, 
2000; Pegman et al, 2006).  Understanding the importance of EBNA2, in particular, 
as a key effector of phenotypic change in EBV-infected cells, and considering the 
finding that the BL cell lines DAUDI and BL41-P3HR1 express high levels of Bik, 
(in contrast to the other BL latency III cells), while also harbouring deletions spanning 
the EBNA2 coding sequence, it was decided to examine EBNA2 as a significant 
participant in the down-regulation of the bik gene during EBV infection. Accordingly, 
this study set out to investigate if EBNA2 was capable of regulating the expression of 
bik.  Stable expression of EBNA2 in EBV-negative BL cell lines leads to cytostatis 
(Floettmann et al, 1996). Here, several established cell lines were used in which 
EBNA2 expression could be induced as the sole EBV protein, the first of these being 
the well established tetracycline-regulated cell line DG75-tTA-EBNA2. 
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4.2  Bik is down-regulated by EB+A2 in cell lines derived from BL 
tumours. 
4.2.1  Induction of EB+A2 leads to decrease in Bik protein and mR+A 
levels in the EBV-negative cell line DG75-tTA-EB+A2.  
 
Initially, the DG75tTA-EBNA2 cell line was employed to obtain inducible expression 
of EBNA2 as the exclusive EBV protein under investigation. This cell line is a stably-
transfected derivative of the EBV-negative BL cell line DG75, in which the 
expression of EBNA2 is tightly repressed by low, non-toxic concentrations of 
tetracycline (≤1µg/ml) in the growth medium (Floettmann et al, 1996). In this cell 
line, DG75 was stably transfected with two plasmids, pJEF-3, a plasmid containing a 
tetracycline regulated transactivator (tTA) that is constitutively expressed from a 
CMV promoter, and pJEF-31, the responsive plasmid, which expresses wild type 
EBNA2. Stable integration of these plasmids was then selected for during cell culture 
using hygromycin, geneticin and tetracycline.  The inducible promoter that drives 
EBNA2 expression contains several binding sites for the tetracycline-regulated trans-
activator (tTA).  Tetracycline binds to the tTA preventing binding to the promoter 
sequences which remains inactive.  Upon removal of tetracycline the tTA binds to the 
promoter activating the transcription of EBNA2 (Floettmann et al, 1996).  
 
EBNA2 expression was induced over a 96 hour time period in the DG75-tTA-EBNA2 
cell line, by the removal of tetracycline from the cell culture medium. Total protein 
and RNA were prepared simultaneously from cells harvested at various time-points 
after EBNA2 induction, (Figure 4.2.1) and used in Western blot analysis and QPCR 
respectively. Western blotting was used to demonstrate the induction of EBNA2 over 
the course of the experiment and to measure Bik and c-Myc protein levels in response 
to EBNA2 (Figure 4.2.1A). Levels of the endogenous control, β-Actin, were also 
examined and confirmed equal loading in every lane (Figure 4.2.1A). Induction of 
EBNA2 was monitored using the anti-EBNA2 murine monoclonal antibody, PE2. c-
Myc protein levels were investigated using an anti-c-Myc rabbit polyclonal antibody 
raised against an N-terminal peptide. In this experiment, EBNA2 was detected in 
induced DG75-tTA-EBNA2 cells at 24 hours after the removal of tetracycline and 
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remained detectable 96 hours after induction (Figure 4.2.1A). A significant decrease 
in the level of Bik protein can be seen to coincide with the induction of EBNA2 
expression over the time course. Bik levels are repressed in conjunction with EBNA2 
expression at 48 hours, and are completely abolished at the 72 and 96 hour time points 
(Figure 4.2.1A). Thus, Bik is down-regulated in response to EBNA2 induction in this 
cell context.
 
c-Myc repression correlated with EBNA2 induction and was significantly 
down-regulated by 72 hours (Figure 4.2.1A), as has been described previously for this 
cell line (Maier et al, 2005). This is to be expected as EBNA2 represses transcription 
regulation from the Igµ enhancer which drives expression of the translocated myc 
gene in BL cells (Jochner et al, 1996).  
 
RT reactions were carried out to generate cDNA, which was subsequently used in 
real-time PCR assays to measure bik mRNA levels in response to EBNA2 activation 
over the same 96-hour time period. mRNA levels of the endogenous control gene 
gapdh were also monitored, and the resulting data obtained was used to normalise 
data acquired for bik.  Differences in bik mRNA levels over time in the DG75-tTA-
EBNA2 cell line in response to EBNA2 induction can be seen in Figure 4.2.1B.  As 
was the case with the Bik protein, bik mRNA levels in DG75 decreased in response to 
EBNA2 activation. A significant decline in bik levels (approximately 2.6-fold) was 
observed by 48 hours following the removal of tetracycline from the culture medium. 
EBNA2 was expressed at high levels at this time point (Figure 4.2.1A).  Levels of bik 
mRNA remained stably repressed from this point on, with the level of bik transcript at 
96 hours similar to that observed at 48 hours.  These results indicate that expression of 
EBNA2 as the sole EBV protein led to a sustained decrease in the level of bik mRNA 
and protein in the EBV-negative BL cell line DG75-tTA-EBNA2.   
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Figure 4.2.1: Induction of EB+A2 leads to decrease in bik protein and mR+A 
levels in the EBV-negative cell line DG75-tTA-EB+A2.  
 
EBNA2 was induced in DG75-tTA-EBNA2 by removal of tetracycline from the 
growth media and both RNA and protein extracts were prepared at the indicated time 
points (hours) following induction. (A) Western Blot analysis of Bik protein 
expression in response to induction of EBNA2 was examined. The level of Bik 
protein was detected using an affinity purifed goat polyclonal IgG (Santa Cruz, sc-
1710). Analysis of EBNA2 induction in DG75-tTA-EBNA2 cells is illustrated in the 
top panel. The second and third panels show c-Myc and Bik protein expression in 
response to the induction of EBNA2 respectively. The lower panel shows the same 
blot probed for β-Actin. (B) RT-Real Time PCR analysis for the level of bik 
expression was also examined. Isolated RNA was reverse transcribed using random 
primers and amplification of DNA was monitored by detection of fluorescence 
intensity using FAM-labeled TaqMan probes for bik and gapdh. Fluorescent signals 
were detected using an ABI Prism 7500 Sequence Detection System. After 
                     * 
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normalisation for gapdh, relative quantitation level of bik mRNA was plotted as a 
function of the control (Cycling cells; arbitrarily assigned a value of 1) (Data are 
Mean±SD,* p < 0.05). 
 
4.2.2  Bik down-regulation by EB+A2 is a general feature of BL-derived 
cell lines. 
 
Experiments with a similar objective were performed using established transfectants 
of two further well-studied EBV-negative B-cell lymphoma cell lines, BL41 and 
BJAB. These transfectants also used a conditional system, in which the function of 
EBNA2 was dependent on the presence of estrogen.  
 
The fusion of a protein with the hormone-binding domain of a steroid receptor can 
cause the function of that particular protein to become dependent on the presence of 
that specific hormone and thus to become inducible (Picard et al, 1988; Eilers et al, 
1989). In accordance with this, an EBNA2-estrogen receptor fusion construct p554-4 
(ER/EBNA2) has been generated elsewhere by fusing the hormone-binding domain of 
the estrogen receptor to the N terminus of EBNA2 and subsequently cloning this 
chimeric gene into a mini-EBV vector (Kempkes et al, 1996). The mini-EBV vector 
carries a viral episomal and lytic origin of replication together with terminal repeats, 
encompassing a packaging signal for encapsidation of the DNA into virions 
(Kempkes et al, 1996). EBNA2 functionality and its ability to interact with CBF1, 
was thus made dependent on the presence of estrogen. Kempkes et al., (1996) 
subsequently transfected the EBV-negative B-cell lymphoma cell lines BL41 and 
BJAB (Burkitt-like lymphoma cell line) with the conditional ER/EBNA2 expression 
plasmid. Stably-transfected clonal derivatives were then selected during cell culture 
using geneticin, giving rise to the cell lines BL41-ER/EBNA2-K3 (BL41K3) and 
BJAB-ER/EBNA2-K3 (BJABK3) respectively.  Addition of estrogen to the cell 
culture medium activates the function of ER/EBNA2, and affects the electrophoretic 
mobility of the ER/EBNA2 fusion protein. B-cells transformed by ER/EBNA2 
express EBNA2 fusion proteins at an apparent molecular weight of 120kDa in 
contrast to the 86kDa protein of wild type EBNA2 (Kempkes et al, 1995a). This 
activation of ER/EBNA2 function is thought to be associated with post-translational 
modifications or profound changes in the tertiary structure of ER/EBNA2 (Kempkes 
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et al, 1995a). In addition, ER/EBNA2 enhances its own transcription from the BamH 
IC promoter (Kempkes et al, 1996), leading to an increase in the level of expression 
of ER/EBNA2 e.g. compare lanes “cycling” and “6H” in Figure 4.2.2A. EBNA2-
estrogen receptor fusion proteins are capable of substituting for wild type EBNA2 in 
primary B-cell transformation and in the trans-activation of viral and cellular genes 
(Kempkes et al, 1995b) and thus because of the specific way in which EBNA2 
activity could be regulated, these cell lines were a useful model to study the regulation 
of bik by EBNA2 in a BL cell background. 
 
In order to monitor Bik levels in the presence of EBNA2 a series of time courses were 
undertaken with the BL cell lines, cultivated in the presence of estrogen.  All cell lines 
were washed twice in PBS and β-estradiol was added to the culturing media to a final 
concentration of 1µM to activate EBNA2, in accordance with previously published 
studies (Kempkes et al, 1996) (Section 2.2.2.3).  
 
EBNA2-mediated changes in Bik protein expression and mRNA levels observed 
during the time courses in both cell lines BL41K3, BJABK3 are shown in Figure 
4.2.2. Western blot analysis (Figure 4.2.2 A, C) confirms that the stably-transfected 
cells grown in the presence of estrogen showed an increase in chimeric EBNA2 
expression over the duration of the time-course (6 hours in BL41K3, and at 24 hours 
in BJABK3).  Cells grown in the presence of estrogen expressed chimeric EBNA2 
with an apparent molecular weight of 120kDa (in contrast to the molecular weight of 
wild type EBNA2, which is 86kDa).  Activated ER/EBNA2 remained detectable for 
the duration of the time course in all cases. Bik levels in response to the activation of 
ER/EBNA2 were monitored as before.  
 
The BL41K3 cell line demonstrated a substantial down-regulation of Bik protein in 
response to EBNA2 activation (Figure 4.2.2A). Bik protein expression was repressed 
by 48 hours but was not completely eliminated. The decrease in Bik expression again 
correlated with an increase in the expression of functional EBNA2 (Figure 4.2.2A).  
Furthermore, in BJABK3, induction of ER/EBNA2 expression also led to a decrease 
in Bik protein levels in conjunction with EBNA2 activation and was totally 
undetectable by 72 hours in response to EBNA2 (Figure 4.2.2C).  
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These results indicated that activation of functional EBNA2, led to a substantial 
decrease in the level of Bik protein in both cell lines investigated. Overall these 
experiments show that Bik levels decrease in response to EBNA2, and are 
significantly diminished at 48-hours in all cases. Importantly, c-Myc down-regulation 
correlated with EBNA2 induction and was significantly repressed by 72 hours in 
BL41K3 (Figure 4.2.2A) as was anticipated (Maier et al, 2005). In the BJABK3 cell 
line c-myc expression was transiently up-regulated at 24 hours in response to
 
EBNA-2 
induction as has been previously reported (Maier et al, 2005), declining to pre-
induced levels by 48 hours (Figure 4.2.2C).  
 
The total RNA harvested (from the same cell pool, and at the same time points as 
protein lysates) was used to assay bik mRNA levels in response to EBNA2 activation 
for each time course. The down-regulation of bik mRNA in response to EBNA2 
activation in the BL41K3 and the BJABK3 cell lines is shown in Figure 4.2.2 B and 
D. Consistently, bik mRNA was repressed in response to EBNA2 activation in both 
cell types. As was the case for the other cell lines examined, bik mRNA levels were 
seen to diminish over time in response to the levels of EBNA2. A considerable 
reduction was observed by 9 hours (approximately 4-fold decrease), which was 
additionally reduced at the time points up to 24 hours (maximum 10-fold decrease).  
The amount of bik mRNA was seen to increase gradually over time after this point, 
with the level at 48 and 72 hours, similar to that observed at 12 and 6 hours 
respectively. These results indicated that turning on functional EBNA2 led to a 
significant transient decrease in the level of bik mRNA in the BL41 derived cell line 
BL41K3.  
Results obtained from the time course undertaken with BJABK3 are illustrated in 
Figure 4.2.2D. As was the case previously, steady state levels of bik mRNA in the 
BJAB derivative were repressed in response to EBNA2 activation. A reduction in bik 
levels (approximately 1.6-fold) was observed by 24 hours following the addition of 
estrogen to the culture medium. The amount of bik decreased gradually over time, 
with the level of bik mRNA at 72 hours approximately 2.4-fold less than the zero hour 
time point.  Thus, a repression in bik mRNA levels coincides with EBNA2 induction 
in this context. 
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Figure 4.2.2: Down-regulation of Bik expression by EB+A2 in EBV-negative cell 
lines.  
 
The EBV-negative cell lines BL41K3 and BJABK3 were induced for EBNA2 by re-
culturing in the presence of estrogen. Cells were harvested and both RNA and protein 
extracts were prepared at the indicated time points after activation (hours). The level 
of Bik protein was detected using an affinity purified goat polyclonal IgG (Santa 
Cruz, sc-1710). Western Blot analysis of Bik protein expression in response to 
activation of EBNA2 was monitored. (A) EBNA2 activation in the EBV-negative cell 
line BL41K3. (C) Estrogen-Regulated activation of EBNA2 expression in the EBV-
negative cell line BJABK3. Induction of EBNA2 protein is illustrated in the upper 
panel. Analysis of c-Myc and Bik in response to EBNA2 activation is shown in the 
second and third panels respectively. The lower panel in each figure shows each blot 
probed for β-Actin. RT-Real Time PCR analysis for the level of bik expression was 
also examined. Isolated RNA was reverse transcribed using random primers and 
amplification of DNA was monitored by detection of fluorescence intensity using 
FAM-labeled TaqMan probes for bik and gapdh. Fluorescent signals were detected 
using an ABI Prism 7500 Sequence Detection System. After normalisation for gapdh, 
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relative quantitation level of bik was plotted as a function of the control (Cycling 
cells; arbitrarily assigned a value of 1). QPCR analysis both cell lines; BL41K3 and 
BJABK3 can be seen in (B), (D) respectively (Data are Mean±SD,* p < 0.05). 
 
 
Another similar cell line was also used in this study, namely BL41P3HR1-
ER/EBNA2-9A (BL419A).  This cell line was generated by infection of the BL41 cell 
line with the EBV-P3HR1 virus genome which is a non-transforming EBNA2-
deficient strain of EBV (Kempkes et al, 1996), and subsequent transfection and 
selection as for each of the previous cell lines (Section 4.2.2).  
 
Since BJABK3 and BL41K3 were established by infecting B-cells with a plasmid that 
just expresses ER/EBNA2, these cell lines express EBNA2 as the sole EBV protein.  
BL419A, in contrast, was co-infected with the mini-EBV plasmid together with the 
EBV P3HR1 virus. This is a non-immortalising viral strain that is deleted for its own 
EBNA2 gene. The activated ER/EBNA2 on the mini-EBV plasmid trans-activates the 
full EBV compliment on the P3HR1 viral genome in the cell, thus complementing the 
EBNA2 deletion on the P3HR1 virus, and so through activation of EBNA2 in 
BL419A, the entire EBV profile of EBV latent genes should be expressed. This cell 
line thus allows the examination of ER/EBNA2 expression against the background of 
the complete EBV genome. However, although EBNA2 expression generally results 
in the transcriptional up-regulation of LMP1, this is not the case for the BL419A cell 
line. The molecular basis for this has yet to be investigated.  
 
Changes to Bik protein and mRNA levels observed upon activation of ER/EBNA2 in 
BL419A are shown in Figure 4.2.3. Western blot analysis (Figure 4.2.3A) confirms 
that cells grown in the presence of estrogen showed an increase in chimeric EBNA2 
expression by 12 hours and remained detectable for the duration of the time course. A 
considerable and sustained reduction in Bik protein levels was observed 48 hours after 
the addition of estrogen to the BL419A cells (Figure 4.2.3A), again indicating that 
activating EBNA2 expression down-regulates the level of Bik protein in BL cells.  
Akin to what was seen in BL41K3, Bik protein expression was not completely 
abolished (Figure 4.2.3A).  
EBNA2-mediated changes in bik mRNA levels over time in BL419A are illustrated in 
Figure 4.2.3B. A decrease in the level of bik transcript (approximately 1.8-fold) was 
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observed by 6 hours following the addition of estrogen to the culture medium. 
Further, significant reductions in bik mRNA were seen in the subsequent time points 
up to 72 hours, where a maximal 6-fold repression was recorded, and the down-
regulation of bik is greatest. There was no further decrease in bik mRNA by 96 hours, 
and interestingly, by 144 hours the levels of bik mRNA increased approximating the 
level of expression observed at the 6 hour time point.  
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Figure 4.2.3: Down-regulation of Bik expression by EB+A2 in the EBV-positive 
cell line BL419A.  
 
The EBV-positive cell line BL419A was induced for EBNA2 by re-culturing in the 
presence of estrogen. Cells were harvested and both RNA and protein extracts were 
prepared at the indicated time points after induction (hours). The level of Bik protein 
was detected using an affinity purifed goat polyclonal IgG (Santa Cruz, sc-1710). (A) 
Western Blot analysis of Bik protein expression in response to induction of EBNA2 
was monitored. The upper panel illustrates EBNA2 induction. The middle panel 
shows Bik protein expression in response to EBNA2 expression and the lower panel 
shows the same blot probed for β-Actin (B) RT-Real Time PCR analysis for the level 
of bik expression was also examined. Isolated RNA was reverse transcribed using 
random primers and amplification of DNA was monitored by detection of 
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fluorescence intensity using FAM-labeled TaqMan probes for bik and gapdh. 
Fluorescent signals were detected using an ABI Prism 7500 Sequence Detection 
System. After normalisation for gapdh, relative quantitation level of bik was plotted 
as a function of the control (Cycling cells; arbitrarily assigned a value of 1) (Data are 
Mean±SD, * p < 0.05).  
 
 
Interestingly, expression of c-Myc correlates with Bik expression in the BL type I 
cells examined, and a reduction in c-Myc expresssion mediated by the activation of 
EBNA2 corresponded to a decrease in the level of Bik protein in all of the cell lines 
tested (BL41K3, BJABK3 and DG75-tTA-EBNA2).  
 
Overall, a direct role for EBNA2 in bik repression has thus been investigated using 
four established BL-derived cell lines DG75-tTA-EBNA2, BL41K3, BJABK3 and 
BL419A and in all cases, induction of EBNA2 led to the repression of both bik 
mRNA (10, 6 and 2.4-fold reduction respectively) and protein (Figure 4.2.1, Figure 
4.2.2 and Figure 4.2.3). These results showed that bik is transcriptionally down-
regulated by EBNA2 in cell lines derived from BL tumours. Together this data 
suggests that EBNA2 contributes to the down-regulation of bik in BL cells.  
 
4.2.3  Down-regulation of Bik expression by EB+A2 in the EBV-negative 
cell line BL41K3: BD Biosciences antibody. 
 
A second Bik antibody was acquired from BD Biosciences (557040; Table 2.1-2) at a 
later stage in this study. Extracts prepared during the time course using the BL41K3 
cell line (detailed in Section 4.2.2) were used in Western blot analysis to monitor 
EBNA2-mediated changes in Bik protein expression (Figure 4.2.4). Western blot 
analysis confirmed that a significant decrease in Bik protein level was observed in 
response to ER/EBNA2 activation (Figure 4.2.4), thus validating this antibody for 
future use. The levels of the endogenous control β-Actin were also monitored and 
confirmed equal loading in each case (Figure 4.2.4). 
 
It was observed in Chapter 3 that Bik protein expressed
 
in BL Type I cells in the 
absence of EBNA2 expression always appeared as 27/26-kDa double
 
bands during 
Western blot analysis. Interestingly, the EBNA2-mediated
 
Bik repression in BL41K3 
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seen here led to the gradual disappearance of the 27kDa band. These observations 
may suggest that the larger band is preferentially down-regulated by EBNA2.   
 
 
 
 
Figure 4.2.4: Down-regulation of Bik expression by EB+A2 in the EBV-negative 
cell line BL41K3: BD Biosciences antibody.  
 
The EBV-negative cell line BL41K3 was induced for EBNA2 by re-culturing in the 
presence of estrogen as before. Cells were harvested and protein extracts were 
prepared at the indicated time points after induction (hours). Western Blot analysis of 
Bik protein expression in response to induction of EBNA2 was monitored. The upper 
panel illustrates Bik protein expression in response to EBNA2 expression and the 
lower panel shows the same blot probed for β-Actin.  
  
 
4.2.4  EB+A2 mediated repression of bik in BL Cell Lines does not require 
CBF1. 
 
Since EBNA-2 lacks an intrinsic DNA binding function (discussed in Chapter 1), it 
gains access to target genes through various cellular adaptor proteins including
 
CBF1, 
Spi-1/PU.1 and Spi-B-related proteins, or ATF-CRE (as reviewed in Zimber-Strobl 
and Strobl, 2001).  The best-studied cellular DNA adapter protein of EBNA-2 to date 
is the CBF1 protein. 
 
It has also recently shown in our laboratory that the anti-
apoptotic bfl-1 gene is a CBF1-dependent transcriptional target of EBNA2 (Pegman et 
al, 2006).  
 
Hence, in order to determine if the bik gene is a CBF1-dependent target of EBNA2, 
an investigation as to whether EBNA2 could suppress bik in DG75
 
cells in which the 
CBF1 gene had been inactivated was undertaken. Accordingly, bik mRNA levels 
were examined by
 
QPCR in the DG75 clones SM296D3 and SM295D6.
 
These cell 
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lines are stably-transfected derivatives of the EBV-negative BL cell line DG75, in 
which the expression of ER/EBNA2 is regulated by the addition of estrogen to the 
growth medium, and in which the human CBF1 gene has (SM296D3)/ or has not 
(SM295D6) been inactivated by the deletion of exon 4 (Maier et al, 2005). 
 
 
Total mRNA extracts were received as a gift from Dr. Bettina Kempkes (GSF-
National Research Centre for Environment and Health, Munich, Germany) and the 
corresponding protein extracts were unavailable. EBNA2-mediated changes in bik 
mRNA levels were monitored by QPCR. Activation of ER/EBNA2 in the SM295D6 
cells led to a sustained decrease in the level of bik mRNA (greatest repression 2.4-fold
 
after 6 hours) (Figure 4.2.5), and this effect was also emulated in the cell line 
containing the knockout
 
of the CBF1 gene (SM296D3) (1.4-fold repression after 6 
hours, greatest repression 1.9-fold after 48 hours) although not to the same extent. The 
down-regulation of bik mRNA levels in SM295D6
 
and SM296D3 was comparable to 
the effect seen in DG75-tTA-EBNA2 and
 
BJABK3, where suppressed bik mRNA 
levels were sustained and did not fall below a 3.2 -fold reduction (Figure 4.2.1A and 
Figure 4.2.2C).  
 
In summary, bik expression was down-regulated
 
in both SM295D6 and in SM296D3 
cells, indicating
 
that EBNA2-mediated bik repression is not CBF1 dependent. While it 
is clear that neither the Notch pathway associated protein, CBF1, nor the EBNA2-
CBF1 interaction are absolutely required for EBNA2-mediated repression of bik, 
some role for the
 
CBF1 gene in this effect cannot be absolutely excluded at this point. 
These
 
experiments further corroborate the finding that EBNA2 down-regulates bik 
expression. 
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Figure 4.2.5: EB+A2 mediated repression of bik in BL Cell Lines is not CBF1-
dependent.  
QPCR analysis was performed to determine the level of bik mRNA. Isolated RNA 
was reverse transcribed using random primers and amplification of DNA was 
monitored by detection of fluorescence intensity using FAM-labeled TaqMan probes 
for bik and gapdh. Fluorescent signals were detected using an ABI Prism 7500 
Detection System as before. After normalisation for gapdh, the level of bik transcript 
was plotted as a function of the control (0H SM295D6; arbitrarily assigned a value of 
1) (Data are Mean±SD). 
.  
 
 
4.2.5  Induction of LMP1 in the EBV-negative cell line DG75-tTA-LMP1 does 
not affect Bik expression. 
 
As discussed in Chapter 1, LMP1 is also required for immortalisation of resting B 
lymphocytes (Kaye et al, 1993), and studies in rodent fibroblast cell lines have 
demonstrated that LMP1 is oncogenic (Wang et al, 1985). LMP1 has been shown to 
up-regulate the expression of anti-apoptotic proteins including Mcl-1 and A20 
(Laherty et al, 1992; Wang et al, 1996). Indeed, in our laboratory, using a system in 
which the expression of LMP1 was inducibly regulated by tetracycline (Floettmann et 
al, 1996), it was shown that LMP1 expression alone can up-regulate transcription 
from the bfl-1 gene in a B-cell specific manner. Further studies using the bfl-1 
promoter also revealed that LMP1 trans-activates the bfl-1 promoter and that this 
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trans-activational effect may be mediated by the NF-κB signaling pathway (D'Souza 
et al, 2000). Considering that both EBNA2 and LMP1 can independently up-regulate 
the anti-apoptotic cellular bfl-1 gene it was decided to determine if LMP1 could also 
down-regulate bik. The well established tetracycline-regulated cell line DG75tTA-
LMP1 was used for this purpose. This cell line was employed to obtain inducible 
expression of LMP1 as the exclusive EBV protein. As was the case for DG75-tTA-
EBNA2, the DG75-tTA-LMP1 cell line is a transfected clonal derivative of the EBV-
negative BL cell line DG75 in which the expression of LMP1 is tightly repressed by 
low concentrations of tetracycline (≥1µg/ml). The inducible promoter driving LMP1 
expression contains several binding sites for the tetracycline-regulated trans-activator 
(tTA) and is continuously expressed.  Elimination of tetracycline from the cell culture 
medium thus leads to binding of the trans-activator to the promoter and the induction 
of LMP1 expression (Floettmann et al, 1996).  
 
DG75-tTA-LMP1 cells were induced to express LMP1 by the removal of tetracycline 
from cell culture medium. Cells were washed in PBS three times, and resuspended in 
tetracycline free media. Total protein and RNA were prepared simultaneously from 
cells harvested at the indicated time-points after LMP1 induction, (Figure 4.2.6) and 
used in Western blot analysis and QPCR respectively. Western blot analysis on 
samples isolated during the induction time course is shown in Figure 4.2.6A.  LMP1 
expression and Bik protein levels in response to LMP1 induction were analysed by 
Western blot analysis as before (Figure 4.2.6A). β-Actin levels were also monitored 
(Figure 4.2.6A). DG75-tTA-LMP1 cells grown in the absence of tetracycline 
expressed LMP1 at a molecular weight of 62kDa as expected, with some additional 
glycosylation/degradation evident at the later time points.  LMP1 was detected in 
induced DG75tTA-LMP1 cells at 6 hours and large amounts remained detectable up 
to 72 hours (Figure 4.2.6A). An increase in LMP1 expression was observed over time. 
No significant alteration in Bik protein levels can be seen to correspond to the 
induction of LMP1 expression over the time course (Figure 4.2.6A). Thus, it appears 
that LMP1 is not directly involved in Bik regulation in this cell context. 
Total RNA harvested was used to measure bik mRNA levels in response to LMP1 
activation over the same 72-hour time period. Differences in bik mRNA levels over 
time in the DG75-tTA-LMP1 cells are shown in Figure 4.2.6B.  It is clear that bik 
mRNA was not repressed in response to LMP1 activation, in fact, a transient increase 
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in bik levels (approximately 2-fold) was observed 6 hours following the removal of 
tetracycline from the culture medium (Figure 4.2.6B).  This experiment indicates that 
expression of LMP1 in the EBV-negative BL cell line DG75 does not appear to be a 
contributor in the regulation of the level of bik mRNA in the absence of other EBV 
proteins. Of note, it was observed that the Bik protein expressed
 
in the DG75-tTA-
LMP1 cell line appeared as 27/26-kDa double
 
bands throughout the course of the 
experiment. This analysis was carried out using the BD Bik Antibody (Table 2.1-2). 
 
 
 
Figure 4.2.6: Induction of LMP1 in the EBV-negative cell line DG75-tTA-LMP1 
does not effect Bik expression.  
 
Total protein and RNA were prepared simultaneously at the indicated time-points 
post- LMP1 induction. The experiment was carried out over 72 hours. The level of 
Bik protein expression was detected using a mouse anti-Bik antibody (BD 
Biosciences 557040) and LMP1 protein levels were monitored using the anti-LMP1 
murine monoclonal antibody CS1-4. (A) Western blot of DG75-tTa-LMP1 cells 
induced to express LMP1. LMP1 induction was carried out over 72 hours. The upper 
panel shows Western blot analysis of LMP1 protein levels in response to induction. 
Analysis of Bik protein expression in response to induction of LMP1 is illustrated in 
the middle panel, and the corresponding β-Actin blot is shown in the lower panel. (B) 
QPCR analysis for the level of bik expression was also analysed. RNA was harvested 
from the same induction as that in panel A. Isolated RNA was reverse transcribed 
using random primers and amplification of DNA was monitored by detection of 
fluorescence intensity using FAM-labeled TaqMan probes for bik and gapdh. 
Fluorescent signals were detected using an ABI 7500 Detection System. After 
normalisation for gapdh, relative quantitation level of bik was plotted as a function of 
the control (Cycling cells; arbitrarily assigned a value of 1). (Data are Mean±SD). 
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4.3 Discussion 
 
Of all the EBV latent proteins LMP1, EBNA2 and EBNA3C are long established as 
the most significant contributors to the promotion of cell survival in EBV-infected 
cells and (Wang et al, 1990). Previous studies in the laboratory have shown that the 
anti-apoptotic, bfl-1 gene, is a CBF1-dependent transcriptional target of EBNA2 
(Pegman et al, 2006) and that LMP1 expression alone can up-regulate transcription 
from the bfl-1 gene in a B-cell specific manner (D'Souza et al, 2000; D'Souza et al, 
2004).  
The experiments in this chapter demonstrate the novel finding that EBNA2 down-
regulates expression of the cellular bik gene at the protein and the mRNA level. The 
fact that both native EBNA2 (expressed in the Dg75-tTA-EBNA2 cell line) and 
chimeric ER/EBNA2 (in the BL41K3 and BJABK3 cell lines) down-regulated the bik 
gene in the absence of other EBV latent proteins provides direct evidence for EBNA2 
regulation of the bik gene. Additionally, the observation of decreased bik mRNA and 
protein in an EBV positive but LMP1 negative cell line (BL419A), further 
substantiates the evidence that bik can be independently regulated by the expression 
of EBNA2. These results clearly demonstrate that bik is transcriptionally down-
regulated by EBNA2 in cell lines derived from BL tumours. To date EBNA2 is 
known to transcriptionally repress the activity of only one cellular gene, IgM (Jochner 
et al, 1996). This is the first indication of the down-regulation of a pro-apoptotic gene 
by this viral protein.  
Bik is induced in estrogen-dependent MCF7 breast cancer cells in response to 
inhibition of estrogen signaling (Hur et al, 2004). Indeed, in that study the suppression
 
of Bik protein revealed that Bik induction
 
was necessary for the antiestrogen-induced 
apoptosis of this
 
cell line. Any correlation between the expression of bik and the 
presence of estrogen however can be ruled out after considering the results obtained 
using the tetracycline-inducible system, DG75-tTA-EBNA2, which confirms that the 
repression of bik is due to the induction of EBNA2, and is not an artefact of estrogen-
dependency in this context. 
Inactivation of CBF1 in DG75 cells did not abrogate the ability of EBNA2 to down-
regulate the expression of the bik gene in these cells. Bik expression was significantly 
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down-regulated
 
in SM295D6 and to a similar degree in SM296D3 cells, indicating
 
that EBNA2-associated down-regulation of bik is independent of its CBF1-binding 
ability.  In contrast, it has previously been shown in the laboratory that EBNA2-
mediated trans-activation of the bfl-1 gene is abolished by the inhibition of 
EBNA2/CBF1 signaling, proving that this signal transduction pathway is essential in 
EBV-mediated regulation of this anti-apoptotic gene (Pegman et al, 2006). This 
finding is significant, as CBF1 is the major rate-limiting factor for EBNA2 activation 
of cellular target genes (Maier et al, 2006). The promoters
 
of several EBV latent 
genes including EB"A Cp, LMP1, LMP-2A, and LMP-2B (Ling et al, 1993a; Zimber-
Strobl et al, 1993; Johannsen et al, 1995) and that of the cellular genes CD21, CD23, 
CCR7 and FcRH5 (Ling et al, 1994; Maier et al, 2005; Mohan et al, 2006) have been 
shown to contain
 
functional CBF1-binding motifs and to be targets of EBNA2-CBF1 
signaling. While it is clear that EBNA2-mediated repression of bik does not require 
CBF1, some role for CBF1 in bik-regulation cannot be ruled out. 
 
Repression of Bik by EBNA2 was readily seen in all cell lines
 
tested. However, 
overall, it could be argued that the BL41 cell system supports the modulation of 
cellular target
 
genes by EBNA2 more efficiently than in DG75 or BJAB. In support of 
this theory, it is illustrated in Figure 4.2.1, Figure 4.2.2 and Figure 4.2.3 that mRNA 
levels in the BL41-derived cell lines, demonstrate a significant reduction at least 24 
hours in advance of that seen in the DG75 and BJAB cell lines, and the overall level 
of repression at the RNA level in BL41 derivatives was not equalled. Also, down-
regulation of the protein is evident at much earlier time points in the BL41-derived 
cells (Figure 4.2.2 and Figure 4.2.3). In concurrence with this, it has previously been 
demonstrated that the cellular context can significantly
 
influence target gene 
modulation in response to EBNA2 (Wang et al, 1990; Cordier-Bussat et al, 1993). 
Significantly in DG75 cells, the levels of CBF1 protein levels are known to equal the 
levels seen in BJAB, while only reaching about half the levels observed
 
in BL41 
(Maier et al, 2005). Thus, although there is no absolute requirement for CBF1 in this 
interaction, it is plausible that EBNA2 may mediate Bik regulation partially through 
CBF1 and a limiting
 
amount of CBF1 might somewhat contribute to the weaker 
EBNA2
 
responses seen in DG75 and BJAB. Other epigenetic factors can also not be 
ruled out. mRNA levels in BL41K3 and BL419A are seen to be rapidly degraded 
(Figure 4.2.2 and Figure 4.2.3), this decrease in the level of bik mRNA could be 
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attributable either to a decreased rate of transcription from the promoter of the bik 
gene and/or a de-stabilising effect of EBNA2 on bik mRNA. The delayed decrease of 
bik mRNA levels in the DG75 and BJAB cells (Figure 4.2.1B and Figure 4.2.2D) 
could therefore also be attributable to its higher stability in this cell background.  
 
 
EBNA2-induced down-regulation of bik mRNA levels in the BL41K3 and BL419A 
cell lines appears transient at the transcriptional level, in contrast to what was seen in 
the DG75 and BJAB derivatives. It would seem that this de-repression of bik is not 
reflective of subsiding EBNA2 expression levels at the relevant time points, as 
indicated by Western Blot analysis (Figure 4.2.1A and Figure 4.2.2C). However, it 
should be considered that these cells have entered growth arrest/growth retardation in 
response to EBNA2 activation (Kempkes et al, 1996), and the increase in the level of  
bik could be attributable to the effects of other complex pathways within the cell, 
triggered in response to an apoptotic signal. Conceivably this response could also be 
attributed to the spurious effect of EBNA2 over-expression and thus may be a stress-
induced artefact caused by high levels of protein in the cell. Alternatively, the 
discrepancy may be due to factors particular to the specific cell type, in this case 
particular characteristics of the BL41 cell line, causing a distinct response to EBNA2 
expression in this context. 
 
 
In all BL cells, the fundamental growth-transforming event appears to be constitutive 
activation of the c-myc oncogene through its translocation into an Ig gene locus 
(Brady et al., 2007). EBNA2 directly regulates c-Myc causing a down-regulation in 
its expression in those BL cell lines carrying the t(8;14) chromosomal translocation 
(Maier et al, 2005) (Figure 4.2.1A and Figure 4.2.2A). A significant subset of 
EBNA2-regulated genes will therefore be targets of c-Myc. Accordingly, considering 
c-Myc as a direct target gene of EBNA2 and an important mediator of cell 
proliferation, it was of interest to consider a possible role for c-Myc in EBNA2-
associated repression of bik. In DG75-tTA-EBNA2 and BL41K3, EBNA2 negatively 
regulates both Bik and c-Myc. However, in BJABK3, a non BL cell line derived from 
a lymphoblastoid B-cell line that does not carry the t(8;14) translocation, c-Myc 
expression is transiently up-regulated in response to EBNA2 (Maier et al, 2005 and 
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Figure 4.2.2C). Since c-Myc is not down-regulated by EBNA2 in that cell line and yet 
Bik is still down-regulated, it appears that Bik is down-regulated by EBNA2 
independently of c-Myc (at least in that cell line). The results presented here 
therefore, indicate that EBNA2 mediated repression of bik is not dependent on c-Myc 
although this does not rule out a role for Myc in bik regulation during the complete 
EBV growth programme where all the EBV latent proteins are expressed. 
 
In BL cell lines carrying the chromosomal translocation juxtaposing the c-myc and
 
the 
immunoglobulin M (IgM) heavy-chain locus, the expression of IgM and c-myc is co-
regulated and repressed (Jochner et al, 1996). Interestingly, it has previously been 
demonstrated that EBNA2 can down-regulate IgM
 
expression (Jochner et al, 1996). 
 
In BJAB,
 
IgM repression and c-myc expression are uncoupled, and it is thus made 
clear that IgM is an EBNA2 target not requiring Myc (Maier et al, 2005). 
Significantly, increased expression of both bik mRNA and protein is induced by sIgM 
ligation in B-cells (Jiang and Clark, 2001). Conceivably, therefore, EBNA2 induction 
may repress IgM expression which in turn affects the down-regulation of expression 
of the bik gene. On this note EBNA-2 mediated down-regulation of both IgM and c-
Myc is only partially CBF1 dependent (Maier et al, 2005) and a putative role for 
either of these genes in the modulation of the bik gene is supported by the finding that 
bik down-regulation by EBNA2 is CBF1 independent. 
The
 
activated Notch receptor is considered to be the functional equivalent of the viral 
EBNA2 protein (Zimber-Strobl and Strobl, 2001). As discussed in Chapter 1, upon 
ligand binding, the transmembrane
 
receptor Notch is proteolytically processed, and an 
intracellular
 
fragment (NotchIC) is translocated to the nucleus, where it binds to
 
the 
transcriptional repression domain of CBF1, activating target gene expression by 
means of replacing co-repressor complexes,
 
(as reviewed in Zimber-Strobl and Strobl, 
2001). EBNA2 then, acts through shortcutting CBF1 signaling
 
and activating a set of 
viral and cellular target genes, which
 
at least partially overlap the target genes of 
activated Notch
 
(Hofelmayr et al, 1999; Strobl et al, 2000; Gordadze et al, 2001; 
Hofelmayr et al, 2001; Hubmann et al, 2002; Johansen et al, 2003). It has been shown 
that constitutively
 
activated Notch can also down-regulate IgM expression (Stuart et 
al, 1995; Strobl et al, 2000; Morimura et al, 2001) and Myc is also a direct 
transcriptional target of Notch1 (Efstratiadis et al, 2007) a further indication that 
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EBNA2 is mimicking the Notch cellular pathway. Since both EBNA-2 and activated 
Notch can repress IgM and c-Myc, it is plausible that EBNA2 interacts with and 
subverts the cellular Notch signaling pathway, executing Notch-like functions 
involved in IgM/c-Myc regulation, consequently affecting bik repression and the 
ensuing disturbance of the apoptotic balance in the cell that is consistent with virus 
survival. It should be noted that there are additional common interaction partners of 
both Notch and
 
EBNA2, such as SKIP, Nur77, PU.1, Spi-1 or Spi-B (Laux et al, 
1994a; Johannsen et al, 1995; Zhou et al, 2000a; Zhou et al, 2000b; Lee et al, 2002), 
which could potentially
 
contribute to this function.  
 
 
Results presented here demonstrate that the induction of LMP1 did not influence the 
expression of the bik gene in response to tetracycline-regulated induction of this 
protein indicating no role for LMP1 in its regulation. Recent findings in the laboratory 
have shown that LMP1 drives bfl-1 promoter
 
activity through interactions with 
components of the TNFR/CD40 signaling pathway. Activation of CD40 receptor also
 
led to increased bfl-1 mRNA levels and an NF-κB-dependent increase
 
in bfl-1 
promoter activity in BL-derived cell
 
lines (D'Souza et al, 2004). In a recent study 
CD40 stimulation enhanced the constitutive anti-apoptotic profile of B-cell chronic 
lymphocytic leukaemia (B-CLL) cells by up-regulation of Bcl-XL and Bfl-1 and 
down-regulation of the BH3-only protein Harakiri, with no change in the level of 
expression of the bik gene (Kater et al, 2004) adding further support to the contention 
that LMP1/CD40 signaling is not involved in Bik down-regulation, while also 
reinforcing its role in bfl-1 regulation.  
Of interest, EBNA2-mediated
 
Bik repression in BL41K3 led to the gradual 
disappearance of the slower moving band (27kDa) which has previously been 
identified as the phosphorylated form of Bik (Verma et al, 2001). These observations 
may suggest that the larger band is preferentially degraded by EBNA2.  Interestingly, 
it is thought that phosphorylation of Bik is required for eliciting efficient
 
apoptotic 
activity (Verma et al, 2001). Thus, while this model is consistent with the role for 
EBV in protecting infected cells from apoptosis, it does not explain the apparent 
resistance of BL Type I cell lines to Bik expression. As suggested in Chapter 3, the 
relative proportion of Bik not associated with Bcl-XL may be a crucial factor in the 
ability of these cells to tolerate the expression of this pro-apoptotic molecule. Bik may 
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also be counteracted by a so far undefined inhibitor in type I cells (EBV latent 
programme) as compared with type III cells and LCLs (EBV growth programme).  
 
It was shown previously that the infection of BL cells with EBV results in a 
significant down-regulation in the expression of the BH3-only bim gene (Clybouw et 
al, 2005; Leao et al, 2007). It has been reported that EBV infection may lead to post-
translational modulation of Bim expression, involving the phosphorylation of BimEL 
by the EBV-activated kinase ERK1/2, followed by its degradation through the 
proteasome pathway (Clybouw et al, 2005). However, a pathway in which EBNA3A 
and EBNA3C co-operate to regulate Bim expression at the level of transcription; has 
also been described (Anderton et al, 2007) and it is formally claimed that EBV does 
not regulate Bim post-translationally; that there is no direct correlation between ERK 
phosphorylation and Bim expression in B-cells. In addition a recent report indicates 
that pro-apoptotic Bax is an important target of the anti-apoptotic
 
activity of LMP-1. 
LMP-1 inhibits bax promoter activity, through activation of NF-κB.
 
Moreover, in 
cells with impaired Bax function or expression the
 
anti-apoptotic activity of LMP-1 is 
significantly reduced (Grimm et al, 2005). The data presented here indicates that 
down-regulation of pro-apoptotic bik by EBV is also at the level of transcription and 
is mediated by EBNA2. This is the first indication of down-regulation of a pro-
apoptotic protein by this viral protein. Thus, the novel discovery that EBNA2 is 
down-regulating transcription from the pro-apoptotic bik gene in combination with the 
up-regulation of the anti-apoptotic bfl-1 gene suggests that EBNA2 expression may 
have a protective effect on BL cells during apoptosis. 
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CHAPTER 5 : 
Regulation of bik by EBV in Lymphoblastoid 
Cell Lines. 
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5.1 Introduction 
 
Since EBV-negative BL cells are immortalised by a mechanism not requiring EBNA2 
expression, it is difficult to assess the contribution of this gene to cell survival in the 
context of this cancer cell.  A critical question is whether bik repression
 
during the 
activation of EBNA2 in BL cells occurs during infection
 
of primary B-cells by EBV. 
In EBV-immortalised lymphoblastoid cell lines (LCLs), EBNA2 maintains the EBV 
growth programme (Kempkes et al, 1995a) and consequently, in contrast to the 
investigation
 
of a gene in the background of a pre-existing tumour
 
cell line, the use of 
the conditionally immortalised LCL EREB 2-5 enables the study of  EBNA2
 
in its 
physiological context; i.e. in B-cells that are induced to proliferate due to EBV 
(Schlee et al, 2004). The EREB 2-5
 
cell system imitates
 
fundamental steps in the 
EBNA2-driven immortalisation of primary B-cells (Schlee et al, 2004) allowing one 
to determine if bik repression is a cellular response that occurs due to the EBV growth 
programme. 
 
It has been shown elsewhere that enforced c-Myc
 
expression is sufficient to sustain B-
cell proliferation independently
 
of both EBNA2 and LMP1 (Polack et al, 1996). The 
proliferation programme imposed by
 
enforced expression of c-Myc in BL cells differs 
considerably
 
from that triggered in EBV-immortalised cells, driven by the expression 
of EBNA2. EBV-immortalised
 
cells grow in clumps, expressing an array of activation
 
markers and adhesion molecules, are particularly resistant to apoptosis,
 
and are 
immunogenic.
 
In contrast, c-Myc-driven cells grow as single cells in suspension,
 
do 
not express the various cell surface molecules expressed on EBV-immortalised
 
cells, 
are highly susceptible to apoptosis, and are non-immunogenic (Schlee et al, 2004).
 
The immense differences in the growth programmes between cells driven into
 
proliferation by EBV and c-Myc indicate that there must be considerable differences 
in the target genes of EBNA2 and c-Myc. Thus, EBNA2 targets, which include viral 
growth programme genes,
 
comprise additional genes that are independent of
 
c-Myc, 
and are not involved in proliferation, but rather play a role in protection against 
apoptosis, or cell-cell communication. 
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This study set out to investigate if bik down-regulation was a feature of the EBV 
growth programme in B-cells proliferating due to EBV latent proteins, and to 
determine if c-Myc, itself a positive EBNA2 target in this context, played a role in bik 
repression. The P493-6
 
cell line was a particularly appropriate tool to use for this 
purpose (Table 2.1-1). This cell line is an EBV-infected LCL that is conditional for 
both EBNA2 and c-Myc. When P493-6 cells are starved of estrogen, EBNA2 function 
is lost leading, in turn, to loss of the EBV growth programme and the cessation of cell 
growth. In this setting, Myc expression can be turned on, as it is tetracycline 
regulated, and the cells therefore approximate EBV-negative BL cells, proliferating 
due to the over-expression of c-Myc (Staege et al, 2002). 
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5.2  Bik is down-regulated by EB+A2 in EBV-immortalised cell lines. 
5.2.1 Bik is down-regulated by EB+A2 in EREB 2-5 cells. 
 
EREB 2-5, a conditional LCL in which the function of EBNA2 can be controlled by 
the presence or absence of estrogen has previously been developed (Kempkes et al, 
1995a). This was achieved by the fusing of the N-terminus of EBNA2 to the hormone 
binding domain of the estrogen receptor. Essentially, this ER/EBNA2 fusion gene was 
then used to compliment the EBNA2 deletion in the EBV P3HR1 viral genome 
(Kempkes et al, 1995a). The resulting ‘conditional’ LCL, designated EREB 2-5, 
generated after immortalising resting B-cells with this recombinant EBV, therefore 
required the presence of estrogen for EBNA2 function and hence cell proliferation. 
Addition of estrogen results in EBV-infected cells with a phenotype similar to those 
found in healthy individuals upon primary infection with the virus, or EBV-infected 
cells found in immuno-suppressed patients. Cells growing in the absence of estrogen 
cease to proliferate due to the expression of only non-functional ER/EBNA2 and the 
shutoff of the EBV growth programme (see Figure 5.2.1). 
 
 
Figure 5.2.1: Schematic diagram of EREB 2-5.  
  
EREB 2-5 is an LCL that contains a mini-EBV plasmid expressing the chimeric 
EBNA2 protein as an autonomously replicating plasmid, plus the P3HR1 viral 
genome, thus complementing the EBNA2 deletion of the P3HR1 virus. EBNA2 
expression and proliferation are dependent on the presence of estrogen.  
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In order to examine changes in bik expression  due to the expression of EBNA2 a time 
course was performed with the EREB 2-5 cell line cultivated in the presence and 
absence of estrogen (Section 2.2.2.3). Cells were washed four times in PBS to remove 
estrogen from the cell culture medium and seeded into estrogen-free medium, 
followed by another two washes 24 hours later.  This was considered time 0. Protein 
and RNA extracts were prepared at various time points over a 120 hour period. After 
this time, these cells were recultured in medium supplemented with 1µM estrogen 
(Kempkes et al, 1995a) and protein and RNA extracts were prepared over the 
subsequent 72 hours. The levels of EBNA2, Bik and β-Actin protein expressed during 
the time-course were analysed by Western blot, and bik mRNA levels were assayed 
by RT followed by QPCR as before. 
 
EBNA2-associated changes in Bik protein expression and mRNA levels observed 
during the time courses in the EREB 2-5 induction are shown in Figure 5.2.2. Western 
blot analysis (Figure 5.2.2A) confirms that EREB 2-5 cells grown in the absence of 
estrogen, only expressed non-functional EBNA2, while cells grown in the presence of 
estrogen expressed chimeric EBNA2 with an apparent molecular weight of 120kDa, 
confirming the activation of EBNA2. It is clear from Figure 5.2.2A that a 
considerable and sustained induction of Bik protein levels occurred 48 hours 
following the removal of estrogen from the EREB 2-5 culture medium. Accordingly 
after the re-activation of EBNA2, Bik expression was completely abolished (72-
hours) (Figure 5.2.2A). 
 
Changes in bik mRNA levels due to EBNA2 expression over time in EREB 2-5 are 
shown in Figure 5.2.2B.  Bik mRNA levels were seen to increase dramatically over 
time (7-fold at 24 hours) in EREB 2-5 cells upon inactivation of EBNA2. The amount 
of bik mRNA was seen to increase dramatically by 120 hours, with a 92-fold increase 
in the level of bik mRNA compared to time 0.  
 
A reduction in bik levels (approximately 1.7-fold) was observed 24 hours following 
the subsequent addition of estrogen to the culture medium (Figure 5.2.2B). A further 
decrease was seen at 48 hours (2.5-fold), and levels of bik mRNA remained stably-
repressed from this point on, with the level of bik at 96 hours similar to that observed 
at 48 hours.  
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These results establish that bik is transcriptionally repressed by the EBNA2-driven 
growth programme in EBV-immortalised B-cells. In EREB 2-5 cells, EBNA2 
function is dependent on estrogen, and the proliferative and growth transformation 
effects of EBV are reversed upon withdrawal of this hormone from the medium. It 
can be seen that the removal of estrogen led to de-repression of bik mRNA and 
protein (Figure 5.2.2), co-incident with the established observation of the onset of 
apoptotic death in the absence of hormone (Kempkes et al, 1995a). The reactivation 
of EBNA2, was also concurrent with a reduction in the level of bik expression.  
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Figure 5.2.2: Modulation of bik expression by EB+A2 in the EBV-infected cell 
line EREB 2-5.  
 
EREB 2-5 cells which had been cultivated in the absence of estrogen for the 
preceding 120 hours, were cultivated in the presence of estrogen for a further of 72 
hour period in order to activate EBNA2. Both RNA and protein extracts were 
prepared at various time points (hours) after activation/repression. (A) Western Blot 
analysis of Bik protein expression in response to activation of EBNA2 was monitored. 
The level of Bik protein expression was detected using a mouse anti-Bik antibody 
(BD Biosciences 557040). Analysis of EBNA2 activation in EREB 2-5 is shown in 
the upper panel. The middle panel illustrates Western blot analysis of Bik protein 
expression in response to activation of EBNA2. The lower panel shows the same blot 
probed for β-Actin (B) QPCR analysis for the level of bik expression was also 
examined. Isolated RNA was reverse transcribed using random primers and 
amplification of DNA was monitored by detection of fluorescence intensity using  
FAM-labeled TaqMan probes for bik and gapdh. Fluorescent signals were detected 
using an ABI Prism 7500 Sequence Detection System. After normalisation for gapdh, 
relative quantitation level of bik was plotted as a function of the control (0H; 
arbitrarily assigned a value of 1). The lower plot illustrates the changes in bik 
expression in response to activation of EBNA2, while the upper plot shows 
differences in bik expression coincident with EBNA2 repression. (Data are Mean±SD, 
*p <0.05) 
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It was also observed that the Bik protein band pattern that emerges upon EBNA2 
repression is similar to that observed in the DG75 BL type I cell line, and contrasts 
with the low level of Bik seen in the BL type III cell line AG876 and the LCL IB4 
where only the lower Bik band is apparent (Figure 5.2.3).  These results show that bik 
mRNA and protein levels are repressed due to the EBV growth programme. 
 
 
 
 
Figure 5.2.3: De-repression of bik following estrogen withdrawl in the 
conditional LCL EREB 2-5  
Western Blot analysis of Bik protein expression in the EREB 2-5 cell line in response 
to repression of EBNA2 for 48 hours, relative to that expressed in DG75, AG876 and 
IB4 was monitored. The level of Bik protein expression was detected using a mouse 
anti-Bik antibody (BD Biosciences 557040). The upper panel illustrates Western blot 
analysis of Bik protein expression and the lower panel shows the same blot probed for 
β-Actin 
 
5.2.2 Modulation of bik expression in the EBV-infected cell line P493-6. 
 
In LCLs, c-myc is a positive transcriptional target of EBNA2. In addition, constitutive 
expression of c-myc can substitute for EBNA2 in the maintenance of proliferation in 
EREB 2-5 cells (Pajic et al, 2000). It was therefore of interest to determine if Bik 
repression also occurred in B-cells driven to proliferate due to c-Myc.  For this 
purpose, the P493-6
 
cell line was employed. This cell line was clonally derived 
elsewhere from EREB 2-5 and conditionally expresses both EBNA2 (regulated
 
by 
estrogen) and ectopic c-Myc (negatively regulated by tetracycline) (Schuhmacher et 
al, 1999; Pajic et al, 2000; Schuhmacher et al, 2001). P493-6 is therefore an EBV-
infected LCL, which when starved of estrogen resembles a resting B-cell and upon 
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induction of Myc the cells approximate BL cells, in that they proliferate due to the 
over-expression of c-myc  (Staege et al, 2002).  
 
In brief, the B-cell line P493-6 was established by stable transfection of a tetracycline-
regulatable c-myc gene into EREB 2-5 cells using an episomal vector; (tet-off system) 
(Pajic et al, 2001). In this vector the two coding exons of myc are under the control of 
a tetracycline regulated promoter, TP-tetO7. pMyc-tet also carries the gene coding for 
the tetracycline repressor-VP16 trans-activator fusion protein, tTA on the same 
molecule (Gossen and Bujard, 1992). Hygromycin resistant and estrogen independent 
cell clones were then selected for during cell culture (Pajic et al, 2001). Addition of 
tetracycline to the cell culture medium abolishes promoter activation by direct 
interaction with tTA (Figure 5.2.4). 
 
 
 
 
Figure 5.2.4: Conditional expression of myc or the EBV growth programme in 
the B-cell line P493-6, a clonal derivative of EREB 2-5.  
 
(A) Schematic illustration of the myc expression construct pMyc-tet. The two coding 
exons of myc (black boxes II and III) were cloned under the control of the promoter 
TP-tetO7. The construct also includes an expression cassette for the trans-activator 
tTA (CMV-tTA). Tetracycline abolishes trans-activation of TP-tetO7 by interfering 
Estrogen  Tetracycline EB+A2 c-Myc 
+ + YES NO 
+ - YES YES 
- + NO NO 
- - NO YES 
A 
B 
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with tTA DNA-binding. pMyc-tet is based on the EBV-derived vector pHEBO. 
Selection marker genes are depicted as arrows, and the origin for latent replication by 
oriP (adapted from Pajic et al, 2001). (B) P493-6 cells were induced to grow on an 
EBV-driven programme; where the cells either proliferate due to the expression of 
EBNA2 (in the presence of estrogen and tetracycline), or on the c-Myc growth 
programme (when estrogen and tetracycline are withdrawn), with the cells 
proliferating due to the over-expression of c-Myc.  In order to activate EBNA2 in its 
functional form, estrogen is added to the culturing media to a final concentration of 
1µM, in agreement with previously published studies (Pajic et al, 2000; Pajic et al, 
2001). Expression of c-myc may be suppressed by treatment with 0.1µg/ml 
tetracycline again in accordance with previously published studies (Pajic et al, 2000; 
Pajic et al, 2001). 
 
5.2.2.1 Bik is regulated by EB+A2 in the B-cell line P493-6 
 
In order to examine EBNA2-associated changes in the level of bik expression a time 
course was undertaken with the P493-6 cell line cultivated in the presence of estrogen 
and tetracycline as per Section 2.2.2.3 (Figure 5.2.4B). Under these conditions the 
cells resemble EREB 2-5, since inducible c-myc expression is switched off, and the 
cells express ER/EBNA2 and endogenous c-Myc. P493-6 cells which had been 
previously been cycling on the EBV growth programme (in the presence of 
tetracycline and estrogen), were cultivated in the absence of estrogen for a period of 
60 hours. After this time cells were washed twice with PBS and were cultivated in the 
presence of estrogen. Protein and RNA extracts were prepared at various time points 
over a 72 hour period. At this point the cells were washed twice with PBS and re-
seeded in the absence of estrogen and RNA extracts were prepared over the 
subsequent 72 hours. The levels of EBNA2, Bik c-Myc and β-Actin protein expressed 
were analysed by Western blot, and bik and gapdh mRNA levels were assayed by RT 
followed by QPCR. 
 
Western blotting was undertaken to demonstrate the activation of ER/EBNA2 over 
the course of the experiment and to analyse Bik and c-Myc protein levels in response 
to EBNA2 expression (Figure 5.2.5A). Levels of the endogenous control, β-Actin, 
were also analysed and confirmed equal loading in each case (Figure 5.2.5A). In this 
experiment, functional ER/EBNA2 was detected in induced P493-6 cells at 24 hours 
and remained detectable up to 72 hours (Figure 5.2.5A). A significant decrease in the 
level of Bik protein can be seen to coincide with the activation of EBNA2 expression 
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over time, Bik levels are repressed in conjunction with EBNA2 expression at 24 and 
48 hours, and are completely abolished at the 72 hour time point. Thus, Bik down-
regulation is again governed by EBNA2/EBV growth programme as was seen in the 
parental cell line EREB 2-5.
 
Endogenous c-Myc expression correlated with EBNA2 
induction and was up-regulated by 24 hours, and remained up-regulated at 72 hours 
(Figure 5.2.5A) as expected.  
 
Steady state levels of bik mRNA in P493-6 were also repressed in response to EBNA2 
activation, reminiscent of the result obtained with the parental EREB 2-5 cell line 
(Figure 5.2.5). A significant and sustained decrease in bik mRNA levels 
(approximately 10-fold) was observed by 24 hours following activation of EBNA2. 
Chimeric EBNA2 was expressed at high levels at this time point (Figure 5.2.5A).  
After removal of estrogen, (and the resulting withdrawal of EBNA2 function), the 
amount of bik mRNA was seen to increase gradually over time after this point, with 
the level at 72 hours approximately 3.4-fold greater than the levels observed upon 
removal of estrogen from the cell culture medium (0H–EBNA2). The levels of bik 
mRNA however, never reached the levels originally observed upon induction of 
EBNA2 (0H+EBNA2).  These results indicate that the activation of ER/EBNA2 and 
consequently the EBV growth programme led to a sustained decrease in the level of 
bik mRNA in P493-6, and subsequent removal of EBNA2 function was concurrent 
with a de-repression in bik mRNA levels.   
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Figure 5.2.5: Regulation of bik by EB+A2 in the EBV-immortalised cell line 
P493-6. 
P493-6 cells which had previously been cycling on EBV growth programme for 72 
hours were cultivated in the absence of estrogen for a further of 72 hour period in 
order to inhibit EBNA2. Total protein and RNA were prepared simultaneously from 
cells harvested at the indicated time-points after ER/EBNA2 activation/repression. 
The level of Bik protein was detected using an affinity purified goat polyclonal IgG 
(Santa Cruz, sc-1710). (A) Western Blot analysis of Bik protein expression in 
response to ER/EBNA2 in the P493-6 cell line. The upper panel illustrates EBNA2 
protein upon activation by reculturing in the presence of estrogen and tetracycline. 
Analysis of c-Myc in response to EBNA2 induction in P493-6 is shown in the second 
panel. Western Blot analysis of Bik protein expression in response to induction of 
EBNA2 expression is shown in third panel. The lower panel shows the same blot 
probed for β-Actin. (B) QPCR analysis for the level of bik expression in response to 
EBNA2 activation/repression was also examined. Isolated RNA was reverse 
transcribed using random primers and amplification of DNA was monitored by 
detection of fluorescence intensity using FAM-labeled TaqMan probes for bik and 
gapdh. Fluorescent signals were detected using an ABI Prism 7500 Sequence 
Detection System. After normalisation for gapdh, relative quantitation level of bik 
mRNA was plotted as a function of the control (Cells cyling –EBNA2/-Myc; 
arbitrarily assigned a value of 1). (Data are Mean±SD, * p<0.05) 
 
 
 
 
 
 
+EB+A2 
A B 
   0H           24H          48H      72H 
  ER/EBNA2 ► 
C-MYC ► 
BIK ► 
β-ACTIN ► 
Cells cycling -EB+A2/-C-MYC
+ EB+A2
- EB+A2
 * 
 181 
5.2.2.2   P493-6 cells express lower levels of Bik when cycling due to EBV 
than when cycling due to c-Myc. 
 
Bik expression in P493-6 cells which were driven to proliferate on the EBV and c-
Myc programmes were next compared. Accordingly, cells that had been previously 
been cycling due to c-Myc were cultivated in medium containing tetracycline for 60 
hours. After this time, cells were washed four times in PBS and re-seeded in the 
absence of tetracyline and estrogen.  This was considered time 0. c-Myc expression 
was induced over the 72 hour period and protein and RNA extracts were prepared at 
72 hours. At the same time, cells that had been cycling on the EBV growth 
programme were cultivated in the absence of estrogen for 60 hours preceding 
induction. After this time cells were washed four times in PBS, and subsequently 
seeded into medium containing estrogen. This was considered time 0. EBNA2 
expression was induced over a 72 hour period and protein and RNA extracts were 
prepared at 72 hours. The levels of Bik and β-Actin proteins expressed were analysed 
by Western blot, and bik and gapdh mRNA levels were assayed by RT followed by 
QPCR. 
 
It can be seen that Bik protein was detectable in P493-6 cells proliferating due to the 
c-Myc in comparison to those cells expressing the EBV growth programme, wherein 
Bik was in fact undetectable (Figure 5.2.6A). Levels of the endogenous control β-
Actin were also monitored and confirmed equal quantity loaded in each case (Figure 
5.2.6A, lower panel).  
 
Differences in bik mRNA expression due to regulation by either c-Myc or the EBNA2 
programmes are shown in Figure 5.2.6B. Relative quantitation of the levels of bik 
transcript after normalising for gapdh indicated that c-Myc-driven P493-6 cells had a 
comparatively high bik mRNA level, approximately 8-fold higher than that observed 
in the EBNA2-driven cells (Figure 5.2.6B). Thus, the steady state level of bik mRNA 
and Bik protein is significantly lower when cells are cycling due to EBV growth (Lat 
III) programme compared to cells proliferating on the c-Myc programme.  
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Figure 5.2.6: Cells cycling on EBV lat III express less Bik than cells proliferating 
on the Myc programme. 
 
P493-6 cells which had been starved of estrogen for the preceding 60 hours were 
cultivated in the presence of estrogen for 72 hours in order to activate EBNA2. At the 
same time, P493-6 cells which had been maintained in the absence of c-Myc 
expression for the preceding 60 hours were cultivated in the absence of tetracycline in 
for a further 72 hours in order to induce c-Myc expression. Total protein and RNA 
were prepared simultaneously from cells harvested at 72 hours. (A) Western Blot 
analysis of Bik protein expression in response to either EBNA2 or c-Myc expression 
in the EBV-positive cell line P493-6. The level of Bik protein was detected using an 
affinity purified goat polyclonal IgG (Santa Cruz, sc-1710). Western Blot analysis of 
Bik protein expression in response to ER/EBNA2/c-Myc expression can be seen in 
the upper panel. The lower panel shows the same blot probed for β-Actin. (B) QPCR 
analysis for the level of bik expression was also examined. Isolated RNA was reverse 
transcribed using random primers and amplification of DNA was monitored by 
detection of fluorescence intensity using FAM-labeled TaqMan probes for bik and 
gapdh. Fluorescent signals were detected using an ABI Prism 7500 Sequence 
Detection System. After normalisation for gapdh, relative quantitation level of bik 
was plotted as a function of the control (Cycling EBNA2 cells; arbitrarily assigned a 
value of 1). (Data are Mean±SD) 
 
5.2.2.3 Bik is negatively regulated by c-Myc in the LCL P493-6. 
 
In order to directly investigate bik expression in response to c-Myc P493-6 cells 
which had been previously been cycling on the c-Myc growth programme (in the 
absence of tetracycline and estrogen) for the preceding 60 hours, were cultivated in 
the presence of tetracycline in for a further 72 hours in order to suppress c-Myc 
expression (Section 2.2.2.3). Protein and RNA extracts were prepared at various time 
points over a 72 hour period.  At this point the cells were washed twice with PBS and 
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re-seeded in the absence of tetracycline and RNA extracts were prepared over the 
subsequent 72 hours. The levels of EBNA2, Bik c-Myc and β-Actin protein expressed 
were analysed by Western blot, and bik and gapdh mRNA levels were assayed by RT 
followed by QPCR. 
 
Western blot analysis (Figure 5.2.7A) confirmed that cells grown in the absence of 
estrogen and tetracycline showed a decrease in c-Myc expression over the duration of 
the 72 hour period.  c-Myc expression was undetectable after 24 hours, and remained 
undetectable up to 72 hours after the-addition of tetracycline. A considerable, if 
transient increase in the level of Bik protein was observed in response to c-Myc 
repression at the 24 and 48 hour time points. Although decreased, Bik still remained 
detectable at 72 hours. These results showed that loss of c-Myc led to a significant 
transient increase in the level of Bik in the LCL P493-6. Inactivated ER/EBNA2 
protein and β-Actin levels were also monitored by Western blot analysis, and neither 
showed any significant variation over the time period (Figure 5.2.7A). 
 
Similar to the result observed with Bik protein, bik mRNA levels were also transiently 
induced in P493-6 cells 24 hours after c-myc repression. Upon removal of tetracycline 
from the cell culture medium, a reduction in the level of bik mRNA in response to 
ectopic c-Myc was again to be seen (Figure 5.2.7B). Bik mRNA levels were seen to 
diminish over time in response to the levels of cMyc. A considerable reduction in bik 
levels was observed by 24 hours (approximately 2.5-fold decrease from the levels 
observed upon induction of c-Myc, which persisted at the subsequent time points up 
to 72 hours.  The amount of bik mRNA was seen to decrease to a level similar to that 
seen upon withdrawal of c-Myc expression (0H-Myc).  
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Figure 5.2.7: Regulation of bik by c-Myc in P493-6 cells 
 
 
P493-6 cells which had been previously been cycling on the c-Myc growth 
programme for the preceding 60 hours, were cultivated in the presence of tetracycline 
in for a further 72 hours in order to suppress c-Myc expression. Protein and RNA 
extracts were prepared at various time points over a 72 hour period.  At this point the 
cells were re-seeded in the absence of tetracycline and RNA extracts were prepared 
over the subsequent 72 hours. Protein and RNA extracts were prepared at various time 
points over a 72 hour period.  The level of Bik protein was detected using an affinity 
purified goat polyclonal IgG (Santa Cruz, sc-1710). (A) Western Blot analysis of Bik 
protein expression in response to repression of c-Myc in the P493-6 cell line. Analysis 
of EBNA2 protein upon in response to c-Myc inhibition by reculturing in the absence 
of estrogen and the presence of tetracycline is illustrated in the upper panel. 
Repression of c-Myc in P493-6 is shown in the second panel. Western Blot analysis 
of Bik protein expression in response to c-Myc repression can be seen in the third 
panel. The lower panel shows the same blot probed for β-Actin. (B) QPCR analysis 
for the level of bik expression in response to c-Myc induction/repression was also 
examined. Isolated RNA was reverse transcribed using random primers and 
amplification of DNA was monitored by detection of fluorescence intensity using 
FAM-labeled TaqMan probes for bik and gapdh. Fluorescent signals were detected 
using an ABI Prism 7500 Sequence Detection System. After normalisation for gapdh, 
relative quantitation level of bik mRNA was plotted as a function of the control (Cells 
cyling –EBNA2/+Myc; arbitrarily assigned a value of 1). (Data are Mean±SD, 
*p<0.05) 
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5.3 Discussion  
 
It is difficult to assess whether EBNA2-associated changes in bik expression
 
in BL 
tumour-derived cell lines reflect events which take place during infection
 
of primary 
B-cells by EBV. Since the lack of detectable bik expression (Chapter 3; Figure 3.2.1) 
was an observation consistent with a potential tumour suppressor role for bik, and 
could have pro-survival consequences during EBV infection of B-cells, it was decided 
to investigate whether bik down-regulation was the result of the EBV growth 
programme in an LCL background. Accordingly experiments were carried out using 
the EREB 2-5 cell line in which the induction of functional EBNA2 activates the EBV 
growth programme and results in an LCL phenotype, similar to that seen in infected 
B-cells found in individuals experiencing EBV primary infection, or EBV-infected B-
cells found in immuno-suppressed patients (Kempkes et al, 1995a). 
 
The experiments presented here demonstrate that an induction of functional EBNA2 
expression coincides with a decrease in the level bik mRNA and protein in the LCL 
cell lines EREB 2-5 and its clonal derivative P493-6. Significantly removal of 
estrogen from the culture medium, and the consequent inhibition of EBNA2 function 
resulted in a de-repression of bik. This novel observation implies that the bik gene is 
directly down-regulated by the EBV growth programme in virus-infected B-cells. 
This is compatible with an anti-apoptotic consequence since the removal of estrogen 
from the cell culture medium is co-incident with the established observation of the 
onset of apoptotic death in the absence of hormone (Kempkes et al, 1995a). 
The repression of bik mRNA levels in EREB
 
2-5
 
was 2.5-fold by 72 hours, in contrast 
to that for P493-6, where repressed bik mRNA levels were 10-fold decreased by just 
24 hours after induction of EBNA2. Additionally, the de-repression observed in 
EREB 2-5 (92-fold) was much greater than that observed in P493-6 (3.4-fold). 
However, it should be considered that EREB 2-5 cells were starved of estrogen for 
only 24 hours prior to time 0 as compared to 60 hours in P493-6, and thus differences 
owing to the physical condition of the cells could be implicated in the differences in 
the extent of bik modulation observed. Significantly, the overall trend is the same. 
Also, P493-6 cells maintain detectable c-myc mRNA protein levels in the presence of 
tetracycline and may therefore be considered ‘pre-activated’ compared to EREB 2-5 
cells, in which EBNA2 activity (and thus also c-Myc) is tightly regulated by hormone 
 186 
(Schlee et al, 2004). It is thus conceivable that a small amount of “leaky” Myc 
expression leads to an already repressed expression of Bik, and thus the effect we see 
is not the “full” effect. Accordingly then, even a small level of Myc expression in the 
cell might hinder the de-repression effect; as would not be the case in EREB 2-5. 
As both EBNA2 and endogenous c-myc are expressed following activation of 
functional EBNA2, with trans-activation of c-myc under the control of EBNA2 
(Kaiser et al, 1999), it is not possible to conclude from the EREB 2-5 experiments if 
Bik is a downstream target of c-Myc or is a c-Myc-independent EBNA2 target. Thus, 
in order to directly ask if c-Myc represses bik in the absence of EBNA2, EREB 2.5 
cells stably transfected with c-myc expression vector was employed. The rationale for 
this was that P493-6 cells are derived from the same parental EREB 2-5 cells and can 
be induced to proliferate on a Myc-driven proliferation programme in the absence of 
the EBV growth programme. Significantly, it was shown that c-Myc can trigger bik 
repression in P493-6 cells in the absence of functional EBNA2. Additionally, 
repression of exogenous c-myc leads to a de-repression of bik. Moreover, the steady-
state level of bik mRNA/Bik protein was considerably lower when cells were cycling 
due to EBV growth programme when compared to cells proliferating on the c-myc 
programme indicating that the effect of EBNA2 was clearly more potent than c-Myc, 
and possibly indicating a co-operative role for both EBNA2 and c-myc in bik 
repression. This finding
 
is consistent with the hypothesis that the decrease in bik is at 
least in part a consequence
 
of c-Myc activation by EBNA2. Previous studies have 
identified several other genes as being c-Myc dependent EBNA2 target genes, 
including eIF5a, PPase, acidic ribosomal protein P0, PA28γ and NM23-H1 (Schlee et 
al, 2004). It was postulated in Chapter 4 that EBNA2-associated repression of IgM 
may mediate the down-regulation of the bik gene. EBNA2 down-regulates sIgM but 
the latter is unaffected by c-Myc expression (Pajic et al, 2001). Conceivably, then, 
since EBNA2 modulates both IgM, and c-Myc expression (Jochner et al, 1996; Kaiser 
et al, 1999) and since both of these genes can affect bik expression (Jiang and Clark, 
2001) (Figure 5.2.7) it is possible that EBNA2 mediates the regulation of bik in part 
through both IgM-dependent and c-Myc-dependent pathways. This premise may at 
least partially explain the considerable differences observed in the levels of bik 
expression when cells are cycling due to EBNA2, (in contrast to cells proliferating 
due to c-myc expression); since EBNA2 would contribute not only to the activation of 
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c-Myc-mediated bik repression (as would be the case in c-Myc-only-driven bik 
repression) but also to the activation of the IgM-associated pathway. Interestingly, 
EBNA2-mediated regulation of both c-Myc and IgM is only partially CBF1 
dependent (Maier et al, 2005). 
While findings in Chapter 4 (Figure 4.2.5) indicate that the CBF1 interaction may not 
be required for EBNA2-mediated bik repression it should be noted that EBNA2 and 
the cellular receptor, Notch, have overlapping functions beyond their capacity to 
interact with CBF1. Significantly, in trans-complementation assays carried out in the 
laboratory (Figure B, Appendix II), bik repression was restored in estrogen-starved 
EREB 2-5 cells following retrovirus transduction with wild-type EB"A2. Transduced 
cells that were selected as expressing high levels of "otch 1IC, also showed enhanced 
transcriptional repression of bik. These results further confirmed that bik is 
transcriptionally repressed by the EBNA2-driven growth programme in EBV-
immortalised B-cells. Rescue of these cells following retrovirus transduction with 
either wild-type EBNA2 or Notch 1IC restored bik repression. Thus, high levels of 
Notch can substitute for EBNA2 to repress bik, although not to the same extent as 
EBNA2. EBNA2 may execute notch-like functions to facilitate the regulation of pro-
apoptotic bik.  Although neither the Notch pathway associated protein CBF1 nor the 
EBNA2-CBF1 interaction are required for EBNA2 repression of bik (Chapter 4), it 
should be considered that CBF1 is
 
not the only common factor connecting Notch and 
EBNA2 signaling.
 
 
 
The EREB 2-5 cell line, in the presence of EBNA2 is a typical proliferating LCL. 
However, withdrawal of estrogen results in cessation of cell growth and a significant 
proportion of the cells die by apoptosis (Kempkes et al, 1995a). The gain of 
expression of this pro-apoptotic EBNA2-regulated gene could contribute substantially 
to this outcome. Significantly, upon removal of EBNA2 it appears that Bik may be 
phosphorylated (Figure 5.2.3), an event required for Bik pro-apoptotic activity 
(Verma et al, 2001).  
This experiment also adds further substance to the argument that bik regulation is not 
an artefact of estrogen regulation, (Chapter 4). While Bik has been shown to be 
induced in estrogen-dependent MCF7 breast cancer cells in response to inhibition of 
estrogen signaling (Hur et al, 2004), any correlation between the expression of bik 
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and the presence of estrogen was previously excluded due to the use of the 
tetracycline-inducible system, DG75-tTA-EBNA2 in Chapter 4. The transduction 
experiment further confirms this, since the repression of bik is due to the transduction 
of exogenous wild-type EBNA2.  
 
EBV positive tonsillar memory B-cells express a restricted pattern of latent gene 
transcripts which resembles the pattern of latent gene expression detected in EBV-
related tumours (Babcock et al, 2000b).  One study in which B-cells were LCM-
captured from lymphoid follicles from the tonsil, reported elevated bik mRNA levels 
in the proliferating germinal centre (GC) cells, (sites where an activated naïve B-cell, 
which is responding to foreign antigen during an immune response, undergoes the 
transition into a long-lived memory B-cell) (MacLennan et al, 1988; Liu and Arpin, 
1997) relative to non-proliferating naïve cells from the mantle zone (MZ). This 
finding correlates with an increased sensitivity of GC cells to apoptosis (Shen et al, 
2004). To assess whether EBNA2 expression was linked to bik repression in vivo an 
experiment was undertaken in the laboratory in which PBMC-derived untouched 
naïve B-cells were infected with EBV. No further decrease in the already low level of 
bik mRNA that was present prior to infection by 96 hours was observed. It may 
therefore be the case that the EBV growth programme represses the bik induction that 
is seen to occur in vivo during the naïve to GC cell transition. This interpretation, 
however, implies that estrogen-starved EREB 2-5 cells in which bik is re-induced 
concomitant with the onset of apoptosis, do not completely assume the phenotype of a 
true naïve B-cell. The ability of EBNA2 to down-regulate bik may also however be 
significant in EBV associated malignancies in which EBNA2 is expressed.  
Thus, the novel discovery that Bik is repressed in B-cell lines in response to the EBV 
growth programme has been presented. It is shown the first time that EBV down-
regulates expression of the cellular bik gene with a key role for the viral transcription 
factor EBNA2, and possibly the cellular gene c-Myc. This host-virus interaction may 
be relevant in the prevention of apoptotic death of infected B-cells that are driven to 
proliferate by EBV.  
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CHAPTER 6                                            
 
 
Ectopic Bik induces Apoptosis in the       
EBV-infected cell line, IB4.  
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6.1 Introduction  
 
A fundamental feature of the overall EBV strategy is the modulation of cellular 
pathways that suppress the cellular apoptotic programme, promoting lymphocyte 
survival and proliferation (Klein, 1994). The ability of the viral latent proteins to 
manipulate the balance of bcl-2 family members has long been recognised, and has 
been exploited to inhibit cancer in preclinical and clinical settings (Ghobrial et al, 
2005; Papadopoulos, 2006). Previous work in our laboratory has shown that the anti-
apoptotic, bcl-2 family member, bfl-1 plays an important role in regulating the 
survival of EBV-infected B-cells (D'Souza et al, 2000) and also has an important role 
in protecting H/RS cells from apoptosis (Loughran, S.T., manuscript in preparation). 
Bik is pro-apoptotic with a death-promoting activity (Boyd et al, 1995; Tong et al, 
2001). Bik has been implicated in several cancers (Castells et al, 2000; Jiang and 
Clark, 2001; Hur et al, 2004; Sturm et al, 2006) and exogenous Bik expression can 
sensitise tumour cells to apoptosis (Daniel et al, 1999; Panaretakis et al, 2002) 
making bik a potential
 
therapeutic gene in cancer treatment (Zou et al, 2002).  
 
It has already been established in chapters 4 and 5 that bik is a transcriptional target of 
EBNA2 and thus has a potential role to play in EBV regulation of cellular apoptosis. 
This chapter set out to investigate the effect of ectopic Bik in B-cells in which 
endogenous Bik expression has been repressed by EBV. 
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6.2 Effects of ectopic Bik on EBV-infected cell lines. 
6.2.1 Bik potently inhibits viability of EBV infected cell lines. 
 
In order to elucidate the significance of the loss of Bik expression to the survival of 
EBV-infected cells in culture, a strategy was devised to substitute for this loss by 
ectopic expression of Bik in the EBV-infected cell line, IB4. A paired set of 
expression plasmids for Bik; pcDNA3-HA-bik and pcDNA3-HA-bik-∆BH3 were thus 
procured for this purpose. The pcDNA3-HA-bik construct (Figure 6.2.1A), contains 
the full length bik ORF sub-cloned downstream of a sequence encoding the HA 
peptide (derived from the human influenza hemagglutinin protein) in the mammalian 
expression vector pcDNA3-HA (Table 2.1-4). HA is a short epitope tag, commonly 
used for detection of fusion proteins mediated by highly specific anti-HA antibodies. 
The partner for this vector pcDNA3-HA-bik-∆BH3 (Figure 6.2.1A) contains a 
deletion of 5 amino acids within the BH3 domain (Figure 6.2.1B). 
 
In order to verify the expression of HA-Bik and HA-Bik-∆BH3 protein from these 
constructs, the EBV positive cell line, AG876 was transiently transfected with 
pcDNA3-HA-bik and pcDNA3-HA-bik-∆BH3, the corresponding empty vector 
(pcDNA3-HA) and a positive control pcDNA3-HA-bfl-1 in AG876 (Table 2.1-1) by 
electroporation (Section 2.2.2.7). AG876 is an EBV-positive BL cell line with a low 
basal level of bik expression (Chapter 3, Figure 3.2.2A). Total protein from these cells 
was prepared at 48 hours after transfection and the presence of HA-tagged Bik and 
HA-tagged Bik-∆BH3 at the expected size was confirmed by Western blotting 
(Section 2.2.4.3) using an anti-HA antibody (Table 2.1-2) (Figure 6.2.1C).  
 
It can be seen that HA-Bik protein was expressed at the anticipated size (27kDA) with 
the slightly smaller size observed for Bik-∆BH3 consistent with the pertinent 5 amino 
acid deletion (Figure 6.2.1C). Western blot analysis revealed that the level of 
expression of exogenous Bik from the bik-transfected cells appeared lower than cells 
expressing the BH3 deletion mutant. Because ectopic Bik levels are compared to the 
total β-Actin protein level in each sample, differences in loading densities between 
samples can be corrected. However, comparing observed differences in expression 
levels of protein, does not take into account that the cells transfected with bik may 
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also be less viable, and therefore express a lower level of protein than the protein 
expressed from the mutant partner. Evaluating differences in expression of potentially 
toxic protein on a per-transfection basis using Western blot analysis does not take into 
account these differences and may therefore underestimate the abundance of the 
protein in a particular cell pool. The potentially toxic effect of Bik relative to BH3-
deleted Bik may lead to a distortion in the apparent levels of expression of these 
ectopic proteins. If ectopic Bik (but not BH3-deleted Bik) has a deleterious effect on  
the transfected cells in which it is expressed, and assuming a transfection efficiency of 
X%, then ‘normalisation’ using total β-actin levels would not sufficiently correct for 
this. Bik would therefore appear to be under-expressed relative to BH3-deleted Bik. 
 
  
The nucleotide sequence of the HA-bik cDNA and the BH3 deletion (∆BH3) mutant 
were verified by sequencing (Section 2.2.1.18) using pcDNA3 vector specific forward 
and reverse primers (pcDNA3-For and pcDNA3-Rev) (Figure 6.2.1B). Sequencing 
results, received as linear nucleotide sequences, were aligned with the established 
nucleotide sequence of the human bik gene using the multiple-sequence alignment 
program MultAlin (Table 2.1-5). The Bik ORF demonstrated 100% homology with 
the published sequence, as obtained from GenBank, (accession number U34584). 
There was a deletion of 5 amino acids in the pcDNA3-HA-bik-∆BH3 plasmid, 
confirming the integrity of the BH3 mutant vector. The HA-Tag sequence was also 
confirmed.   
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Figure 6.2.1: Detection of ectopic HA-Bik and HA-Bik-∆BH3 from pcD+A3-HA-
bik and pcD+A3-HA-bik-∆BH3 plasmids. 
 
(A) Schematic circular maps of the pcDNA3-HA-bik expression vector and its mutant 
partner pcDNA3-HA-bik-∆BH3. The human cytomegalovirus immediate-early 
promoter (designated as CMV), is suitable for high-level expression in mammalian 
cells. The plasmids contain the neomycin resistance gene for selection of transfected 
cell lines (B) Section of Bik ORF sequence highlighting the BH3 domain in pcDNA3-
HA-bik, and the corresponding deletion of the BH3 domain in pcDNA3-HA-bik-
∆BH3. The nucleotide sequence of the HA-tagged
 
bik cDNA and the BH3 deletion 
(∆BH3) were verified by sequencing using pcDNA3 vector specific forward and 
reverse primers. Sequence results were aligned with the published bik sequence. 
Sequences highlighted in red demonstrated 100% homology. BH3 domain sequence is 
highlighted in black. (C) The expression of HA-tagged Bik and HA-tagged Bik-∆BH3 
were confirmed by Western blotting at 48 hours following after transfection using an 
anti-HA antibody (upper panel) and normalised for β-actin levels (lower panel) using 
an anti-β-Actin antibody. pcDNA3-HA and pcDNA3-HA-bfl-1 were used as controls. 
 
 
 
 
 
 
 
A B 
C 
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6.2.2  Luciferase Expression Assay. 
 
It was next set out to examine the effect of exogenous Bik expression on a variety of 
EBV-infected cell lines. A cell viability assay, which relies on the expression of a 
reporter gene in transiently transfected cells as a measure of their viability has 
previously been reported (Kumar et al, 1994; Boyd et al, 1995; Hsu et al, 1995; Han 
et al, 1996a; Mayo et al, 1997; Heussler et al, 1999). Thus, a co-transfection 
luciferase (luc)-based assay as an index of cell survival (Mathai et al, 2002; Li et al, 
2003; Lan et al, 2007) was adapted here to examine the potential inhibitory effect of 
HA-bik on the viability of LCLs in vitro.  
 
In this assay, different EBV-infected cells were transiently co-transfected with 2µg of 
pCMV-Luc, which carries a luc reporter gene driven by the cytomegalovirus (CMV) 
immediate-early
 
promoter and 5µg of pcDNA3-HA-bik, pcDNA3-HA-bik-∆BH3 or 
pcDNA3HA. Forty-eight
 
hours after transfection, cells were harvested, and luc 
activity
 
was measured using the Luc assay system (Promega) (Section 2.2.2.13). The 
relative activities
 
were calculated by setting the luc activities obtained from
 
the control 
plasmid, pcDNA3-HA, at 100%.  
 
It can be seen from Figure 6.2.2A that exogenous Bik was consistently and potently 
associated with decreased luc levels, indicating inhibited cell viability in all three 
transfected EBV infected cell lines. An examination of the growth-inhibitory effect of 
Bik on the different cell lines: AG876; a BL type 3 cell line (18.2%), and the LCLs 
EREB2.5; (22.9%) and IB4; (12.0%) suggests that the delivery of  HA-bik may 
alleviate the protection provided by the elevated anti-apoptotic phenotype imposed on 
the cell due to EBV infection. Expression of HA-Bik was coincident with a large 
decrease in the levels of co-expressed luc and the reduction in luc values was seen to 
be considerably less when the BH3-domain deleted Bik was expressed AG876 
(48.3%), EREB2.5 (47.2%) and IB4 (29.1%) and virtually absent when the anti-
apoptotic Bfl-1 was substituted for Bik in the same experiment (AG876; 95.0%). 
These results indicate that Bik may have an anti-survival effect on B-cell lines 
proliferating due to the EBV growth programme, since co-expression of Bik resulted 
in a marked reduction in the number
 
of luc-expressing cells. In addition the Bik BH3 
domain may play a crucial role in this death promoting activity since the reduction in 
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luc values was seen to be considerably less when the BH3-domain deleted Bik was 
expressed.  
 
In a second transfection, it was decided to examine if the negative effect on luc 
activity was dependent on the level of co-transfected bik expression plasmid. To this 
end, AG876 cells were co-transfected with 2µg CMV-Luc and increasing amounts (0, 
0.1, 0.5, 1, 2, 3, 5, or 7µg) of pcDNA3-HA-bik or pcDNA3-HA-bik-∆BH3. Forty-
Eight hours after transfection, cells were harvested and luc activity was assayed as 
before. The dose dependent response was calculated against the luc activity of the 
data point with the corresponding quantity of pcDNA3-HA, defined as 100% as 
before.  
 
Overall, it was observed that ectopic bik exerted a consistently more toxic effect than 
the BH3–deleted derivative suggesting that the BH3 domain is crucial to death-
promoting activity of bik in this cell background, as has previously been observed in 
other cell backgrounds elsewhere. This finding
 
suggests that these cells maybe dying 
by apoptosis (Tong et al, 2001; Letai et al, 2002). 
Strikingly at a ratio of one tenth the amount of luc plasmid, bik expression vector 
decreased luc expression levels to 7.11% of the control values, compared to 77.5% 
observed with the equivalent quantity of the BH3-deleted mutant (Figure 6.2.2B). 
Interestingly, the growth inhibitory effect of bik appears to increase in the presence of 
decreasing amounts of the HA-bik expression plasmid. Luc activity decreased by 14-
fold (to 7.11%) with the addition of 0.5µg of pcDNA3-HA-bik. Any further increase 
in the level of this plasmid did not lead to any further reduction in luc levels. Indeed at 
quantities of 1, 2, 3, and 5µg the luc activity actually increased the luc activity to an 
average 23.66% of the control.  
 
In general these results indicate that 0.5µg of pcDNA3-HA-bik may be the optimal 
quantity of vector required to achieve maximal potency under the conditions used. 
Bik expression has an anti-survival effect on B-cell lines proliferating due to the EBV 
growth programme, and a consistently more toxic effect than pcDNA3-HA-bik-∆BH3 
at all quantities suggesting that this mutation alters the death-promoting activity of bik 
in this cell background. 
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Figure 6.2.2: Luc expression assay to measure the effect of ectopic expression of 
Bik in EBV-infected cell lines. 
 
(A) In order to determine the effect of Bik expression on cell viability different EBV-
infected cells were transiently co-transfected with 2µg of pCMV-Luc, and 5µg of 
pcDNA3-HA-bik or pcDNA3-HA-bik ∆BH3. pcDNA3-HA was used as a control 
vector. The total amount
 
of DNA transfected was kept constant
 
by adding an 
appropriate amount of pcDNA3-HA vector. Forty-eight
 
hours after transfection, cells 
were harvested, and luc activity
 
was measured using the Luc assay system. The 
relative activities
 
were calculated by setting the luc activities obtained from
 
the control 
plasmid, pcDNA3-HA, at 100%. (B) To determine the Bik dose effect on cell 
survival, AG876 was co-transfected with 2µg of CMV-Luc and increasing amounts of 
pcDNA3-HA, pcDNA3-HA-bik or pcDNA3-HA-bik-∆BH3 (as indicated on the 
  ** 
   ** 
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graph). The total amount of DNA transfected at each dose was again kept constant by 
adding an appropriate amount of pcDNA3-HA vector. Cells were harvested 48 hours 
after transfection, and luc activity was measured as before. The relative activities were 
calculated by setting the Luc activities obtained from transfections with pcDNA3 at 
100% (Data are Mean ±SD, ** P<0.01).  
 
6.2.3 The effect of maintenance of Bik expression in EBV-infected cell 
lines. 
 
pcDNA3-derived vectors can be used to select for transformants by exploiting their 
encoded geneticin resistance function. To facilitate the generation of stable cell lines, 
a geneticin drug curve was performed to establish the minimum concentration of drug 
to cause cell death in this cell line. Geneticin at a concentration of 600µg/ml optimally 
kills IB4 cells over a twelve day period (data not shown) and was thus selected as a 
suitable working concentration. In transfection experiments, attempts to develop 
genetecin-resistant IB4 (Table 2.1-1) cell pools that stably expressed ectopic HA-Bik 
repeatedly met with failure, whereas the cell pools generated with pcDNA3-HA, 
pcDNA3-HA-bik-∆BH3 and pcDNA3-HA-bfl1 did not (not shown). Further attempts 
to establish a stable cell line expressing HA-tagged bik in another cell line L428, met 
with the same outcome.  
 
6.2.4 Inducible expression of Bik to examine the effect of Bik expression in 
EBV-infected cell lines. 
 
Given the failure to establish stable cell pools expressing HA-tagged bik and taking 
into account the finding that transient expression of Bik affects cell viability in several 
EBV-infected cell lines (Section 6.2.1) it was reasoned that a plasmid capable of 
inducible Bik expression, might be the most amenable to examining the effect of Bik 
over-expression on a larger cell pool. The tetracycline-regulatable plasmid pRTS-1 
(Table 2.1-4), a novel EBV-derived episomally replicating plasmid that carries all the 
elements for conditional expression of a gene of interest was used for this purpose 
(Bornkamm et al, 2005). In this plasmid, the gene of interest is expressed from the 
bidirectional promoter Ptetbi-1 (Figure 6.2.3) that allows simultaneous expression of 
two genes, one of which may be used as marker for the expression of the gene of 
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interest. Tight down regulation is achieved through binding of the silencer tTSKRAB to 
Ptetbi-1 in the absence of tetracycline (or doxycycline). Addition of tetracycline 
releases repression and via binding of rtTA2S-M2 activates Ptetbi-1. The expression 
cassette contained on the plasmid conferring tetracycline responsiveness is composed 
of the chicken-β-actin promoter (CAG) flanked by the mouse Ig heavy chain intron 
enhancer (Eµ) and drives expression of the two genes encoding rtTA2S-M2 and 
tTSKRAB separated by an internal ribosomal entry site (IRES). The Eµ intron enhancer 
was included for efficient expression of tetracycline-controlled regulators in B-cells 
and makes this plasmid especially suited to the study of B-cell lymphomagenesis. 
 
Figure 6.2.3: Schematic map of pRTS-1 vector 
Schematic circular map of pRTS-1 vector (From Bornkamm et al, 2005). The 
luciferase gene is designated as luc. The bicistronic expression cassette driving 
expression of rtTAs-M2 and tTSKRAB, separated by an internal ribosomal entry site 
(IRES), is placed behind the chicken β-actin intron and transcribed from a 
promoter/enhancer consisting of the mouse heavy chain intron enhancer (Eµ) and the 
chicken β-actin promoter (CAGp). Ptetbi-1 denotes the bidirectional tetracycline-
regulated promoter and oriP the EBV episomal origin of replication. EBNA1, the 
EBV gene EBNA1; bla, β-lactamase; SVp, the SV40 early promoter; ori, the bacterial 
origin of replication derived from pMB1; and hyg, the hygromycin 
phosphotransferase gene. 
 
6.2.4.1 Cloning of pRTS-1-HA-bik 
 
In order to generate the tetracycline-responsive HA-tagged Bik and HA-tagged-Bik-
∆BH3 expression plasmids, pRTS-1-HA-bik and pRTS-1-HA-bik-∆BH3, a cloning 
strategy was employed which involved the PCR amplification of the target sequence 
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and its subsequent sub-cloning into pRTS-1 in place of the luc gene. A schematic 
diagram outlining the construction of the vectors is illustrated in Figure 6.2.4. The 
steps involved in the generation of pRTS-1-HA-bik are illustrated in Figure 6.2.5. The 
vector was firstly characterised by restriction digestion in order to verify its identity 
(Section 2.2.1.3). Prior to ligation, the plasmid was linearised by digestion with Sfi I 
to excise the luc gene (Figure 6.2.5A), followed by dephosphorylation using CIP to 
prevent recircularisation of the linearised DNA, or re-cloning of the luc ORF (Section 
2.2.1.4). The linearised, CIP-treated DNA was then purified by phenol:chloroform 
extraction followed by ethanol precipitation (Section 2.2.1.2).   
pcDNA3-HA-bik and pcDNA3-HA-bik-∆BH3 were used as template DNA for PCR 
in conjunction with a forward primer (HABikForSfiI) with HA tag sequence 
homology and a reverse primer (BikRevSfiI) specific to the region downstream of the 
bik termination codon (sequences in Table 2.1-5). The primers included Sfi I 
restriction sites for cloning. Following PCR, the products were analysed by agarose 
gel electrophoresis (Section 2.2.1.15) to check for migration of fragments at the 
expected size. The PCR products were subsequently purified using the Promega 
Wizard
® 
DNA purification system (Section 2.2.1.6), digested with Sfi I and purified 
by phenol: chloroform extraction followed by ethanol precipitation (Figure 6.2.5B). 
The individual digested, purified PCR products were then sub-cloned into the Sfi I 
sites of pRTS-1.   Ligations of vector and insert DNA were carried out overnight at 16 
˚C (Section 2.2.1.7). 
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Figure 6.2.4: Cloning strategy 
Flow diagram detailing the steps involved in the construction of pRTS-1-HA-bik and 
pRTS-1-HA-bik-∆BH3 constructs.  The diagram represents the generation of pRTS-1-
HA-bik but is reflective of the strategy used in the construction of both pRTS-1-HA-
bik and pRTS-1-HA-bik-∆BH3. See text for details. 
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Figure 6.2.5: Construction of the pRTS-1-HA-bik and pRTS-1-HA-bik-∆BH3 
constructs. 
(A) Restriction digestion of pRTS-1 with Sfi I excised the luc gene (1652bp), as 
expected in lanes 2 and 3. A 1kb ladder is seen in lane 1. Fragments were analysed 
using a 0.7% agarose-1X TAE gel and electrophoresis was carried out at 100V for 1 
hour in 1X TAE. (B) PCR products amplified from pcDNA3-HA-bik and pcDNA3-
HA-bik-∆BH3 using forward and reverse primers; HABikForSfiI and BikRevSfiI, 
were and subsequently digested with Sfi I restriction endonuclease, in preparation for 
ligation, and were then analysed by agarose gel electrophoresis on a 2% agarose-1X 
TAE gel and electrophoresis was carried out at 100V for 1 hour in 1X TAE. 
Amplification and subsequent digestion with the Sfi I restriction enzyme of the HA-
bik fragment resulted in a band at 590 bp (lane 2), and a fragment of 575bp in the case 
of HA-bik-∆BH3 (lane 3). A 100 bp DNA ladder (Invitrogen) is shown in lanes 1 and 
4. (C) Recombinant DNA was subject to PCR amplification using the pEBNAseqFor 
forward primer and the BikRevSfiI reverse primer, to check for orientation. 
Fragments were analysed by agarose gel electrophoresis on a 2% agarose-1X TAE gel 
and electrophoresis was carried out at 100V for 1 hour in 1X TAE. A PCR product 
was generated if the insert DNA had ligated in the forward orientation. Amplification 
of the pEBNA-HA-bik fragment resulted in a band of 597bp (lanes 1-4 correct 
orientation), while amplification of the pEBNA-HA-bik-∆BH3 resulted in a fragment 
at 582bp (lanes 5 and 7 correct orientation, lanes 6 and 8 incorrect orientation) (D) 
Restriction analysis of recombinant pRTS-1-HA-bik and pRTS-1-HA-bik-∆BH3 
clones to determine correct insert orientation by digestion using Xma I enzyme 
followed by agarose gel electrophoresis on a 1% agarose-1X TAE gel. Correct insert 
orientation would yield ten fragments of 4236bp, 2220bp, 1729bp, 1641bp 1122bp, 
916bp, 639bp, 454bp, 157bp and 59bp while incorrect orientation would produce ten 
fragments of 4236bp, 2220bp, 1729bp, 1641bp 1122bp, 916bp, 639bp, 157bp, 152bp 
and 59bp upon digestion. A 1kb ladder is seen in lane 1 and a 100bp ladder is seen in 
lane 18. Undigested plasmid for each sample analysed is seen in lanes 2, 4, 6, 8, 10, 
12, 14 and 16. pRTS-1-HA-bik clones (lanes 2-9) harboured the HA-bik fragment in 
A C 
1       2     3     4     5     6      7     8      9 
D 
1      2   3    4    5    6    7    8   9   10  11  12  13  14  15  16 17  18 1       2       3       4       5    
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the correct orientation as discerned by the presence of a digested fragment at 454bp 
(lane 5 and 9), which was absent from clones with the fragment ligated in the wrong 
orientation (lanes 3 and 7). While pRTS-1-HA-bik-∆BH3 (lanes 10-17) clones were 
also discerned by this pattern (lanes 13 and 17 positive clones, lanes 11 and 15 display 
fragments in the incorrect orientation). (E) The condition and quality of the DNA was 
assessed by resolving the DNA by agarose gel electrophoresis. In this case 1µg of 
DNA from the pRTS-1 (lane 2), pRTS-1-HA-bik (lane 3) and pRTS-1-HA-bik-∆BH3 
(lane 4) and pRTS-1-HA-bfl-1 (lane 5) expression plasmids are shown after 
electrophoresis at 100V for 1 hour through a 1% agarose gel using 1X TAE.  A 1kb 
ladder is shown in lane 1. 
 
 
Following the ligation reaction, competent E. coli JM109 cells were transformed with 
the recombinant plasmid DNA. Single colonies were used to inoculate cultures from 
which DNA mini-preparations were prepared. Restriction digestion analysis and a 
PCR assay were performed on the DNA to monitor for the presence of insert DNA. 
Although both Sfi I sites used for cloning were different in base-pair composition it 
was possible for the insert DNA to ligate into the vector in either the forward or 
reverse orientation as the overhangs produced are palindromes. To determine whether 
insert DNA had ligated in the forward orientation, a PCR based strategy was first 
employed using the pEBNAseqFor forward primer (homologous to region upstream 
of start codon of pRTS-1) and the BikRevSfiI reverse primer used in PCR 
amplification of the HA-bik /HA-bik-∆BH3 fragments (sequences in Table 2.1-5). A 
PCR product was generated if the insert DNA had ligated in the forward orientation 
(Figure 6.2.5C). Correct/incorrect insert orientation was also differentiated by 
restriction analysis using Xma I restriction enzyme (Figure 6.2.5D). Once it was 
established that both the HA-bik and the HA-bik-∆BH3 sequences had ligated into 
pRTS-1 in the correct orientation, DNA maxi-preparations were carried out using the 
Qiagen
®
 Midi Kit (Section 2.2.1.12) and the identity of the cloned sequence was 
verified by DNA sequencing (Section 2.2.1.18) using the pEBNAseqFor primer. Both 
the pRTS-1-HA-bik and the pRTS-1-HA-bik-∆BH3 derived plasmid DNA 
demonstrated 100% homology with the predicted sequences as derived from the 
known HA-tag and bik (GenBank accession number U34584) coding sequences (not 
shown). The condition and quality of the recombinant DNA was subsequently 
assessed by resolving the DNA by agarose gel electrophoresis at 100V for 1 hour in 
1X TAE, and as Figure 6.2.5E reveals DNA used in transfection analysis was in the 
same topological condition and at similar concentration. 
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In order to test expression of HA-tagged Bik and HA-tagged Bik-∆BH3, transient 
transfection of the pRTS-1-HA-bik, pRTS-1-HA-bik-∆BH3, pRTS-1-HA-bfl1 (Table 
2.1-4) and  the corresponding empty vector pRTS-1 was carried out in various EBV 
negative cell lines including DG75, BJAB and AKATA-4E3 cells and in the highly 
transfectable human embryonic kidney cell line HEK 293 (Table 2.1-1). Cell pools 
were induced to express their respective proteins by addition of tetracycline (1µg/ml), 
or not induced by addition of an equal volume of vehicle (100% ethanol) to the 
culture media. Total protein extracts of induced cell pools were examined for the 
expression of HA-tagged proteins by Western blotting at 48 hours after addition of 
tetracycline (Figure 6.2.6). Attempts to detect HA-tagged Bik and HA tagged Bik-
∆BH3 proteins from the harvested cell pools consistently failed however. The 
expression of HA-tagged Bik and HA-tagged Bik-∆BH3 were successfully detected 
from pcDNA3 constructs.  
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Figure 6.2.6:  Western blot analysis of the transiently-transfected cell line     
HEK-293. 
 
To test the expression of HA-tagged Bik and HA-tagged Bik-∆BH3 transient 
transfection of the pRTS-1-HA-bik, pRTS-1-HA-bik-∆BH3, pRTS-1-HA-bfl1 and the 
corresponding empty vector pRTS-1 was carried out in HEK 293 cells and various 
EBV-negative cell lines. The pcDNA3 derived constructs, pcDNA3-HA-bik and 
pcDNA3-HA-bik-∆BH3 were also transfected as controls. The expression of the 
respective HA-tagged proteins was examined by Western blotting at 72 hours after 
addition of tetracycline using an anti-HA antibody (upper panel) and normalised for 
β-actin levels (lower panel) using an anti-β-Actin antibody. The Stable clone L428-
pRTS-1-HA-Bfl-1 was used as control for the anti-HA antibody. 
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In a second series of transfections, the same plasmids were also used to transfect the 
DG75 cell line (Table 2.1-1) by electroporation (Section 2.2.2.7) followed by 
selection of positive clones using hygromycin (400µg/ml). DG75 is a readily 
transfectable, EBV-negative BL cell line,  it was once again apparent that cells 
transfected with pRTS-1-HA-bik gave rise to no drug resistant cells as compared to 
cells transfected with control vector or other constructs. As before, transfected cell 
pools were induced or non-induced to express their respective proteins. Total protein 
from these cells was prepared at 48 hours after induction and the extracts were subject 
to Western blotting (Section 2.2.4.3). Again, the cells transfected with pRTS-1-HA-
bik cells did not express detectable levels of HA-tagged Bik, in contrast to cells 
transfected with pRTS-1-HA-bik-∆BH3 and pRTS-1-HA-bfl1. It was plausible that a 
relatively low level of expression of Bik protein from a leaky tet-inducible promoter 
on the pRTS-1 vector was lethal to the transfected cell population, causing all bik-
transfected cells to die. In short it seemed likely that these cells could not support Bik 
expression, providing further, yet indirect evidence that low levels of ectopic Bik was 
toxic to these cells. Despite several attempts, all efforts to establish stable positive 
clones of pRTS-1-HA-bik in EBV negative (DG75 (Figure 6.2.7A), BJAB (Figure 
6.2.7B), AKATA-4E3) and EBV positive cell lines (EREB2.5, IB4, LCL 327) by 
hygromycin selection were futile. Strikingly however it proved possible to establish 
both pRTS-1-HA-Bfl-1 and pRTS-1-HA-bik-∆BH3 stable cell pools expressing HA-
tagged proteins (HA-Bfl-1 and HA-∆BH3) every time. On the basis of this data and 
also considering that it was possible to establish stable cell pools using pcDNA3-HA-
bik-∆BH3 and pcDNA3-HA-bfl-1 but not pcDNA3-HA-bik in IB4 and L428, it was 
clear that the HA-Bik expressing vectors imposed a powerful negative selection on 
their host cells and HA-bik-transfected cells ultimately died. It should be noted that 
HA-Bik protein could be detected from the original vector, pcDNA3-HA-bik in 
transient transfection experiments (Figure 6.2.1C) and that the fidelity of the 
recombinant pRTS-1 cloned vector was confirmed by sequencing analysis (data not 
shown); all indicative of the production of a functional protein. Additionally, further 
attempts to express a second tagged Bik protein (MYC-Bik) failed from constitutive 
(pcDNA3) and inducible (pRTS-1) backgrounds (data not shown).  
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Figure 6.2.7: Western Blot analysis of the stably-transfected EBV-negative cell 
lines, DG75 and BJAB. 
 
(A) To examine the expression of HA-tagged Bik and HA-tagged Bik-∆BH3 stable 
transfection of the pRTS-1-HA-bik, pRTS-1-HA-bik-∆BH3, pRTS-1-HA-bfl1 and the 
corresponding empty vector pRTS-1 was undertaken in the BL DG75 cells by 
electroporation followed by selection of positive clones using hygromycin 
(400µg/ml). After a 12 day period of selection DG75-pRTS-1-HA-bik, DG75-pRTS-
1-HA-bik-∆BH3, DG75-pRTS-1-HA–bfl-1 and DG75-pRTS-1 clones were induced, 
by addition of tetracycline (1µg/ml), to express their respective proteins. The 
expression of HA-tagged Bik and HA-tagged Bik-∆BH3 were examined by Western 
blotting at 72 hours after addition of tetracycline using an anti-HA antibody (upper 
panel) and normalised for β-actin levels (lower panel) using an anti-β-Actin antibody. 
The Stable clone pRTS-1-HA-Bfl-1 was used as control for the anti-HA antibody. (B) 
This experiment was also undertaken in the BL BJAB cell line, as in (A).  
 
Co-expression of GFP from the bi-directional promoters of pRTS-1-HA-bik-∆BH3 
and pRTS-1 upon induction with tetracycline was also confirmed using fluorescence 
microscopy (Section 2.2.2.11) (Figure 6.2.8A).  
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Figure 6.2.8: Ectopic expression of HA-tagged and GFP proteins from DG75 
transfected cell pools.  
DG75-pRTS-1-HA-bik-∆BH3 cell pools were induced or non-induced by addition of 
tetracycline to express HA-bik-∆BH3 and GFP proteins. (A) The induction of GFP 
protein expression was monitored at 48 hours using an Olympus DP-50 fluorescent 
microscope. (B) Extracts of tetracycline induced/non-induced cell pools were 
examined for the expression of HA-tagged proteins by Western blotting at 48 hours 
after addition of tetracycline using an anti-HA antibody (upper panel) and normalised 
for β-Actin levels (lower panel) using an anti-β-Actin antibody. 
 
These results further confirmed the expression of HA-tagged Bik-∆BH3 protein from 
pRTS-1-HA-bik-∆BH3 construct in DG75 cells.  
 
It was next decided to examine the expression of the co-expressed marker, GFP, by 
fluorescence activated cell-sorting (FACS), to determine if these cells transfected with 
pRTS-1-HA-bik were actually dying due to Bik over-expression. The failure to 
establish transfected cell pools that could be induced to express Bik, due to its own 
likely toxicity towards the cell, meant that such cell phenotype assays had to be 
performed on transiently transfected cells. Initially, the EBV-infected cell lines, 
EREB2.5 and IB4, were transfected by electroporation (Section 2.2.2.7) with 0.5µg of 
pRTS-1-HA-bik, pRTS-1-HA-bik-∆BH3, pRTS-1-HA-bfl-1 or the corresponding 
control construct pRTS-1. Cells were harvested 12 hours after transfection (Section 
2.2.2.12 ). GFP fluorescence was measured on a BD FACSCalibur flow cytometer 
and CellQuest software was employed for data analysis. No GFP expression was 
observed upon transfection of IB4 or EREB2.5 cells with any of the pRTS-1 
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constructs as is represented in Figure 6.2.9, which illustrates the percentage 
transfection efficiencies achieved in EREB2.5. This experiment was repeated with 
various quantities of DNA (0.5 – 5µg) but to no avail. Electroporation parameters 
(voltage setting (200 – 270 V), volume of media in which cells were electroporated 
(200 – 300µl and supplemented serum/serum-free media), incubation times and 
duration of transfection were also varied but the cells remained adverse to efficient 
pRTS-1 uptake by electroporation (data not shown). 
 
In an effort to overcome this obstacle, a range of different EBV negative (DG75, 
BJAB and L428) and EBV positive cell lines (EREB2.5, IB4, LCL 327) were tested 
in an attempt to efficiently deliver the pRTS-1 DNA to the cells for the purpose of 
examining GFP expression. Again, the extent of transfection efficiency was generally 
too inadequate to permit subsequent phenotypic assays by flow cytometry (usually 
<1%). A modest transfection efficiency was observed using the IB4 cell line (4.61% 
pRTS-1). However, the level of transfection efficiency was not sufficient for the 
purpose intended, since the level of transfection of pRTS-1-HA-bik was never more 
than 0.5% (data not shown). Transfection conditions were again modified as before, 
and another transfection method was employed (DEAE-Dextran, Section 2.2.2.10) in 
an attempt to improve efficiency, but no further progress was made.  
 
Next, a modified electroporation technique known as nucleofection (Section 2.2.2.8), 
which benefited from optimised cell line-specific electroporation parameters together 
with a cell line-specific buffer, was employed in an attempt to realise a sufficient 
efficiency of transfection. Satisfactory expression of GFP however was still 
unattainable. In a parallel experiment, nucleofection with the GFP-reporter plasmid, 
pmaxGFP revealed a transfection efficiency of 19.36% when transfected IB4 cells 
were analysed for GFP expression and 51.78% when transfected BJAB cells were 
examined by FACS analysis (data not shown), indicating the efficacy of transfection 
seen in this experiment may be specifically due to the properties and quality of pRTS-
1 DNA molecules. Recent studies have suggested that the purity of plasmid DNA 
strongly influences transfection efficiency since contamination with endotoxins may 
inhibit transfection in various cell lines (Weber et al, 1995). In order to improve 
transfection efficiency, a protocol to isolate endotoxin-free plasmid DNA was 
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employed (Section 2.2.1.13). However, elimination of pyrogenic endotoxins from the 
plasmid preparation did not correlate with an improvement in transfection efficiency.   
In summary, in spite of numerous attempts, all efforts to efficiently transfect pRTS-1 
vectors and examine the expression of GFP in several EBV negative (DG75, BJAB, 
L428) and EBV positive cell lines (EREB2.5, IB4, LCL 327) were ineffective, most 
likely due to the poor uptake of plasmid DNA during electroporation. It is conceivable 
that the transfection efficiency was negatively affected by the relatively large size of a 
the plasmid DNA (18kb) (Kreiss et al, 1999). Recognising that an efficient delivery 
protocol for bik was an essential step in this experiment, and that this objective 
seemed unattainable in the pRTS-1 vector background, it was decided not to proceed 
with these vectors for these experiments. A co-transfection strategy involving 
pmaxGFP with pcDNA3-HA-bik, pcDNA3-HA-bik-∆BH3 or the corresponding 
control vector pcDNA3, was therefore adopted in order to realise this goal.  
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Figure 6.2.9: +o GFP expression was observed upon transfection of EREB2.5 
cells with the pRTS-1 constructs.  
EREB2.5 cells, were transfected by electroporation with 0.5µg of pRTS-1-HA-bik, 
pRTS-1-HA-bik-∆BH3, pRTS-1-HA-bfl-1 or the corresponding control construct 
pRTS-1. For analysis of GFP fluorescence the cells were washed twice with PBS and 
re-suspended in PBS before analysis. GFP fluorescence was measured on BD 
FACSCalibur flow cytometer 12 hours after transfection. CellQuest software was 
employed for data analysis. The percentage of transfected cells 12 hours after 
transfection is indicated inside the box. 
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6.2.5 Green Fluorescent Protein (GFP) Expression Assay 
 
A second cell viability assay was employed in which the expression of intracellular 
GFP in transfected IB4 cells was used as a measure of cell viability (adapted from 
Heussler et al, 1999). This assay was carried out using the pmaxGFP expression 
vector, which encodes the green fluorescent protein (GFP) from copepod Pontellina 
plumata. In this experiment, IB4 cells were transiently co-transfected with the 
pmaxGFP expression plasmid and bik or bik-∆BH3-coding plasmids in the pcDNA3 
background. The number of cells expressing GFP in the presence of HA-Bik or HA-
Bik-∆BH3 mutant expression was then analysed at 12 hours. Following transfection, 
cells were washed twice with PBS and re-suspended in PBS at a concentration of 1 X 
10
6
 cells/ml prior to analysis. GFP fluorescence was measured on BD FACSCalibur 
flow cytometer. CellQuest software was employed for data analysis and the 
background level of fluorescence in the IB4 cell line was monitored and used as a 
template for subsequent analysis Figure 6.2.10A(i).  
 
It is demonstrated in Figure 6.2.10B that when Bik is expressed the number of cells 
expressing GFP decreases in a dose dependent manner further supporting the 
hypothesis that Bik expression has a potentially cytotoxic effect on cells. The most 
obvious observation from the co-transfection experiments was the reduction in the 
number of GFP-positive cells for the bik expression vector compared with empty 
vector (pcDNA3-HA) or other plasmid constructs (pcDNA3-HA-bik-∆BH3 and 
pcDNA3-HA-Bfl-1), which produced comparable levels of GFP-expressing 
transfected cells (Figure 6.2.10A(iv)). This observation is representative of at least 
three independent experiments. The decrease in the number of GFP expressing cells is 
consistent with the observations made above when a period of drug selection was 
introduced following transfection (Sections 6.2.3 and 6.2.4) and with the Luc assay 
experiment (Section 6.2.2) and indicates that the biological effects of exogenous Bik 
expression may require only a relatively short period to take effect. Signifcantly, these 
bik-transfected cells did not express high levels of GFP as compared with those cells 
transfected with the vector control or other constructs (Figure 6.2.10A(ii) and Figure 
6.2.10A(iii)), suggesting that cells that express high GFP levels (and by deduction, 
high levels of Bik protein), may already be dying or dead. Indeed, microscopic 
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observations indicated that the majority of the Bik expressing cells were smaller and 
more condensed as opposed to the morphology of the cells transfected with other 
constructs (data not shown). This observed effect on IB4 morphology was only seen 
with the transfection of bik and not with the expression of the empty vector or the 
expression construct carrying the bfl-1 gene. Furthermore, expression of BH3-deleted 
Bik cDNA, bik-∆BH3, also failed to show any biological effects upon transfection 
into IB4 cells, indicating that the bik-induced cell death is most likely dependent on 
the BH3 domain in concordance with previously published findings (Tong et al, 2001; 
Germain et al, 2002). 
 
 
 
 
     
   
 
Figure 6.2.10: GFP co-expression in the presence of co-transfected plasmids in 
IB4.  
(A) In order to determine the effect of Bik expression on cell viability, IB4 cells were 
transiently co-transfected with 2µg of pmaxGFP, and 0.5µg of pcDNA3-HA-bik and 
pcDNA3-HA-bik ∆BH3. The vectors pcDNA3 and pcDNA3-HA-bfl-1 were used as 
control vectors. The total amount
 
of DNA transfected was kept constant
 
by adding an 
appropriate amount of pcDNA3-HA vector. Twelve hours after transfection, cells 
were harvested, and GFP expression
 
was monitored using FACS analysis. GFP 
fluorescence was measured on BD FACSCalibur flow cytometer. CellQuest software 
was employed for data analysis. Figures (A) (i),(ii) and (iii) illustrate the level of GFP 
expression in mock transfected IB4 cells, and in pcDNA3 and pcDNA3-HA-bik 
transfected cells respectively. Figure (A)(iiv) is a comparison of the number of GFP 
positive cells for bik, vector control (pcDNA3-HA), pcDNA3-HA-bik-∆BH3 and 
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pcDNA3-HA-Bfl-1. All observations are representative of at least 3 experiments.  (B) 
To examine the Bik dose effect on cell survival, IB4 was co-transfected with 2µg of 
pmaxGFP and increasing amounts (0.05, 0.5, 5µg) of pcDNA3, pcDNA3-HA-bik and 
pcDNA3-HA-bik-∆BH3. The total amount of DNA transfected at each dose was kept 
constant by adding an appropriate amount of pcDNA3 vector. Cells were harvested 12 
hours after transfection, and GFP fluorescence was analysed as in (A). These 
observations are representative of at least 3 experiments. 
 
6.2.6 Ectopic Bik triggers apoptosis in EBV-infected cell lines. 
 
6.2.6.1 MG132 treatment induced apoptosis in the EBV-infected cell line, IB4. 
 
Bik has previously been shown to induce cell death by apoptosis in various cell 
backgrounds (Han et al, 1996a; Tong et al, 2001; Germain et al, 2002; Hur et al, 
2004; Oppermann et al, 2005). Previous experiments in this chapter have 
demonstrated that Bik expression is incompatible with IB4 cell viability. Accordingly, 
it was essential to determine if exogenous Bik could induce death by apoptosis. The 
premise that ectopic Bik could drive these cells into apoptosis was tested using 7-
AAD/Annexin V staining and FACS analysis (Section 2.2.2.16).  
A control experiment was initially undertaken to identify the profile of apoptotic cells 
using 7-AAD/Annexin V staining and FACS. Drastic alterations in membrane 
structure occur during the apoptotic process (Wyllie et al, 1980) principally a 
progressive loss of membrane permeability that can be evaluated by 7-
aminoactinomycin D incorporation (7-AAD) (Schmid et al, 1992). This vital dye is 
excluded from live, healthy cells and early apoptotic cells, but permeates late-stage 
apoptotic and dead cells that do not have an intact plasma membrane, staining them 
red, and was detected on the FL3 parameter. Cells were stained with 7-AAD in order 
to distinguish between cells that were viable (7-AAD-negative) and either dead or in 
the late stage of apoptosis (7-AAD-positive). Annexin V is a calcium-dependent 
phospholipid binding protein with high affinity for phosphatidylserine (PS), a 
membrane component normally localised to the internal face of the cell membrane. 
Early in the apoptotic pathway, molecules of PS are translocated to the outer surface 
of the cell membrane thus exposing them to the external environment where Annexin 
V can readily bind to them. The use of Annexin V to monitor the loss of membrane 
phospholipid asymmetry is thus an indicator of the onset of apoptosis. Annexin V is 
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detected on the FL2 parameter. The application of Annexin V for PS detection, 
together with 7-AAD as an indicator of membrane permeability, allows for the easy 
differentiation of early/late apoptotic, necrotic/nuclear debris and viable cells by 
FACS analysis. This two-dye strategy allows for identification of these four 
populations as follows; Non-apoptotic cells (Annexin V
-
 and 7-AAD
-
), early apoptotic 
cells (Annexin V
+
 and 7-AAD
-
) late stage apoptotic and dead cells (Annexin V
+
 and 
7-AAD
+
) and mostly cell debris/apoptotic bodies (Annexin V
-
 and 7-AAD
+
). 
Abrogation of proteasome activity in EBV-derived cell lines by chemical treatment 
with the potent proteasome inhibitor Z-Leu-Leu-Leu-al (MG132) was chosen to 
directly investigate the profile of apoptotic IB4 cells. Proteasome inhibition has been 
reported to induce apoptosis that is mediated by caspase activation (Wu et al, 1999). 
MG132 is a specific, membrane-permeable inhibitor of proteasome activity.  MG132 
has been shown to induce apoptosis in a number of different cell types (Giuliano et al, 
1999; Almond et al, 2001; Emanuele et al, 2002; Lauricella et al, 2003), thus far 
however, the effect of MG132 in the IB4 cell line has not been reported.  
 
IB4 cells were treated/untreated with 15µM MG132/DMSO and the cell survival 
profile was analysed at 24 hours after treatment by 7-AAD/Annexin V staining and 
subsequent flow cytometric analysis (Section 2.2.2.16).  Initially measurements were 
made using forward light scatter (FSC) and side light scatter (SSC). Forward light 
scatter provides information on the relative size of individual cells, whereas side light 
scatter provides information on the relative granularity of individual cells. For the 
purposes of this study these two parameters are combined to identify the light scatter 
pattern emitted by a healthy population of cells. A population of lymphocytes was 
gated on region 1 (R1) using forward (FSC) and side scatter (SSC) (data not shown). 
These cells were subsequently analysed for apoptosis using 7-AAD/Annexin V 
staining.  
 
MG132-treated IB4 cells were shown to die by apoptosis using an Annexin V/7-AAD 
dual stain followed by FACS analysis (Figure 6.2.11A). The sets of data are presented 
as scatter plots. As can be seen in Figure 6.2.11A within the DMSO treated 
population of cells, 8.0% of cells were non-viable, appearing in the upper right 
quadrant (Annexin V
+
 and 7-AAD
+
). Approximately 92% of cells appeared in the 
upper right quadrant (Annexin V
+
 and 7-AAD
+
) at 24 hours after treatment with 
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MG132. These results show clearly the detection of apoptotic cells using 7-
AAD/Annexin V staining in response to treatment of IB4 cells with MG132. 
6.2.6.2 MG132 treatment increased the population of IB4 cells in the sub-G1 
phase of the cell cycle. 
 
A second method commonly used to assay apoptosis, the sub-G1 DNA content method 
was also used here. The enzymatic cleavage of nuclear DNA is a fundamental event 
in the apoptotic cascade, being the first irreversible step in the process leading to cell 
death, creating large numbers of small fragments of DNA (Arends et al, 1990). The 
cellular DNA content can be measured following cell fixation which leads to a partial 
leakage of degraded DNA within apoptotic cells. As a consequence, apoptotic cells 
contain reduced DNA content and can be recognised, following staining of cellular 
DNA with Propidium Iodide (PI) (Nicoletti et al, 1991; Afanasyev et al, 1993). 
Apoptotic nuclei appear as a broad hypo-diploid DNA peak which is easily 
discernable from the narrow peak of cells with a normal diploid DNA content in the 
red fluorescence channels. Further to the previous results, after Annexin V/7-AAD 
staining, the percentage of cells in G0/G1, S phase and G2/M of the cell cycle was 
calculated by subjectively applying markers which provide a measurement of the 
percentage of cells in each phase. The reduced fluorescence of PI in cells undergoing 
apoptosis resulted in the appearance of a characteristic sub-G1 fluorescence peak with 
respect to the G0/G1 cell cycle region. In this experiment, cell extracts from the cell 
pools cultured in MG132 were analysed. The data is displayed in histogram format 
with the intensity of fluorescence from the propidium iodide stained cells on the X-
axis representing the number of cells. 
 
Thirty minutes prior to FACS analysis the cells were stained with PI (Section 
2.2.2.19) to detect total DNA within cells. Samples were collected on the FACCalibur 
flow cytometer as before, and the percentage of cells in each phase of the cell cycle 
was calculated and analysed using CellQuest software. Cells with increased sub-G1 
DNA content were considered to be apoptotic. The resultant histogram plot of IB4 
cells which have been treated with 15µM MG132 for 24 hours is shown in Figure 
6.2.11B. The sub-G1 population was increased from 13.0% of the cells treated with 
DMSO to 49.6% of the total cell population after treatment with MG132. These 
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results comply with the apoptosis assay (Figure 6.2.11A), which also indicates a 
higher proportion of apoptotic cells (92.30%) in the MG132 treated cell pools relative 
to the DMSO treated cell pool. Table 6-1 indicates that there is a change in the 
distribution of the cells within in the cell cycle with a reduction in the number of cells 
in the synthesis phase from 25.80% to 10.63%. Treated cells also failed to accumulate 
in G0/G1, indicated by the percentage of cells in the G0/G1 phase of the cell cycle of 
treated cells (21.0%) as compared to the DMSO control (38.09%). The G2/M phases 
in both populations were comparable. Overall this data indicated that compared with 
DMSO treated cells, the populations of MG132 treated cells displayed a significant 
decrease in G0/G1 phase and S phases, and a dramatic emergence of a sub-G1 phase. 
In summary treatment with MG132 caused cell cycle arrest in the IB4 cell line and an 
accumulation of cells in sub-G1, indicative of apoptosis.  
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Figure 6.2.11: Treatment of IB4 cells with the proteasome inhibitor, MG132. 
(A) IB4 cells were treated with or without 15µM MG132 and the cell survival profile 
was analysed at 24 hours after treatment by 7-AAD/Annexin V staining and 
subsequent flow cytometric analysis. Quadrant markers were based on 
stained/unstained controls and values reflect the percentage of cells in each quadrant. 
Cells in the lower left quadrant are viable (7-AAD
-
/Annexin V
-
), cells in the lower 
right quadrant are early apoptotic (7-AAD
-
/Annexin V
+
), cells in the upper right 
quadrant are late apoptotic (7-AAD
+
/Annexin V
+
) and cells in the upper left quadrant 
are necrotic/mostly nuclear debris (7-AAD
+
/Annexin V
-
). (B) Apoptosis was assayed 
using the sub-G1 DNA content method. Thirty minutes before the assay, cells were 
stained with PI. Fluorescence-activated cell sorting (FACS) analysis of sub-G1 was 
performed by PI staining and flow cytometry. Apoptotic cells determined by sub-G1 
assay in cell samples treated as in (A). The DNA content in the cells was determined 
24 hours after treatment. Markers identify cells with hypodiploid DNA content (sub-
G1; indicated by the black arrow), and also those cells in stages G0/G1, S, and G2/M of 
the cell cycle. The percentage of apoptotic cells 24 hours after treatment is indicated 
on the left hand side of each box. 
 
8.03% 0.64% 
◄87.48% 3.85% 
DMSO treated Cells MG132 treated Cells 
92.30% 3.68% 
◄1.66% 2.36% 
A 
B 
 217 
Table 6.2-1: Representative flow cytometric profiles of IB4 cells after incubation 
with MG132. 
Treatment Distribution (% cells) 
 Sub-G1  G0/G1 G2/M S 
DMSO 13.05 38.09 10.23 25.77 
MG132 49.64 21.03 9.54 10.63 
 
Apoptosis was assayed using the sub-G1 DNA content. Cells were analysed as in 
Figure 6.2.11. The percentage of cells present in the different phases of the cell cycle 
(G0/G1, S, G2/M) are given in the table. 
 
6.2.7 Ectopic Bik induces apoptosis in IB4 cells. 
 
IB4 cells were co-transfected with 2µg pmaxGFP and increasing
 
amounts (0.05, 0.5, 
or 5µg) of pcDNA3-HA-bik, pcDNA3-HA-bik-∆BH3 or the corresponding control 
plasmid pcDNA3-HA. The total amount of expression plasmid was adjusted in all 
cases to 7µg with the empty vector pcDNA3-HA. Cell viability was analysed at 6 
hours after transfection by double labelling the cells with Annexin V/7-AAD and flow 
cytometry (Section 2.2.2.16). Using Annexin V/7-AAD staining, FACS analysis for 
cell surface molecules was performed as described previously (Section 6.2.6.1). A 
minimum of 4,500 GFP-expressing cells were examined in isolation (by analysing 
cells in region 2 (R2)).  
Co-transfection of IB4 cells with pmaxGFP and together with either bik or bik-∆BH3 
resulted in death of the Bik-expressing cells only (Figure 6.2.1). A clear dose 
dependent increase in apoptotic activity occurred in response to addition of increasing 
quantities of the HA-Bik expression plasmid pcDNA3-HA-bik (Figure 6.2.12). 
Dramatically, cells in late apoptosis accounted for 70.30% of the transfected cell 
population with the addition of 5µg of pcDNA3-HA-bik. The number of cells 
expressing GFP also decreased with increasing quantities of bik plasmid (data not 
shown). In striking contrast, cells ectopically expressing the same quantites of the 
BH3-deleteted pcDNA3-HA-bik-∆BH3 did not succumb to apoptosis at all quantities 
of plasmid used (Figure 6.2.12B). Overall a significant increase in apoptosis occurred 
in response to the addition of increasing quantities of the HA-Bik expression plasmid.  
The transfection method may account for the significant numbers of apoptotic cells 
seen in control transfection (Figure 6.2.12A). 
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Figure 6.2.12: Increasing quantities of HA-Bik expression augments the 
apoptotic response at 6 hours. 
To examine the Bik dose effect on cell survival, IB4 was co-transfected with 2µg of 
pmaxGFP and increasing amounts (0.05, 0.5, 5µg) of pcDNA3-HA, pcDNA3-HA-bik 
or pcDNA3-HA-bik-∆BH3. The total amount of DNA transfected at each dose was 
kept constant at 7µg by adding an appropriate amount of pcDNA3-HA vector. Cells 
were harvested 6 hours after transfection and analysed by 7-AAD/Annexin V staining 
27.29% 4.51% 
◄63.76% 4.44% 
0.05µg Bik +pMAXGFP 
36.25% 
3.65% 
2.88% 
◄57.23% 
0.5µg Bik + pMAXGFP 
3.68% 
6.90% 
◄19.09% 
70.32% 
5µg Bik +pMAXGFP 
22.96% 4.27% 
◄70.28% 2.49% 
pCD+A3-HA + pMAXGFP 
B 
A 
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and subsequent flow cytometric analysis. CellQuest software was employed for data 
analysis. (A) Scatter plots for 0, 0.05, 0.5, and 5µg of pcDNA3-HA-bik are shown. 
Quadrant markers were based on stained/unstained controls and values reflect the 
percentage of cells in each quadrant. Cells in the lower left quadrant are viable (7-
AAD
-
/Annexin V
-
), cells in the lower right quadrant are early apoptotic (7-AAD
-
/Annexin V
+
), cells in the upper right quadrant are late apoptotic (7-AAD
+
/Annexin 
V
+
) and cells in the upper left quadrant are necrotic/mostly nuclear debris (7-
AAD
+
/Annexin V
-
). (B) The percentage of GFP-expressing dead cells was plotted 
against the quantity of pcDNA3, pcDNA3-HA-bik or pcDNA3-HA-bik-∆BH3 vector 
(µg) transfected. (Data are Mean ±SD)  
 
6.2.7.1 Apoptosis is a potent and early effect of Bik expression. 
 
IB4 cells were transiently co-transfected with 2µg of pmaxGFP and 0.5µg, of either 
pcDNA3-HA-bik, pcDNA3-HA-bik-∆BH3, pcDNA3-HA-bfl-1 or the corresponding 
control plasmid pcDNA3-HA. Cell viability was examined by Annexin V/7-AAD 
staining and subsequent flow cytometric analysis. Transfected cells were initially 
examined 3 hours after-transfection, on the basis that the toxic effect of bik may 
require only a relatively short period of time to exert a killing effect on transfected 
cells (Section 6.2.5). This early analysis was accommodated by the early detectable 
expression of GFP from the pmaxGFP expression plasmid. Cells were assayed for 
apoptosis using Annexin V/7-AAD staining, and flow cytomertry as before (Section 
2.2.2.16). A minimum of 2,000 GFP-expressing cells were examined in isolation as 
before.  
 
Examining the effect of Bik expression on viability of IB4-transfected-HA-bik cells it 
can be seen that 33.78% of the transfected population were in the late stages of 
apoptosis (Figure 6.2.13) (Annexin V
+
/7-AAD
+
), and 22.11% of the total GFP 
population exhibited signs of early apoptosis (Annexin V
+
/7-AAD
-
). In contrast, cells 
expressing HA-Bik-∆BH3 comprised a 19% late apoptotic and an 18.32% early 
apoptotic population. Overall, cells expressing HA-Bik were 18.57% more apoptotic 
than cells harbouring the HA-Bik-∆BH3. Significantly, only 40.94% of the bik-
transfected population were viable as compared to pcDNA3-HA (67.94%), pcDNA3-
HA-bik-∆BH3 (60.24%) and pcDNA3-HA-bfl-1 (61.03%). Thus, Bik-expressing cells 
showed an average 22.73% reduction in cell viability relative to the controls.  
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It is obvious from these results that the toxic effect of Bik expression is clear and 
detectable just 3 hours after transfection. In contrast, cells expressing HA-∆BH3 were 
significantly less apoptotic (Figure 6.2.13). This distinction between cells expressing 
HA-Bik and those that express HA-∆BH3 indicates that these cells are dying by a 
mechanism that is dependent on the presence of the BH3 domain, as has been found 
by others (Tong et al, 2001; Germain et al, 2002).  
 
Based on these observations, it is clear that Bik can induce cells to die by apoptosis. 
Transfection with HA-bik caused an average 18.8% increase in the number of 
apoptotic cells relative to the controls (Figure 6.2.13).  The observation that some of 
the cells in the HA-Bik-expressing pool continue to survive may reflect heterogeneity 
in the levels of transfection or expression between individual transfected cells, some 
of which may express HA-Bik at very low levels. In addition these results also 
highlight a key role for the BH3 domain in Bik-mediated apoptosis. 
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Figure 6.2.13:  Ectopic Bik causes IB4 cells to die by apoptosis after 3 hours. 
 
In order to determine the effect of Bik expression on cell survival after three hours, 
IB4 cells were transiently co-transfected with 2µg of pmaxGFP, and 0.5µg of 
pcDNA3-HA-bik and pcDNA3-HA-bik ∆BH3. pcDNA3 and pcDNA3-HA-bfl-1 were 
used as control vectors. The total amount
 
of DNA transfected was kept constant
 
by 
adding an appropriate amount of pcDNA3 vector. Three hours after transfection, cells 
were harvested, and analysed by 7-AAD/Annexin V staining and subsequent flow 
cytometric analysis. CellQuest software was employed for data analysis. A minimum 
of 2,000 GFP-expressing cells were examined in isolation (by analysing cells in R2). 
Quadrant markers were based on stained/unstained controls and values reflect the 
percentage of cells in each quadrant. Cells in the lower left quadrant are viable (7-
AAD
-
/Annexin V
-
), cells in the lower right quadrant are early apoptotic (7-AAD
-
/Annexin V
+
), cells in the upper right quadrant are late apoptotic (7-AAD
+
/Annexin 
V
+
) and cells in the upper left quadrant are necrotic/mostly nuclear debris (7-
AAD
+
/Annexin V
-
). 
 
 
This experiment was also performed at 6, 12, and 24 hour time intervals using 0.5µg 
of DNA to examine the effect of bik expression over time in these cells. The survival 
of GFP expressing cells was again monitored using Annexin V/7-AAD staining using 
FACS analysis. Consistent with the earlier time point, at 6 and 12 hours after 
14.59% 2.57% 
◄67.97% 14.86% 
33.78% 3.17% 
◄40.94% 22.11% 
pcD+A3-HA-bik + pmaxGFP  pcD+A3-HA + pmaxGFP  
19.00% 2.44% 
◄60.24% 18.32% 
20.97% 2.39% 
◄61.03% 15.61% 
pcD+A3-HA-bfl-1 + pmaxGFP  pcD+A3-HA-bik∆BH3 + pmaxGFP  
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transfection over-expression of Bik caused significant apoptosis in the IB4 cell line. 
However, there is a time-dependent decrease in the level of apoptosis recorded, with 
cells ectopically expressing HA-Bik at 3, 6 and 12 hours exhibiting 18.57%, 16.12% 
and 12.51%  respectively more apoptotic cells relative to pcDNA3-HA-bik-∆BH3 at 
the given time points (Figure 6.2.13 and Figure 6.2.14). 
 
Interestingly, in contrast to these results, at 24 hours, the effect of Bik expression had 
disappeared, and the level of apoptosis in the other transfected cell pools surpassed 
that of HA-bik (data not shown). The use of electroporation-based methods for the 
delivery of DNA across the cell membrane has a negative effect on cell viability 
(Canatella et al, 2001). It is therefore possible that the cytotoxic effect of 
nucleofection on the transfected-cell pools led to an ultimate loss of cell viability and 
committed a substantial number of the transfected cell population to death by 
apoptosis. The toxic effect of ectopic Bik was most visible in the early stages after-
transfection, at 3, 6 and 12 hours (Figure 6.2.14) and the prevalence of cells dying due 
to apoptosis becomes more evident after 12 hours. Thus, this short-time period of 3-
12 hours after-transfection was the most appropriate time to analyse the effect of HA-
Bik expression.  
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Figure 6.2.14: Ectopic HA-bik causes significant apoptosis in the IB4 cell line at 6 
and 12 hours. 
 
In order to determine the effect of Bik expression on cell survival over the course of 
24 hours, IB4 cells were transiently co-transfected with 2µg of pmaxGFP, and 0.5µg 
of pcDNA3-HA-bik and pcDNA3-HA-bik ∆BH3. pcDNA3 and pcDNA3-HA-bfl-1 
were used as control vectors. The total amount
 
of DNA transfected was kept constant
 
by adding an appropriate amount of pcDNA3 vector. At 6 and 12 after transfection, 
cells were harvested, and analysed by 7-AAD/Annexin V staining and subsequent 
flow cytometric analysis. A minimum of 6,000 GFP-expressing cells were examined 
in isolation (by analysing cells in R2).  CellQuest software was employed for data 
analysis.  Quadrant markers were based on stained/unstained controls and values 
reflect the percentage of cells in each quadrant. Cells in the lower left quadrant are 
viable (7-AAD
-
/Annexin V
-
), cells in the lower right quadrant are early apoptotic (7-
AAD
-
/Annexin V
+
), cells in the upper right quadrant are late apoptotic (7-
AAD
+
/Annexin V
+
) and cells in the upper left quadrant are necrotic/mostly nuclear 
debris (7-AAD
+
/Annexin V
-
). 
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6.2.7.2 Sub-G1 analysis of bik-transfected cells. 
 
The cell cycle status of cells expressing ectopic Bik was next examined by analysing 
their DNA content of cells as determined by PI staining. However, as illustrated in 
Figure 6.2.15, since only a small minority of the cells actually take up and express the 
genes available in the transient transfection, the overall result of the experiment is 
shrouded by the non-GFP expressing population many of which are undoubtedly 
apoptotic due to the nucleofection procedure. It can be seen from the results, that the 
percentage of cells in the sub-G1  phase of the cell cycle in the pcDNA3-HA, HA-bik 
and ∆BH3 cell pools was 53.29%, 52.06% and 63.21% respectively (Figure 6.2.15). 
This data illustrates that a protocol to identify and segregate the transfected cell 
population is required here. This is generally accomplished by including a plasmid 
that expresses a marker gene in the transfection cocktail, as with pmaxGFP (Section 
6.2.5). However the simultaneous detection of GFP and DNA content using 
propidium iodide (PI) by flow cytometry is made difficult by virtue of the unique 
nature of these two fluorogenic reagents. In order for PI to enter cells efficiently and 
to stain DNA quantitatively, the cells must first be permeabilised; and ethanol 
treatment is a routine method to achieve this. However, this permeabilisation step 
causes GFP, which is normally found in the cytoplasm, to leach out of the cells thus 
abrogating the possibility of examining the GFP population. In order to circumvent 
the problem of simultaneous detection of transfected cells and PI-based cell cycle 
analysis, a protocol (adapted from Lamm et al, 1997) was employed, using 
paraformaldehyde-based fixatives which allow GFP to be maintained in cells and 
retain its fluorescence even after ethanol permeabilisation. The use of fixatives, 
however, resulted in poor staining of the DNA with PI and provided data of 
insufficient resolution for quantitative cell cycle analysis (data not shown). 
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Figure 6.2.15: Sub-G1 analysis of Bik-transfected cells.  
Apoptotic cells determined by sub-G1assay in cell samples treated as in Figure 6.2.14 
above after 12 hours. Apoptosis was assayed using the sub-G1 DNA content. Thirty 
minutes before the assay, cells were stained with PI. FACS analysis of sub-G1 was 
performed by PI staining and flowcytometry. The DNA content in the cells was 
determined 24 hours after treatment. Markers identify cells with hypodiploid DNA 
content (sub-G1), and also those cells in stages G0/G1, S, and G2/M of the cell cycle. 
The percentage of apoptotic cells is indicated on the left hand side of each box. 
 
6.2.8 The effect of the pan-caspase inhibitor, zVAD-fmk, on Bik-mediated 
apoptosis.  
The caspase protease family plays a central role in the execution of apoptosis  
(reviewed in Cryns and Yuan, 1998) and the Bcl-2 family members are known to 
regulate caspase activation (Youle and Strasser, 2008). Bik is known to elicit pro-
apoptotic signals which lead to cell death by pathways which involve the activation of 
caspases (Germain et al, 2002; Gillissen et al, 2003; Mathai et al, 2005; Zhao et al, 
2007). It is widely published that caspase dependent Bik-induced cell death can be 
inhibited by the broad spectrum caspase inhibitor "-benzyloxycarbonyl-Val-Ala-
Asp(OMe)-fluoromethyl ketone (zVAD-fmk) (Mathai et al, 2002; Naumann et al, 
2003; Hur et al, 2004). zVAD-fmk is a tripeptide-based inhibitor (VAD) linked to a 
chemical moiety; fluoromethyl ketone (fmk) which covalently modifies the enzyme, 
thereby inactivating its catalytic function. zVAD-fmk is an irreversible inhibitor of 
several caspases, including caspases 1, 3, 5, 7, 8 and 9. Since IB4 cells transfected 
with HA-bik show the classical changes characteristic of the apoptotic phenotype 
(Figure 6.2.13), it was next important to investigate if the mechanism of apoptosis 
was caspase dependent, by analysing the affect of the caspase inhibitor zVAD-fmk on 
HA-bik and HA-bik-∆BH3-transfected cells. 
Sub G1
G1
G2/M
S
Sub G1
G1
G2/M
S
Sub G1
G1
G2/M
S
pCD+A3+pMAXGFP
53.29% 63.41%52.06%
pCD+A3-HA-Bik+pMAXGFP pCD+A3-HA-∆BH3+pMAXGFP
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Initially, the efficacy of zVAD-fmk inhibitor in the IB4 cell line was confirmed in a 
control experiment.  Since proteasome inhibition has been reported to induce 
apoptosis that is mediated by caspase activation (Wu et al, 1999), extracts derived 
from IB4 cells treated with the proteasome inhibitor MG132 were monitored for cell 
viability in the absence or presence of the caspase inhibitor zVAD-fmk. Cytotoxicity 
was assessed at 12 hours by Annexin V/7-AAD staining and FACS analysis. It can be 
seen that, the abrogation of proteasome activity by MG132 was significantly reversed 
in the presence of zVAD-fmk (44%) confirming that this inhibitor was biochemically 
effective in
 
this model system (Figure 6.2.16). Furthermore, the inhibition of 
apoptosis is specific to the zVAD-fmk reagent and not due to the DMSO solvent. 
These results demonstrate that MG132-induced activation of apoptosis is significantly 
inhibited by hindering cysteine protease activity in IB4 cells. 
 
 
 
Figure 6.2.16: MG132-Induced Apoptosis is significantly inhibited by the pan-
caspase inhibitor zVAD-fmk. 
IB4 cells were treated with 15µM MG132 in the presence or absence of 50µM zVAD-
fmk. Cytotoxicity was evaluated at 12 hours after treatment by 7-AAD/Annexin V 
staining and subsequent flow cytometric analysis. 10,000 cells were analysed per 
scatter plot. Quadrant markers were based on stained/unstained controls and values 
reflect the percentage of cells in each quadrant. Cells in the lower left quadrant are 
viable (7-AAD
-
/Annexin V
-
), cells in the lower right quadrant are early apoptotic (7-
AAD
-
/Annexin V
+
), cells in the upper right quadrant are late apoptotic (7-
AAD
+
/Annexin V
+
) and cells in the upper left quadrant are necrotic/mostly nuclear 
debris (7-AAD
+
/Annexin V
-
). 
 
6.2.8.1 Pre-treatment of cells does not increase the inhibitory effect of zVAD-fmk 
on MG132 mediated apoptosis.  
It has previously shown that a period of pretreatment with zVADfmk yields increased 
protection from apoptosis compared to just treatment alone (Clayton et al, 1997). 
Since the observed inhibition of MG132 mediated apoptosis by zVAD-FMK (Figure 
6.76% 0.84% 
◄90.20% 2.20% 
79.76% 8.06% 
◄9.17% 3.01% 
10.51% 
◄52.78% 
35.80% 
0.91% 
      DMSO MG132+DMSO MG132+ZVAD-FMK 
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6.2.16) did not completely rescue the cells, it was decided to pre-treat the cells for 1 
hour prior to the addition of 15µM MG132, in an effort to enhance the protective
 
efficacy of the caspase inhibitor. Extracts were monitored for cell viability in the 
absence or presence of the caspase inhibitor zVAD-fmk as before at 12 hours by 
Annexin V/7-AAD staining and FACS analysis. As the result in Figure 6.2.17 
indicates, pre-treatment with zVAD-fmk had no significant effect relative to treatment 
alone (Figure 6.16). In fact inhibition of MG132-induced cytotoxicity by zVAD-fmk 
accounted for a 43% increase in cell viability in this instance as compared to 44% 
without pretreatment (Figure 6.2.16 and Figure 6.2.17). 
 
 
 
 
Figure 6.2.17: Pre-treatment of cells does not increase the inhibitory effect of 
zVAD-fmk on MG132 mediated apoptosis. 
 
IB4 cells were pretreated with 50µM zVAD-fmk 1 hour prior to the addition of 15µM 
MG132. Cell viability was evaluated at 12 hours after treatment by 7-AAD/Annexin 
V staining and subsequent flow cytometric analysis. 10,000 cells were analysed per 
scatter plot. Quadrant markers were based on stained/unstained controls and values 
reflect the percentage of cells in each quadrant. Cells in the lower left quadrant are 
viable (7-AAD
-
/Annexin V
-
), cells in the lower right quadrant are early apoptotic (7-
AAD
-
/Annexin V
+
), cells in the upper right quadrant are late apoptotic (7-
AAD
+
/Annexin V
+
) and cells in the upper left quadrant are necrotic/mostly nuclear 
debris (7-AAD
+
/Annexin V
-
). 
 
6.2.8.2  The pan-caspase inhibitor zVAD-fmk blocks the activation of caspases 
and loss of cell viability resulting from exposure of IB4 cells to 
exogenous Bik expression. 
 
The effect of zVAD-fmk treatment on IB4 Bik-transfected cell pools was examined 
by FACS analysis. In this experiment, IB4 cells were transiently co-transfected with 
the 2µg pmaxGFP expression plasmid and 5µg bik or bik ∆BH3 as before. 
71.06% 6.55% 
◄19.33% 3.06% 
27.64% 1.94% 
◄61.89% 7.60% 
MG132 MG132+ZVAD-FMK Untreated Cells 
3.44% 1.58% 
◄94.42% 0.56% 
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Transfected cell pools were immediately divided and subsequently treated, or 
untreated with 50µM zVAD-fmk. The population of cells expressing GFP in the 
presence of Bik or Bik-∆BH3 expression was assessed for apoptosis by Annexin V/7-
AAD staining. GFP fluorescence of 10,000 events for each sample was measured on 
the BD FACSCalibur flow cytometer. CellQuest software was employed for data 
analysis (BD). 
 
Significantly, zVAD-fmk treatment of IB4-pcDNA3-HA-bik cells caused a 25% 
decrease in the number of apoptotic cells relative to IB4-pcDNA3-HA and a 22% 
decrease relative to IB4-pcDNA3-HA-bik-∆-BH3 after 3 hours (Figure 6.2.18). Bik-
expressing cells were 25% more viable in the presence of zVAD-fmk, compared with 
-0.17% for pcDNA3-HA and 3.2% for pcDNA3-HA-bik-∆-BH3. Thus, induction of 
cell death by Bik was strongly inhibited by the caspase inhibitor zVAD-fmk, 
indicating the requirement
 
for caspases in this context. Cell death in the presence of 
HA-Bik showed the largest reversal of fate in the presence of the caspase inhibitor. 
From these results it is clear that zVAD-fmk effectively blocks the activation of 
caspases and loss of cell viability (Figure 6.2.18) that can result from exposure of 
these cells to exogenous Bik. 
 
In summary, Bik induces apoptosis through a caspase-dependent pathway in the IB4 
LCL. During caspase inhibition, Bik-induced apoptosis decreased substantially. This 
result further corroborates the involvement of apoptosis in Bik-induced inhibition of 
cell survival, clearly demonstrating that the zVAD-fmk cysteine protease inhibitor can 
block Bik-triggered cell death in IB4. In conclusion, this data identifies that Bik 
initiates a pathway, upstream of the caspases stimulating the induction of apoptosis in 
IB4. This pathway is likely to be dependent on zVAD-fmk-sensitive caspases and is 
dependent on a functional BH3 domain. 
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Figure 6.2.18: Ectopic Bik induces apoptosis through a caspase-dependent 
pathway in IB4 cells. 
 
(A) IB4 cells were firstly transiently co-transfected with 2µg of pmaxGFP, and 5µg of 
pcDNA3-HA-bik and pcDNA3-HA-bik ∆BH3. pcDNA3 and pcDNA3-HA-bfl-1 were 
used as control vectors. The total amount
 
of DNA transfected was kept constant at 
7µg by adding an appropriate amount of pcDNA3 vector. Transfected cells were 
treated or untreated with of 50µM zVAD-fmk immediately after transfection. Three 
hours after transfection, cells were harvested, and cell viability was analysed by 7-
AAD/Annexin V staining and subsequent flow cytometric analysis. CellQuest 
software was employed for   data analysis and representative scatter plots are 
presented above.  GFP fluorescence (10,000 events for each sample) was measured on 
the BD FACSCalibur flow cytometer. Quadrant markers were based on 
stained/unstained controls and values reflect the percentage of cells in each quadrant. 
Cells in the lower left quadrant are viable (7-AAD
-
/Annexin V
-
), cells in the lower 
right quadrant are early apoptotic (7-AAD
-
/Annexin V
+
), cells in the upper right 
quadrant are late apoptotic (7-AAD
+
/Annexin V
+
) and cells in the upper left quadrant 
are necrotic/mostly nuclear debris (7-AAD
+
/Annexin V
-
). (B) The percentage of GFP-
expressing cells in late apoptosis over the course of three experiments was plotted 
(Data are Mean ±SD, *P<0.5). 
 
 
 
 
 
 
 
 
 
 
B 
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6.3 Discussion  
 
EBV has been shown to protect B-cells from apoptosis via the expression of select 
EBV proteins and up-regulation of Bcl-2 or its homologues (Henderson et al, 1991; 
Wang et al, 1996; Pegman et al, 2006). The virus has specifically been thought to 
counter apoptosis during latency, principally through LMP1-mediated activation of 
NF-κB-regulated genes (Fries et al, 1996; Cahir-McFarland et al, 2000). More 
recently EBNA2 mimicry of Notch activity has been identified as having the ability to 
protect B-cells against various apoptotic agents, including Nur-77 mediated cell death 
(Lee et al, 2002; Lee et al, 2004b). In recent months, LMP2A has also been 
implicated with a role in averting apoptosis through the activation of NF-κB-regulated 
genes (Guasparri et al, 2008). 
 
Previous work in our laboratory has shown that the anti-apoptotic, bfl-1 gene, a 
CBF1-dependent transcriptional target of EBNA2 (Pegman et al, 2006), plays an 
important role in regulating the survival of EBV-infected B-cells (D'Souza et al, 
2000). Thus, the findings presented here demonstrating that the EBNA2-mediated 
suppression of Bik contributes to the protection of infected cells from apoptosis, is an 
indication that this viral protein contributes to cell survival, by up-regulating  the anti-
apoptotic bfl-1 and down-regulating the pro-apoptotic bik.  
 
Aberrations in the expression of many of the pro-apoptotic Bcl-2 family members has 
previously been shown to be involved in protecting malignant cells from apoptosis.  
Bax is mutated in human colon cancer as well as in some leukaemias
 
(Rampino et al, 
1997; Meijerink et al, 1998) and loss of Bax increases tumourigenicity and reduces 
apoptosis (McCurrach et al, 1997; Yin et al, 1997; Ionov et al, 2000). Bak was found 
to be mutated in some human gastric and colorectal cancers (Rampino et al, 1997; 
Kondo et al, 2000). Furthermore, the absence of both Bax and Bak can enhance 
transformation, to a greater extent than loss of either protein alone (Zong et al, 2001). 
Preliminary evidence also suggests that the absence of bim accelerates Myc-induced 
lymphomagenesis (Cory and Adams, 2002) and there is also indication that the p53 
targets, Noxa and Puma, might mediate p53 apoptotic function, and that Bmf might 
inhibit metastasis (Puthalakath et al, 2001). Importantly loss of Bik expression has 
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been implicated in renal cell carcinoma, and in human breast and colorectal cancers 
(Castells et al, 2000; Sturm et al, 2006; Zantl et al, 2007).  
 
In this chapter the effect of bik expression in EBV-infected cell lines was examined. 
Evidence is presented that exogenous Bik can induce apoptosis in EBV-infected B-
cells by a mechanism that is dependent on its BH3 domain. The evidence presented 
thus far indicates that down-regulation of bik promotes B-cell survival during the 
Epstein-Barr virus growth programme. Other results in this thesis suggest that 
EBNA2 plays a key role in repressing bik and it is now clear that this host-virus 
interaction contributes to the survival of EBV-infected B-cells and may therefore play 
a role in pathogenesis of EBV. 
 
The results presented here indicate that the death-promoting activity of Bik is 
dependent on a functional BH3 domain in this context. The BH3 domain is of central 
importance in mediating apoptosis in the pro-apoptotic members of the Bcl-2 family. 
It has been reported that mutations within the BH3 domain of Bik abrogate its ability 
to induce cell death and to complex with anti-apoptotic proteins (Chittenden et al, 
1995). This result is consistent with the hypothesis that Bik may promote cell death 
by complexing with and antagonising the function of endogenous cellular anti-
apoptosis proteins such as Bcl-2 and Bcl-XL. 
 
It has been postulated that Bik may induce apoptosis by preferentially sequestering 
Bcl-2-like apoptosis inhibitors (Boyd et al, 1995). The fact that the growth inhibitory 
effect of Bik appeared to increase in the presence of decreasing amounts of its effector 
plasmid HA-bik in the Luc assay experiment, (seen in Figure 6.2.2B) could possibly 
indicate that a relatively low level of Bik protein is required to reach the saturation 
point of inhibition, by which time all the binding sites of the pro-survival molecule in 
question may be engaged by Bik. In that case, Bcl-2 would be the effector that is 
inhibited by interaction with the BH3-containing Bik protein. In support of this 
theory, Bik has an affinity for Bcl-2, Bcl-XL and Mcl-1 (Boyd et al, 1995; Chen et al, 
2005) and the Bcl-2 homolog encoded by EBV; BHRF1 (Boyd et al, 1995). Thus, the 
ratio of Bik to its anti-apoptotic homologues may influence cell survival. Any further 
small increases
 
in the expression of Bik may amplify signals from any of several anti-
apoptotic molecules, thus relieving some of the death effect, although this effect is not 
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seen in the later FACs experiments. Of interest, at 7ug, the level of luc activity 
decreases again to an absolute minimum of 4.28%.  However, it is conceivable that 
this effect is due to non-specific effects of high levels of protein over-expression. 
Earlier studies have shown that Bik-induced apoptosis is dependant on caspase 
activation in a variety of mammalian cell lines, and can be inhibited by the pan-
caspase inhibitor zVAD-fmk (Orth and Dixit, 1997; Mathai et al, 2002; Naumann et 
al, 2003; Hur et al, 2004) (Chapter 1). While apoptosis mediated by Bcl-2 family 
members predominantly leads to caspase activation (Youle and Strasser, 2008) the 
ability of these proteins to mediate caspase-independent cell death has also been 
established (Xiang et al, 1996), and indeed the caspase dependency of Bik is thought 
to be cell type specific (Orth and Dixit, 1997; Mathai et al, 2002; Naumann et al, 
2003; Hur et al, 2004; Oppermann et al, 2005). It was therefore important to 
determine if Bik-induced cell death triggers the activation of caspases in this context. 
The data presented here demonstrates that Bik induces apoptosis by a caspase 
dependent pathway in the EBV-infected cell line, IB4.  
Thus, it has been established that the EBNA2 mediated suppression of bik has a role 
to play in the EBV regulation of cellular apoptosis, with the down-regulation of Bik 
contributing to the protection of infected cells from apoptosis. Conceivably then the 
apoptosis deficiency of EBV-associated malignancies may be overcome by enforced 
expression of pro-apoptotic Bcl-2 proteins such as Bik.  
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CHAPTER 7  
Regulation of bik by EBV 
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7.1 Introduction 
 
The regulation of gene expression in eukaryotic cells is the consequence of a series of 
intricate mechanisms that are instigated in the nucleus by transcription and completed 
by translation in the cytoplasm (Lorkowski and Cullen, 2003). Evolution has led to 
the development of multiple different BH3-only proteins, and several mechanisms 
have been put in place to keep these pro-apoptotic proteins under control (Huang and 
Strasser, 2000). The existence of many, otherwise distinct proteins, that share a 
common functional domain, is indicative of a sophisticated and intricately structured 
intracellular regulatory system (Kelekar and Thompson, 1998).  
The pro-apoptotic activity of BH3-only molecules may be kept in check by either 
transcriptional control or post-translational modification (as reviewed in Huang and 
Strasser, 2000; Puthalakath and Strasser, 2002). Since the steady state level of a 
particular mRNA species in a cell is dependent on both the rates of transcription and 
decay a co-ordinated balance between transcriptional and post-transcriptional events 
is required. It is clear that external and internal stimuli lead to regulation of bik at 
several different levels, including tissue-specific expression, transcriptional and 
translational control and intracellular localisation. This study attempts to define the 
transcriptional and post-translational mechanisms that regulate bik during EBV-
infection.  
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It has been established in previous chapters that EBNA2 is capable of directly 
regulating bik expression at a transcriptional level (Chapters 4 and 5). Indeed, in all of 
the nine Lat III cell lines analysed (disregarding DAUDI and BL419A which both 
harbour deletions spanning the EBNA2 coding sequence), only low or undetectable 
levels of bik mRNA were detected by QPCR. Also, significantly, the induction of 
EBNA2 correlated with a substantial decrease in the level of bik mRNA in both BL-
derived cell lines and LCLs. 
7.2 Regulation of the bik Promoter 
 
Having established that EBNA2 alone can regulate bik in B-cell lines, it was thus of 
interest to determine if this down-regulation was due to a decrease in the rate of 
transcription initiation from the bik promoter  
7.2.1 Bik promoter construct, p-1710/+203-bik-Luc. 
 
A suitable bik promoter-reporter construct was first generated. Two of the most 
commonly used reporter genes in promoter reporter constructs encode the enzymes 
chloramphenicol acetyl transferase (CAT) and luciferase (Luc). In recent years, the 
greater sensitivity and rapidity of luciferase assays has resulted in the popular usage 
of Luc-based rather than CAT-based promoter-reporter constructs for evaluating 
transcriptional activity in transfected cells. It was therefore decided to investigate the 
regulation of bik promoter activity by EBNA2 using a luciferase based system. For 
this purpose the pGL2-Basic Luciferase reporter vector (Table: 2.1-4) was employed 
to monitor transcriptional activity of the bik promoter in transfected BL-derived cells. 
A schematic circular map of the pGL2-basic vector can be seen in Figure 7.2.1. 
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Figure 7.2.1: Schematic circular map of pGL2-basic vector (Promega). 
 
The pGL2-Basic Vector
 
is a reporter construct lacking eukaryotic promoter and 
enhancer sequences. The vector carries the coding region for firefly (Photinus pyralis) 
luciferase which is designated ‘luc’ on the map. The multiple cloning site, which 
contains recognition sites for "he I and Bgl II sites amoung others is also indicated. 
 
A 1.9kb DNA sequence from the 5’ flanking region of the bik gene (position -
1710/+203) was obtained as a fragment cloned into the promoterless pBLCAT-2 ∆TK 
(in which the tk promoter has been deleted) (Verma et al, 2000). This plasmid, 
designated p-1710/+203BikCAT-2 (Table: 2.1-4) was firstly characterised by 
restriction digestion in order to confirm its identity (data not shown). In order to 
change the reporter context of the p-1710/+203BikCAT-2 construct to a luciferase-
based system, an approach based on sub-cloning the -1710/+203Bik fragment from 
the p-1710/+203Bik-CAT-2 construct into the pGL2-basic vector was employed. 
Initially, since PCR was the method of choice, a cloning strategy which involved the 
PCR amplification of the -1710/+203-bik promoter fragment, and subsequent sub-
cloning into the pGL2-basic plasmid upstream of the lucifearse gene was used. 
The -1710/+203-bik promoter fragment was used as template DNA and PCR was 
undertaken using primers specific to the bik promoter region (BikPromFor and 
BikPromRev, Table: 2.1-5). The primers included Bam HI restriction sites in order to 
facilitate directional cloning. Following PCR, the products were analysed by agarose 
gel electrophoresis (Section 2.2.2.15) to check for migration of fragments at the 
expected size, however, no PCR product was observed. This experiment was repeated 
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with various dilutions of template DNA (1/10–1/500) and primers (25pmole-
100pmole) but to no benefit. Further PCR parameters including annealing and 
denaturation temperatures, MgCl2 concentration (increased in 0.5mM increments from 
15mM), concentration and commercial source of Taq DNA polymerase (REDTaq™, 
AmpliTaq Gold
®
 and SYBR
®
 Green PCR Master Mix), extension times and dNTP 
concentration were also varied but amplification of PCR product was not obtained 
(data not shown). Although, in some instances non-specific bands were observed, no 
product of the correct size was amplified. Conventional PCR conditions were 
modified to include a ‘Hot-Start’ step (95
o
C, 15mins) at the beginning of the reaction, 
in a further attempt to reduce non-specific artifacts and increase potential PCR 
product yield, however once again no amplification was achieved. Another modified 
PCR method, ‘Touchdown PCR’ was also employed in an additional attempt to 
reduce any non-specific amplification. This technique involved the use of an 
annealing temperature greater than the target optimum in the early PCR cycles. The 
annealing temperature was then decreased by 1°C every cycle until the specified or 
'touchdown' annealing temperature was reached. The ‘touchdown’ temperature was 
then used for the remaining number of cycles, allowing for the enrichment of the 
correct product over any non-specific product. Once again however no progress was 
made. In a final attempt to optimise the reaction, a separate new set of primers (lower 
self-annealing/self-hybridisation potential Table: 2.1-5) were designed, however no 
amplification was achieved and consequently a new strategy which involved the 
excision of the -1710/+203Bik fragment from the p-1710/+203BikCAT-2 construct 
using restriction digestion, and its insertion into pGL2-basic, was successfully 
adopted. A schematic diagram outlining the construction of the vector is illustrated in 
Figure 7.2.2. The steps involved in the generation of -1710/+203 bik Luc can be seen 
in Figure 7.2.3. 
 
pGL2-basic was first characterised by restriction digestion in order to confirm its 
identity using Rsa I and Hind III (Figure 7.2.3A). Prior to ligation, pGL2-Basic was 
linearised by digestion with "he I and Bgl II, followed by dephosphorylation using 
CIP to prevent recircularisation of the linearised DNA (Section 2.2.1.4). The 
linearised, CIP-treated DNA was then purified by phenol: chloroform extraction 
followed by ethanol precipitation (Section 2.2.1.2).   
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The bik promoter region (-1710/+203) had previously been inserted by directional 
cloning into the Xba I and Bam HI sites of pBLCAT-2 ∆TK to create the p-
1710/+203BikCAT-2 plasmid (Verma et al, 2000). Thus, in order to construct the p-
1710/+203 bik Luc plasmid, the 1.9kb Xba I - BamH I DNA fragment (containing the 
bik promoter region) was excised from p-1710/+203Bik-CAT by digestion with these 
enzymes. The digested product was analysed by agarose gel electrophoresis (Section 
2.2.1.15) to check for migration of fragments at the expected size (Figure 7.2.3B) and 
the integrity of the Xba I and Bam HI digested bik promoter fragment was tested by 
restriction digestion using Kpn I, Rsa I and Hind III (Figure 7.2.3C). The Xba I-Bam 
HI fragment was subsequently purified using the Promega Wizard
® 
DNA purification 
system (Section 2.2.1.6) and the digested, purified product was then sub-cloned into 
the "he I and Bgl II sites of pGL2-basic.   Ligations of vector and insert DNA were 
carried out overnight at 16 ˚C (Section 2.2.1.7). 
Following the ligation reaction, competent E. coli JM109 cells were transformed with 
the recombinant plasmid DNA. Single colonies were used to inoculate cultures from 
which DNA mini-preparations were prepared. Restriction digestion analysis was 
performed on the DNA to monitor for the presence of insert DNA using Kpn I, Hind 
III and Eco RI restriction enzymes (Figure 7.2.3D). Once it was established that the 
reporter plasmid contained the –1710/+203 region of the human bik promoter cloned 
just upstream of the luciferase gene in pGL2-basic, DNA maxi-preparations were 
carried out using the Qiagen
®
 Midi Kit (Section 2.2.1.12) and the fidelity of the 
cloned sequence was verified by sequencing (Section 2.2.1.18) using pGL2-Basic 
specific primers (Table 2.1-5). The pGL2-1710/+203 bik Luc derived plasmid DNA, 
demonstrated 100% homology with the predicted sequences as derived from the 
known bik promoter sequence (GenBank accession number U34584) (data not 
shown). 
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Figure 7.2.2: Cloning Strategy.  
Flow diagram detailing the steps involved in the construction of the pGL2-1710/+203 
bik Luc construct.  See text for details.  
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Figure 7.2.3: Construction of the p-1710/+203-bik Luc construct. 
 
(A) Restriction digestion of the 5,598bp pGL2-basic with Rsa I and Hind III. 
Fragments were analysed using a 1% agarose 1X TAE gel and electophoresis was 
carried out at 100V for 1 hour in 1X TAE. Undigested pGL2-basic plasmid is shown 
in lane 2. Digestion with the Rsa I restriction enzyme resulted in 12 bands at 1932bp, 
1000bp, 795bp, 702bp, 336bp, 318bp 209bp, 169bp, 53bp, 52bp, 21bp and 10bp (lane 
3, bands at 53bp, 52bp, 21bp and 10bp to faint to discern), and digestion with Hind III 
(lane 4) linearised the 5,598bp fragment as expected. A 1Kb DNA ladder is shown in 
lane 1. (B)  Restriction digestion of the p-1710/+203BikCAT-2 construct with Xba I 
and Bam HI excised the promoter fragment (1913bp), as expected in lane 2. 
Fragments were analysed using a 0.7% agarose-1X TAE gel and electrophoresis was 
carried out at 100V for 1 hour in 1X TAE. A 1Kb ladder is shown in lane 1. (C) The 
Xba I-Bam HI digested bik promoter fragment was subject to restriction digestion 
using Kpn I, Rsa I and Hind III to check integrity and was then analysed by agarose 
gel electrophoresis on a 1.2% agarose-1X TAE gel and electrophoresis was carried 
out at 100V for 1 hour in 1X TAE. Digested, purified bik promoter fragment is shown 
in lane 2 (1913bp). Lanes 3, 4 and 5 show Kpn I, Rsa I and Hind III digestions 
respectively. Digestion with the Kpn I restriction enzyme resulted in 2 bands at 
1058bp and 855bp (lane 3), restriction analysis using Rsa I yielded 3 fragments at 
853bp, 656bp and 404bp (lane 4) while Hind III digestion resulted in 4 fragments at 
945bp, 558bp, 268bp and 142bp (lane 5). A 1Kb DNA ladder is shown in lane 1. (D) 
Restriction analysis of recombinant p-1710/+203-bik Luc clones by digestion using 
Kpn I, Hind III and Eco RI enzymes followed by agarose gel electrophoresis on a 1% 
agarose-1X TAE gel at 100V for 1 hour. Undigested pGL2-Basic Vector is shown in 
lane 2. Restriction digestion of pGL2-basic with Kpn I (lane 3) and Hind III (lane 4) 
linearised the plasmid. Lanes 5-12 illustrate analysis of selected positive clones. 
Lanes 5-8 show DNA from a single recombinant clone, while lanes 9-12 show DNA 
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from a second recombinant clone. Undigested recombinant plasmid is shown in lanes 
5 and 9. Restriction analysis of p-1710/+203 bik Luc with Kpn I yielded fragments at 
6613bp and 869bp (lanes 6 and 10). Digestion of recombinant DNA with Hind III 
resulted in 4 bands at 6523bp, 558bp, 277bp and 142bp (lanes 7 and 11) while 
digestion with Eco RI linearised the DNA (7511bp; lanes 8 and 12). A 1Kb DNA 
ladder is shown in lane 1 and a 100bp ladder in lane 13.                     
 
7.2.2 Effect of EB+A2 on bik promoter activity in the DG75 cell line. 
 
A strategy involving co-transfection experiments with either of two EBNA2 
expression plasmids, pSG5EBNA2 and pSG5EBNA2ww323sr (Table 2.1-4), together 
with the -1710/+203 construct p-1710/+203 bik Luc was employed.  pSG5EBNA2 
expresses wild-type EBNA2. pSG5EBNA2ww323sr on the other hand expresses a 
non-CBF1 binding EBNA2 mutant in which two tryptophan residues at positions 323 
and 324 in the CBF1 binding domain were replaced with a serine and arginine residue 
respectively, thus abrogating the ability of EBNA2 to bind CBF1 (Ling et al, 1993a). 
The down-regulation of bik mRNA by EBNA2 has been observed in the context of 
the EBV BL cell lines, DG75, BL41 and BJAB (Chapter 4).  Thus, to examine if the 
sub-cloned bik promoter fragment could be trans-activated by EBNA2 in BL cell 
lines, co-transfection experiments were undertaken in DG75, BL41K3 and BJAB.  
 
The EBNA2 expression vector and the CBF1-regulated luciferase reporter construct 
pGa981-6 (Table 2.1-4) were co-transfected as a control in each transfection 
experiment to monitor EBNA2/CBF1 trans-activation. pGa981-6 contains a 50bp 
oligonucleotide harbouring both CBF1 binding sites of the EBV TP1 promoter sub-
cloned as a hexamer into the plasmid pGa50-7 (Minoguchi et al, 1997) .  EBNA2 is a 
well established trans-activator of this CBF1-regulated reporter construct, and a 
consistent trans-activation of the CBF1-responsive artificial promoter was detected in 
every assay. 
 
In a second control experiment to validate the promoter-reporter assay, co-
transfections were carried out using a known EBNA2-responsive reporter construct, -
1374/+81 Bfl-1 Luc. Accordingly DG75 cells were transiently co-transfected with 
7µg of pSG5EBNA2 or pSG5ww323sr with 1µg of the bfl-1 promoter-reporter 
construct (-1374/+81 Bfl-1 Luc). The total quantity of transfected plasmid was 
adjusted in all cases to 10µg using empty vector (pSG5). Bfl-1 promoter activity was 
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then analysed 48 hours after transfection using the luciferase assay (Section 2.2.2.13). 
Trans-activation rates were determined by standardising the luciferase values 
obtained with luciferase values recorded from transfections with 1374/+81 Bfl-1 Luc 
alone. A plasmid carrying the Lac Z (pCMVLac Z) gene was also included in each 
transfection and efficiency was accounted for by measuring beta-galactosidase (β-gal) 
activity (Section 2.2.2.14). As can be seen in Figure 7.2.4A an increase in bfl-1 
promoter activity (approximately 6-fold) is apparent in response to the addition of the 
EBNA2 expression plasmid, pSG5EBNA2. The non-CBF1 binding mutant 
pSG5ww323sr, however, failed to trans-activate the promoter (Figure 7.2.4A) thus 
confirming the significance of the EBNA2-CBF1 interaction in this context as 
previously established (Pegman et al, 2006), and also verifying the reliability of the 
promoter-reporter assay. In the same experiment EBNA2 trans-activated the pGa981-
6 reporter construct approximately 1,600-fold (Figure 7.2.4B). 
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Figure 7.2.4: EB+A2 is a well established trans-activator of CBF1-regulated 
promoters. 
 
(A) DG75 cells were co-transfected with wild type bfl-1 promoter (–1374/+81-Luc) 
reporter construct, pCMVLacZ and either the EBNA2 expression vector 
pSG5EBNA2 or pSG5EBNA2ww323sr. The total quantity of transfected plasmid was 
adjusted to 10µg with the empty vector pSG5. Cells were harvested 48 hours after 
transfection and luciferase and β-gal assays were performed. Normalised luciferase 
values were expressed relative to the corresponding value obtained the –1374/+81-
Luc reporter construct when co-transfected with control vector pSG5. The absolute 
luciferase values obtained for pSG5 and –1374/+81-Luc after transfection was set at 
1. (B) DG75 cells were co-transfected with the pGa981-6 artificial reporter construct, 
pCMVLacZ and EBNA2. The total quantity of transfected plasmid was adjusted to 
10µg with the empty vector pSG5. Normalised luciferase values were expressed 
relative to the corresponding value obtained for the pGa981-6 reporter construct when 
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co-transfected with control vector pSG5. The absolute luciferase values obtained for 
pSG5 and 981-6 after transfection was set at 1. (Data are Mean ±SD). 
 
Having established an appropriate assay for analysis of promoter activity in response 
to EBNA2 expression, DG75 cells were co-transfected with 7µg of pSG5EBNA2 or 
pSG5EBNA2ww323sr with 1µg of the bik promoter-reporter construct -1710/+203-
bik-Luc and pCMVLac Z. Bik promoter activity was then analysed using the 
luciferase assay as before. Normalised luciferase values were expressed relative to the 
corresponding value obtained for each reporter construct when co-transfected with 
control vector pSG5. As can be seen from Figure 7.2.5 a clear reduction in bik 
promoter activity (approximately 40%) was observed in response to EBNA2. 
Moreover, a decrease in promoter activity was also observed in response to 
pSG5EBNA2ww323sr, at levels equivalent to that seen for pSG5EBNA2. This result 
indicates that EBNA2 regulates the bik promoter via a mechanism not requiring the 
cellular DNA binding protein CBF1. EBNA2 trans-activated the pGa981-6 reporter 
construct approximately 1,400-fold (data not shown). 
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Figure 7.2.5: EB+A2 represses the bik promoter; repression does not require the 
EB+A2-CBF1 interaction 
 
DG75 cells were co-transfected with bik promoter (–1710/+203-Luc) reporter 
construct, pCMVLacZ and the EBNA2 expression vector pSG5EBNA2 or 
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pSG5EBNA2ww323sr. The total quantity of transfected plasmid was adjusted to 
10µg with the empty vector pSG5. Cells were harvested 48 hours after transfection 
and luciferase and β-gal assays were performed. Normalised luciferase values were 
expressed relative to the corresponding value obtained for the -1710/+203-Luc-bik 
reporter construct when co-transfected with control vector pSG5. The absolute 
luciferase values obtained for pSG5 and -1710/+203-Luc-bik after transfection was set 
at 100. (Data are Mean ±SD). 
 
7.2.3 EB+A2 mediated repression of the bik promoter is not potentiated by 
EB+A-LP in DG75. 
 
The EBNA Leader Protein (EBNA-LP), together with EBNA2 is the first viral gene 
product to be expressed during EBV-induced B-cell immortalisation (Alfieri et al, 
1991). EBNA-LP is known principally as a transcriptional co-activator of EBNA2. It 
has previously been shown that EBNA-LP co-operates with EBNA2 in the up-
regulation of LMP1 in B-cells (Harada and Kieff, 1997; Nitsche et al, 1997) and that 
EBNA-LP and EBNA2 co-operate to stimulate expression of cyclin D2 in resting B-
cells in addition to mediating G0 to G1 transition during immortalisation (Sinclair et 
al, 1994). Furthermore, co-transfection of EBNA-LP also considerably potentiates 
EBNA2 trans-activation of the bfl-1 promoter (Pegman,P.M. unpublished data). Thus, 
considering EBNA-LP as a co-activator of EBNA2, it was decided to determine if 
there was a co-operative role for EBNA2 and EBNA-LP in the repression of the bik 
promoter. For this purpose an EBNA-LP expression plasmid, pJT125, (Table 2.1-4) 
and the corresponding non-functional mutant, pRSP83 (Table 2.1-4) were employed. 
The construction of these plasmids has been published elsewhere (Harada and Kieff, 
1997; Peng et al, 2000). 
 
Co-transfection experiments were performed using DG75 with 5µg of the EBNA-LP 
expression plasmids together with 7µg of EBNA2 and 1µg of the bik-promoter 
construct. The total quantity of transfected plasmid was adjusted in all cases to 12µg 
using empty vector (pSG5). Luciferase activities which were normalised for 
transfection efficiency (based on β-galactosidase activity). Normalised luciferase 
values were expressed relative to the corresponding value obtained for the reporter 
construct when co-transfected with control vector pSG5. The results are shown in 
Figure 7.2.6. In this experiment, EBNA2 trans-activated the pGa981-6 reporter 
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construct approximately 1,500-fold (data not shown). Co-transfection with 
pSG5EBNA2 resulted in 50% decrease in promoter activity, while co-transfection of 
EBNA2 with both the EBNA-LP expression plasmid, pJT125, and the non-functional 
mutant partner pRSP83, caused a similar decrease in bik promoter activity. Thus, co-
transfection of EBNA2 with EBNA-LP did not result in any further decrease in 
promoter activity than was the case with EBNA2 alone. Thus, EBNA-LP does not 
appear to potentiate EBNA2 repression of the bik promoter in this context.  
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Figure 7.2.6: EB+A2 mediated repression of the bik promoter is not potentiated 
by EB+A-LP in DG75. 
 
DG75 cells were co-transfected with bik promoter (–1710/+203-Luc) reporter 
construct, pCMV LacZ and the EBNA2 expression vector pSG5EBNA2, and either 
the EBNA-LP expression plasmid pJT125, or its non-functional mutant partner 
pRSP83. The total quantity of transfected plasmid was adjusted to 12µg with the 
empty vector pSG5. Cells were harvested 48 hours after transfection and luciferase 
and β-gal assays were performed. Normalised luciferase values were expressed 
relative to the corresponding value obtained for the -1710/+203-Luc-bik reporter 
construct when co-transfected with control vector pSG5. The absolute luciferase 
values obtained for pSG5 and -1710/+203-Luc-bik after transfection was set at 100. 
(Data are Mean ±SD). 
 
 
Of note, co-transfection experiments with the EBNA2 expression vector failed to 
consistently show repression of the bik promoter, whereas consistent responses from 
the bfl-1 and 981-6 promoters were readily detectable in every experiment. These 
experiments were repeated on different occasions; however, as can be seen from the 
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summary of the results given in Table 7.2-1, no consistency between different 
experiments could be achieved. While 8 out of 11 (approximately 72%) transfections 
indicate some degree of down-regulation nonetheless it cannot be concluded that 
EBNA2 down-regulated transcription initiated from the 1.9kb bik promoter fragment 
in these experiments. 
 
 
Table 7.2-1: Summary of bik promoter Transfections in DG75 
 
Transfection Luc Activity of in response to 
EB+A2  
1 200% 
2 200% 
3 100% 
4 90% 
5 90% 
6 50% 
7 78% 
8 50% 
9 58% 
10 50% 
11 76% 
 
 
Accordingly, it was thus important to establish if this inconsistency was specific to 
DG75. For this reason, similar experiments were carried out in another well-studied 
BL cell line, namely BL41K3. 
7.2.4 Effect of EB+A2 on bik promoter activity in the BL41K3 cell line. 
 
BL41K3 cells were transfected by electroporation (Section 2.2.4.1). In all cases, cells 
were harvested 48 hours after transfection and activity of the bik promoter was then 
assessed using the luciferase assay. Luciferase activities which were normalised for 
transfection efficiency (based on β-galactosidase activity).   
 
Initially, in order to validate the promoter-reporter assay in another cellular context, 
pSG5EBNA2 and pSG5EBNA2ww323sr were used in a co-transfection experiment 
with bfl-1 promoter-reporter construct -1374/+81 Bfl-1 Luc. As before an increase in 
bfl-1 promoter activity occurred in response to addition of the EBNA2 expression 
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plasmid, while the CBF1-mutant pSG5EBNA2ww323sr failed to trans-activate the 
promoter (Figure 7.2.7A).  
 
A similar strategy to that just described for DG75 was then employed to investigate 
the effect of EBNA2 on bik promoter activity in the BL41K3 cell line. Again, EBNA2 
trans-activated the artificial CBF-1 responsive promoter in pGa981-6 reporter as 
reflected in an approximately 40-fold increase in luciferase activity (data not shown). 
As illustrated in Figure 7.2.7B, an obvious reduction in bik promoter activity was 
observed in response to addition of the EBNA2 expression plasmid. Furthermore, a 
decrease in promoter activity was also observed in response to the CBF1 non-binding 
EBNA2 mutant vector, comparable to that seen using pSG5EBNA2. Thus, the ability 
of EBNA2 to bind CBF1 does not appear essential for EBNA2-mediated repression of 
the bik promoter in BL41K3. 
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Figure 7.2.7: EB+A2 represses the bik promoter; repression does not require the 
EB+A2-CBF1 interaction. 
 
(A) BL41K3 cells were co-transfected by electroporation with wild type bfl-1 
promoter (–1374/+81-Luc) reporter construct, pCMVLacZ and either the EBNA2 
expression vector pSG5EBNA2 or pSG5EBNA2ww323sr. The total quantity of 
transfected plasmid was adjusted to 10µg with the empty vector pSG5. Cells were 
harvested 48 hours after transfection and luciferase and β-gal assays were performed. 
Normalised luciferase values were expressed relative to the corresponding value 
obtained for the –1374/+81-Luc reporter construct when co-transfected with control 
vector pSG5. The absolute luciferase values obtained for pSG5 and –1374/+81-Luc 
after transfection was set at 100. (B) BL41K3 cells were co-transfected by 
electroporation with bik promoter (–1710/+203-Luc) reporter construct, pCMVLacZ 
and the EBNA2 expression vector pSG5EBNA2 or pSG5EBNA2ww323sr. The total 
quantity of transfected plasmid was adjusted to 10µg with the empty vector pSG5. 
Cells were harvested 48 hours after transfection and luciferase and β-gal assays were 
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performed. Normalised luciferase values were expressed relative to the corresponding 
value obtained for the -1710/+203-Luc-bik reporter construct when co-transfected 
with control vector pSG5. The absolute luciferase values obtained for pSG5 and -
1710/+203-Luc-bik after transfection was set at 100. (Data are Mean ±SD). 
 
 
The influence of EBNA2 expression on bik promoter activity was also examined in 
BL41K3, which although EBV negative, does expresses an inactive ER/EBNA2. 
BL41K3 cells were transiently transfected with the –1710/+203-bik-Luc as before. 
After transfection the cells were cultured in the presence of 1µM estrogen, and cells 
were harvested after 48 hours. A control transfection, in which the EBNA2 expression 
vector was co-transfected with the bik promoter and cells were incubated in the 
absence of estrogen was also performed. As can be seen in Figure 7.2.8, transient co-
transfection with pSG5EBNA2 led to approximately 70% reduction bik promoter 
activity. Significantly less promoter repression was observed due to the effect of 
ER/EBNA2, where bik promoter activity was reduced by approximately 30% (Figure 
7.2.8) upon addition of estrogen to the medium.  This might reflect the limited 
quantity of ER/EBNA2 molecules available in comparison to the quantity of EBNA2 
expressed from co-transfected pSG5EBNA2. These results are evidence of a role for 
EBNA2 in repression on the bik promoter in the BL41 background.  
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Figure 7.2.8: Repression of the bik promoter in response to EB+A2 activation by 
estrogen in BL41K3.  
BL41K3 cells were transiently co-transfected by electroporation with the wild type 
bik promoter (–1710/+203-Luc) reporter construct and pCMVLacZ. A co-transfection 
with EBNA2 expression vector pSG5EBNA2 and the bik promoter was also 
undertaken. The total quantity of transfected plasmid was adjusted to 10µg with the 
empty vector pSG5. Cells were induced to express ER/EBNA2 by the addition of 
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1µM estrogen to the cell culture medium and harvested 48 hours after transfection, 
luciferase and β-gal assays were performed as before. Normalised luciferase values 
were expressed relative to the corresponding value obtained for the -1710/+203-Luc-
bik reporter construct when cultivated in the absence of estrogen. The absolute 
luciferase values obtained for -1710/+203-Luc-bik after transfection was set at 100. 
(Data are Mean ±SD). 
  
 
The results obtained using the BL41K3 cell line were more consistent than those 
obtained in DG75, and undoubtedly EBNA2 down-regulates the bik promoter in this 
cell context. For this reason, DG75 cells were not used in any further EBNA2-related 
promoter co-transfection experiments in this study. However, it should be noted that 
the level of repression observed in BL41K3 varied considerably, ranging from 88%-
18% reduction in promoter activity (Table 7.2-2).  
 
Table 7.2-2: Summary of bik promoter transfections in BL41K3 
 
Transfection Luc Activity in response to 
EB+A2 
1 82% 
2 67% 
3 61.5% 
4 54% 
5 50% 
6 30.4% 
7 23% 
8 20% 
9 12% 
 
 
The summation of these results is clear, while there is the observation that the level of 
repression varies considerably, nevertheless, EBNA2 consistently represses the 
activity of the bik reporter construct in transfections using BL41K3.   
 
7.2.5 Generation of promoter deletion constructs -855/+203 bik Luc and -
191/+203 bik Luc. 
 
In order to delineate the DNA sequence elements that mediate down-regulation by 
EBNA2 it was initially important to examine the sequence of the bik promoter for 
putative transcription factor binding sites that may be relevant to this study.  
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7.2.5.1 Putative CBF1 and Ets-family transcription factor binding sites exist on 
the bik promoter sequence. 
 
To identify possible regions of regulatory significance on the bik promoter, the 
upstream sequences were analysed for putative transcription factor binding sites using 
the MatInspector search tool on the transfac database (http://www.genomatix.de/) in 
combination with Transcription Element Search Software (TESS) available on the 
BCM Search Launcher website (http://dot.imgen.bcm.tmc.edu/) (Table 2.1-6). 
Examination of the –1710 to +203 region of the promoter region revealed putative 
transcription factor binding sites for a number of transcription factors including 
transcription factors such as GATA-1, Oct-1, Sp1 and NF-kB as has been previously 
reported (Verma et al, 2000). As discussed in Chapter 1 EBNA2 has no inherent 
DNA-binding activity, but it can associate with EBNA2-responsive promoters 
through contact with multiple cellular factors including CBF1, PU.1 and CBP  
(Zimber-Strobl et al, 1993; Henkel et al, 1994; Laux et al, 1994a; Ling et al, 1994; 
Waltzer et al, 1994; Johannsen et al, 1995; Wang et al, 2000; Pegman et al, 2006).  
 
Of interest to this study, analysis of the sequence indicated that the promoter 
contained the sequence motif gaggTGGGaagaaca at position –871 to –895 (Figure 
7.2.9). This sequence has previously been found in many EBNA2-responsive 
promoters that have been characterised to date, and is part of the consensus binding 
sequence for CBF1 (CGTGGGAA; (Tun et al, 1994)). Further analysis of the 
promoter sequence, revealed additional ‘5-GGAA-3’ sites, which is the core sequence 
motif recognised as fundamental in binding of the Ets family of transcription factors 
(Karim et al, 1990). This sequence was identified in two separate regions; between –
968 and –984, and also between -1017 and -1033 on the promoter (Figure 7.2.9). 
Nucleotides adjacent to this core sequence serve to determine the binding specificity 
of the individual members of this family to the DNA and in this way the two sites 
were additionally designated putative Elk-1 (-1017 and -1033) and PU.1 (–968 and –
984) binding sites. Another potential EBNA2-related regulatory transcription factor 
binding site, CREB, was found in six places on the promoter, and there was also a 
consensus ATF/CRE site between -314 and -294. There were 14 potential Myc- 
related binding sites spread throughout the 1.9kb sequence (Figure 7.2.9), although 
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this is not surprising since Myc is a central transcriptional hub in growth and 
proliferation control. Indeed, it is thought that Myc could regulate up to 10–15% of all 
genes, occupying 4,296 genomic loci in B-cells (Zeller et al, 2006) 
 
 
 
 
 
 
Figure 7.2.9: Schematic representation of the bik promoter fragment under study 
indicating possible transcription factor binding sites.  
 
The region of the bik-Luc promoter from position -1710 to +203 relative to the 
transcription start site is illustrated on the schematic diagram. Transcription Element 
Search Software from the Transfac database and from the BCM Search Launcher 
website, revealed putative transcription factor binding sites for a number of relevant 
transcription factors including potential binding sites for various transcription factors 
such ATF/CRE (-314 and -294), CBF1/RBPJκ (–871 to –895), Ets (–968 and –984, 
and also between -1017 and 1033) and CREB  (-1395 and -1375, -1165 and -1145, -
569 and -549, -418 and -398, -281 and -261 and between -136 and -116). The 
locations of putative RBP-Jĸ/CBF1 (orange), Ets (green) transcription factor binding 
sites and others are indicated in the legend. There were 14 potential Myc- related 
binding sites spread throughout the promoter.   
 
7.2.5.2 Cloning of the 5’ progressive deletion fragments -855/+203-bik Luc             
and -191/+203-bik Luc.  
 
Hence, two further bik-luciferase constructs containing progressive deletions from the 
5’ end of the promoter were developed for use in transient transfection assays. Two 
distinct regions were nominated for examination, (1) the region upstream of –855 
eliminating the putative CBF1 binding site, two potential CREB sites and both 
potential Ets binding sites, and (2) the area upstream of –191, thus abolishing the 
potential for binding to most of the relevant transcription factor sites, including 
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ATF/CRE, CBF1, and Ets. The area downstream of -191 harbours one consensus 
CREB site and several possible Myc binding sites.   
 
Since the -1710/+203-bik Luc reporter construct had already been generated (Section 
7.2.1) it was decided to generate the series of bik promoter-luciferase reporter 
constructs to compliment this –1710/+203 promoter. The –855/+203 and -191/+203 
regions of the bik promoter fused to the luciferase gene were thus derived from the -
1710/+203-bik-Luc construct using a similiar approach to that employed in the 
derivation of the p-1710/+203-bik-Luc construct (Figure 7.2.2).   
 
The individual promoter deletion fragments were generated by restriction digestion 
targeted to specific regions of the promoter. Briefly, the 2 truncated promoter regions 
were excised from -1710/+203-bik-Luc by double digestion using Kpn I and Bgl II in 
the case of p-855/+203 bik Luc and Sac I and Bgl II in the case of pGL2-191/+203 bik 
Luc. Prior to ligation, the pGL2-Basic plasmid was linearised by digestion with Kpn I 
and Bgl II (for ligation to the Kpn I-Bgl II bik-promoter fragment), and Sac I and Bgl 
II (for ligation to the Sac I- Bgl II bik-promoter fragment), followed by 
dephosphorylation using CIP to prevent recircularisation of the linearised DNA 
(Section 2.2.1.4). The linearised, CIP-treated DNA was then purified by phenol: 
chloroform extraction followed by ethanol precipitation (Section 2.2.1.2). The Kpn I-
Bgl II and Sac I- Bgl II fragments were subsequently purified using the Promega 
Wizard
® 
DNA purification system (Section 2.2.1.6) and the digested, purified product 
was then sub-cloned into the Kpn I and Bgl II sites and Sac I and Bgl II sites of pGL2-
basic respectively.   Ligations of vector and insert DNA were carried out overnight at 
16 ˚C (Section 2.2.1.7). 
 
Following the ligation reaction, competent E. coli JM109 cells were transformed with 
the recombinant plasmid DNA (Section 2.2.1.9). Single colonies were used to 
inoculate cultures from which DNA mini-preparations were prepared. Restriction 
digestion analysis was performed on the DNA to monitor for the presence of insert 
DNA using Hind III and Sma I restriction enzymes (Figure 7.2.10). Once it was 
established that the two reporter plasmids contained the –855/+203 region and –
191/+203 region of the human bik promoter cloned just upstream of the luciferase 
gene in pGL2-basic, DNA maxi-preparations were carried out using the Qiagen
®
 Midi 
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Kit (Section 2.2.1.12) and these constructs were then used in transient co-transfection 
assays of BL-derived cell lines. A schematic representation of the luciferase reporter 
gene constructs driven by various regions of the bik promoter is shown in Figure 
7.2.11A. Agarose gel electrophoresis confirmed the quality of the bik-promoter-
luciferase constructs used in transfection studies (Figure 7.2.11B). 
 
 
 
Figure 7.2.10: Generation of the bik-luc Promoter Reporter Constructs, -
855/+203 bik Luc, and -191/+203 bik Luc. 
 
(A) Restriction analysis of recombinant p-855/+203-bik-Luc and p-191/+203-bik-Luc 
clones by digestion using Hind III enzyme followed by agarose gel electrophoresis on 
a 1% agarose-1X TAE gel at 100V for 1 hour. Lanes 2-10 illustrate analysis of 
potential -855/+203 bik Luc recombinant clones. Lanes 11-19 show DNA from 
putative p-191/+203-bik-Luc recombinant clones. A 100bp ladder and a 1Kb ladder 
are shown in lanes 1 and 20 respectively. Digestion of positive p-855/+203-bik-Luc 
clones with Hind III resulted in 5 bands at 5563bp, 558bp, 277bp, 142bp and 91bp 
(lanes 4,5,7,8 and 10, band at 91bp to faint to discern). Restriction digestion analysis 
of positive p-191/+203-bik-Luc yielded 2 fragments at 5969bp and 277bp (lanes 11-
19). (B)  Restriction digestion analysis comparing recombinant p-1710/+203-bik-Luc, 
p-855/+203-bik-Luc and p-191/+203-bik-Luc clones using Sma I. Restriction analysis 
of the promoter p-1710/+203-bik-Luc using Sma I yielded 5 fragments at 5601bp, 
1802bp, 51bp, 27bp and 17bp (lane 2, bands at 51bp, 27bp and 17bp to faint to 
discern) while Sma I digestion of -855/+203-bik-Luc resulted in 5 fragments at 
5601bp, 924bp, 51bp, 27bp and 17bp (lane 3, again bands at 51bp, 27bp and 17bp to 
faint to discern). Sma I digestion of the shortest promoter fragment p-191/+203-bik-
Luc resulted in 5 fragments, 5601bp, 260bp, 51bp, 27bp and 17bp (lane 4, bands at 
51bp, 27bp and 17bp to faint to discern). Agarose gel electrophoresis on a 1% 
agarose-1X TAE gel at 100V was carried out for 1 hour. A 1Kb DNA ladder is shown 
in lane 1 and a 100bp ladder is shown in lane 5.  
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Figure 7.2.11: 5’ progressive deletion bik-Luc promoter-reporter constructs.  
 
 (A) Schematic representation of the -1710/+203 region wild type bik promoter and 
the truncated promoter-reporter constructs. These constructs share a common 3’ 
terminus 203bp downstream from the transcription initiation site (designated by a 
bent arrow), at which point they are joined to the luciferase gene (Luc). (B) The 
condition and quality of the DNA was assessed by resolving the DNA by agarose gel 
electrophoresis. In this case 1µg of DNA from the pGL2-1710/+203-bik Luc (lane 2), 
pGL2-855/+203-bik Luc (lane 3), pGL2-191/+203-bik Luc (lane 4) and  pGL2-basic 
(lane 5) reporter plasmids are shown after electrophoresis at 100V for 1 hour through 
a 1% agarose gel using 1X TAE.  A 1kb ladder is shown in lane 1. 
 
7.2.6 Transfection experiments using the 5’progressive deletion bik 
promoter-reporter constructs. 
 
DG75 cells were transiently co-transfected with the bik-promoter-luciferase constructs 
and luciferase activity was measured 48 hours after transfection. Importantly, an 
equivalent number of reporter molecules of each of the individual constructs was 
transfected in each case, rather than the same concentration of DNA, in order to 
account for the size differences of the individual constructs. The total quantity of 
plasmid was adjusted in all cases to 2µg with the empty vector pSG5. As seen in 
Figure 7.2.12, the
 
level of luciferase activity fell as the promoter fragment was 
progressively deleted from the 5’ end. The difference between the activity of the 
longest promoter sequence (-1710/+203-bik-Luc) and the shorter fragments suggests 
that several sequence elements along the length of the promoter contribute to 
positively affect its activity. 
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Figure 7.2.12: Analysis of 5’ progressive deletion promoter- constructs in DG75 
 
DG75 cells were transiently co-transfected by electroporation with bik promoter (–
1710/+203-Luc) reporter construct or the promoter deletion constructs (-855/+203-
Luc /-191/+203-Luc) and pCMVLacZ. The total quantity of transfected plasmid was 
adjusted to 2µg with the empty vector pSG5. Cells were harvested 48 hours after 
transfection and luciferase and β-gal assays were performed. Normalised luciferase 
values were expressed relative to the corresponding value obtained for the -
1710/+203-Luc-bik reporter construct. The absolute luciferase value obtained for -
1710/+203-Luc-bik after transfection was set at 100. (Data are Mean ±SD) 
 
 
In EBV-infected cell lines EBNA2 is expressed and only low levels of bik mRNA are 
detectable (Chapter 3), and so low levels of bik promoter activity are to be expected. 
Thus, in order to examine the activity of the bik promoter in this background, AG876 
and IB4 were transiently co-transfected by electroporation with the bik-promoter-
luciferase constructs and luciferase activity was measured 48 hours after transfection. 
Again, an equivalent number of reporter molecules of each of the individual 
constructs was transfected in each case. The total quantity of transfected plasmid was 
adjusted in all cases to 2µg with the empty vector pSG5. As seen in Figure 7.2.13A 
and B, similar to what was seen in DG75, luciferase activity fell as the promoter 
fragment was progressively deleted from the 5’ end. However, the 
 
level of basal 
activity observed with the –855/+203-Luc-bik fragment was considerably different in 
both cell lines. The 191/+203-Luc-bik fragment was consistently
 
lower than the 
levels observed with the longer promoter construct, 1710/+203.  
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Figure 7.2.13: Analysis of 5’ progressive deletion constructs in AG876 and IB4 
 
IB4 (A) and AG876 (B) were transiently co-transfected by electroporation with bik 
promoter (–1710/+203-Luc) reporter construct or the promoter deletion constructs (-
855/+203-Luc /-191/+203-Luc) and pCMVLacZ. The total quantity of transfected 
plasmid was adjusted to 2µg with the empty vector pSG5. Cells were harvested 48 
hours after transfection and luciferase and β-gal assays were performed. Normalised 
luciferase values were expressed relative to the corresponding value obtained for the -
1710/+203-Luc-bik reporter construct. The absolute luciferase value obtained for -
1710/+203-Luc-bik after transfection was set at 100. (Data are Mean ±SD). 
 
 
In an attempt to directly investigate the effect of expression of EBNA2 on the 
transcriptional activity of the bik promoter fragments, a number of transient co-
transfection experiments were carried out in the BL41K3 and BJAB cell lines. As 
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shown in Figure 7.2.14A, EBNA2 expression in BL41K3 cells mediated a 30% 
reduction in transcription from the –1710/+203 region of the bik promoter, and 
analysis of 5' deletions of the promoter again revealed a gradual loss of activity, 
indicating the loss of elements that are necessary to promote gene transcription in this 
context. The repression effect by EBNA2 was lost upon deletion to
 
-855, indicating 
the possible deletion of elements conferring EBNA2 responsiveness within this region 
of the promoter.  Thus, these results indicate that sequence elements in the -1710 to -
855 region of the bik promoter may make a considerable contribution to promoter 
activity in this context. 
 
In contrast to this a different trend was observed when this experiment was performed 
in the BJAB cell line. The longest construct illustrated a 65% reduction in 
transcription from the bik promoter as a consequence of EBNA2 expression (Figure 
7.2.14B). Again the basal level of the bik promoter was greatly decreased by the 
removal of elements downstream of this region, but the suppressive effect of EBNA2 
on the bik promoter was still effective down to -855/+203. Therefore, the deletion of 
potential CBF1 and Ets binding sites from the
 
promoter did not prevent EBNA2-
mediated
 
activation in this experiment. EBNA2 expression however, failed to repress 
the shorter promoter fragment -191/+203 (Figure 7.2.14B). This result indicated that 
the region -855 to -191 may harbour a transcription factor binding site essential for 
EBNA2 associated bik repression and is inconsistent to what was found in BL41K3.   
 
 
Deletion analysis of the bik promoter revealed that removal of sequences containing 
several consensus DNA binding sequences did not affect EBNA2-mediated repression 
of the bik promoter in the same way between different cell lines. When comparing the 
constructs themselves in all three cell lines, irrespective of EBNA2 expression; it is 
clear that there is a gradual loss of promoter activity upon deletion down to –191, as 
was seen in IB4, AG876 previously, seemingly indicating the loss of elements that are 
important for promoter activity. Overall these results were inconclusive, and did not 
indicate the significance of any specific region within the bik promoter that be 
important in EBNA-associated bik repression. 
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Figure 7.2.14 : Analysis of promoter deletion constructs BL41K3 and BJAB  
 
BL41K3 (A) BJAB (B) were transiently co-transfected by electroporation with bik 
promoter (–1710/+203-Luc) reporter construct, the promoter deletion constructs (-
855/+203-Luc/-191/+203-Luc) or pGL2-basic (empty vector), pCMV LacZ and either 
the EBNA2 expression plasmid pSG5EBNA2 or the CBFI-deleted 
pSG5EBNA2ww323sr. The total quantity of transfected plasmid was adjusted to 
10µg with the empty vector pSG5. Cells were harvested 48 hours after transfection 
and luciferase and β-gal assays were performed. Normalised luciferase values were 
expressed relative to the corresponding value obtained for the -1710/+203-Luc-bik 
reporter construct when co-tranfected with the control vector pSG5. The absolute 
luciferase value obtained for -1710/+203-Luc-bik after transfection was set at 100. 
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7.2.7 Effect of c-MYC on bik promoter activity. 
 
 
Having established that c-Myc alone can down-regulate bik mRNA and protein levels 
in the P493-6 LCL, (Chapter 5), it was decided to determine if this down-regulation in 
the levels of bik mRNA was due to a decrease in the rate of transcription from the 
promoter of the bik gene in response to c-Myc and so the effect of expression of this 
cellular gene on the promoter activity of bik was also analysed.  For this reason, the 
effect of the c-Myc expression on the bik-promoter constructs was examined in the 
P493-6 cell line, where c-Myc function was induced by the removal of tetracycline 
from the cell culture medium (Section 2.2.2.3). P493-6 cells, which had been seeded 
in tetracycline supplemented medium (- c-Myc) for the previous 24 hours were 
transiently transfected with the –1710/+203-bik-Luc construct by electroporation. 
After transfection the cells were cultured in tetracycline-free medium. At 48 hours 
after transfection the cells were harvested and cell extracts were assayed for luciferase 
activity and β-gal as before. As seen in Figure 7.2.15, progressive deletion of the –
1710/+203 region of the bik promoter to position –191 revealed a gradual loss of the 
basal activity of the promoter. This data indicates that cis-elements located between -
1710 and -855 are important in bik promoter activity in these cells which are driven 
into proliferation due to the c-myc gene (Pajic et al, 2001). 
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Figure 7.2.15: P493-6 Myc transfections 
 
P493-6 cells were transiently co-transfected by electroporation with bik promoter (–
1710/+203-Luc) reporter construct, the promoter deletion constructs (-855/+203-Luc/-
191/+203-Luc) or pGL2-basic (empty vector) and pCMV LacZ. Cells were induced to 
express c-Myc by removal of tetracycline from the cell culture medium. The total 
quantity of transfected plasmid was adjusted to 2µg with the empty vector pSG5. 
Cells were harvested 48 hours after transfection and luciferase and β-gal assays were 
performed. Normalised luciferase values were expressed relative to the corresponding 
value obtained for the -1710/+203-Luc-bik reporter construct. The absolute luciferase 
value obtained for -1710/+203-Luc-bik after transfection was set at 100. (Data are 
Mean ±SD). 
 
 
Thus, in an attempt to directly investigate the effect of expression of c-Myc 
expression on the activity of the bik promoter a number co-transfection experiments 
were carried out using the bik promoter (–1710/+203-Luc) reporter construct, the 
promoter deletion constructs (-855/+203-Luc/-191/+203-Luc) or pGL2-basic (empty 
vector), pCMV LacZ and various quantities (0µg, 3µg, 5µg and 7µg) of the c-Myc 
expression plasmid pcDNA3-HA-Myc (Table 2.1-4) in the BL41K3, BJAB and DG75 
cell lines. Bik promoter activity was then analysed using the luciferase assay as 
before. However, results obtained from these experiments were highly inconsistent; c-
Myc failed to consistently show direct trans-repression by c-Myc in any cell line (data 
not shown).  These results indicate that under these conditions, c-Myc may have no 
role in the regulation of transcription initiated from the bik promoter in question and 
that transcriptional regulation of bik by c-Myc is potentially mediated by far upstream 
or downstream/intronic regulatory elements, or by changes in RNA stability. 
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A number of co-transfection experiments involving both EBNA2 and c-Myc together 
with the –1710/+203-Luc bik promoter reporter construct were undertaken in the 
BL41K3 cell line in order to determine if there was a synergistic effect on bik 
promoter activity when both proteins were expressed together. However the 
expression of these proteins did not consistently repress the bik promoter, and the 
results obtained were also inconclusive (data not shown). 
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7.3 R+A Stability 
 
mRNA stability plays a major role in gene expression, affecting the rates at which 
mRNAs disappear following transcriptional repression and at which they accumulate 
following transcriptional induction. The abundance of a particular mRNA can 
fluctuate several fold following a change in the mRNA half-life (Ross, 1995). 
Investigations into the mechanism of up-regulation of bfl-1 mRNA levels by LMP-1 
in the laboratory revealed the importance of a role for both mRNA stabilisation and 
increased promoter activity (D'Souza et al, 2000; D'Souza et al, 2004). The observed 
decrease in the levels of bik mRNA upon activation of EBNA2 could also be 
attributable to the altered stability of previously transcribed mRNA. It was therefore 
of interest to investigate if mRNA stability was a factor in regulating bik expression in 
B-cells in response to EBNA2 expression.  
7.3.1 The effect of Actinomycin D treatment on the levels of bik mR+A 
expression in response to EB+A2 in BL41K3. 
 
Accordingly then, BL41K3 was treated with an inhibitor of RNA polymerase II, 
actinomycin D, to block transcription and monitor the rate of decay of bik transcript in 
the presence and absence of EBNA2. It was initially important to establish an 
appropriate interval to ensure the activation of functional EBNA2, prior to the 
inhibition of transcription. Thus, in order to monitor EBNA2 induction following 
addition of estrogen, a time course was undertaken with the BL41K3 cell line 
cultivated in the presence of 1µM estrogen. Protein extracts were prepared at various 
time points over a 24 hour period, and the levels of EBNA2 expression were 
monitored by Western blotting. Changes in EBNA2 expression over time are shown 
in Figure 7.3.1.  
 
Western blot analysis confirmed that the activation of functional ER/EBNA2 
(indicated by a molecular weight shift) in BL41K3 cells had occurred as early as 2 
hours after the addition of estrogen to the cell culture medium. Hence actinomycin D 
was added in subsequent experiments two hours after the addition of estrogen.  
 
 266 
 
 
Figure 7.3.1: Western Blot analysis of induction of EB+A2 protein expression in 
the BL-derived cell line BL41K3.  
 
ER/EBNA2 was activated in BL41K3 cells by the addition of estrogen to the cell 
culture medium. Total protein was prepared at the indicated time points after 
induction, and was used in Western blot analysis. Binding of primary antibodies was 
detected using an anti-mouse conjugated alkaline phosphatase secondary antibody.  
 
In order to monitor the rate of decay of bik mRNA a time course experiment was 
performed in which BL41K3 cells were first seeded in the presence and absence of 
estrogen. Cells were washed twice with PBS and divided into medium supplemented 
with either 1µM estrogen or and equal volume of vehicle (ETOH) (Kempkes et al, 
1995a). Estrogen treated samples were run in parallel with a vehicle-treated control. 
After a two hour time interval, cells were then treated with 5µg/ml actinomycin D or 
an equal volume of second vehicle (DMSO). A control experiment in which BL41K3 
cells were cultivated in the presence of estrogen only was also performed. Total RNA 
was prepared at various time points over a 24 hour time period. RT reactions were 
carried out to generate cDNA, which was subsequently used in a QPCR assay to 
measure bik mRNA levels as before. mRNA levels of the endogenous control gene 
gapdh were also monitored, and the CT values for gapdh transcripts in the treated and 
untreated
 
RNA samples were used as a control, and results were normalised
 
to gapdh. 
Importantly, gapdh CT values indicated that
 
the quantity of mRNA reverse transcribed 
and potentially amplifiable
 
by PCR was similar in estrogen-treated and estrogen-
untreated
 
samples. 
   
Changes in bik mRNA levels due to EBNA2 and in the presence of actinomycin D 
over the 24 hour time course are shown in Figure 7.3.2. In the control experiment bik 
mRNA levels were seen to diminish over time in response to increasing levels of 
EBNA2 expression as previously established (Checkered boxes Figure 7.3.2; see also 
Chapter 4). In contrast to this, a significant increase in bik mRNA levels is seen in the 
 267 
actinomycin D treated cells after 12 hours, particularly in the presence of EBNA2 
(approximately 3-fold -EBNA2, 7-fold +EBNA2). Cells induced to express EBNA2 
showed an approximately 11-fold increase in bik transcript by 24 hours after treatment 
with actinomycin D, and in contrast to this bik mRNA levels had returned to a near 
basal level in the uninduced, actinomycin D treated cell pool by this time.   
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Figure 7.3.2: Investigation of bik R+A stability in response to induction of 
EB+A2 in BL41K3 cells.  
The Effect of EBNA on the stability of bik mRNA. Exponentially proliferating cells 
were exposed to β-estradiol (1µM), or vehicle for 2 hours. After this time, total 
cellular transcriptional activity was suppressed by Actinomycin D (5µg/ml). Total 
cellular RNA was then extracted at the indicated time points up to 24 hours. Amounts 
of the bik mRNA transcripts were determined by Taqman QPCR assay as before. 
(Data are Mean ±SD). 
 
In general, it is clear from these results that the degradation pathway for bik mRNA is 
different in the presence of EBNA2.  
 
 
 
 
 
R
e
la
ti
v
e 
Q
u
an
ti
ta
ti
o
n
b
ik
 268 
7.4 Investigation into the Epigenetic Regulation of Bik in EBV-
infected cell lines.  
Epigenetic alterations, chages that affect gene expression but not the gene sequence 
itself, have been widely implicated in the inactivation of tumour suppressor genes in 
human cancers (Jones and Laird, 1999). Epigenetic gene regulation involves 
methylation of cytosine residues in CpG islands and post-translational covalent 
modifications of the N-terminal residues of histones within the nucleosome. A tightly 
regulated relationship between DNA methylation and histone modifications 
guarantees the stability and integrity of the epigenetic programming. Aberrant 
expression of histone-modifying enzymes or DNA methyltransferases can result in 
deregulated gene expression, leading to the establishment of pathologic epigenetic 
alterations in human malignancies (Jones and Baylin, 2002; Zelent et al, 2005).  
Acetylation and deacetylation of histone proteins, DNA-binding transcription factors, 
nuclear hormone receptors and signal-transduction proteins, have critical roles in 
regulating gene expression. Aberrant protein acetylation stemming from 
misregulation of either histone acetyltransferases (HATs) or histone deacetylases 
(HDACs) has been linked to cancer and various neurological diseases (Di Prospero 
and Fischbeck, 2005; Drummond et al, 2005; Langley et al, 2005). HDAC inhibitors 
(HDACi) may revert silent heterochromatin to an active chromatin conformation and 
restore the normal function of genes that are silenced in these diseases
 
(Di Prospero 
and Fischbeck, 2005).  
Thus, histone modifications including acetylation and methylation can affect gene 
transcription forming interacting epigenetic networks that regulate gene expression 
(Fuks, 2005). The inhibition of histone-modifying enzymes and DNA 
methyltransferases might restore the expression profile of several genes that are 
implicated in tumourogenesis. Accordingly, two main groups of drugs have been 
developed for this purpose. The first group is comprised of substances that target the 
action of DNA methyltransferases (DNMTs), through either competing with cytosine 
or with S-adenosylmethionine (SAM, AdoMet) or acting over the DNMTs 
themselves, (including 5-azacytidine, (5-azaC), Doxorubicin and Zebularine). The 
second group involves compounds that inhibit subunits of the repressor complexes, 
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such as HDACs (including Sodium Butyrate (NaB), Trichostatin A (TSA), Apicidin, 
APHA Compound 8, (-)-Depudecin and suberoylanilide hydroxamic acid (SAHA)).  
It has been established in Chapter 3 that loss of Bik protein expression is a general 
feature of BL-derived cell lines exhibiting type III latency and in LCLs. In order to 
assess the possibility that epigenetic change might contribute to silencing of the bik 
gene during EBV infection the sequence of the bik promoter was initially examined to 
investigate the presence of CpG islands in order to give an indication of a potential 
role for methylation.  
7.4.1 A CpG islands is present on the bik promoter sequence. 
 
The identification of a CpG island on the bik promoter might indicate a potential role 
for methylation in bik promoter silencing in EBV-infected cells. To investigate the 
methylation status of the bik 5’ region by identifing possible CpG rich regions on the 
bik promoter, the upstream sequences were analysed for C+G content using ‘CpG 
island searcher’ software (http://cpgislands.usc.edu/cpg.aspx) (Table 2.1-6). A CpG 
island is generally accepted as a 200bp stretch of DNA with a C+G content of 50% 
and an observed CpG/expected CpG (ObsCpG/ExpCpG) ratio in excess of 0.6 (Gardiner-
Garden and Frommer, 1987). Examination of the –1710 to +203 region of the 
promoter region, revealed a CpG island from position –590bp to +203bp (52% GC, 
ObsCpG/ExpCpG 1.051, 793bp) of the bik promoter (Figure 7.4.1). Thus, the bik 5’ 
region is associated with CpG island as indicated by an elevated GC content in this 
region.  
 
 
 
Figure 7.4.1: Schematic representation of the bik promoter indicating a CpG 
island around the transcriptional start site.  
 
The region of the bik promoter from position -1710 to +203 relative to the 
transcription start site is illustrated on the schematic diagram. CpG island searcher, 
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revealed a CpG island from postition -590bp to +203bp (52% GC) on the promoter. 
The location of the CpG island is indicated by a blue line.  
 
This analysis indicates that bik contains a CpG island around its transcriptional start 
site, thus rendering it susceptible to control by methylation.   
 
7.4.2 Treatment of EBV-infected cell lines IB4 and AG876 with the D+MT 
Inhibitor, 5-azacytidine. does not lead to de-repression of bik. 
 
Initially, the pyrimidine analog 5-Azacytidine (5-azaC), a potent effector of decreased 
DNA methylation in mammalian cells, was employed. Cells are known to incorporate 
5-5-azaC into their DNA, forming covalent adducts with cellular DNMT1, thereby
 
depleting the cells from enzyme activity and causing demethylation
 
of genomic DNA 
as a secondary consequence (Christman, 2002). 
 
IB4 (EBV-positive LCL) and AG876 (EBV-positive Lat III) cells were treated with 5-
azaC at a range of concentrations (0.5µM to 1.5µM as determined from literature) or 
an equal volume of vehicle (acetic acid). Protein extracts were prepared at various 
time points after treatment and Bik protein expression was monitored by Western 
blotting (Section 2.2.4.3). Levels of the endogenous control, β-Actin, were also 
examined and confirmed equal loading in each case (Figure 7.4.2). A representation 
of the results is given in Figure 7.4.2. As can be seen from the results illustrated in 
Figure 7.4.2A and B, no significant increase in the level Bik protein could be detected 
upon treatment with this compound over the course of the experiment.   
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Figure 7.4.2: Western Blot analysis of Bik protein expression in response to 
induction of treatment with 5azaC in AG876 (A) and IB4 (B). 
 
(A) AG876 and (B) IB4 were treated with 1.5µM 5azaC or an equal volume of vehicle 
(acetic acid) and total protein was prepared at various time following treatment and 
used in Western blot analysis. The level of Bik protein expression was detected using 
a mouse anti-Bik antibody (BD Biosciences 557040). The upper panel illustrates the 
analysis of Bik protein expression in response to 5azaC treatment. The lower panel 
shows the same blot probed for β-Actin. Binding of primary antibodies was detected 
using an anti-mouse conjugated alkaline phosphatase secondary antibody in each 
case.  
 
Both
 
cell lines examined showed no evidence of bik promoter methylation after 
treatment. These results may suggest that promoter
 
methylation is not a mechanism of 
bik down-regulation
 
during the EBV growth programme.   
7.4.3 Treatment of EBV-infected cell lines with the HDAC Inhibitiors, 
Sodium Butyrate (+aB) and Trichostatin A (TSA). 
 
Induction
 
of apoptosis by HDACi has been shown to induce changes
 
in several of the 
pro-apoptotic and anti-apoptotic members of the Bcl-2 family, including Bcl-2, Bcl-
XL, Mcl-1, Bim, Bax, Bak, Bmf and Noxa
 
(Mandal and Kumar, 1996; Hague et al, 
1997; Cao et al, 2001; Zhang et al, 2004; Zhao et al, 2005; Zhang et al, 2006; Inoue 
et al, 2007), suggesting
 
that HDACi may induce apoptosis by altering the balance 
between
 
pro-apoptotic and anti-apoptotic proteins in the cell.  
 
In an attempt to assess whether histone modifications are involved in Bik silencing in 
EBV infected cell lines, two well-established HDACi were employed to examine the 
effects of histone deactylation on Bik expression in the EBV-infected cell lines 
AG876 and IB4. The first of these compounds was the naturally occurring fatty acid 
A B 
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Sodium Butyrate (Boffa et al, 1978; Candido et al, 1978; Sealy and Chalkley, 1978; 
Vidali et al, 1978) and the second, Trichostatin A (TSA) is a well-established 
inhibitor which leads to loss of structure of the heterochromatin compartment 
(Yoshida et al, 1990; Taddei et al, 2001). 
  
IB4 and AG876 cells were treated with a range of concentrations of these chemical 
inhibitors; either NaB (0.5mM to 1.5mM) or TSA (200ng/ml to 400ng/ml) 
(concentrations as determined from literature) or an equal volume of vehicle (cell 
culture medium/ETOH respectively). Protein extracts were prepared at various time 
points after treatment and Bik protein expression was monitored by Western blot as 
before (Section 2.2.4.3). Levels of the endogenous control, β-Actin, were also 
examined and confirmed equal loading of protein in each lane (Figure 7.4.3). A 
representation of the results is illustrated in Figure 7.4.3A and B and it can be seen 
that no significant increase in the level Bik protein could be detected with either 
compound over the course of the experiment.   
 
 
 
Figure 7.4.3: Western Blot analysis of Bik protein expression in response to 
induction of treatment with the HDACi Sodium Butyrate and 
Trichostatin A in AG876 (A) and IB4 (B).  
 
(A) AG876 cells were treated with 1.5mM NaB or an equal volume of vehicle (cell 
culture medium) and total protein was prepared at various time points after treatment 
and used in Western blot analysis. (B) AG876 and IB4 cells were treated with 
400ng/ml TSA or an equal volume of vehicle (ETOH) and total protein was prepared 
at the indicated time points and used in Western blot analysis. The level of Bik protein 
expression was detected using a mouse anti-Bik antibody (BD Biosciences 557040). 
The upper panel (A and B) illustrates the analysis of Bik protein expression in 
response to NaB treatment. The lower panel shows the same blot probed for β-Actin. 
A B 
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Binding of primary antibodies was detected using an anti-mouse conjugated alkaline 
phosphatase secondary antibody in each case.  
 
Thus, neither of the HDACi tested affected the level of Bik protein expression in 
either of the cell lines examined. Although, the effects of the HDACi were assessed at 
a range of concentrations; there was no apparent correlation between HDAC 
inhibition and the activity of bik. It may be that the acetylation status and chromatin 
structure of the bik gene are unlikely to be dominant regulators of transcription in this 
context. 
It is clear from the results presented here, that neither of the HDACi investigated, nor 
the DNMT inhibitor, had any effect on the level of bik expression in this context. 
 
7.4.4 The HDAC inhibitor, Trichostatin A inhibits ER/EB+A2 activation 
and the expression of plasmid encoded EB+A2. 
 
In order to investigate if TSA was capable of directly regulating the expression of 
ER/EBNA2-mediated Bik repression the levels of Bik protein in ER/EBNA2-induced 
BJABK3 cells were examined after treatment TSA. ER/EBNA2 was induced over an 
84 hour time period in the BJABK3 cell line, by the addition of estrogen to the cell 
culture medium. Treated cells were immediately divided, into medium supplemented 
with either 200ng/ml TSA, or an equal volume of vehicle (ETOH). Total protein was 
prepared from cells harvested at various time-points after ER/EBNA2 induction, 
(Figure 7.4.4) and subsequently used in Western blot analyses for ER-EBNA2, Bik 
and c-Myc (Figure 7.4.4). Levels of the endogenous control, β-Actin, were also 
examined and confirmed equal loading in each case (Figure 7.4.4). In the control 
experiment, (in which estrogen-induced cells were incubated in the presence of 
vehicle), the activation of functional ER/EBNA2 (indicated by a molecular weight 
shift) was confirmed, and can be seen at 24 hours after induction (Figure 7.4.4). 
ER/EBNA2 remained detectable for up to 84 hours (Figure 7.4.4). A significant 
decrease in the level of Bik protein can be seen to coincide with the induction of 
ER/EBNA2 activation over the course of the experiment, confirming Bik down-
regulation in response to ER/EBNA2 induction as previously established.
 
c-Myc 
expression was transiently up-regulated at 24 hours in response to
 
ER/EBNA2 
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expression after which time, the levels of c-Myc protein returned to the pre-induction 
level of expression.  
 
However, TSA inhibited the activation of ER/EBNA2 (Figure 7.4.4). ER/EBNA2 is a 
fusion protein of an apparent molecular weight of 120kDa in contrast to the 86kDa 
protein of wild type EBNA2 (Kempkes et al, 1995a). Addition of estrogen activates 
the function of ER/EBNA2, and affects the electrophoretic mobility of the 
ER/EBNA2 fusion protein. While an initial activation of ER/EBNA2 is apparent at 24 
hours, the levels induced are low relative to the control experiment and by 48 hours, 
only non-functional EBNA2 is detectable. Thus, TSA does not inhibit the basal level 
of ER/EBNA2, rather it appears to interfere with its ability to retain bound estrogen, 
the loss of which is reflected in the inability of ER/EBNA2 to positively regulate its 
own promoter. Accordingly, ER/EBNA2-mediated Bik repression is inhibited, and 
Bik levels remain unchanged over the course of the experiment. c-Myc protein levels 
are also unaffected and remain constant over the 84 hour time course.  
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Figure 7.4.4: Western Blot analysis of protein expression in response to 
treatment with the HDAC inhibitor TSA in BJABK3.  
 
BJABK3 cells were induced to express ER/EBNA2 by addition of estrogen to the cell 
culture medium and cells were immediately treated with the HDAC inhibitor TSA 
(200ng/ml). Total protein was prepared at the indicated time points after induction 
and used in Western blot analysis. The level of Bik protein expression was detected 
using a goat anti-Bik antibody (Santa Cruz, sc-1710). Analysis of ER/EBNA2 
induction is shown in the upper panel. c-Myc protein expression is illustrated in the 
second panel. Western blot analysis of EBNA2-mediated Bik protein repression in the 
presence of TSA treatment is illustrated in the third panel. The lower panel shows the 
same blot probed for β-Actin. Binding of primary antibodies was detected using an 
anti-mouse conjugated alkaline phosphatase secondary antibody in the case of 
EBNA2, c-Myc and β-Actin and an anti-goat conjugated horseradish peroxidase 
secondary in the case of Bik. 
  
 
Having established that the HDAC inhibitor, TSA, inhibits the activity of ER/EBNA2 
in the BJABK3 cell line, and in an attempt to establish a suitable context to 
investigate the effect of the methylation inhibitor on EBNA2-associated bik 
repression, it was next decided to do a similar experiment using the DG75-tTA-
EBNA2 cell line, in which EBNA2 expression is not under EBNA2 control, rather its 
expression is driven by a heterologous promoter. 
 
Accordingly, EBNA2 was induced over a 72 hour time period in the DG75-tTA-
EBNA2 cell line, by the removal of tetracycline from the cell culture medium as 
before (Chapter 4). Cells were immediately divided, either into medium supplemented 
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with 200ng/ml TSA, or an equal volume of vehicle (ETOH). Total protein was 
prepared from cells harvested at various time-points after EBNA2 induction, (Figure 
7.4.5) and used in Western blot analysis (Figure 7.4.5).  
 
In the control experiment, EBNA2 was detected 24 hours after induction and 
remained detectable up to 72 hours over the entire course of the experiment (Figure 
7.4.5). However, it can be seen that EBNA2 expression was completely inhibited in 
the presence of TSA and was not detected at any point over the 72 hours.  
 
 
Figure 7.4.5: Western Blot analysis of EB+A2 protein expression in response to 
treatment with the HDAC inhibitor TSA in the BL-derived cell 
line DG75-tTA-EB+A2.  
 
EBNA2 was induced in DG75-tTA-EBNA2 cells by removal of tetracycline from the 
cell culture medium. Cells were immdediately divided and treated with TSA or an 
equal volume of vehicle (ETOH). Total protein was prepared at the indicated time 
points after induction, and was used in Western blot analysis. Western Blot analysis 
of EBNA2 protein expression in response to TSA treatment was monitored. Binding 
of primary antibody was detected using an anti-mouse conjugated alkaline 
phosphatase secondary antibody.  
 
These results were unexpected and they indicate that expression/activation of 
exogenous EBNA2 from both ER/EBNA2 expressed in the BJABK3 cell line and 
wild type EBNA2 expressed in DG75-tTA-EBNA2 was inhibited in the presence of 
TSA. This experiment revealed a novel affect of TSA, as it appears that EBNA2 
expression/activation is potently inhibited by this histone deacetylase inhibitor in 
these BL-derived cell lines. TSA is known to modulate gene expression, and, since it 
is a well-established inhibitor of histone deacetylases, a likely mechanism of this 
effect is the alteration by TSA of chromatin conformation through hyperacetylation of 
histones. The data presented thus suggests that the inhibition of expression/activation 
of exogenous EBNA2 by TSA in these engineered cells is linked to its ability to 
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inhibit HDAC activity thus suggesting a correlation between the acetylation status of 
histones and EBNA2 expression. Although chromatin reorganisation due to histone 
hyperacetylation generally correlates positively with gene activation, there are some 
examples in which histone acetylation has been associated with gene repression 
(Turner et al, 1992; De Rubertis et al, 1996; Braunstein et al, 1996). There is also an 
increasing appreciation of the fact that TSA may act through mechanisms other than 
induction of histone acetylation. Indeed, experimental data has indicated that TSA 
activates PI3K/AKT signaling (Eickhoff et al, 2000). In addition to this, inhibition of 
protein kinase C abrogates TSA mediated up-regulation of NFκB transcriptional 
activity and p21 expression that is associated with apoptosis (Maxhimer et al, 2005). 
 
Thus, it was not possible to examine the effects of TSA on EBNA2 associated bik 
repression using either of these two different expression systems. 
 
Overall, the results presented here give a preliminary indication that under these 
conditions, EBV-mediated repression of the bik gene occurs by a mechanism that 
does not involve either of the well known epigenomic mechanisms, DNA methylation 
or histone acetylation.  
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7.5 Investigation into a possible role for Proteasomal degradation in 
the regulation of Bik protein. 
 
Since it has been reported that Bik can be degraded by the proteasome pathway, it was 
of interest to investigate if the proteasomal
 
degradation of bik prevents EBV-infected 
cells from succumbing to bik-dependent
 
apoptosis. Changes in total Bik levels were 
monitored upon proteasome inhibitor treatment in two EBV positive cell lines. A 
direct a role for proteasome-mediated protein degradation during EBNA2-associated 
regulation of bik was also investigated. 
7.5.1 Effect of proteasome inhibition on Bik expression in EBV-infected 
cell lines 
 
Accordingly IB4 and AG876 cells were treated with 10µM MG132 or an equal 
volume of vehicle (DMSO) and protein extracts were prepared at various time points 
after treatment. The levels of Bik, p53 and β-Actin proteins expressed were analysed 
by Western blotting (Section 2.2.4.3). Initially, in order to test the effect of 
proteasome inhibition, the membrane was probed with antibodies against p53, a short-
lived
 
protein degraded through the proteasome pathway (Kubbutat et al, 1997). 
Western blotting was also undertaken to analyse Bik protein levels in response to 
MG132 treatment (Figure 7.5.1) and levels of the endogenous control, β-Actin, were 
analysed in order to confirm equal quantity loading in each case (Figure 7.5.1A, lower 
panel).  In this experiment, p53 was detected in MG132 and DMSO-treated cells at 0 
hours and remained detectable up to 72 hours. An increase in p53 protein expression 
was observed in both IB4 and AG876 cells and can be seen to coincide with MG132 
treatment in a time-dependent manner (Figure 7.5.1) Thus, MG132 treatment led to 
the accumulation of
 
wild-type p53 in IB4 and AG876 cells in accordance with 
previously
 
published data (Kubbutat et al, 1997). In DMSO-treated cells the levels of 
p53 expression remained constant over the course of the experiment.  As can be seen 
in Figure 7.5.1A and B, Bik was hardly detectable in cells at 0 hours after treatment 
and levels remained unchanged after treatment of either IB4 or AG876 cells with 
MG132. Unlike p53, the failure of Bik to accumulate in the presence of the 
proteasomal inhibitor argues that the proteasomal degradation of Bik does not play a 
significant role in maintaining low Bik levels in these EBV-infected B-cell lines.  
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Figure 7.5.1: Western Blot analysis of Bik protein expression in response to 
treatment with the proteasome inhibitor MG132 in the EBV-
infected cell lines IB4 (A) and AG876 (B).  
 
Western blot of DMSO- or MG132-treated IB4 (A) and AG876 (B) cells. Cells were 
treated with 10µM MG132 or an equal volume of vehicle (DMSO) and total protein 
was prepared at various time points after treatment and used in Western blot analysis. 
The level of Bik protein expression was detected using a mouse anti-Bik antibody 
(BD Biosciences 557040). Bik protein expression in response to MG132 treatment 
was monitored. Analysis of p53 level is shown in the upper panel. Western blot 
analysis of Bik protein expression in response to MG132 treatment is illustrated in the 
middle panel. The lower panel shows the same blot probed for β-Actin. Binding of 
primary antibodies was detected using an anti-mouse conjugated alkaline phosphatase 
secondary antibody in each case.  
 
  
In a second experiment, P493-6 cells that had been previously cycling on the EBV 
growth programme, were washed four times with PBS and seeded in estrogen-free 
A 
B 
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medium and subsequently treated with 10µM MG132 or an equal volume of vehicle 
(DMSO). This was considered time 0.  Protein extracts were prepared at various time 
points following treatment. The levels of EBNA2, Bik and β-Actin protein expressed 
were monitored by Western blot analysis. Western blotting was used to demonstrate 
the inactivation of EBNA2 over the course of the experiment and to monitor Bik 
protein levels in response to EBNA2 repression in the presence of MG132 (Figure 
7.5.2). Levels of the endogenous control, β-Actin, were also examined and confirmed 
equal quantity loading in each case (Figure 7.5.2, lower panel). In this experiment, 
functional EBNA2 was detected at 0 hours after removal of estrogen from the culture 
medium. Subsequent to this time point only non-functional EBNA2 was detected in 
both the MG132 and the DMSO-treated cell pools (Figure 7.5.2). In the DMSO-
treated cells, a significant increase in the level of Bik protein can be seen to coincide 
with the removal of EBNA2 function over the course of the experiment as expected. 
Bik levels are induced in conjunction with EBNA2 repression by 48 hours, and 
remain up-regulated at the 72 and 96 hour time points (Figure 7.5.2). MG132 
treatment however inhibits the up-regulation of Bik protein in reponse to withdrawal 
of EBNA2 function. Indeed Bik de-repression is in fact strongly inhibited by 24 
hours, and remained suppressed over the 96 hour time course (Figure 7.5.2). 
 
 
 
Figure 7.5.2: Western Blot analysis of Bik protein repression in response to 
treatment with the proteasome inhibitor MG132 in P493-6.  
ER/EBNA2 function was repressed by removal of estrogen from the growth medium. 
Cells were treated with 10µM MG132 and total protein was prepared at the indicated 
time points after repression and used in Western blot analysis. The level of Bik 
protein expression was detected using a mouse anti-Bik antibody (BD Biosciences 
557040). EBNA2-associtaed Bik expression in response to MG132 treatment was 
monitored by Western Blot analysis. Analysis of ER/EBNA2 levels is indicated in the 
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upper panel. Western blot analysis of ER/EBNA2-regulated Bik protein repression in 
response to MG132 treatment is illustrated in the middle panel. The lower panel 
shows the same blot probed for β-Actin. Binding of primary antibodies was detected 
using an anti-mouse conjugated alkaline phosphatase secondary antibody in each 
case.  
 
Thus, decreased proteasomal turnover of Bik is not a significant contributory factor to 
Bik up-regulation following the loss of EBNA2 activity. Furthermore, inhibition of 
the proteasome inhibits the relief of repression due to the removal of EBNA2. This 
interesting and unexpected result could mean that (a) EBV may positively stimulate 
the turnover of Bik through an intermediary factor, such as c-Myc or IgM, which 
itself is subject to degradation by the proteasomal pathway or (b) MG132 may inhibit 
the turnover of a genetic repressor or a protease, thus retarding the re-emergence of 
Bik following the removal of EBNA2.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 282 
7.6 Discussion 
 
Overall, this study suggests that EBNA2 may down-regulate expression of bik gene 
by decreasing transcription from the bik promoter and that this down-regulation is 
independent of the EBNA2-CBF1 interaction. It is not clear as to why co-
transfections using EBNA2 and the bik promoter-luciferase construct, p-1710/+203-
bik-luc, failed to elicit a consistently similar EBNA2 response in DG75, although it is 
clear this effect was not an artefact specific to the assay, since responses from both the 
bfl-1 and 981-6 promoters were consistent and readily detectable in the same assay. 
Nevertheless, in 72% of assays carried out in DG75 cells, EBNA2-mediated down-
regulation of the bik promoter was evident. While there was the observation that the 
level of repression varied considerably, EBNA2 expression consistently repressed the 
bik promoter-reporter construct in BL41K3. The bik–Luc construct was repressed by 
EBNA2 in every instance in this context. 
 
The EBNA2 mutant pSG5EBNA2ww323sr which was
 
defective in CBF1-binding 
was found to reduce bik promoter activity to the same extent as wild type (wt) 
EBNA2 in these experiments. This finding adds additional credence to a role for 
EBNA2-mediated repression of the bik promoter, and also further corroborates results 
in Chapter 4, which showed transcriptional repression of bik in the ∆CBF1 cell line, 
SM296D3. The lack of CBF1 involvement in the interaction is of significance 
considering that many of the EBNA2-responsive promoters including those of several 
EBV latent genes and of the numerous cellular genes have all been shown to contain 
functional CBF1-binding motifs and to be targets of the EBNA2-CBF1 interaction 
(discussed in Chapter 1). Elsewhere, EBNA2-associated suppression of transcription 
of the immunoglobulin µ (IgM) gene has previously been shown to occur via a CBF1-
independent mechanism (Jochner et al, 1996; Maier et al, 2005), and thus is in 
agreement with the results presented here. To date, this is the only other indication of 
EBNA2-associated down-regulation of a cellular gene. Interestingly the c-myc gene 
has previously been shown to be only partially CBF1-dependent (Maier et al, 2005). 
 
EBNA2 is known to associate with several cellular factors in order to facilitate 
contact with EBNA2-responsive promoters. Experiments in the laboratory indicate a 
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potentially important role for Ets family members in the EBNA2-associated activation 
of the bfl-1 promoter (Pegman et al, 2006). Furthermore, EBNA2 mediated activation 
of LMP1 is facilitated by several factors including PU.1/Spi-1, a POU domain 
protein, an ATF/CRE element and the CREB-binding protein, CBP (Laux et al, 
1994a; Johannsen et al, 1995; Sjoblom et al, 1995; Sjoblom et al, 1998; Cahir-
McFarland et al, 2000). Furthermore, a CBF2 binding site adjacent to the CBF1 
binding site on the Cp promoter contributes to EBNA2 responsiveness in addition to 
the effect mediated by CBF1 (Ling et al, 1993a; Fuentes-Panana et al, 2000). 
Considering this, sequence analysis of the bik promoter, identified seven potential 
CREB binding motifs (including one consensus ATE/CRE motif) along the length of 
the -1710/+203bp promoter and also two putative Ets binding motifs which were 
located in close proximity to the consensus CBF1 binding site already identified. The 
identification of a number of putative Ets binding sites in close proximity to each 
other and proximal to the CBF1 consensus sequence on the bik promoter, is 
reminiscent of the EBNA2 responsive elements (E2RE) in other EBNA2 responsive 
promoters including bfl-1 and LMP1  (Johannsen et al, 1995; Pegman et al, 2006). It 
is possible that EBNA2 mediated repression of the bik promoter may require 
downstream targeting of the putative Ets sites identified on the bik promoter.  
 
At least four BH3-only genes are subject to transcriptional control, including 
harakiri/hrk/dp5 (Imaizumi et al, 1997; Inohara et al, 1997), noxa (Oda et al, 2000),  
puma/bbc3 (Han et al, 2001; Nakano and Vousden, 2001; Yu et al, 2001) and bim 
(Dijkers et al, 2000; Harris and Johnson, 2001; Putcha et al, 2001; Shinjyo et al, 
2001; Whitfield et al, 2001), and at least five are regulated by different post-
translational mechanisms, including bad (Zha et al, 1996; del Peso et al, 1997), bid 
(Zha et al, 2000), bik (Verma et al, 2001), bim (Puthalakath et al, 1999) and bmf 
(Puthalakath et al, 2001). 
 
Analysis of 5' deletions of the bik promoter revealed that removal of sequences 
containing several consensus DNA binding sequences did not affect EBNA2-
mediated repression of the bik promoter consistently. These results were inconclusive, 
and did not indicate the significance of any specific region within the bik promoter. 
Hence, with this type
 
of analysis, it was impossible to assign the sequences involved
 
in EBNA2-mediated repression more precisely. When comparing the constructs 
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themselves, irrespective of EBNA2 expression; it is clear that there is an incremental 
loss of promoter activity with deletion down to –191bp upstream of the transcription 
start site, seemingly indicating the loss of elements that are necessary to promote gene 
transcription in this context.  
 
Although both EBNA2 and c-Myc can independently down-regulate bik transcription, 
and EBNA2 can repress transcription from the bik promoter, EBNA2 and c-Myc do 
not co-operate to down-regulate the transcriptional activity of the bik promoter 
fragment under study nor is there an apparent independent role for c-Myc in this 
regard. Although it has been reported that the majority of genomic loci occupied by c-
Myc in B-cells are located in proximal promoter regions (Zeller et al, 2006) 
regulation of bik by c-Myc may be mediated by far upstream or downstream/intronic 
regulatory elements, or alternatively by changes in RNA stability. It is also 
conceivable that c-Myc indirectly influences bik gene expression. Indeed 
transcriptional control of bik mediated independently of promoter regulation has 
previously been reported. In a recent study in which bik mRNA levels were clearly 
up-regulated by p53, a direct stimulation of the bik promoter could not be detected, 
even though genomic sequence analysis identified several elements that exhibit 
homology to potential p53 response elements within -1700bp upstream of the 
transcriptional start site and within the 13kb intron 1 of the bik gene (Mathai et al, 
2002). In addition, EBNA2-mediated repression of the bik promoter is not potentiated 
by EBNA-LP in DG75.  
 
Limited studies examining the regulation of the bik promoter have been published to 
date. The earliest of these (Verma et al, 2000) was the first to identify the 1.9 kb 
promoter region of the bik gene and to establish the minimal bik promoter region, 
localised to a region between −211 to +153bp flanking the transcriptional start site. 
Since this, it has also been established that DNMT1 knockdown induces the 
expression of bik mRNA, without a change in the DNA
 
methylation state or a change 
in acetylation status and the effect is thought to be mediated by a Sp1 element on the 
promoter (Milutinovic et al, 2004). In a second report, the chemotherapeutic agent, 
adriamycin (doxorubicin), provoked an approximately 40-fold induction in bik mRNA 
in SHSY-5Y cancer cells and this effect was the result of transcriptional activation of 
the bik promoter by the E2F proteins; E2F1, E2F2 and E2F3 through a consensus 
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binding sequence for E2F on the bik gene promoter, 104bp upstream from the 
transcription start site (Real et al, 2006). Results presented in this chapter establish 
that EBNA2 has a role to play in the regulation of transcription from the bik promoter.
  
Since the observed decrease in the levels of bik mRNA upon activation of EBNA2 
could also be attributable to the stability of previously transcribed mRNA in the cell, 
it was therefore of interest to investigate if an altered mRNA stability was involved in 
the regulation bik expression in B-cells in response to EBNA2. The findings presented 
here indicate that actinomycin D, an inhibitor of DNA-dependent RNA synthesis, 
substantially increased the level of bik mRNA in the presence of EBNA2. 
Actinomycin D has been shown to increase the level of several mRNAs, a 
phenomenon termed "superinduction" (Thompson et al, 1966; Tomkins et al, 1972; 
Chatterjee et al, 1979). Since actinomycin D inhibits mRNA synthesis, it may 
obstruct the ability of a repressor molecule, (such as c-Myc) to down-regulate the 
expression of bik. Although a role for mRNA stabilisation in the regulation of the bik 
gene cannot be determined from the results presented here, it is clear that the 
degradation pathway for bik mRNA is different in the presence of EBNA2. Little is 
known about the role of RNA stability in the regulation of the bik gene. It has recently 
been established that the intracellular stability of bik mRNA is not affected during its 
induction by fulvestrant in MCF7 cells, and that fulvestrant induces bik mRNA in 
MCF7 cells primarily by enhancing
 
transcription through cis-elements located outside 
the
 
2.0kb proximal promoter (Hur et al, 2006).  
 
The genomic organisation of bik reveals that it has an unusually long 5′ untranslated 
(UTR) sequence in exon 1 (Verma et al, 2000). In this regard, the structure of the bik 
gene resembles that of the anti-apoptotic bcl-2 proto-oncogene in which the first exon 
is also untranslated (Seto et al, 1988). Interestingly numerous reports have indicated a 
role for mRNA in bcl-2 regulation (Bevilacqua et al, 2003; Donnini et al, 2004; Lee 
et al, 2004; Otake et al, 2004; Otake et al, 2005). Two separate degradation systems 
have been revealed to play a key role in the regulation of the half life of mammalian
 
mRNAs; deadenylation decapping-mediated decay (Gao et al, 2001; Bail and 
Kiledjian, 2006); and decay mediated
 
by the ARE motifs (Guhaniyogi and Brewer, 
2001; Raijmakers et al, 2004). Both mechanisms, require specific motifs for 
degradation
 
and these are frequently
 
situated in the 3'-UTR and 5'-UTR (Hughes, 
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2006). Indeed, several oncogenes, tumour suppressors and other genes associated with 
cell proliferation have been found to express atypically long and complex 5’ UTRs 
that frequently contain regulatory elements (Hughes, 2006). Thus, the presence of 
unusually long UTR in these bcl-2 family members may indicate a role in regulation. 
Of note, it has recently been reported that cytokines direct the regulation of the BH3-
only bim gene through enhancing the stability of mRNA by the action of the heat-
shock cognate protein 70 (Hsc70) (Matsui et al, 2007) and furthermore, investigations 
into the mechanism of up-regulation of bfl-1 mRNA levels by LMP-1 in our 
laboratory revealed the importance of a role for both mRNA stabilisation and 
increased promoter activity (D'Souza et al, 2000; D'Souza et al, 2004). However in 
contrast to this, experiments in the laboratory have revealed no significant change in 
the stability of bfl-1 mRNA in response to EBNA2 induction (Pegman et al, 2006).  
 
Aberrant promoter methylation of tumor suppressor
 
genes is a common feature in 
human malignancies, and this fact has stimulated the development of
 
DNA 
methylation inhibitors as potential cancer therapies (Lyko and Brown, 2005).
 
Since
 
sequence analysis indicated the presence of a CpG island around the transcriptional 
start site of the bik promoter, it was thus hypothesised that the loss of bik
 
expression in 
EBV-infected cell lines might be due to methylation. However treatment with 5-azaC 
failed to lead to increased amounts of Bik protein in either AG876 or IB4 arguing that 
bik is not repressed by a methylation-dependent mechanism in this context. 
Histone deacetylase
 
inhibitors, such as trichostatin A (TSA) and sodium
 
butyrate 
(NaB), increase the level of histone acetylation in many
 
types of cells (Yoshida et al, 
1990; Yoshida et al, 1995; Monneret, 2005). The involvement of histone acetylation 
in the regulation of bik has been implied by the ability of sodium butyrate to induce 
the bik gene when added to the human hepatoma cell line, HuH-6 (Ogawa et al, 2004) 
(reviewed in Chapter 1). In order to test whether the bik promoter is actively repressed 
by a similar mechanism in EBV-infected cell lines, AG876 and IB4 cells were treated 
with the HDAC inhibitors, trichostatin A and Sodium Butyrate separately. Treatment 
with either molecule did not affect the steady-state level of Bik, arguing that the 
acetylation status and chromatin structure of the bik gene are unlikely to be dominant 
regulators of transcription in this cell context. 
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The effect of TSA on the expression of bik during EBNA2 induction was also 
investigated. Unlike sodium butyrate which elicits a broad range
 
of effects on cells, 
TSA is a highly specific, reversible inhibitor
 
of histone deacetylase. However, both 
the activation of ER/EBNA2 and the induction of EBNA2 from a tet-regulated 
heterologous promoter was inhibited in the presence of TSA and it was therefore not 
possible to examine the mechanism of EBNA2-mediated bik repression using the 
chosen cell lines.  
Treatment of IB4 and AG876 cells with the proteasome
 
inhibitor MG132 did not 
increase the level of Bik protein. Significantly, however, the up-regulation of bik 
during EBNA2 repression was strongly inhibited by MG132, suggesting an indirect 
role for the ubiquitin proteasome pathway in the EBV-associated modulation of the 
bik gene. While the possibility of an indirect role for the involvement of the 
proteasome in the degradation of Bik protein remains, a direct role for the 
involvement of the proteasome in the degradation of Bik could not be established 
from this data.  
 
It appears that inhibition of the proteasome inhibits the relief of repression due to the 
removal of EBNA2. Thus, EBV may positively stimulate the turnover of Bik through 
an intermediary factor, such as c-Myc or IgM, which itself is subject to degradation 
by the proteasomal pathway or alternatively MG132 may inhibit the turnover of a 
genetic repressor or a protease, thus inhibiting the re-emergence of Bik following the 
removal of EBNA2. This hypothesis is substantiated by the premise that EBNA2-
mediated Bik regulation may involve the modulation of IgM and/ or c-Myc as 
suggested in Chapters 4 and 5, and is further supported by the fact that both IgM and 
c-Myc are subject to degradation by the ubiquitin-proteasome pathway (Elkabetz et 
al, 2003; Mallette et al, 2007).  
  
The targeting of proteins for ubiquitin-dependent degradation is often controlled by 
phosphorylation or dephosphorylation of the
 
target protein (Musti et al, 1997; 
Weissman, 1997). In this regard, the proteasome pathway has been shown previously 
to be involved in the degradation of Bcl-2 following its phosphorylation (Breitschopf 
et al, 2000) and indeed, it has also been reported that in various cell types, including 
BL cell lines, BimEL
 
degradation is strictly dependent on the phosphorylation of 
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BimEL by ERK1/2 (Ley et al, 2003; Luciano et al, 2003; Mouhamad et al, 2004). It is 
plausible then, that in an EBV infected cell line EBNA2 expression mediates a 
conformational change in an intermediary factor, possibly by 
phosphorylation/dephosphorylation, and this facilitates its degradation by the 
proteasome. Thus, while EBNA2 is being expressed this molecule is constantly 
degraded. Upon removal of EBNA2 expression, the intermediary molecule maybe 
phosphorylated/dephosphorylated and thus become adverse to degradation by the 
proteasome. These observations suggest that the disappearance of Bik protein in Lat 
III cells may at least in part be an indirect effect of degradation by an MG132-
sensitive proteolytic activity in the infected cell.  
 
Taken together, the data presented here indicates that the mechanism by which 
EBNA2 represses bik is complex. The mechanism is primarily transcriptional, with 
the likelihood that a decrease in promoter activity is important, and that this repressive 
effect may be cell line-dependent. While, EBV-mediated bik repression may occur by 
a mechanism that does not involve either of the well known epigenomic mechanisms, 
DNA methylation or histone acetylation, observations suggest that the mechanism by 
which Bik protein is turned over is different in the presence of EBNA2.  It has been 
previously shown that the infection of BL cells with EBV results in a significant 
down-regulation in the expression of the BH3-only bim gene (Clybouw et al, 2005; 
Leao et al, 2007) and that bim expression and function are regulated at both 
transcriptional and post-translational levels in this context (Clybouw et al, 2005; 
Anderton et al, 2007). Therefore it seems that tight control of BH3-only gene 
expression by EBV is necessary and consequently complex. Regulation may occur on 
many levels, providing multiple means for the virus to keep these killer proteins in 
check. 
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General Discussion  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 290 
Many viruses exploit and manipulate the differentiation state of infected cells, 
promote or block cell cycling and make use of a variety of mechanisms to evade 
innate cellular anti-viral responses and encourage cell survival (Hayward, 2004). 
Since apoptosis is regulated by functional pro-apoptotic and anti-apoptotic proteins, it 
is not surprising that EBV controls the cellular response to apoptosis by regulating 
both pro- and anti-apoptotic
 
genes and their products. EBV immortalises B-cells in 
culture to generate continually proliferating B lymphoblastoid cell lines. EBNA2, 
EBNA3A and EBNA3C are essential for this process, as is LMP1 (Kieff, 1996). 
LMP1 is the viral protein predominantly responsible for the promotion of cell survival 
through activation of NF-κB, Bcl-2 family members, A20 and Akt activity (Hayward, 
2004). EBNA2, in addition clearly stimulates B-cell survival and growth proliferation 
in the setting of EBV infection (reviewed in Hayward, 2004). This viral transcription 
factor acts as a pleiotropic activator of viral and cellular genes involved in growth 
control and plays a decisive role in the induction and maintenance of proliferation of 
the infected cell. EBNA2 is the master transcription factor that regulates the 
expression of EBV genes during the growth programme. It also regulates the 
expression of genes encoding cell surface and soluble proteins that
 
modulate the cell's 
interaction with the environment, like the
 
receptors CD21, CD23, and CCR7 and the 
cytokines TNF-α,
 
LT-α
 
and IL-18 (Cordier et al, 1990; Burgstahler et al, 1995; 
Spender et al, 2001; Pages et al, 2005) in addition to cellular
 
genes that are implicated 
in intrinsic growth and survival regulation,
 
like cyclinD2,
 
c-myc, bfl-1 and c-fgr 
(Knutson, 1990; Sinclair et al, 1994; Kaiser et al, 1999; Pegman et al, 2006). 
Furthermore, in a study using Sindbis virus infection to induce Nur77 synthesis and 
apoptosis, it was demonstrated that EBNA2 could bind to Nur77 and protect against 
Nur77-induced cell death (Lee et al, 2002).  
The ability of EBV latent proteins to manipulate cell survival by directly regulating 
members of the Bcl-2 family is well established. As discussed in Chapter 1, EBV 
LMP1 is known to induce the expression of several anti-apoptotic Bcl-2 family 
members such as Bcl-2, Bfl-1, Mcl-1 and recently has been shown to down-regulate 
the expression of pro-apoptotic Bax and Bim (Laherty et al, 1992; Fries et al, 1996; 
Wang et al, 1996; D'Souza et al, 2000; Clybouw et al, 2005; Grimm et al, 2005; 
Pegman et al, 2006; Anderton et al, 2007). EBNA2 in particular has previously been 
implicated in the modulation of the anti-apoptotic bcl-2 (Finke et al, 1992). 
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Significantly the over-expression of Bcl-2 in group I BL cell lines resulted in 
diminished apoptosis in response to a number of stimuli as compared with group III 
BL cell lines, and cell death inhibition was directly correlated to the amount of Bcl-2 
expressed (Henderson et al, 1991; Milner et al, 1992).  It has also been shown in the 
laboratory that EBNA2 up-regulates the anti-apoptotic bfl-1 gene. EBNA2 trans-
activation of bfl-1 requires CBF1, a nuclear component of the Notch signaling 
pathway, and bfl-1 expression is induced and maintained at high levels by the EBV 
growth programme in an LCL (Pegman et al, 2006).  
In our laboratory, preliminary RNA multiriboprobe nuclease assays had indicated a 
possible correlation between the EBV growth programme and the down-regulation of 
the pro-apoptotic bik gene in BL-derived cell lines and LCLs. Since Bik has been 
implicated in several cancers and given that repression of bik or inactivation of its 
product is thought to play a role in tumour development (Reviewed in Chapter 1), 
these observations prompted an investigation to determine the role and mechanism of 
bik down-regulation in this context.  
 
Here, evidence is presented in Chapter 3 that loss of Bik protein appears to be a 
common feature of LCLs and BL type IIIs expressing the full compliment of EBV 
latent genes. The fact that both native EBNA2 (expressed in the Dg75-tTA-EBNA2 
cell line) and active chimeric ER/EBNA2 (in the BL41K3 and BJABK3 cell lines) 
down-regulated bik in the absence of other EBV latent proteins provides compelling 
evidence that bik can be regulated by EBNA2 alone (Chapter 4). Further evidence of 
this is seen in EBV-negative BL cells superinfected with the EBNA2-defective 
P3HR1 virus (BL41P3HR1) and the EBNA2-deficient EBV-positive DAUDI cell 
line, which both show elevated Bik expression (Chapter 3). Repression of bik by 
EBNA2 demonstrates for the first time that EBNA2 targets the transcriptional 
regulation of a pro-apoptotic protein and may provide an explanation for the 
observation that BL type I cells in culture tend to have higher levels of bik expression 
than their type III counterparts. Overall it appears that repression of bik at the level of 
transcription, with an associated loss of Bik protein appears to be a feature of LCLs 
relative to BL-derived cell lines. However, transcriptional regulation of bik by EBV 
may vary between cell lines since it is less apparent in BL type III cells.  
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The detection of Bik in BL type I cells was not consistent with a pro-apoptotic role in 
this cell context. However, no mutations leading to loss-of-function were identified 
nor was a lack of Bax expression implicated in the apparent survival of BL cell lines 
to this pro-apoptotic gene. Interestingly, whereas the Bik protein expressed
 
in BL 
Type I cells in the absence of EBNA2 expression always appeared as 27/26kDa 
double
 
bands during Western blotting, the low level of Bik detected in LCLs and BL 
Type III cells always appeared
 
as a faint 26kDa single band. Evidence indicates that 
Bik is phosphorylated, and as such may become active (Verma et al, 2001). Thus, it 
appears that there is a loss of total Bik expression upon induction of EBNA2, and the 
low level of Bik that remains is not phosphorylatyed. Bik phosphorylation has 
previously been detected in SW480 cells (human, colon, adenocarcinoma) (Verma et 
al, 2001). In addition, the PI3K pathway is required for both sIgM-mediated sustained 
Bik protein expression and apoptosis in B104 cells (Jiang and Clark, 2001). 
Conceivably then, phosphorylation of Bik may confer conformational changes
 
that 
expose the BH3
 
domain rendering the protein active in BL Type I cells and the low 
levels of unphosphorylated Bik which is found in LCLs is inactive. While this model 
is consistent with the role for EBV in protecting infected cells from apoptosis, it does 
not explain the apparent resistance of BL Type I cell lines to Bik expression. As was 
reviewed in Chapter 1, several lines of evidence suggest that the balance between pro-
apoptotic Bik and the anti-apoptotic Bcl-XL
 
protein may play a key role in determining 
B-cell fate (Saltzman et al, 1998; Jiang and Clark, 2001). Thus, the relative proportion 
of Bik not associated with Bcl-XL may play a crucial factor in the ability of these cells 
to tolerate the expression of this pro-apoptotic molecule. This hypothesis is consistent 
with the stable transfection experiments described in Chapter 6, where neither DG75 
nor BJAB were able to sustain ectopic Bik expression. Bik may also be counteracted 
by a so far undefined inhibitor in type I cells (EBV latent programme) as compared 
with type III cells and LCLs (EBV growth programme). 
 
The evidence presented in Chapter 6 indicates that ectopic expression of Bik causes 
IB4 cells to die by apoptosis and a clear dose dependent increase in apoptotic activity 
occurred in response to addition of increasing quantities of the Bik expression plasmid 
pcDNA3-HA-bik. The toxic effect of Bik relative to the BH3-deleted Bik indicates 
that the death-promoting activity of Bik is dependent on a functional BH3 domain. In 
addition, induction of cell death by Bik was strongly inhibited by the pan-caspase 
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inhibitor zVAD-fmk, indicating that Bik induces apoptosis by a pathway that is 
upstream of the caspases. Together, these results indicate for the first time that down-
regulation of the pro-apoptotic bik gene promotes B-cell survival during the EBV 
growth programme. Since it is clear that EBNA2 plays a key role in repressing bik it 
is now apparent that this host-virus interaction contributes to the survival of EBV-
infected B-cells that are proliferating on the viral growth programme, thus implicating 
a contributory role for Bik in setting the elevated threshold of resistance of these cells 
during EBV infection.  
 
As discussed in Chapter 6 down-regulation of pro-apoptotic Bcl-2 family members 
has been shown previously to protect malignant cells from apoptosis. Loss of Bax 
increases tumourigenicity and reduces apoptosis (McCurrach et al, 1997; Yin et al, 
1997; Ionov et al, 2000) and the absence of both Bax and Bak can enhance 
transformation, to a greater extent than the loss of either protein alone (Zong et al, 
2001). Preliminary data also indicates that the absence of bim accelerates Myc-
induced lymphomagenesis (Cory and Adams, 2002) and there is also evidence that the 
p53 targets, Noxa and Puma, might mediate p53 apoptotic function and that Bmf 
might inhibit metastasis (Puthalakath et al, 2001).  
  
In the EREB 2-5 conditional LCL, withdrawal of estrogen results in cessation of cell 
growth and a significant proportion of the cells die by apoptosis (Kempkes et al, 
1995a). Loss of expression of EBNA2-regulated genes such as cellular c-myc, 
cyclinD2 and cdk4 (Kempkes et al, 1995a; Kaiser et al, 1999) and EBV LMP1 and 
LMP2 (TP) (Kempkes et al, 1995b) contribute substantially to this outcome. 
Experiments presented in Chapter 5 demonstrate a role for EBNA2 in regulation of 
the bik gene in this context. Conceivably, since EBNA2 modulates both IgM, and c-
Myc expression (Jochner et al, 1996; Kaiser et al, 1999) and since both of these genes 
can affect bik expression (Jiang and Clark, 2001 and Chapter 5) it is possible that 
EBNA2 mediates the regulation of bik through both IgM-dependent and c-Myc-
dependent pathways. The c-myc gene is transcriptionally activated by EBNA2 in a
 
CBF1-independent manner (Maier et al, 2005) and is known to share similar 
functions with EBNA2 as a transcriptional regulator and hence, was a good candidate 
to
 
mediate Bik suppression by EBNA2. c-Myc over-expression
 
in P493-6 cells did 
down-regulate bik in the absence of EBNA2 (Chapter 5), but the steady state level of 
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bik mRNA/Bik protein was considerably lower when cells were cycling due to EBV 
Lat III. Thus, since EBNA2 contributes not only to the activation of c-Myc-mediated 
bik repression (as would be the case in c-Myc-only-driven bik repression) but also to 
the activation of the IgM-associated pathway, and since EBNA2-mediated regulation 
of both of these genes is only partially CBF1 dependent (Maier et al, 2005) the  
hypothesis that EBNA2 mediates bik repression through both c-myc and IgM may 
explain the considerable differences observed in the levels of bik expression when 
cells are cycling due to EBNA2 in contrast to cells proliferating due to c-Myc 
expression. The data presented here demonstrates for the first time that the bik gene is 
repressed through a mechanism driven by EBNA2, and that c-Myc can also drive bik 
repression independently of functional EBNA2 expression during the EBV growth 
programme.  
 
In BL type I cells, however, c-Myc is overexpressed due to chromosomal 
translocation (Brady et al, 2007), and yet these cells express detectable Bik. 
Introduction of EBNA2 into these cells leads to repression of both c-Myc and Bik, 
arguing against a role for c-Myc as a negative regulator of Bik.  Furthermore, in 
BJABK3, a non BL cell line derived from a lymphoblastoid B-cell line that does not 
carry the t(8;14) translocation, c-Myc expression is transiently up-regulated in 
response to EBNA2 (Maier et al, 2005) and yet Bik is still down-regulated. Thus, it 
appears that EBNA2 mediated repression of Bik is not dependent on c-Myc in this 
context. 
 
Genomic deletion of CBF1 in DG75 cells did not abrogate the ability of EBNA2 to 
down-regulate bik in these cells (Chapter 4). In contrast, it has previously been shown 
in the laboratory that EBNA2-mediated trans-activation of the bfl-1 gene is abolished 
by the inhibition of EBNA2/CBF1 signaling (Pegman et al, 2006). This is interesting 
as CBF1 is the major rate-limiting factor for EBNA2 activation of cellular target 
genes (Maier et al, 2006). This finding is further supported by observations made 
using the non-CBF1-binding EBNA2www323sr (promoter regulation studies in 
Chapter 7).  
EBV down-regulates the expression of two further pro-apoptotic members of the Bcl-
2 family; bax and bim (discussed in Chapter 1) (Clybouw et al, 2005; Grimm et al, 
2005; Anderton et al, 2007). Aberrations in the expression of several pro-apoptotic 
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proteins would increase the variety of apoptotic stimuli against which the host cell can 
protect itself, since the range of apoptotic stimuli to which the individual pro-
apoptotic proteins can respond is not always absolute; different proteins are known to 
respond to different types of stimulus. For example, Bid-deficient mice appear 
normal, but their hepatocytes
 
(but not their lymphocytes) are resistant to anti-Fas 
antibody-induced
 
killing while in contrast, Bim is required for
 
haematopoietic cell 
homeostasis and as a barrier against autoimmune
 
disease (reviewed in Bouillet and 
Strasser, 2002). In addition, the fact that EBV mediates an elevated level of several 
anti-apoptotic proteins including Bcl-2, Bfl-1 and Mcl-1 (Henderson et al, 1991; 
Wang et al, 1996; Pegman et al, 2006) provides compelling evidence the regulation of 
both pro- and anti-apoptotic
 
genes is central to the overall strategy that EBV employs 
to control the cellular response to apoptosis in infected
 
cells.  
 
The cellular proteins Notch and c-Myc and the EBV LMP1 are known to have 
overlapping functions with EBNA2, particularly as transcriptional regulators. LMP1 
can partially substitute for EBNA2 in mediating cell survival (Zimber-Strobl et al, 
1996) and in the up-regulation of the surface markers CD21, CD23, intercellular 
adhesion molecule 1 (ICAM-1), and lymphocyte function antigen-1 (LFA-1) (Peng 
and Lundgren, 1992; Peng and Lundgren, 1993). It is presented in Chapter 4 that 
LMP1 does not influence the expression of bik in DG75 cells. In the presence of the 
EBNA2-deleted P3HR1 genome, Notch can partly, and c-Myc fully replace EBNA2 
in the maintenance of B-cell proliferation (Pajic et al, 2000; Hofelmayr et al, 2001). 
While findings in Chapters 4 and 7 established that the EBNA2-CBF1 interaction was 
not required for EBNA2-mediated bik repression it should be noted that EBNA2 and 
Notch have overlapping functions beyond their capacity to interact with CBF1. 
Significantly, as discussed in Chapter 5, it has also been shown in the laboratory that 
high levels of Notch 1IC can substitute for EBNA2 to repress bik, although not to the 
same extent. Thus, EBNA2 may execute notch-like functions to facilitate the 
regulation of pro-apoptotic bik and additional common interaction partners of both 
Notch and
 
EBNA2, such as SKIP, Nur77, PU.1, Spi-1 or Spi-B could potentially
 
contribute to this function (Laux et al, 1994a; Johannsen et al, 1995; Zhou et al, 
2000a; Zhou et al, 2000b; Lee et al, 2002). Interestingly Myc is also a direct 
transcriptional target of Notch1 participating as an indispensable downstream effector 
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in Notch 1IC-induced tumourigenic action (Efstratiadis et al, 2007) a further 
indication that EBNA2 is mimicking the Notch cellular pathway. 
The down-regulation of bik by EBNA2 may be a key event in the rescue of EBV-
infected B-cells from apoptosis and an important route by which EBV gains access to 
the memory B-cell pool and contributes to oncogenesis. In Chapter 6 it was shown 
that the reintroduction of Bik causes IB4 cells to die by apoptosis. The anti-apoptotic 
function of EBNA2 may
 
complement the LMP1-induced survival signals mediated 
through
 
NF-κB and provide initial protection prior to LMP1
 
expression during 
primary EBV infection of B-cells (as suggested in Lee et al, 2002). While most EBV-
associated tumours do not express
 
EBNA2, this viral protein is expressed in EBV-
associated tumours arising in immuno-compromised
 
patients such as PTLD
 
and in 
primary central nervous system lymphomas in AIDS patients
 
(Cen et al, 1993; 
Auperin et al, 1994; Delecluse et al, 1995) and its anti-apoptotic activity may be a 
factor in the development
 
of these
 
malignancies. Thus, dual proliferative and anti-
apoptotic roles for EBNA2 may emulate the activities attributed to cellular Notch 
(Miele and Osborne, 1999; Shelly et al, 1999). Indeed, EBNA2
 
mimicry of Notch IC 
has previously been extended beyond the recognised
 
shared mechanism of regulation 
through CBF1 (Zimber-Strobl and Strobl, 2001). In this regard EBNA2 has been 
shown to inhibit Nur77-mediated apoptosis demonstrating a mutual mechanism for 
anti-apoptotic activity (Lee et al, 2002).  
 
Taken together the data presented in Chapter 7 indicates that the mechanism by which 
EBNA2 represses bik is complex. The findings demonstrate that EBNA2 may down-
regulate expression of bik by decreasing transcription from the bik promoter and that 
this down-regulation involves a mechanism that is independent of CBF1 and is not 
potentiated by EBNA-LP. EBNA2 and c-Myc do not co-operate in the down-
regulation of the bik promoter fragment nor is there an apparent independent role for 
c-Myc although these conclusions are limited to the 1.9kb promoter fragment used. 
An abundance of genes have been shown to interact with Myc in this context; in fact 
one group recently identified 668 direct Myc-regulated gene targets, including 48 
transcription factors in the P493-6 cell line, indicating that Myc is a central 
transcriptional hub in growth and proliferation control (Zeller et al, 2006). Analysis in 
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chapter 7 indicated that there were 14 putative Myc-related binding sites spread 
throughout the -1710/+203 region of the bik promoter. However, recent studies have 
suggested that binding sites
 
for transcription factors are not necessarily near the 
transcriptional start
 
sites of genes or in CpG islands. In this regard, it has been 
reported that only 18% of Myc-binding sites are
 
within 1kb of a 5'-exon and only 24% 
are within 1kb of a CpG
 
island (Cawley et al, 2004). Indeed a recent genomics study 
found that approximately half of all Myc-bound sites were intergenic (>10 kb away 
from transcriptional start sites) (Bieda et al, 2006). In another recent study c-Myc 
binding sites on DNA from the P493-6 cell line were analysed, and showed that c-
Myc may regulate up to 10-15% of all genes in this B-cell context, and could occupy 
approximately 4,296 genomic loci. The majority of these (63%) are located within a 
10kb range around known gene regions with a strong binding preference toward 5’ 
proximal promoter regions (Zeller et al, 2006). Significantly only 36% of Myc 
binding loci are within 5kb of a CpG island in this context also.  Thus, bik regulation 
may be effected through a consensus c-myc binding element located either far 
upstream (or downstream) of the -1710/+203 region of the promoter. A global binding 
model for Myc has recently been suggested (Bieda et al, 2006). In this model Myc 
binding is widespread encompassing possibly thousands of sites per chromosome and 
including both genic and intergenic sites. This global binding regulates general 
chromatin structure and in that way directs cell biology through influencing functions 
such as cell cycling and fate that depend on overall chromatin structure (Bieda et al, 
2006).  
 
Interestingly in support of the hypothesis presented in Chapter 4, findings in Chapter 
7 indicate that EBV may stimulate the turnover of Bik through either the modulation 
of an intermediary factor such as c-Myc or IgM or through the inhibition of the 
turnover of a genetic repressor or a protease.  In the presence of ER/EBNA2, the level 
of bik mRNA is affected by actinomycin D, to a greater extent than in the absence of 
EBNA2.  Following ER/EBNA2 activation there is a substantial accumulation in bik 
mRNA levels.  Since actinomycin D inhibits mRNA synthesis, an accumulation in 
mRNA levels after treatment with this drug indicates an apparent contradiction, the 
resolution of which may offer important evidence concerning the mechanism of gene 
regulation in question (Chatterjee et al, 1979). The steady-state level of mRNA is 
determined by the dynamic interaction between its rate of synthesis and its rate of 
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degradation. In the presence of transcriptional inhibitors, the rate of mRNA synthesis 
is diminished and a lower steady-state level of the mRNA would normally result. It is 
assumed that quantitating the decreasing amounts of mRNA as a function of time in 
the presence of transcriptional inhibitors would be a measure of the degradation rate. 
However, this assumption is based on the conditions that (1) mRNA synthesis is 
successfully blocked by the inhibitor and (2) the inhibitor does not interfere (directly 
or indirectly) with the degradation mechanism of the mRNA in question. Indeed 
actinomycin D has previously been shown to lead to an accumulation in the levels of 
several mRNAs including alpha 2u and P-Glycoprotein mRNAs, a phenomenon 
termed "superinduction" (Chatterjee et al, 1979; Lee and Ling, 2003). When 
superinduction is observed in the presence of transcriptional inhibitors, one or both of 
these criteria presumably do not hold. It has been proposed that the superinduction in 
the presence of transcriptional inhibitors could be due to the inhibition of expression 
of an intermediary factor involved in mRNA regulation. It is clear from the result 
presented in Chapter 7, that the degradation pathway for bik mRNA is different in the 
presence of EBNA2. On the basis of these observations, treatment of BL41K3 cells 
(in which ER/EBNA2 is activated), with actinomycin D may result in the loss of an 
intermediary factor. This intermediary factor(s) may be preferentially eliminated by 
actinomycin D due to a short half life, thus leading to an accumulation of the bik 
mRNA. Significantly, this is supported by findings in Chapter 5, which indicate that 
the up-regulation of bik during EBNA2 repression was significantly inhibited by 
MG132, suggesting that EBNA2-mediated repression of the bik gene requires an 
intermediary factor and is further substantiated by the premise that EBNA2-mediated 
Bik regulation may involve the modulation of IgM and/ or c-Myc (Chapter 4). This 
result is complex to interrupt, yet significantly, gapdh mRNA levels appear stable and 
were similar in estrogen-treated and estrogen-untreated
 
samples. Overall, it is clear 
from the result presented in Chapter 7, that the degradation pathway for bik mRNA is 
different in the presence of EBNA2. 
 
A protein similar to Bik has also been discovered in rodents (Hegde et al, 1998) this 
gene, designated bik-like killer (blk), is considered the murine ortholog of human bik 
on the basis of their location in syntenic regions, gene organisation, and nucleic acid 
as well as amino acid sequence homology (Coultas et al, 2004). However, B-cells 
from blk 
-/-
 knockout mice developed and reproduced normally (Coultas et al, 2004) 
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and deletion of this gene was shown to have a little effect on the sensitivity of murine 
cells to apoptotic stimuli (Coultas et al, 2004) including p53 over-expression (Mathai 
et al, 2005). Remarkably, therefore, murine blk and human bik respond differently to 
stress stimuli (Coultas et al, 2004; Mathai et al, 2005). This apparent distinction 
between the function of Bik and its murine ortholog, Blk may be explained by the 
substantial differences in structure and expression from its human counterpart. In this 
regard, the human and mouse bik orthologs are only 43% identical, despite having 
very similar gene structures (Hegde et al, 1998) and furthermore unlike Bik, Blk is 
largely restricted to hematopoietic and endothelial cells (Coultas et al, 2004). 
 
Viral infection represents a cellular stress that induces host cell pro-apoptotic 
responses. To overcome this barrier to productive infection, viral polypeptides 
modulate a variety of host cell pathways. The general strategy of some viruses to 
down-regulate pro-apoptotic genes is well established, and in this regard the human 
cytomegalovirus encodes "viral mitochondria-localised inhibitor of apoptosis" 
(vMIA), which functions as a potent cell death suppressor by binding to and inhibiting 
pro-apoptotic Bcl-2 family members Bax and Bak (Arnoult et al, 2004). The 
inactivation of the pro-apoptotic tumour suppressor p53 by the papillomavirus E6 
oncogene is an important mechanism by which E6 promotes cell growth (Li et al, 
2005). In addition, adenovirus L4-100K assembly protein is a granzyme B substrate 
that potently inhibits granzyme B-mediated cell death (Andrade et al, 2001). 
 
The inhibition of pro-apoptotic pathways is a fundamental step in tumour 
development and may be responsible for therapy resistance. Apoptosis-based 
strategies are important tools for the development of effective anticancer strategies. 
Such strategies may seek to correct specific genetic defects as in the case of 
mutations, or substitute for deregulated tumour suppressor genes (Whartenby et al, 
1995). Indeed studies have shown that over-expression of several pro-apoptotic genes, 
including Bax, Bcl-XS, apoptin, and TRAIL, can display an anti-tumour effect 
(Ealovega et al, 1996; Ashkenazi et al, 1999; Walczak et al, 1999; Huh et al, 2001; Li 
et al, 2001; Backendorf et al, 2008). Conceivably the apoptosis deficiency of EBV-
associated malignancies could be overcome by targeted enforced expression of pro-
apoptotic Bcl-2 proteins such as Bik or Bim or targeted knockdown of anti-apoptotic 
proteins such as Bfl-1. Potentially, high expression of Bik alone might kill cells, and 
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lower expression levels of anti-apototic proteins could increase cellular sensitivity to 
radiation or chemotherapy. In view of the fact that expression of Bik served to induce 
apoptosis in an EBV-infected cell line, this avenue may be of considerable interest for 
the future treatment of malignancies in which bik is repressed, possibly in tandem 
with low-dose chemotherapy. The anti-tumour activity of Bik in melanoma has 
previously been demonstrated in vivo in a human xenotransplant nude mouse model. 
Induction of Bik resulted in significantly reduced tumour size and delayed tumour 
growth. Comparable results were also reported for xenotransplanted colon and 
prostate carcinoma, for which tumour formation could be prevented by intratumoral 
injection of a Bik-expressing Adenovirus (Tong et al, 2001).  
 
Bik has also been found to sensitise tumour cells to apoptosis mediated
 
by several 
chemotherapeutic agents including etoposide,
 
epirubicin, paclitaxel, pamidronate and 
doxorubicin
 
(Daniel et al, 1999; Panaretakis et al, 2002; Oppermann et al, 2005) and 
also to CD95/Fas-triggered
 
apoptosis (Daniel et al, 1999; Oppermann et al, 2005). 
Additionally undecylprodigiosin (UP), a bacterial bioactive metabolite with 
anticancer properties, enhanced the levels of Bik protein in several human breast 
cancer cell lines (Ho et al, 2007) as did treatment with neurotoxins Maneb and MPP
+
 
in a human neuroblastoma cell line (Fei and Ethell, 2008). Bik is also induced in 
estrogen-dependent MCF7 breast cancer cells in response to inhibition of estrogen 
signaling (Hur et al, 2004) and has been identified as one of a set of genes classified 
as ‘molecular markers’ for thermoradiosensitivity in cervical cancer (Harima et al, 
2004). Furthermore, delivery of a liposome and bik gene complex dramatically 
inhibited tumour growth and prolonged survival in a mouse orthotopic breast cancer 
model (Zou et al, 2002). One recent study showed that bik can function as a mediator 
of apoptosis triggered by viral infection-induced shutoff of protein synthesis (Shimazu 
et al, 2007). 
 
Indeed, several molecular therapeutic approaches against cancer are targeted to 
overcome drug resistance, and are based on the combination with chemotherapeutic 
drugs. Since most chemotherapeutic agents require the activation of caspases to 
induce apoptosis, chemoresistance may be caused by a defect in apoptosis-inducing 
pathways. In this context, it has been reported that ectopic Bik expression can 
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overcome drug resistance in breast cancer and in lymphoma and melanoma cells 
(Daniel et al, 1999; Radetzki et al, 2002; Oppermann et al, 2005). Thus, triggering 
Bik in EBV-associated malignancies may support the pro-apoptotic activities exerted 
by the immune system or those resulting from chemotherapies. In this regard, Bik can 
be transcriptionally induced by BCR-triggering in B104 cells (Jiang and Clark, 2001) 
and an increase in bik mRNA was also observed
 
in TGF-β-mediated apoptosis of the 
Ramos B-cell line (Saltzman et al, 1998). Interestingly, certain chemotherapeutic 
agents have been shown to induce Bik expression, which in turn contributes to the 
apoptotic response of cancer cells to chemotherapy including adriamycin, antiestrogen
 
fulvestrant, doxorubicin and γ-radiation (Thiantanawat et al, 2003; Mathai et al, 2005; 
Real et al, 2006). 
Undoubtedly, the efficacy of bik would depend largely on its targeting to the infected 
cell in question, a practice which requires a delivery system that can both withstand 
intravenous conditions and can also transport the therapeutic gene to the target cell. 
Ad-mediated
 
gene transfer is a clinically relevant cancer treatment and has been 
shown to induce
 
apoptosis of tumour cells while sparing the ‘normal’ adjacent cells
 
(Liu et al, 1995). Indeed intratumoural injection of
 
adenoviral wt bik led to tumour 
regression in one study (Tong et al, 2001). Nonviral gene delivery by liposomes is 
another promising strategy since the liposome vehicle has very low immunogenicity 
and toxicity. In one study, a modified cationic liposome formulation (SN) containing 
a surface-protection polymer to stabilize the liposome-DNA particles for intravenous 
injection was employed and SN-bik was seen to successfully inhibit tumour growth in 
nude mice (Zou et al, 2002). Delivery of genes that encode apoptosis-related proteins 
could potentially have many advantageous effects on malignancy. Firstly not only 
would tumour cell proliferation be correctly balanced by an increase in cell death, but 
the barriers to the immune response would collapse, tumour invasiveness would be 
hindered, and sensitivity cytotoxicity would be restored (as reviewed in Gomez-
Navarro et al, 2000). Importantly, the need that tumour cells have for mechanisms 
that allow them to avoid apoptosis is universal, shared by all tumour localisations in 
the body. This evasion represents a common ground that can be targeted in the vast 
environment of tumour heterogeneity. With the increasing identification oncogenes or 
tumour suppressor genes involved in the apoptotic pathway, gene therapy has 
emerged as a promising strategy in the attempted modulation of apoptosis. (As 
reviewed in (Gomez-Navarro et al, 2000). 
 302 
Recently interest has been growing in the potential of anticancer drugs that, like the 
pro-apoptotic BH3 domain, bind one or more Bcl-2 homologs and trigger apoptosis. It 
is thought that such ‘BH3 mimetics’ may prove to be more effective than anti-tumour 
agents acting further upstream. Furthermore, BH3 selectivity holds the ability of 
specifically targeting the Bcl-2 homolog(s) required to maintain a particular tumour 
type, potentially avoiding injury of the healthy cell population. Indeed the ability of a 
Bid BH3 peptide to activate Bax in vitro has previously been shown and may mean 
that Bax (or Bak) could also be targeted. Moreover, a Bik BH3 peptide can effectively 
compete with natural myristoylated (myr) Bid protein for binding Bcl-2, thus 
abrogating the anti-apoptotic activity of Bcl-2 and enabling myrBid induced 
cytochrome c release (Letai et al, 2002). BH3 mimetics may also prove to be 
important adjuvants in conventional therapy, sensitising cells to diverse chemotherapy 
agents, and potentially facilitating lower doses of a conventional agent or more 
durable responses (reviewed in Adams and Cory, 2007).  
In this study it has been established that the EBNA2 mediated suppression of bik has a 
potential role to play in the regulation of B-cell apoptosis by EBV. It is possible that a 
combinatorial strategy will be key for the treatment of lymphomas, and by 
understanding the interactions of viral and cellular signaling pathways involved in 
tumourigenicity, the most effective strategy may be developed. A combinatorial 
approach involving the enhanced expression of a pro-apoptotic molecule such as bik, 
(either through direct activation for example via BCR-triggering or direct delivery of 
a BH3 mimetic), in tandem with the targeted down-regulation of expression of anti-
apoptotic genes involved in the pathway such as bfl-1 (by means of a functional 
blockade or inhibition of expression) may be most effective in restoring the apoptotic 
machinery in the cell and sensitising EBV-associated malignancies to chemo- or 
radiotherapies. In addition, the identification of viral proteins that provide survival 
signals to naturally infected tumour cells provides us with an opportunity to link 
pathway deregulation with potential therapeutic strategies. 
 
In summary, this thesis presents the novel finding that EBV down-regulates the 
cellular pro-apoptotic bik gene. Significantly, restoration of Bik expression in IB4 
cells induces a pathway upstream of the caspases stimulating the induction of 
apoptosis that is dependent on a functional BH3 domain. The EBV latent transcription 
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factor EBNA2 plays a key role, and possibly c-Myc and this down-regulation is 
independent of the cellular transcription factor CBF1. This is the first indication of the 
down-regulation of expression of a pro-apoptotic gene by EBNA2 and to date EBNA2 
is known to transcriptionally repress the activity of only one other cellular gene, the 
immunoglobulin heavy chain locus (IgM). A more complete understanding of the role 
and regulation of the bik gene in BL-derived cells has benefits for the biology of EBV 
and will undoubtedly further the understanding of malignant disease.  Collectively, 
these findings suggest that functional
 
deactivation of bik expression in EBV-infected 
cells and modulation of its expression by EBNA2 may be a contributory factor in the 
development of EBV-associated B-lymphomas.  
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CHAPTER 9  
Summary and Concluding Remarks 
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Bik is expressed in BL-derived cell lines 
• Loss of Bik protein appears to be a common feature of LCLs and BL type 
IIIs expressing the full compliment of EBV latent genes.  
• Loss-of-function mutations in the bik gene are unlikely to be a feature of 
BL cells since no mutations leading to changes in the primary amino acid 
sequence were found.  
• Bax was expressed in a range of cell lines including BL Type I (except 
DG75), BL type III and LCLs. 
 
Expression of exogenous bik in EBV infected cell lines 
• Ectopic Bik triggers apoptosis in the EBV-infected cell line, IB4, by a 
mechanism which dependent on the BH3 domain. 
• Bik-induced cell death was inhibited by the pan-caspase inhibitor zVAD-
fmk. 
• Expression of exogenous Bik but not BH3-domain deleted Bik led to 
reduced cell viability in a range of EBV infected cell lines using 
Luciferase and GFP expression assays. 
• A dose dependent apoptotic response to increasing quantities of HA-Bik 
expression was observed. 
Regulation of bik by EBNA2 in BL-derived cell lines 
• The EBV latent protein EBNA2 can transcriptionally repress bik 
expression in EBV-negative BL-derived cell lines DG75-tTA-EBNA2, 
BL41K3 and BJABK3 and in the EBV positive cell line BL419A. 
• Neither the Notch pathway associated protein CBF1/RBPJκ nor the 
EBNA2-CBF1 interaction are necessary for EBNA2-associated repression 
of bik. 
• EBNA2 mediated repression of the bik gene is not dependent on c-myc 
expression in BL. 
• The induction of LMP1 did not influence the expression of the bik gene in 
response to tetracycline-regulated induction of this protein, indicating no 
role for LMP1 in its regulation. 
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Regulation of bik by EBNA2 in LCLs. 
• Inactivation of the EBV growth programme in the conditional 
Lymphoblastoid cell line EREB2-5 leads to the de-repression of bik 
mRNA and protein.  
• c-Myc can trigger bik repression in P493-6 cells in the absence of 
functional EBNA2.  
• The steady state level of bik was considerably lower when cells were 
cycling due to the EBV growth programme when compared to cells 
proliferating on the c-Myc programme, indicating a possible co-operative 
role for both EBNA2 and its cellular target gene c-myc in bik repression in 
this context. 
 
 
Regulation of the bik promoter in BL-derived cell lines 
• Transient transfection assays using bik promoter reporter constructs 
indicate repression of the bik promoter by EBNA2. 
• EBNA2-mediated repression of the bik promoter in DG75 cells does not 
require RBP-Jκ/CBF1 and is not potentiated by EBNA-LP. 
• EBNA2 and c-Myc do not co-operate in the down-regulation of the bik 
promoter nor is there an apparent independent role for c-Myc in the 
regulation of the 1.9kb bik promoter fragment.  
 
Other  Mechanisms  
• Actinomycin D substantially increased the concentration of bik mRNA in 
the presence of EBNA2. 
• Treatment of EBV infected cell lines with 5-azaC failed to lead to 
increased amounts of Bik protein, arguing that Bik is not repressed by a 
methylation-dependent mechanism in this context.   
• Treatment of EBV infected cell lines with the HDAC inhibitors, TSA and 
Sodium Butyrate did not affect the steady state level of Bik, suggesting 
that the acetylation status and chromatin structure of the bik gene are 
unlikely to be dominant regulators of transcription in this cell context. 
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• Trichostain A, a HDAC inhibitor potently inhibited the activation of 
ER/EBNA2 and the induction of EBNA2 from a tet-regulated 
heterologous promoter.  
• EBV may indirectly stimulate the turnover of Bik through a) the 
modulation of an intermediary factor such as c-Myc or IgM or b) through 
the inhibition of the turnover of a genetic repressor or a protease. No direct 
role for the involvement of the proteasome in the degradation of Bik was 
established.   
 
Concluding Remarks 
 
In view of the fact that expression of Bik served to induce apoptosis in an EBV-
infected cell line this avenue may be of considerable interest for the future treatment 
of EBV-associated malignancies possibly in tandem with low-dose chemotherapy. 
The antitumor activity of Bik in melanoma has previously been demonstrated in vivo 
in a human xenotransplant nude mouse model. Induction of Bik resulted in 
significantly reduced tumour size and delayed tumour growth. Comparable results 
were also reported for xenotransplanted colon and prostate carcinoma, for which 
tumour formation could be prevented by intratumoral injection of Bik adenovirus 
(Tong et al, 2001).   
 
It is now clear that EBNA2 mediated suppression of bik has a potential role to play in 
the regulation of B-cell apoptosis.  Importantly, EBNA2-mediated down-regulation of 
bik may contribute to the survival of EBV-infected B-cells in vivo, and the effect on 
bik may contribute to the development of EBV-associated B-cell malignancies in 
which EBNA2 is expressed.  
 
Of interest, the EBV anti-apoptotic vBcl-2 homologues, BHRF1 and BALF1, are 
transiently expressed immediately following EBV infection, and are essential for B-
cell immortalisation (Altmann and Hammerschmidt, 2005). BHRF1 has been shown 
to interact with and inhibit Bik (Boyd et al, 1995; Elangovan and Chinnadurai, 1997), 
and hence negative transcriptional modulation of bik by the EBV growth programme 
may supersede these early events to extend this survival advantage, thus favouring 
immortalisation and potentially lymphomagenesis. 
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APPE+DIX I 
 b 
Solutions for D+A Manipulation 
 
Storage of D+A 
 
0.5 M EDTA (pH 8.0) 
 
186.1g   EDTA 
800ml   dH2O 
 
The pH was adjusted to 8.0 by addition of NaOH pellets and the volume adjusted to 
1L with dH2O.  The solution was sterilised by autoclaving and stored at room 
temperature. 
 
TE buffer (pH 8.0) 
 
10mM   Tris-Cl (pH 8.0) 
1mM   EDTA  (pH 8.0) 
 
 
Solution for Bacterial Growth Media  
 
Ampicillin stock solution 
 
A stock solution of ampicillin was made up to a concentration of 100mg/ml in dH2O. 
The stock solution was filter sterilised and stored at -20˚C. 
 
LB broth 
 
5g   Tryptone 
2.5g   Yeast extract 
5g   NaCl 
 
The volume was adjusted to 500ml, followed by autoclaving for 20 minutes at 
15lb/sq. and storage at 4˚C. 
 
 
LB broth with ampicllin  
 
Ampicillin was added to autoclaved LB broth to a final concentration of 100µg/ml 
and stored at 4˚C. 
 
 
 
 
 
 c 
LB agar 
 
5g   Tryptone 
2.5g   Yeast extract 
5g   NaCl 
7.5g   Agar 
 
The volume was adjusted to 500ml with dH20, followed by autoclaving and agar 
plates were stored at 4˚C. 
 
LB agar with antibiotics 
 
Antibiotics were added to autoclaved LB broth to a final concentration of 100µg/ml 
(Ampicillin), after cooling the LB agar to ~50˚C.  Plates were stored at 4˚C. 
 
SOB medium 
 
10g   Tryptone 
2.5g   Yeast extract 
0.025g   NaCl 
5ml   KCl (250 mM) 
 
 
The pH was adjusted to 7.0 with 5M NaOH.   
The volume was adjusted to 500ml with dH20 and the medium autoclaved.   
2.5ml of 2M MgCl2 was added after cooling the broth to 5˚C and the medium was 
stored at 4˚C.   
 
 
SOC medium 
 
98ml  SOB medium 
2ml  1M glucose (filter sterilised) 
 
Stored at 4˚C.  
 
Solutions for Preparation of Competent Cells 
 
1M MgSO4 
 
24.65g  MgSO4.7H20 
100ml  dH20 
 
Sterilised by filtering and stored at room temperature. 
 
 
 
 
 d 
TFB1 
 
30mM   potassium acetate 
10mM   CaCl2 
50mM   MnCl2 
100mM  RbCl 
15%   glycerol 
 
The pH was adjusted to 5.8 with 1M acetic acid, and the solution filter sterilised and 
stored at room temperature. 
 
TFB2 
 
100mM  MOPS (pH 6.5) 
75mM   CaCl2 
10mM   RbCl 
15%    Glycerol 
 
The pH was adjusted to 6.5 with 1M KOH, and the solution filter sterilised and stored 
at room temperature. 
 
Solutions for D+A preparations 
   
Buffer P1 (Re-suspension buffer) 
 
50mM   Tris-Cl (pH 8.0) 
10mM   EDTA (pH8.0) 
100µg/ml   RNase A 
 
Stored at 4˚C following addition of RNase A. 
 
D+ase-free R+ase 
 
RNase A (1mg/ml) in upH2O. 
Heated to 100˚C for 30 minutes.   
Cooled slowly and stored at -20˚C. 
 
Buffer P2 (Lysis buffer) 
 
200mM  NaOH 
1% (w/v)  SDS 
 
Stored at room temperature.  
 
 
 
 
 e 
Buffer P3 (+eutralisation buffer; (3M potassium acetate) 
 
29.6g   potassium acetate 
50ml    dH2O 
11.5ml   glacial acetic acid 
 
Adjust volume to 100ml with dH2O. 
The resulting solution is 3 M with respect to potassium and 5M with respect to 
acetate. 
 
Stored at room temperature. 
 
 
Buffer QBT (Equilibration buffer) 
 
750mM  NaCl 
50mM   MOPS (pH 7.0) 
15% (v/v)  Isopropanol 
0.15% (v/v)  Triton-X 100 
 
Stored at room temperature. 
 
Buffer QC (Wash buffer) 
 
1M   NaCl 
50mM   MOPS (pH 7.0) 
15% (v/v)  Isopropanol 
 
Stored at room temperature. 
 
Buffer QF (Elution buffer) 
 
1.25M   NaCl 
50mM   Tris-Cl (pH 8.5) 
15%   Isopropanol 
 
Stored at room temperature. 
 
50% (v/v) Glycerol 
 
25ml   glycerol 
25ml   dH2O 
 
The solution was autoclaved and stored at room temperature. 
 
 
 
 
 
 
 f 
Annealing buffer 
 
100mM  Potassium acetate  
30mM   Hepes-KOH, pH 7.4  
2mM   Magnesium acetate 
 
Stored at 4 – 8 ˚C. 
Solutions for Agarose Gel Electrophoresis 
 
50X TAE (Tris-acetate/EDTA electrophoresis buffer) 
 
242g   Tris base 
57.1ml   Glacial acetic acid 
100ml   0.5M EDTA (pH 8.0) 
 
The volume was adjusted to 1L with dH2O and the buffer was stored at room 
temperature. 
 
1X TAE (Working solution) 
 
20ml   50X TAE 
980ml   dH2O 
 
Stored at room temperature. 
 
Agarose gel loading dye 
 
40% (w/v)  Sucrose 
0.25% (w/v)  Bromophenol blue 
 
Stored at room temperature. 
 
Ethidium bromide 
 
10mg   Ethidium bromide 
1ml   dH2O 
 
The solution was stored in the dark at 4 ºC. 100µl of stock solution was added to 1L 
of dH2O for TAE gel staining.  
 
 
 
 
 
 
 
 
 
 g 
Solutions for Cell Culture  
 
Media and Supplements 
 
Supplemented RPMI 1640 (200 ml) 
 
176ml   RPMI 1640  
20ml   Foetal bovine serum (decomplemented at 50˚C for 30 minutes) 
2ml   200mM L-glutamine 
2ml   penicillin/streptomycin (10mg/ml) 
 
 
Estrogen (β-Estradiol) 
 
A 20mM solution was prepared in 100% ethanol and stored at -20˚C. 
 
Tetracycline 
 
A 5mg/ml stock was prepared in 100% ethanol and stored at -20˚C.   
 
Geneticin (G418) 
 
A 50mg/ml stock was prepared in cell culture medium and stored at -20˚C 
 
MG132 
 
A 5mM stock was prepared in in DMSO and stored at -20˚C. 
 
zVAD-fmk 
 
A 20mM solution was prepared in DMSO and stored at -20˚C. 
 
Phosphate buffered saline (PBS) 
 
5 tablets were dissolved in 500ml dH2O to give a 1X working concentration of PBS, 
and the solution was sterilised by autoclaving.   
 
Thiol supplements 
 
The following were added to 200 ml of supplemented media: 
200µl   α-Thiolglycerol 
2ml   Sodium pyruvate 
2ml   HEPES 
 
 
 h 
Bathocuproine disulfonic acid (BCS) 10mM stock solution 
 
36.4mg  BCS 
10ml   1X PBS 
 
Aliquoted and stored at –20
0
C. 
 
α-Thiolglycerol 
 
A stock solution of 50mM in PBS containing 20µM BCS was prepared. 
 
20µl   10mM BCS 
10ml   1 X PBS 
43.3 µl   100% α-thiolglycerol 
 
Aliquoted and stored at –20
0
C. 
 
Solutions for DEAE-Dextran Tranfections Protocol 
 
Tris buffered saline (TBS)      
 
25mM   Tris-Cl (pH 7.4)    
137mM  NaCl 
5mM   KCL 
0.7mM  CaCl2 
0.5mM  MgCl2 
0.6mM  Na2HPO4 
 
To make 200ml TBS: 
 
5ml   1M Tris-Cl (pH 7.4) 
5.48ml   5M NaCl 
0.5ml   2M KCl 
1.4ml   100mM CaCl2 
0.1ml   1M MgCl2 
0.2ml   0.6M Na2HPO4 
187.32ml  upH2O 
 
TBS was prepared from autoclaved stocks, aliquoted and filter sterilised before use.   
 
 
 i 
DEAE dextran 
 
DEAE dextran was prepared at a concentration of 1mg/ml in TBS on the day of use 
and filter sterilised. 
 
β-Galactosidase Assay 
 
100X Mg solution 
 
0.1M   MgCl2 
4.5M   2-mercaptoethanol 
 
Stored at -20˚C. 
 
0.1M sodium phosphate buffer 
 
41ml   0.2M Na2HPO4.2H2O 
9ml   0,2M NaH2PO4.2H2O 
50ml   dH2O 
 
1X O+PG substrate 
 
ONPG was prepared at a concentration of 4mg/ml in 0.1M sodium phosphate buffer 
(pH 7.5) and stored at -20˚C.   
 
1M sodium carbonate 
 
10.59g  Sodium Carbonate 
100ml  dH2O 
 
Stored at room temperature. 
 
Propidium Iodide Solution 
 
69µM   Propidium Iodide  
38MM   NACITRATE (PH 7.4) 
 
Solutions for R+A Analysis 
 
DEPC-treated H2O 
 
1ml   DEPC 
1000ml  dH2O 
 
The mixture was left in a fume cupboard overnight, followed by autoclaving.   
 
 
 
 j 
R+A loading buffer 
 
50%    Glycerol 
1mM   EDTA (pH 8.0) 
0.25%   Bromophenol blue 
0.25%   Xylene cyanol FF 
1µg/ul   Ethidium bromide 
 
 
Solutions for Protein Analysis 
 
Solutions for Protein Isolation 
 
Suspension buffer 
 
0.1M   NaCl 
0.01M   Tris-Cl (pH 7.6) 
0.001M  EDTA (pH 8.0) 
1µg/ml   leupeptin 
1µg/ml   Aprotinin 
100µg/ml  PMSF 
 
Stored at 4˚C 
 
Leupeptin 
 
A stock solution of leupeptin was made to a concentration 2mg/ml in dH2O and stored 
at –20˚C. 
 
Aprotinin 
 
0.1M stock solution of aprotinin was made up in dH2O and stored at -20˚C. 
 
PMSF 
A stock solution of PMSF was made up in isopropanol and stored at -20˚C in the 
dark.  
 
2X SDS loading buffer 
 
100mM  Tris-Cl (pH 7.6) 
4% (w/v)   SDS 
20% (w/v)  Glycerol 
10% (v/v)  2-mercaptoethanol 
0.2%   Bromophenol blue 
 
Stored at room temperature. 
 
 k 
Solutions for SDS-PAGE/ Western Blotting 
 
Table A: 10% (v/v) resolving gels and 5% (v/v) stacking polyacrlyamide gels 
 
Component 10% Resolving Gel (ml) 5% Stacking Gel (ml) 
Acrylagel  3.33 0.42 
Bis-Acrylagel 1.35 0.168 
1.5M Tris (pH 8.8) 2.5 0 
1M Tris (pH 6.8) 0 0.312 
dH2O  2.61 1.5475 
10% (v/v) SDS 0.10 0.025 
10% (v/v) APS 0.10 0.025 
TEMED 0.01 0.0025 
Total 10 ml 2.5 ml 
 
 
5X Tris-glycine running buffer 
 
15.1g   Tris base 
95.4g   glycine (pH 8.3) 
50ml   10% (w/v) SDS 
 
Made up to 1L with dH2O and stored at room temperature. 
 
1X Tris-glycine running buffer  
 
200ml   5X Tris-glycine running buffer 
800ml   dH2O 
 
Transfer buffer 
 
750ml   dH2O 
2.9g   Glycine 
5.8g   Tris base 
3.7ml   10% (w/v) SDS 
200ml   Methanol 
 
Adjusted volume to 1L with dH2O and stored at 4˚C. 
 
1X Tris buffered saline (TBS) 
 
6.1g   Tris base 
8.8g    NaCl 
800ml   dH2O 
 
The pH was adjusted to 7.5 with HCl and the volume adjusted to 1L.  Stored at room 
temperature. 
 
 
 l 
TBS-T 
 
1L   1X TBS 
1ml   Tween 20 
 
Stored at room temperature. 
 
Blocking Buffer 
 
5g   non fat dry milk powder 
100ml   TBS-T 
 
Stored at 4˚C. 
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Figure A: EBV-associated modulation of the steady-state levels of mR+As from 
bcl-2 related genes in the MUTU I and MUTU III cell lines.  
 
mRNA levels from the apoptosis related genes bclXL/S, bfl-1, bik, bak, bax, bcl-2 and 
mcl-1 were analysed in a range of BL cell lines and LCLs by RPA (18 hour 
exposure). Unprotected [32-P]-labeled antisense riboprobes (5000cpm, per lane) were 
loaded alongside RPA-processed samples and are shown linked to their smaller 
RNase-protected fragments which correspond to steady state levels of mRNA in each 
sample. (Adapted from D'Souza et al, 2000).  
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Figure B: High Levels of +otch 1IC can substitute for EB+A2 to repress bik  
 
(A) Transduction of estrogen-deprived EREB 2-5 with HIV-based defective 
lentiviruses expressing either EBNA2 (pLIG-E2) or high levels of human Notch 1IC 
(pLIG-NIC(H)) (Gordadze et al, 2001). mRNA levels from the apoptosis related 
genes bcl-XL/S, bfl-1, bik, bak, bax, bcl-2 and mcl-1 were analysed by RPA. 
Unprotected [32-P]-labeled antisense riboprobes (5000cpm, per lane) were loaded 
alongside RPA-processed samples and are shown linked to their smaller RNase-
protected fragments which correspond to steady state levels of mRNA in each sample.  
(B) Levels of EBNA2, ER/EBNA2 and LMP1 in the experiment shown in (A)+/- e 
(plus/minus estrogen) (courtesy of Dr. Brendan D’Souza). 
 
 
 
 
 
